

# OptiPrep™ Mini-Review MV02

## Recombinant-AAV bibliography

- ◆ This OptiPrep™ Mini-Review provides a comprehensive reference list of all the papers reporting the use of OptiPrep™ for rAAV purification, published before the end of December 2016.
- ◆ The references are divided alphabetically into “**Site of delivery**” and/or “**Research topic**” sections.
- ◆ All references are listed alphabetically according to **First Author**. Multiple references by the same first author are presented chronologically.

### Adipose tissue delivery

**Kallendrusch, S.**, Schopow, N., Stadler, S.J., Büning, H. and Hacker, U.T. (2016) *Adeno-associated viral vectors transduce mature human adipocytes in three-dimensional slice cultures* Hum. Gene Ther., **27**, 171-173

**Liu, X.**, Magee, D., Wang, C., McMurphy, T., Slater, A., During, M. and Cao, L. (2014) *Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype* Mol. Ther. Methods Clin. Dev., **1**: 8

### AdV receptor (see “Coxsackie virus”)

### Airway delivery (see “Respiratory system delivery ”)

### Amyotrophic lateral sclerosis

**Ceballos-Díaz, C.**, Rosario, A.M., Park, H.-J., Chakrabarty, P., Sacino, A., Cruz, P.E., Siemienski, Z., Lara, N. et al (2015) *Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice* Mol. Neurodegener., **10** :25

**Dirren, E.**, Aebischer, J., Rochat, C., Towne, C., Schneider, B.L. and Aebischer, P. (2015) *SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice* Ann. Clin. Transl. Neurol., **2**, 167–184

**Filézac de L’Etang, A.**, Maharjan, N., Braña, M.C., Ruegsegger, C., Rehmann, R., Goswami, A., Roos, A., Troost, D. et al (2015) *Marinesco-Sjögren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS* Nat. Neurosci., **18**, 227-238

**Foust, K.D.**, Poirier, A., Pacak, C.A., Mandel, R.J. and Flotte, T.R. (2008) *Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons* Hum. Gene Ther., **19**, 61-69

**Foust, K.D.**, Flotte, T.R., Reier, P.J. and Mandel, R.J. (2008) *Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat* Hum. Gene Ther., **19**, 71-81

**Jara, J.H.**, Villa, S.R., Khan, N.A., Bohn, M.C., et al (2012) *AAV2 mediated retrograde transduction of corticospinal motor neurons reveals initial and selective apical dendrite degeneration in ALS* Neurobiol. Dis., **47**, 174–183

**Koerber, J.T.**, Klimczak, R., Jang, J.-H., Dalkara, D., et al (2009) *Molecular evolution of adeno-associated virus for enhanced glial gene delivery* Mol. Ther., **17**, 2088–2095

**Kubodera, T.**, Yamada, H., Anzai, M., Ohira, S., et al (2011) *In vivo application of an RNAi strategy for the selective suppression of a mutant allele* Hum. Gene Ther., **22**, 27-34

**Mancuso, R.**, Martínez-Muriana, A., Leiva, T., Gregorio, D., Ariza, L., Morell, M., Esteban-Pérez, J., García-Redondo, A. et al (2016) *Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1<sup>G93A</sup> ALS mice and after partial muscle denervation* Neurobiol. Dis., **95**, 168–178

**Stoica, L.**, Todeasa, S.H., Cabrera, G.T., Salameh, J.S., ElMallah, M.K., Mueller, C., Brown, Jr, R.H., and Sena-Esteves, M. (2016) *Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model* Ann. Neurol., **79**, 687–700

**Tatom, J.B.**, Wang, D.B., Dayton, R.D., Skalli, O., et al (2009) *Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig’s disease in rats via TDP-43 overexpression* Mol. Ther., **17**, 607–613

**Towne, C.**, Schneider, B.L., Kieran, D., Redmond, D.E., et al (2010) *Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6* Gene Ther., **17**, 141–146

**Uchida, A.**, Sasaguri, H., Kimura, N., Tajiri, M., et al (2012) *Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43* Brain, **135**, 833–846

**Xu, Y-F.**, Prudencio, M., Hubbard, J.M., Tong, J., et al (2013) *The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43* PLoS One, **8**: e69864

## Anaphylaxis

**Pagovich, O.E.**, Wang, B., Chiuchiolo, M.J., Kaminsky, S.M., Sondhi, D., Jose, C.L., Price, C.C., Brooks, S.F. et al (2016) *Anti-IgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy* J. Allergy Clin. Immunol., **138**, 1652-1662

## Anhedonia

**Lim, B.K.**, Huang, K.W., Grueter, B.A., Rothwell, P.E. and Malenka, R.C. (2012) *Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens* Nature, **487**, 183-189

## Anthrax toxin protection

**De, B.P.**, Hackett, N.R., Crystal, R.G. and Boyer, J.L. (2008) *Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV* Mol. Ther., **16**, 203-209

## Anti-angiogenesis (cancer therapy); see also “**Tumour cells, effect on**”

**Batchu, R.B.**, Qazi, A.M., Seward, S., Haider, M., et al (2010) *B cell transduction of capsid mutant (Y730F) adeno-associated virus-2 vectors with mage-A3 gene for immunotherapy of colorectal cancer* J. Surg. Res., **158**, 197

**Hacker, U.T.**, Wingenfeld, L., Kofler, D. M., Schuhmann, N.K., et al (2005) *Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency* J. Gene Med., **7**, 1429-1438

**Igarashi, T.**, Miyake, K., Masuda, I., Takahashi, H. and Shimada, T. (2010) *Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model* Hum. Gene Ther., **21**, 631-637

**Isayeva, T.**, Ren, C. and Ponnazhagan, S. (2005) *Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer* Clin. Cancer Res., **11**, 1342-1347

**Isayeva, T.** and Ponnazhagan, S. (2007) *Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway* Gene Ther., **14**, 138-146

**Isayeva, T.**, Chanda, D., Kallman, L., Eltoum, I-E.A. and Ponnazhagan, S. (2007) *Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model* Cancer Res., **67**, 5789-5797

**Kuo, C-H.**, Chen, P-K., Chang, B-I., Sung, M-C., et al (2012) *The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen*. Blood, **119**, 1302-1313

**Kuo, C-H.**, Chang, B-I., Lee, F-T., Chen, P-K., Lee, J-s., Shi, G-Y. and Wu, H-L. (2015) *Development of recombinant adeno-associated virus serotype 2/8 carrying kringle domains of human plasminogen for sustained expression and cancer therapy* Hum. Gene Ther., **26**, 603-613

**Levy, H.C.**, Bowman, V.D., Govindasamy, L., McKenna, R., et al (2009) *Heparin binding induces conformational changes in Adeno-associated virus serotype 2* J. Struct. Biol., **165** 146–156

**Mahendra, G.**, Kumar, S., Isayeva, T., Mahasreshti, P.J., et al (2005) *Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor* Cancer Gene Ther., **12**, 26-34

**Mu, W.**, Long, D.A., Ouyang, X., Agarwal, A., et al (2009) *Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism* Am. J. Physiol. Renal. Physiol., **296**: F145–F152

**Nieto, K.**, Stahl-Hennig, C., Leuchs, B., Müller, M., et al (2012) *Intranasal vaccination with AAV5 and 9 vectors against hman papillomavirus type 16 in rhesus mcaques* Hum. Gene Ther., **23**, 3–741

**Ponnazhagan, S.**, Mahendra, G., Kumar, S., Shaw, D.R., et al (2004) *Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor* Cancer Res., **64**, 1781-1787

**Ren, C.**, Kumar, S., Chanda, D., Kallman, L., et al (2008) *Cancer gene therapy using mesenchymal stem cells expressing interferon- $\beta$  in a mouse prostate cancer lung metastasis model* Gene Therapy **15**, 1446–1453

**Ren, C.**, Kumar, S., Chanda, D., Chen, J., et al (2008) *Therapeutic potential of mesenchymal stem cells producing interferon- $\alpha$  in a mouse melanoma lung metastasis model* Stem Cells, **26**, 2332-2338

**Shi, W.**, Teschendorf, C., Muzyczka, N. and Siemann, D. (2002) *Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo* Cancer Gene Ther., **9**, 513-521

**Shi, W.**, Teschendorf, C., Muzyczka, N. and Siemann, D.W. (2003) *Gene therapy delivery of endostatin enhances the treatment efficacy of radiation* Radiother. Oncol., **66**, 1-9

**Shi, W.**, Hemminki, A. and Bartlett, J.S. (2006) *Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma* Gynecol. Oncol., **103**, 1054-1062

**Shi, W-F.** and Bartlett, J.S. (2008) *Estrogen plays a critical role in AAV2-mediated gene transfer in ovarian cancer* Acta Pharmacol. Sin., **29**, 1440-1450

- Subramanian, I.V.**, Ghebre, R. and Ramakrishnan, S. (2005) *Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice* Gene Ther., **12**, 30-38
- Tahara, I.**, Miyake, K., Hanawa, H., Kurai, T., et al (2007) *Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24* Mol Ther., **15**, 1805-1811
- Takei, Y.**, Mizukami, H., Saga, Y., Yoshimura, I., et al (2006) *Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector* Int. J. Cancer, **120**, 278-284
- Teschendorf, C.**, Emons, B., Muzyczka, N., Graeven, U. and Schmiegel, W. (2010) *Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells* Anticancer Res., **30**, 1931-1936
- Vanrell, L.**, Di Scala, M., Blanco, L., Otano, I., Gil-Farina, I., et al (2011) *Development of a liver-specific Tet-On inducible system for AAV vectors and its application in the treatment of liver cancer* Mol. Ther., **19**, 1245–1253
- Watanabe, M.**, Boyer, J.L. and Crystal, R.G. (2010) *AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors* Gene Ther., **17**, 1042–1051
- Yanamandra, N.**, Kondraganti, S., Gondi, C.S., Gujrati, M., et al (2005) *Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line* Int. J. Cancer, **115**, 998-1005
- Yoo, J.**, Choi, S., Hwang, K-S., Cho, W-K., et al (2006) *Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model* J. Gene Med., **8**, 163-174

### Antibody response to

- Calcedo, R. and Wilson, J.M. (2016) *AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees* Hum. Gene Ther. Clin. Dev., **27**, 79-82

### Antigen presentation/reactivity

- Huang, L-Y.**, Patel, A., Ng, R., Miller, E.B., Halder, S., McKenna, R., Asokan, A. and Agbandje-McKenna, M. (2016) *Characterization of the adeno-associated virus 1 and 6 sialic acid binding site* J. Virol., **90**, 5219-6230
- Perrin, G.Q.**, Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y.P., Terhorst, C., Davidoff, A.M. and Herzog, R.W. (2016) *Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer* Mol. Ther. Meth. Clin. Devel., **3**: 16083
- Tseng, Y-S.**, Gurda, B.L., Chipman, P., McKenna, R., Afione, S., Chiorini, J.A., Muzyczka, N., Olson, N.H. et al (2015) *Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity* J. Virol., **89**, 1794-1808

### Anti-viral activity

- Rothe, D.**, Gisela Wajant, G., Grunert, H-P., Zeichhardt, H., et al (2010) *Rapid Construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30* Oligonucleotides, **20**, 191-198

### Apolipoproteins (see “Lipoprotein related disorders”)

#### Arthritic joint delivery

- Adriaansen, J.**, Tas, S.W., Klarenbeek, P.L., Bakker, A.C., et al (2005) *Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy* Ann. Rheum. Dis., **64**, 1677-1684
- Grimstein, C.**, Choi, Y-K., Satoh, M., Lu, Y., et al (2010) *Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis* J. Gene Med., **12**, 35–44
- Kay, J.D.**, Gouze, E., Oligino, T.J., Gouz, J-N., et al (2009) *Intra-articular gene delivery and expression of interleukin-1Ra mediated by self-complementary adeno-associated virus* J. Gene Med., **11**, 605-614
- Kyostio-Moore, S.**, Piraino, S., Berthelette, P., Moran, N., Serriello, J., Bendele, A., Sookdeo, C., Nambiar, B. et al (2015) *Overexpression of cystatin C in synovium does not reduce synovitis or cartilage degradation in established osteoarthritis* Arthritis Res. Ther., **17**: 5
- Tas, S.W.**, Adriaansen, J., Hajji, N., Bakker, A.C., et al (2006) *Amelioration of arthritis by intraarticular dominant negative IKKβ gene therapy using adeno-associated virus type 5* Hum. Gene Ther., **17**, 821-832
- Watson, R.S.**, Broome, T.A., Levings, P.P., Rice, B.L., et al (2013) *scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints* Gene Ther., **20**, 670–677

### **Arsenic trioxide**

**Mitchell, A.M.**, Li, C. and Samulski, R.J. (2013) *Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo* J. Virol., **87**, 4571–4583

### **Atherosclerosis (see “Lipoprotein related disorders”)**

### **Baculovirus expression system**

**Buclez, P-O.**, Florencio, G.D., Relizani, K., Beley, C., Garcia, L. and Benchaouir, R. (2016) *Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system* Mol. Ther. Meth. Clin. Dev., **3**: 16035

**Steel, M.**, Woodburn, K., Kniffin, T., Gebretsadik, K., Chan, J., Vijay, S., Chen, H., Chalberg, T.W. and Gasmi, N. (2015) *In vitro and in vivo comparability assessment of an AAV vector manufactured by triple transfection in HEK293 cells or in the baculovirus expression system* Hum. Gene Ther., **26**, A70

### **Behavioural changes**

**Chen, J.L.**, Carta, S., Soldado-Magraner, J., Schneider, B.L. and Helmchen, F. (2013) *Behaviour-dependent recruitment of long-range projection neurons in somatosensory cortex* Nature, **499**, 336-340

**Muhia, M.**, Willadt, S., Yee, B.K., Feldon, J., Paterna, J-C., Schwendener, S., Vogt, K., Kennedy, M.B. and Knuese, I. (2012) *Molecular and behavioral changes associated with adult hippocampus-specific SynGAPI knockout* Learn. Mem., **19**, 268-281

### **Bile salt metabolism**

**Boesjes, M.**, Bloks, V.W., Hageman, J., Bos, T., van Dijk, T.H., Havinga, R., Wolters, H., Jonker, J.W., Kuipers, F. and Groen, A.K. (2014) *Hepatic farnesoid X-receptor isoforms  $\alpha 2$  and  $\alpha 4$  differentially modulate bile salt and lipoprotein metabolism in mice* PLoS One, **9**: e115028

### **Blood-brain barrier**

**Foley, C.P.**, Rubin, D.G., Santillan, A., Sondhi, D., Dyke, J.P., Gobin, Y.P., Crystal, R.G. and Ballon, D.J. (2014) *Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption* J. Control. Release, **196**, 71–78

### **Body weight control (see “Obesity”)**

### **Bone disorders**

**Dai, J.** and Rabie, A.B.M. (2007) *The use of recombinant adeno-associated virus for skeletal gene therapy* Orthod. Craniofacial Res., **10**, 1-14

**Kumar, S.**, Mahendra, G., Nagy, T.R. and Ponnazhagan, S. (2004) *Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocomponent mouse model for ex vivo osteoporosis gene therapy* Hum. Gene Ther., **15**, 1197-1206

**Kumar, S.**, Mahendra, G. and Ponnazhagan, S. (2005) *Determination of osteoprogenitor-specific promoter activity in mouse mesenchymal stem cells by recombinant adeno-associated virus transduction* Biochim. Biophys. Acta, **1731**, 95-103

**Kumar, S.**, Nagy, T.R. and Ponnazhagan, S. (2010) *Therapeutic potential of genetically modified adult stem cells for osteopenia* Gene Ther., **17**, 105–116

**Kumar, S.**, Wan, C., Ramaswamy, G., Clemens, T.L. and Ponnazhagan, S. (2010) *Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect* Mol. Ther., **18**, 1026–1034

### **Caffeine, effect of**

Lazarus, M., Shen, H-Y., Cherasse, Y., Qu, W-M., et al (2011) *Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens* J. Neurosci., **31**, 10067–10075

### **Capsid – assembly, specificity, structure, peptide ligand insertion**

**Agbandje-McKenna, M.** and Kleinschmidt, J. (2011) *AAV capsid structure and cell interactions* In Adeno-Associated Virus: Methods and Protocols, Methods Mol. Biol., **807** (ed. Snyder, R.O. and Moullier, P.), Springer Science+Business Media, pp 47-92

**Aslanidi, G.V.**, Rivers, A.E., Ortiz, L., Song, L., et al (2013) *Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?* PLoS One, **8**: e59142



- Aydemir, F.**, Salganik, M., Resztak, J., Singh, J., Bennett, A., Agbandje-McKenna, M. and Muzyczka, N. (2016) *Mutants at the 2-fold interface of adeno-associated virus type 2 (AAV2) structural proteins suggest a role in viral transcription for AAV capsids* J. Virol. **90**, 7196-7204
- Batchu, R.B.**, Gruzdyn, O.V., Kung, S.T., Weaver, D.W., et al (2014) *Novel AAV-DJ capsid tyrosine mutants with enhanced transgene expression in a pancreatic cancer cell line* J. Surg. Res., **186**, 637-638
- Bleker, S.**, Sonntag, F. And Kleinschmidt, J.A. (2005) *Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity* J. Virol., **79**, 2528-2540
- Boucas, J.**, Lux, K., Huber, A., Schievenbusch, S., et al (2009) *Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations* J. Gene Med., **11**, 1103-1113
- Büning, H.**, Perabo, L., Coutelle, O., Quadt-Humme, S. and Hallek, M. (2008) *Recent developments in adeno-associated virus vector technology* J. Gene Med., **10**, 717-733
- Büning, H.**, Bolyard, C.M., Hallek, M. and Bartlett, J.S. (2011) *Modification and labeling of AAV vector particles* In Adeno-Associated Virus: Methods and Protocols, Methods Mol. Biol., **807** (ed. Snyder, R.O. and Moullier, P.), Springer Science+Business Media, pp 273-300
- Chen, C-L.**, Jensen, R.L., Schnepp, B.C., Connell, M.J., et al (2005) *Molecular characterization of adeno-associated viruses infecting children* J. Virol., **79**, 14781-14792
- Chen, Y.H.**, Clafin, K., Geoghegan, J.C. and Davidson, B.L. (2012) *Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease* Mol. Ther., **20**, 1393-1399
- Choudhury, S.R.**, Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A. et al (2016) *Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector* Mol. Ther., **24**, 726-735
- Choudhury, S.R.**, Fitzpatrick, Z., Harris, A.F., Maitland, S.A., Ferreira, J.S., Zhang, Y., Ma, S., Sharma, R.B. et al (2016) *In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy* Mol. Ther., **24**, 1247-1257
- DiPrimio, N.**, Asokan, A., Govindasamy, L., Agbandje-McKenna, M. and Samulski, R.J. (2008) *Surface loop dynamics in adeno-associated virus capsid assembly* J. Virol., **82**, 5178-5189
- Drouin, L.M.**, Lins, B., Janssen, M., Bennett, A., Chipman, P., McKenna, R., Chen, W., Muzyczka, N., Cardone, G., Baker, T.S. and Agbandje-McKenna, M. (2016) *Cryo-electron microscopy reconstruction and stability studies of the wild type and the R432A variant of adeno-associated virus type 2 reveal that capsid structural stability is a major factor in genome packaging* J. Virol., **90**, 8542-8541
- Gabriel, N.**, Hareendran, S., Sen, D., Gadkari, R.A., et al (2013) *Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo* Hum. Gene Ther. Methods, **24**, 80-93
- Gigout, L.**, Rebollo, P., Clement, N., Warrington, K.H., et al (2005) *Altering AAV tropism with mosaic viral capsids* Mol. Ther., **11**, 856-865
- Grieger, J.C.** and Samulski, R.J. (2005) *Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and post-entry steps* J. Virol., **79**, 9933-9944
- Grieger, J.C.**, Snowdy, S. and Samulski, R.J. (2006) *Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly* J. Virol., **80**, 5190-5210
- Greieger, J.C.**, Johnson, J.S., Gurda-Whitaker, B., Agbandje-McKenna, M. and Samulski, R.J. (2007) *Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3 only capsids but not that of fivefold pore mutant virions* J. Virol., **81**, 7833-7843
- Gurda, B.L.**, Raupp, C., Popa-Wagner, R., Naumer, M., et al (2012) *Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8* J. Virol., **86**, 7739-7751
- Gurda, B.L.**, DiMattia, M.A., Miller, E.B., Bennett, A., et al (2013) *Capsid antibodies to different adeno-associated virus serotypes bind common regions* J. Virol., **87**, 9111-9124
- Horowitz, E.D.**, Rahman, K.S., Bower, B.D., Dismuke, D.J., et al (2013) *Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release* J. Virol., **87**, 2994-3002
- Huttner, N.A.**, Girod, A., Perabo, L., Edbauer, D., et al (2003) *Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies* Gene Ther., **10**, 2139-2147
- Judd, J.**, Wei, F., Nguyen, P.Q., Tartaglia, L.J., et al (2012) *Random insertion of mCherry into VP3 domain of adeno-associated virus yields fluorescent capsids with no loss of infectivity* Mol. Ther. Nucleic Acids, **1**, e54
- Kern, A.**, Schmidt, K., Leder, C., Muller, O.J., et al (2003) *Identification of a heparin-binding motif on adeno-associated virus type 2 capsids* J. Virol., **77**, 11072-11081

**Kronenberger, S.**, Böttcher, B., von der Lieth, C.W., Bleker, S. and Kleinschmidt, J.A. (2005) *A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini* J. Virol., **79**, 5296-5303

**Krüger, L.**, Eskerski, H., Dinsart, C., Cornelis, J., et al (2008) *Augmented transgene expression in transformed cells using a parvoviral hybrid vector* Cancer Gene Ther., **15**, 252-267

**Ling, C.**, Li, B., Ma, W. and Srivastava, A. (2016) *Development of optimized AAV serotype vectors for high-efficiency transduction at further reduced doses* Hum. Gene Ther. Meth., **27**, 143-149

**Lux, K.**, Goerlitz, N., Leike, K., Goldnau, D., et al (2004) *Incorporation of the green fluorescent protein into the adeno-associated virus type 2 capsid* Mol. Ther., **9**, Suppl. 1 S8

**Mays, L.E.**, Wang, L., Tenney, R., Bell, P., et al (2013) *Cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33* J. Virol., **87**, 9473-9485

**Michelfelder, S.**, Varadi, K., Raupp, C., Hunger, A., et al (2011) *Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo* PLoS One **6**: e23101 942

**Nam, H-J.**, Gurda, B.L., McKenna, R., Potter, M., et al (2011) *Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking* J. Virol., **85**, 11791-11799

**Naumer, M.**, Ying, Y., Michelfelder, S., Reuter, A., et al (2012) *Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions* Hum. Gene Ther., **23**, 492-507

**Naumer, M.**, Popa-Wagner, R. and Kleinschmidt, J.A. (2012) *Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction* J. Gen. Virol., **93**, 2131-2141

**Nicolson, S.C.** and Samulski, R.J. (2014) *Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus* J. Virol., **88**, 4132-4144

**Nony, P.**, Chadeuf, G., Tessier, J., Moullier, P. and Salvetti, A. (2003) *Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles* J. Virol., **77**, 776-781

**Opie, S.R.**, Warrington, K.H., Agbandje-McKenna, M., Zolotukhin, S. and Muzyczka, N. (2003) *Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding* J. Virol., **77**, 6995-7006

**Peden, C.S.**, Manfredsson, F.P., Reimsnider, S.K., Poirier, A.E., et al (2009) *Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented* Mol. Ther., **17**, 524-537

**Popa-Wagner, R.**, Porwal, M., Kann, M., Reuss, M., et al (2012) *Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry* J. Virol., **86**, 9163-9174

**Raupp, C.**, Naumer, M., Müller, O.J., Gurda, B.L., et al (2012) *The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as post-attachment processing* J. Virol., **86**, 9396-9408

**Salganik, M.**, Venkatakrishnan, B., Bennett, A., Lins, B., Yarbrough, J., et al (2012) *Evidence for pH-dependent protease activity in the adeno-associated virus capsid* J. Virol., **86**, 11877-11885

**Salganik, M.**, Aydemir, F., Nam, H-J., McKenna, R., et al (2014) *Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes* J. Virol., **88**, 1071-1079

**Sen, D.**, Gadkari, R.A., Sudha, G., Gabriel, N., (2013) *Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo* Hum. Gene Ther. Methods, **24**, 104-116

**Shi, W.**, Arnold, G.S. and Bartlett, J.S. (2001) *Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors* Hum. Gene Ther., **12**, 1697-1711

**Stilwell, J.L.** and Samulski, R.J. (2004) *Role of viral vectors and virion shells in cellular gene expression* Mol. Ther., **9**, 337-346

**Van Vliet, K.**, Blouin, V., Agbandje-McKenna, M. and Snyder, R.O. (2006) *Proteolytic mapping of the adeno-associated virus capsid* Mol. Ther., **14**, 809-821

**Van Vliet, K.M.**, Blouin, V., Brument, N., Agbandje-McKenna, M. and Snyder, R.O. (2008) *The role of the adeno-associated virus capsid in gene transfer* Methods Mol Biol., **437**, 51-91

**Wang, Y.**, Ling, C., Song, L., Wang, L., Aslanidi, G.V., et al (2012) *Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation* Hum. Gene Ther. Methods, **23**, 225-233

**Warrington, K.H.**, Gorbatyuk, O.S., Harrison, J.K., Opie, S.R., et al (2004) *Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus* J. Virol., **78**, 6595-6609

**White, A.F.**, Mazur, M., Sorscher, E.J., Zinn, K.R. and Ponnazhagan, S. (2008) *Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells* Hum. Gene Ther., **19**, 1407-1414

**Wu, P.**, Xiao, W., Conlon, T., Hughes, J., et al (2000) *Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism* J. Virol., **74**, 8635-8647

## **Cardiac delivery and cardiomyocytes (see Vascular smooth muscle delivery)**

## **Celiac artery delivery (see Pancreatic cells”)**

## **Central nervous system**

### **Addictive behaviours**

**Zweifel, L.S.**, Argilli, E., Bonci, A. and Palmiter, R.D. (2008) *Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors* Neuron, **59**, 486-496

### **Adrenoleukodystrophy**

**Gong, Y.**, Mu, D., Prabhakar, S., Moser, A., Musolino, P., Ren, J-Q., Breakefield, X.O., Maguire, C.A. and Eichler, F.S. (2015) *Adeno-associated virus serotype 9-mediated gene therapy for X-linked adrenoleukodystrophy* Mol. Ther., **23**, 824–834

### **Age-related effects**

**Bourdenx, M.**, Dovero, S., Engeln, M., Bido, S., Bastide, M.F., Dutheil, N., Vollenweider, I., Baud, L. et al (2015) *Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by  $\alpha$ -synuclein overexpression* Acta Neuropathologica Comm., **3**: 46

**Polinski, N.K.**, Gombash, S.E., Manfredsson, F.P., Lipton, J.W., Kemp, C.J., Cole-Strauss, A., Kanaan, N.M. et al (2015) *Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain* Neurobiol. Aging, **36**, 1110-1120

### **Aldehyde dehydrogenase**

**Mudannayake, J.M.**, Mouravlev, A., Fong, D.M. and Young, D. (2016) *Transcriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transfer* Mol. Ther. Meth. Clin. Devel., **3**: 16075

### **Alzheimer’s disease (see also “Amyloid $\beta$ precursor protein”)**

**Asai, H.**, Ikezu, S., Tsunoda, S., Medalla, M., Luebeck, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S. and Ikezu, T. (2015) *Depletion of microglia and inhibition of exosome synthesis halt tau propagation* Nat. Neurosci., **18**, 1584-1593

**Chu, J.**, Giannopoulos, P.F., Ceballos-Diaz, C., Golde, T.E. and Pratico, D. (2012) *Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice* Mol. Neurodegen., **7**:1

**Condello, C.**, Yuan, P., Schain, A. and Grutzendler, J. (2015) *Microglia constitute a barrier that prevents neurotoxic protofibrillar Ab42 hotspots around plaques* Nat. Commun., **6**: 6176

**Dayton, R.D.**, Wang, D.B., Cain, C.D., Schrott, L.M., et al (2012) *Frontotemporal lobar degeneration-related proteins induce only subtle memory-related deficits when bilaterally overexpressed in the dorsal hippocampus* Exp. Neurol., **233**, 807–814

**Gowrishankar, S.**, Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., De Camilli, P. and Ferguson, S.M. (2015) *Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer’s disease amyloid plaques* Proc. Natl. Acad. Sci. USA, **112**, E3699–E3708

**Hu, J.**, Liu, C-C., Chen, X-F., Zhang, Y-w., Xu, H. and Bu, G. (2015) *Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and  $\beta$  metabolism in apoE4-targeted replacement mice* Mol. Neurodegen., **10**:6

**Jaworski, T.**, Dewachter, I., Lechat, B., Croes, S., et al (2009) *AAV-Tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice* PLoS One, **4**: e2780

**Klein, R.L.**, Dayton, R.D., Tatom, J.B., Diaczynsky, C.G. and Salvatore, M.F. (2008) *Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states* Eur. J. Neurosci., **27**, 1615-1625

**Kou, J.**, Yang, J., Lim, J-E., Pattanayak, A., Song, M., Planque, S., Paul, S. and Fukuchi, K-i. (2015) *Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer’s disease: prophylactic and therapeutic applications* Mol. Neurobiol., **51**, 43–56

**Levites, Y.**, O’Nuallain, B., Puligedda, R.D., Ondrejcek, T., Adekar, S.P., Chen, C., Cruz, P.E., Rosario, A.M. et al (2015) *A human monoclonal IgG that binds  $\beta$  assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo* J. Neurosci., **35**, 6265- 6276

**Ljungberg, M.C.**, Ali, Y.O., Zhu, J., Wu, C-S., et al (2012) *CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy* Hum. Mol. Genet., **21**, 251-267

**Pascual-Lucas, M.**, da Silva, S.V., Di Scala, M., Garcia-Barroso, C., González-Aseguinolaza, G., Mulle, C., Alberini, C.M., Cuadrado-Tejedor, M. and Garcia-Osta, A. (2014) *Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice* EMBO Mol. Med., **6**, 1246-1262

**Ramirez, J.J.**, Poulton, W.E., Knelson, E., Barton, C., et al (2011) *Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory* Behav. Brain Res., **216**, 332–340

**Thinschmidt, J.**, López-Hernández, G.Y., Ren, K., King, M.A., et al (2008) *Modulation of spontaneous hippocampal synaptic events with 5-hydroxyindole, 4OH-GTS-21, and rAAV-mediated  $\alpha 7$  nicotinic receptor gene transfer* Brain Res., **1203**, 51-60

**Wang, D.B.**, Dayton, R.D., Zweig, R.M. and Klein, R.L. (2010) *Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response* Exp. Neurol., **224**, 197–206

**Woodling, N.S.**, Colas, D., Wang, Q., Minhas, P., Panchal, M., Liang, X., Mhatre, S.D., Brown, H., Ko, N., Zagol-Ikapitte, I. et al (2016) *Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice* Brain, **139**, 2063–2081

**Yang, J.**, Pattanayak, A., Song, M., Kou, J., et al (2013) *Muscle-directed anti-A $\beta$  single-chain antibody delivery via AAV1 reduces cerebral A $\beta$  load in an Alzheimer's disease mouse model* J. Mol. Neurosci., **49**, 277–288

**Yang, S.**, Cacquevel, M., Saksida, L.M., Bussey, T.J., Schneider, B.L., Aebischer, P., Melani, R. et al (2015) *Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology* Exp. Neurol., **265**, 48–58

**Zhao, L.**, Gottesdiener, A.J., Parmar, M., Li, M., Kaminsky, S.M., Chiuchiolo, M.J., Sondhi, D., Sullivan, P.M., Holtzman, D.M., Crystal, R.G. and Paul, S.M. (2016) *Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models* Neurobiol. Aging, **44**, 159-172

### Amygdal delivery

**Bahi, A.**, Mineur, Y.S. and Picciotto, M.R. (2009) *Blockade of protein phosphatase 2B activity in the amygdala increases anxiety- and depression-like behaviors in mice* Biol. Psychiatry, **66**, 1139-1146

**Banerjee, A.**, Luong, J.A., Ho, A., Saib, A.O. and Ploski, J.E. (2016) *Overexpression of Homer1a in the basal and lateral amygdala impairs fear conditioning and induces an autism-like social impairment* Mol. Autism, **7**: 16

**De Backer, M.W.A.**, Fitzsimons, C.P., Brans, M.A.D., Luijendijk, M.C.M., et al (2010) *An adeno-associated viral vector transduces the rat hypothalamus and amygdala more efficient than a lentiviral vector* BMC Neurosci., **11**: 81

**Del Boca, C.**, Lutz, P.E., Le Merrer, J., Koebal, P. and Kieffer, B.L. (2012) *Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice* Neuroscience, **218**, 185–195

**De Solis, C.A.**, Holehonnur, R., Banerjee, A., Luong, J.A., Lella, S.K., Ho, A., Pahlavan, B. and Ploski, J.E. (2015) *Viral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioning* Neurobiol. Learn. Mem., **124**, 34–47

**Holehonnur, R.**, Luong, J.A., Chaturvedi, D., Ho, A., et al (2014) *Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala* BMC Neurosci., **15**: 28

**Huang, Y.H.**, Ishikawa, M., Lee, B.R., Nakanishi, N., et al (2011) *Searching for presynaptic NMDA receptors in the nucleus accumbens* J. Neurosci., **31**, 18453–18463

**Kwon, J-T.**, Nakajima, R., Kim, H-S., Jeong, Y., Augustine, G.J. and Han, J-H. (2014) *Optogenetic activation of presynaptic inputs in lateral amygdala forms associative fear memory* Learn. Mem., **21**, 627-633

**Ma, Y-Y.**, Wang, X., Huang, Y., Marie, H., Nestler, E.J., Schlüter, O.M. and Dong, Y. (2016) *Re-silencing of silent synapses unmasks anti-relapse effects of environmental enrichment* Proc. Natl. Acad. Sci. USA, **113**, 5089–5094

**Mineur, Y.S.**, Taylor, S.R. and Picciotto, M.R. (2014) *Calcineurin downregulation in the amygdala is sufficient to induce anxiety-like and depression-like behaviors in C57BL/6J male mice* Biol. Psychiatry, **75**, 991–998

**Tasan, R.O.**, Nguyen, N.K., Weger, S., Sartori, S.B., et al (2010) *The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression* J. Neurosci., **30**, 6282– 6290

**Verma, D.**, Wood, J., Lach, G., Mietzsch, M., Weger, S., Heilbronn, R., Herzog, H., Bonaventure, P., Sperk, G. and Tasan, R.O. (2015) *NPY Y2 receptors in the central amygdala reduce cued but not contextual fear* Neuropharmacology, **99**, 665-674



### Amyloid $\beta$ precursor protein (see also “Alzheimer’s disease”)

- Batista, A.R.**, Sena-Esteves, M. and Saraiva, M.J. (2013) *Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model* Biochim. Biophys. Acta, **1832**, 1183–1193
- Chakrabarty, P.**, Ceballos-Diaz, C., Beccard, A, Janus, C., et al (2010) *IFN- $\gamma$  promotes complement expression and attenuates amyloid plaque deposition in amyloid  $\beta$  precursor protein transgenic mice* J. Immunol., **184**, 5333-5343
- Chu, J.**, Giannopoulos, P.F., Ceballos-Diaz, C., Golde, T.E. and Pratico, D. (2012) *Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice* Mol. Neurodegen., **7**:1
- Fo11, R.**, Braudeau, J., Ludewig, S., Abel, T., Weyer, S.W., Roederer, J-P., Brod6, F., Audrain, M. et al (2016) *Viral gene transfer of APPs $\alpha$  rescues synaptic failure in an Alzheimer’s disease mouse model* Acta Neuropathol., **131**, 247–266
- Fukuchi, K-i.**, Tahara, K., Kim, H-D., Maxwell, A., et al. (2006) *Anti-A $\beta$  single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer’s disease* Neurobiol. Dis., **23**, 502-511
- Gong, Y.**, Meyer, E.M., Meyers, C.A., Klein, R.L., et al (2006) *Memory-related deficits following selective hippocampal expression of Swedish mutation amyloid precursor protein in the rat* Exp. Neurol., **200**, 371-377
- Hu, J.**, Liu, C-C., Chen, X-F., Zhang, Y-w., Xu, H. and Bu, G. (2015) *Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A $\beta$  metabolism in apoE4-targeted replacement mice* Mol. Neurodegen., **10**:6
- Kim, J.**, Miller, V.M., Levites, Y., West, K.J., et al (2008) *BRI2 (ITM2b) inhibits A $\beta$  deposition in vivo* J. Neurosci., **28**, 6030-6036
- Latta, C.H.**, Sudduth, T.L., Weekman, E.M., Brothers, H.M., Abner, E.L., Popa, G.J., Mendenhall, M.D., Gonzalez-Oregon, F. Braun, K. and Wilcock, D.M. (2015) *Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid- $\beta$  using BV2 microglial cells and APP/PS1 transgenic mice* J. Neuroinflam., **12**: 41
- Lawlor, P.A.**, Bland, R.J., Das, P., Price, R.W., et al *Novel rat Alzheimer’s disease models based on AAV-mediated gene transfer to selectively increase hippocampal A $\beta$  levels* Mol. Neurodegener., **2**:11
- Levites, Y.**, Jansen, K., Smithson, L.A., Dakin, R., et al (2006) *Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid $\beta$ , amyloid  $\beta$ 40, and amyloid  $\beta$ 42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice* J. Neurosci., **26**, 11923-11928
- Levites, Y.**, O’Nuallain, B., Puligedda, R.D., Ondrejcek, T., Adekar, S.P., Chen, C., Cruz, P.E., Rosario, A.M. et al (2015) *A human monoclonal IgG that binds A $\beta$  assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo* J. Neurosci., **35**, 6265- 6276
- Liu, Y.**, Studzinski, C., Beckett, T., Guan, H., et al (2009) *Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease* Mol. Ther., **17**, 1381–1386
- Liu, Y.**, Studzinski, C., Beckett, T., Murphy, M.P., et al (2010) *Circulating neprilysin clears brain amyloid* Mol. Cell. Neurosci., **45**, 101–107
- Ludwig, A.**, Blume, J., Diep, T-M., Yuan, J., et al (2009) *Calsyntenins mediate TGN exit of APP in a kinesin-1-dependent manner* Traffic, **10**, 572–589
- Meyer-Luehmann, M.**, Mielke, M., Spires-Jones, T.L., Stoothoff, W., et al (2009) *A reporter of local dendritic translocation shows plaque-related loss of neural system function in APP-transgenic mice* J. Neurosci., **29**, 12636-12640
- Mosser, S.**, Alattia, J-R., Dimitrov, M., Matz, A., Pascual, J., Schneider, B.L. and Fraering, P.C. (2015) *The adipocyte differentiation protein APMAP is an endogenous suppressor of A $\beta$  production in the brain* Hum. Mol. Genet., **24**, 371–382
- Rodríguez-Lebrón, E.**, Gouvion, C.M., Moore, S.A., Davidson, B.L., et al (2009) *Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer’s disease* Mol. Ther., **17**, 1563–1573
- Wang, X.**, Blanchard, J., Kohlbrenner, E., Clement, N., et al (2010) *The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment* FASEB J. **24**, 4420–4432
- Weekman, E.M.**, Sudduth, T.L., Abner, E.L., Popa, G.J., Mendenhal, M.D., Brothers, H.M., Braun, K., Greenstein, A. and Wilcock, D.M. (2014) *Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice* J. Neuroinflam., **11**: 127
- Yang, J.**, Pattanayak, A., Song, M., Kou, J., et al (2013) *Muscle-directed anti-A $\beta$  single-chain antibody delivery via AAV1 reduces cerebral A $\beta$  load in an Alzheimer’s disease mouse model* J. Mol. Neurosci., **49**, 277–288

### Angelman syndrome

- Daily, J.L.**, Nash, K., Jinwal, U., Golde, T., et al (2011) *Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome* PLoS One **6**: e27221

### Antidepressant effect

**Del Boca, C.**, Lutz, P.E., Le Merrer, J., Koebal, P. and Kieffer, B.L. (2012) *Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice* Neuroscience, **218**, 185–195

**Mineur, Y.S.**, Obayemi, A., Wigestrand, M.B., Fote, G.M., et al (2013) *Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior* Proc. Natl. Acad. Sci. USA, **110**, 3573-3578

### Anxiety

**Mineur, Y.S.**, Obayemi, A., Wigestrand, M.B., Fote, G.M., et al (2013) *Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior* Proc. Natl. Acad. Sci. USA, **110**, 3573-3578

**Sink, K.S.**, Chung, A., Ressler, K.J., Davis, M., and Walker, D.L. (2013) *Anxiogenic effects of CGRP within the BNST may be mediated by CRF acting at BNST CRFR1 receptors* Behav. Brain Res., **243**, 286– 293 **Zhu, L-J.**, Li, T-Y., Luo, C-X., Jiang, N., Chang, L., Lin, Y-H., Zhou, H-H., Chen, C., Zhang, Y., Lu, W. et al. (2014) *CAPON-nNOS coupling can serve as a target for developing new anxiolytics* Nat. Med., **9**, 1050-1054

### Arcuate nucleus delivery

**Benskey, M.J.**, Manfredsson, F.P., Lookingland, K.J. and Goudreau, J. L. (2015) *The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure* Neurotoxicology, **46**, 1–11

### Astrocyte delivery

**Drinkut, A.**, Tereshchenko, Y., Schulz, J.B., Bähr, M., et al (2012) *Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery* Mol. Ther., **20**, 534–543

**Li, K.**, Nicaise, C., Sannie, D., Hala, T.J., et al (2014) *Overexpression of the astrocyte glutamate transporter GLT1 exacerbates phrenic motor neuron degeneration, diaphragm compromise, and forelimb motor dysfunction following cervical contusion spinal cord injury* J. Neurosci., **34**, 7622–7638

**Mächler, P.**, Wyss, M.T., Elsayed, M., Stobart, J., Gutierrez, R., von Faber-Castell, A., Kaelin, V., Zuend, M., San Martín, A. et al (2016) *In vivo evidence for a lactate gradient from astrocytes to neurons* Cell Metabolism **23**, 94–102

**Meng, X.**, Yang, F., Ouyang, T., Liu, B., Wu, C. and Jiang, W. (2015) *Specific gene expression in mouse cortical astrocytes is mediated by a 1740bp-GFAP promoter-driven combined adeno-associated virus* Neurosci. Lett., **593**, 45–50

**Shinohara, Y.**, Konno, A., Takahashi, N., Matsuzaki, Y., Kishi, S. and Hirai, H. (2016) *Viral vector-based dissection of marmoset GFAP promoter in mouse and marmoset brains* PLoS One, **11**: e0162023

**Weller, M.L.**, Stone, I.M., Goss, A., Rau, T., Rova, C. and Poulsen, D.J. (2008) *Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia* Neuroscience, **155**, 1204-1211

**Young, D.**, Fong, D.M., Lawlor, P.A., Wu, A., Mouravlev, A., McRae, M., Glass, M., Dragunow, M. and Doring, M.J. (2014) *Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy* Gene Ther., **21**, 1029–1040

### Autism

**Banerjee, A.**, Luong, J.A., Ho, A., Saib, A.O. and Ploski, J.E. (2016) *Overexpression of Homer1a in the basal and lateral amygdala impairs fear conditioning and induces an autism-like social impairment* Mol. Autism, **7**: 16

**Benskey, M.J.**, Manfredsson, F.P., Lookingland, K.J. and Goudreau, J. L. (2015) *The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure* Neurotoxicology, **46**, 1–11

**Rothwell, P.E.**, Fuccillo, M.V., Maxeiner, S., Hayton, S.J., Gokce, O., Lim, B.K., Fowler, S.C., Malenka, R.C. and Südhof, T.C. (2014) *Autism-associated neuroligin-3 mutations commonly impair striatal circuits to boost repetitive behaviors* Cell **158**, 198–212

### Axonal responses

**Alves, J.N.**, Muir, E.M., Andrews, M.R., Ward, A., et al (2014) *AAV vector-mediated secretion of chondroitinase provides a sensitive tracer for axonal arborisations* J. Neurosci. Methods, **227** 107–120

**Kneysberg A.**, Collier, T.J., Manfredsson, F.P. and Kanaan, N.M. (2016) *Quantitative and semi-quantitative measurements of axonal degeneration in tissue and primary neuron cultures* J. Neurosci. Meth., **266**, 32–41

**Van der Kallen, L.R.**, Eggers, R., Ehlert, E.M., Verhaagen, J., Smit, A.B. and van Kesteren, R.E. (2015) *Genetic deletion of the transcriptional repressor NFIL3 enhances axon growth in vitro but not axonal repair in vivo* PLoS One, **10**: e0127163

### Basal ganglia

**Dardou, D.**, Monlezun, S., Foerch, P., Courade, J-P., et al (2013) *A role for Sv2c in basal ganglia functions* Brain Res., **1507**, 61-73

**Dodiya, H.B.**, Bjorklund, T., Stansell III, J., Mandel, R.J., et al (2010) *Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates* Mol. Ther., **18**, 579–587

**Lazarus, M.**, Shen, H-Y., Cherasse, Y., Qu, W-M., et al (2011) *Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens* J. Neurosci., **31**, 10067–10075

### Blood-brain barrier

**Dashkoff, J.**, Lerner, E.P., Truong, N., Klickstein, J.A., Fan, Z., Mu, D., Maguire, C.A., Hyman, B.T. and Hudry, E. (2016) *Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9* Mol. Ther. Meth. Clin. Devel., **3**: 16081

**Mendez-Gomez, H.R.**, Galera-Prat, A., Meyers, C., Chen, W., Singh, J., Carrion-Vazquez, M. and Muzyczka, N. (2015) *Transcytosis in the blood–cerebrospinal fluid barrier of the mouse brain with an engineered receptor/ligand system* Mol. Ther. Methods Clin. Dev., **2**: 15037

**Winner, L.K.**, Beard, H., Hassiotis, S., Lau, A.A., Luck, A.J., Hopwood, J.J. and Hemsley, K.M. (2016) *A preclinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome* Hum. Gene Ther., **27**, 363-375

### Caudate delivery

**Dodiya, H.B.**, Bjorklund, T., Stansell III, J., Mandel, R.J., et al (2010) *Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates* Mol. Ther., **18**, 579–587

### Cerebellum delivery

**Huda, F.**, Fan, Y., Suzuki, M., Konno, A., Matsuzaki, Y., Takahashi, N., Chan, J.K.Y. and Hirai, H. (2016) *Fusion of human fetal mesenchymal stem cells with degenerating cerebellar neurons in spinocerebellar ataxia Type 1 model mice* PLoS One, **11**: e0164202

**Roberts, M.S.**, Macauley, S.L., Wong, A.M., Yilmaz, D., et al (2012) *Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis* J. Inherit. Metab. Dis., **35**, 847–857

**Shinohara, Y.**, Konno, A., Takahashi, N., Matsuzaki, Y., Kishi, S. and Hirai, H. (2016) *Viral vector-based dissection of marmoset GFAP promoter in mouse and marmoset brains* PLoS One, **11**: e0162023

**Sondhi, D.**, Scott, E.C., Chen, A., Hackett, N.R., Wong, A.M.S., Kubiak, A., Nelvagal, H.R., Pearse, Y., Cotman, S.L., Cooper, J.D. and Crystal, R.G. (2014) *Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene* Hum. Gene Ther., **25**, 223–239

**Yoon, S.Y.**, Gay-Antaki, C., Ponde, D.E., Poptani, H., Vite, C.H. and Wolfe, J.H. (2014) *Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene* Mol. Ther. Methods Clin. Dev., **1**, 14016

### Cerebral cortex delivery

**Alves, J.N.**, Muir, E.M., Andrews, M.R., Ward, A., et al (2014) *AAV vector-mediated secretion of chondroitinase provides a sensitive tracer for axonal arborisations* J. Neurosci. Methods, **227** 107–120

**Boudreau, R.L.**, Martins, I. and Davidson, B.L. (2009) *Artificial micro-RNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo* Mol. Ther., **17**, 169–175

**Boudreau, R.L.**, Spengler, R.M. and Davidson, B.L. (2011) *Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease* Mol. Ther., **19**, 2169–2177

**Cao, X.**, Li, L-P., Wang, Q., Wu, Q., et al (2013) *Astrocyte-derived ATP modulates depressive-like behaviors* Nat. Med., **19**, 773-777

**Chen, J.L.**, Carta, S., Soldado-Magraner, J., Schneider, B.L. and Helmchen, F. (2013) *Behaviour-dependent recruitment of long-range projection neurons in somatosensory cortex* Nature, **499**, 336-340

**Chen, J.L.**, Margolis, D.J., Stankov, A., Sumanovski, L.T., Schneider, B.L. and Helmchen, F. (2015) *Pathway-specific reorganization of projection neurons in somatosensory cortex during learning* Nat. Neurosci., **18**, 1101-1108

**Chu, J.**, Giannopoulos, P.F., Ceballos-Diaz, C., Golde, T.E. and Pratico, D. (2012) *Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice* Mol. Neurodegen., **7**:1

**Ellinwood, N.M.**, Ausseil, J., Desmaris, N., Bigou, S., et al (2011) *Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes* Mol. Ther., **19**, 251–259

**Huang, Y.H.**, Ishikawa, M., Lee, B.R., Nakanishi, N., et al (2011) *Searching for presynaptic NMDA receptors in the nucleus accumbens* J. Neurosci., **31**, 18453–18463

**Hutson, T.H.**, Verhaagen, J., Yáñez-Muñoz, R.J. and Moon, L.D.F. (2012) *Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector* Gene Ther., **19**, 49–60

**Janelidze, S.**, Nordström, U., Kügler, S. and Brundin, P. (2014) *Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease* J. Gene Med., **16**, 300–308

**Jara, J.H.**, Genc, B., Cox, G.A., Bohn, M.C., Roos, R.P., Macklis, J.D., Ulupinar, E. and Ozdinler, P.H. (2015) *Corticospinal motor neurons are susceptible to increased ER stress and display profound degeneration in the absence of UCHL1 function* Cerebral Cortex **25**, 4259–4272

**Jaworski, T.**, Dewachter, I., Lechat, B., Croes, S., et al (2009) *AAV-Tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice* PLoS One, **4**: e2780

**Leker, R.R.**, Soldner, F., Velasco, I., Gavin, D.K., et al (2007) *Long-lasting regeneration after ischemia in the cerebral cortex* Stroke, **38**, 153–161

**McBride, J.L.**, Pitzer, M.R., Boudreau, R.L., Dufour, B., et al (2011) *Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease* Mol. Ther., **19**, 2152–2162

**McCown, T.J.** (2006) *Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo* Mol. Ther., **14**, 63–68

**Mendez-Gomez, H.R.**, Galera-Prat, A., Meyers, C., Chen, W., Singh, J., Carrion-Vazquez, M. and Muzyczka, N. (2015) *Transcytosis in the blood–cerebrospinal fluid barrier of the mouse brain with an engineered receptor/ligand system* Mol. Ther. Methods Clin. Dev., **2**: 15037

**Meyer-Luehmann, M.**, Mielke, M., Spires-Jones, T.L., Stoothoff, W., et al (2009) *A reporter of local dendritic translocation shows plaque-related loss of neural system function in APP-transgenic mice* J. Neurosci., **29**, 12636–12640

**Nathanson, J.L.**, Yanagawa, Y., Obata, K. and Callaway, E.M. (2009) *Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors* Neuroscience, **161** 441–450

**Prabhakar, S.**, Goto, J., Zuang, X., Sena-Esteves, M., et al (2013) *Stochastic model of Tsc1 lesions in mouse brain* PLoS One, **8**: e64224

**Roberts, M.S.**, Macauley, S.L., Wong, A.M., Yilmaz, D., et al (2012) *Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis* J. Inher. Metab. Dis., **35**, 847–857

**Shinohara, Y.**, Konno, A., Takahashi, N., Matsuzaki, Y., Kishi, S. and Hirai, H. (2016) *Viral vector-based dissection of marmoset GFAP promoter in mouse and marmoset brains* PLoS One, **11**: e0162023

**Stoica, L.**, Todeasa, S.H., Cabrera, G.T., Salameh, J.S., ElMallah, M.K., Mueller, C., Brown, Jr, R.H., and Sena-Esteves, M. (2016) *Adeno-associated virus–delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model* Ann. Neurol., **79**, 687–700

**Suska, A.**, Lee, B.R., Huang, Y.H., Dong, Y. and Schlüter, O.M. (2013) *Selective presynaptic enhancement of the prefrontal cortex to nucleus accumbens pathway by cocaine* Proc. Natl. Acad. Sci. USA, **110**, 710–718

**Tan, E.M.**, Yamaguchi, Y., Horwitz, G.D., Gosgnach, S., et al (2006) *Selective and quickly reversible inactivation of mammalian neurons in vivo using the Drosophila allatostatin receptor* Neuron, **51**, 157–170

**Tardieu, M.**, Zerah, M., Husson, B., de Bournonville, S., Deiva, K., Adamsbaum, K., Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V. et al (2014) *Intracerebral administration of adeno-associated viral vector Serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with muco-polysaccharidosis type IIIA disease: results of a phase I/II trial* Hum. Gene Ther., **25**, 506–516

**Wang, X.**, Blanchard, J., Kohlbrenner, E., Clement, N., et al (2010) *The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment* FASEB J. **24**, 4420–4432

**Weekman, E.M.**, Sudduth, T.L., Abner, E.L., Popa, G.J., Mendenhall, M.D., Brothers, H.M., Braun, K., Greenstein, A. and Wilcock, D.M. (2014) *Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice* J. Neuroinflamm., **11**: 127

**Winner, L.K.**, Beard, H., Hassiotis, S., Lau, A.A., Luck, A.J., Hopwood, J.J. and Hemsley, K.M. (2016) *A preclinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome* Hum. Gene Ther., **27**, 363–375



### Cerebrospinal fluid delivery

**Pasta, S.**, Akhile, O., Tabron, D., Ting, F., Shackleton, G. and Watson, G. (2015) *Delivery of the 7-dehydrocholesterol reductase gene to the central nervous system using adeno-associated virus vector in a mouse model of Smith-Lemli-Opitz Syndrome* Mol. Genet. Metab. Rep., **4**, 92–98

### Cerebroventricular delivery

**Boender, A.J.**, Koning, N.A., van den Heuvel, J.K., Luijendijk, M.C.M., et al (2014) *AAV-mediated gene transfer of the obesity-associated gene Etv5 in rat midbrain does not affect energy balance or motivated behavior* PLoS One, **9**: e94159

**Carty, N.**, Berson, N., Tillack, K., Thiede, C., Scholz, D., Kottig, K., Sedaghat, Y., Gabrysiak, C. et al (2015) *Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study* PLoS One, **10**: e0123527

**Ceballos-Diaz, C.**, Rosario, A.M., Park, H-J., Chakrabarty, P., Sacino, A., Cruz, P.E., Siemienski, Z., Lara, N. et al (2015) *Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice* Mol. Neurodegener., **10** :25

**Cook, C.**, Kang, S.S., Carlomagno, Y., Lin, W-L., Yue, M., Kurti, A., Shinohara, M., Jansen-West, K., Perkerson, E. et al (2015) *Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model* Hum. Mol. Genet., **24**. 6198-6212

**Dirren, E.**, Towne, C.L., Setola, V., Redmond Jr. D.E., et al (2014) *Intra-cerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord* Hum. Gene Ther., **25**, 109–120

**Gong, Y.**, Mu, D., Prabhakar, S., Moser, A., Musolino, P., Ren, J-Q., Breakefield, X.O., Maguire, C.A. and Eichler, F.S. (2015) *Adeno-associated virus serotype 9-mediated gene therapy for X-linked adrenoleukodystrophy* Mol. Ther., **23**, 824–834

**Kou, J.**, Yang, J., Lim, J-E., Pattanayak, A., Song, M., Planque, S., Paul, S. and Fukuchi, K-i. (2015) *Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications* Mol. Neurobiol., **51**, 43–56

**Levites, Y.**, O'Nuallain, B., Puligedda, R.D., Ondrejcek, T., Adekar, S.P., Chen, C., Cruz, P.E., Rosario, A.M. et al (2015) *A human monoclonal IgG that binds A $\beta$  assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo* J. Neurosci., **35**, 6265- 6276

**Platt, T.L.**, Beckett, T.L., Kohleer, Niedowicz, K.D.M. and Murphy, M.P. (2016) *Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease* Neuroscience **315**, 162–174

**Prabhakar, S.**, Zhang, X., Goto, J., Han, S., Lai, C., Bronson, R., Sena-Estevés, M., Ramesh, V. et al (2015) *Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model* Neurobiol. Dis., **82**, 22–31

**Rosario, A.M.**, Cruz, P.E., Ceballos-Diaz, C., Strickland, M.R., Siemienski, Z., Pardo, M., Schob, K-L., Li, A., Aslanidi, G.V. et al (2016) *Microglia-specific targeting by novel capsid-modified AAV6 vectors* Mol. Ther. Meth. Clin. Dev., **3**: 16026

**Sasaguri, H.**, Chew, J., Xu, Y-F., Gendron, T.F., Garrett, A., Lee, C.W., Jansen-West, K., Bauer, P.O. et al (2016) *The extremeN-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo* Brain Res., **1647**, 57–64

### Cholecystokinin knock-down

**Del Boca, C.**, Lutz, P.E., Le Merrer, J., Koebal, P. and Kieffer, B.L. (2012) *Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice* Neuroscience, **218**, 185–195

### Cholinergic neuron regulation

**Aldrin-Kirk, P.**, Davidsson, M., Holmqvist, S., Li, J-Y. and Björklund, T. (2014) *Novel AAV based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons* PLoS One, **9**: e100869

**Tomioka, T.**, Shimazaki, T., Yamauchi, T., Oki, T., et al (2014) *LIM homeobox 8 (Lhx8) is a key regulator of the cholinergic neuronal function via a tropomyosin receptor kinase A (TrkA)-mediated positive feedback loop* J. Biol. Chem., **289**, 1000–1010

### Chondroitinase

**Alves, J.N.**, Muir, E.M., Andrews, M.R., Ward, A., et al (2014) *AAV vector-mediated secretion of chondroitinase provides a sensitive tracer for axonal arborisations* J. Neurosci. Methods, **227** 107–120

### Circadian system

- Enokja, R.**, Ono, D., Hasan, M.T., Honma, S. et al (2012) *Single-cell resolution fluorescence imaging of circadian rhythms detected with a Nipkow spinning disk confocal system* J. Neurosci. Methods, **207**, 72–79
- Landgraf, D.**, Long, J.E., Proulx, C.D., Barandas, R., Malinow, R. and Welsh, D.K. (2016) *Genetic disruption of circadian rhythms in the suprachiasmatic nucleus causes helplessness, behavioral despair, and anxiety-like behavior in mice* Biol. Psych., **80**, 827–835
- Roybal, K.**, Theobald, D., Graham, A., DiNieri, J.A., et al (2007) *Mania-like behaviour induced by disruption of CLOCK* Proc. Natl. Acad. Sci. USA, **104**, 6406–6411

### Cisterna magna delivery

- Hinderer, C.**, Bell, P., Vite, C.H., Louboutin, J-P., Grant, R., Bote, E., Yu, H., Pukenas, B., Hurst, R. and Wilson, J.M. (2014) *Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna* Mol. Ther. Methods Clin. Dev., **1**: 14051
- Lukashchuk, V.**, Lewis, K.E., Coldicott, I., Grierson, A.J. and Azzouz, M. (2016) *AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice* Mol. Ther. Methods Clin. Dev., **3**: 15055

### Cocaine

- Chandra, R.**, Francis, T.C., Konkalmatt, P., Amgalan, A., Gancarz, A.M., Dietz, D.M. and Lobo, M.K. (2015) *Opposing role for Egr3 in nucleus accumbens cell subtypes in cocaine action* J. Neurosci., **35**, 7927–7937
- Harasta, A.E.**, Power, J.M., von Jonquieres, G., Karl, T., Drucker, D.J., Housley, G.D., Schneider, M. and Klugmann, M. (2015) *Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior* Neuropsychopharmacology, **40**, 1969–1978
- Ma, Y-Y.**, Wang, X., Huang, Y., Marie, H., Nestler, E.J., Schlüter, O.M. and Dong, Y. (2016) *Re-silencing of silent synapses unmasks anti-relapse effects of environmental enrichment* Proc. Natl. Acad. Sci. USA, **113**, 5089–5094
- Murthya, V.**, Gao, Y., Geng, L., LeBrasseur, N.K., et al (2014) *Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice* Vaccine, **32**, 4155–4162
- Neumann, P.A.**, Wang, Y., Yan, Y., Wang, Y., Ishikawa, M., Cui, R., Huang, Y.H. et al (2016) *Cocaine-induced synaptic alterations in thalamus to nucleus accumbens projection* Neuropsychopharmacology, **41**, 2399–2410
- Suska, A.**, Lee, B.R., Huang, Y.H., Dong, Y. and Schlüter, O.M. (2013) *Selective presynaptic enhancement of the prefrontal cortex to nucleus accumbens pathway by cocaine* Proc. Natl. Acad. Sci. USA, **110**, 710–718

### Cognitive aging/defects

- Gerstein, H.**, Lindstrom, M.J. and Burger, C. (2013) *Gene delivery of Homer1c rescues spatial learning in a rodent model of cognitive aging* Neurobiol. Aging, **34**, 1963–1970
- Hall, H.**, Jewett, M., Landeck, N., Nilsson, N., Schagerlof, U., et al (2013) *Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors* PLoS One **8**: e64844

### Corpus callosum

- Francis, J.S.**, Wojtas, I., Markov, V., Gray, S.J., McCown, T.J., Samulski, R.J., Bilaniuk, L.T. Wang, D-J. et al (2016) *N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase* Neurobiol. Dis., **96**, 323–334

### Corticotropin-releasing hormone type 1 receptor

- Bender, J.**, Engholm, M., Ederer, M.S., Breu, J., Möller, T.C., Michalakis, S., Rasko, T. 5, Wanker, E.E. et al (2015) *Corticotropin-releasing hormone receptor type 1 (CRHR1) clustering with MAGUKs is mediated via its C-terminal PDZ binding motif* PLoS One, **10**: e0136768

### CRE

- Deverman, B.E.**, Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W-L., Yang, B., Huber, N., Pasca, S.P. and Gradinaru, V. (2016) *Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain* Nat. Biotech., **34**, 204–209
- Ljungberg, M.C.**, Ali, Y.O., Zhu, J., Wu, C-S., et al (2012) *CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy* Hum. Mol. Genet., **21**, 251–267
- Prabhakar, S.**, Goto, J., Zuang, X., Sena-Esteves, M., et al (2013) *Stochastic model of Tsc1 lesions in mouse brain* PLoS One, **8**: e64224

**Schindler, S.E.,** McCall, J.G., Yan, P., Hyrc, K.L., Li, M., Tucker, C.L., Lee, J-M., Bruchas, M.R. and Diamond, M.I. (2015) *Photo-activatable Cre recombinase regulates gene expression in vivo* Sci. Rep., **5**: 13627  
**Werfel, S.,** Jungmann, A., Lehmann, L., Ksienzyk, J., Bekeredjian, R., Kaya, Z., Leuchs, B., Nordheim, A., Backs, J., Engelhardt, S. et al (2014) *Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase* Cardiovasc. Res., **104**, 15–23

### **Cynomolgus CNS delivery**

**Hinderer, C.,** Bell, P., Vite, C.H., Louboutin, J-P., Grant, R., Bote, E., Yu, H., Pukenas, B., Hurst, R. and Wilson, J.M. (2014) *Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna* Mol. Ther. Methods Clin. Dev., **1**: 14051

### **Delivery and expression in the CNS – methodologies and reviews**

**Brockman, M.L.D.,** Comer, L.A., Hyman, B.T. and Sena-Esteves, M. (2006) *Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain* Neuroscience, **138**, 501-510

**Burger, C.,** Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., et al (2004) *Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2 and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system* Mol. Ther., **10**, 302-317

**Dashkoff, J.,** Lerner, E.P., Truong, N., Klickstein, J.A., Fan, Z., Mu, D., Maguire, C.A., Hyman, B.T. and Hudry, E. (2016) *Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9* Mol. Ther. Meth. Clin. Devel., **3**: 16081

**Davis, A.S.,** Federici, T., Ray, W.C., Boulis, N.M., O'Connor, D., Clark, K.R. and Bartlett, J.S. (2015) *Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery* Neurosurgery, **76**, 216-225

**Dirren, E.** and Schneider, B.L. (2014) *Application of viral vectors to motor neuron disorders* In Viral Vector Approaches in Neurobiology and Brain Diseases, Neuromethods, vol. **82**, (ed. Brambilla, R.) Springer Science+Business Media, LLC, pp 221-242

**Dutheil, N.** and Bezar, E. (2014) *Adeno-associated virus-based vectors* In Viral Vector Approaches in Neurobiology and Brain Diseases, Neuromethods, vol. **82**, (ed. Brambilla, R.) Springer Science+Business Media, LLC, pp 27-49

**Gray, S.J.,** Kalburgi, S.N., McCown, T.J. and Samulski, R.J. (2013) *Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates* Gene Ther., **20**, 450–459

**Klein, R.L.,** Wang, D.B. and King, M.A. (2009) *Versatile somatic gene transfer for modeling neurodegenerative diseases* Neurotox. Res., **16**, 329–342

**Miyake, N.,** Miyake, K., Yamamoto, M., Hirai, Y. and Shimada, T. (2011) *Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors* Brain Res., **1389**, 19-26

**Okada, T.,** Nomoto, T., Shimazaki, K., Lijun, W., et al (2002) *Adeno-associated virus vectors for gene transfer to the brain* Methods, **28**, 237-247

**Paterna, J-C.** and Büeler, H. (2002) *Recombinant adeno-associated virus vector design and gene expression in the mammalian brain* Methods, **28**, 208-218

**Peden, C.S.,** Burger, C., Muzyczka, N. and Mandel, R.J. (2004) *Circulating anti-wild type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain* J. Virol., **78**, 6344-6359

**Peel, A.L.** and Klein, R.L. (2000) *Adeno-associated virus vectors: activity and applications in the CNS* J. Neurosci. Meth., **98**, 95-104

**Ruitenber, M.J.,** Eggers, R., Boer, G.J. and Verhaagen, J. (2002) *Adeno-associated viral vectors as agents for gene delivery: application in disorders and trauma of the central nervous system* Methods, **28**, 182-194

**Tang, W.,** Ehrlich, I., Wolff, S.B.E., Michalski, A-M., Wölfl, S., et al (2009) *Faithful expression of multiple proteins via 2A-peptide self-processing: a versatile and reliable method for manipulating brain circuits* J. Neurosci., **29**, 8621– 8629

**Volpicelli-Daley, L.A.,** Kirik, D., Stokya, L.E., Standaert, D.G. and Hartms A.S., J. Neurochem. (2016) *How can rAAV- $\alpha$ -synuclein and the fibril  $\alpha$ -synuclein models advance our understanding of Parkinson's disease?* J. Neurochem., **139** (Suppl. 1), 131–155

**Van der Perren, A.,** Toelen, J., Taymans, J-M. and Baekelandt, V. (2012) *Using recombinant adeno-associated viral vectors for gene expression in the brain* In Controlled Genetic Manipulations, Neuromethods, vol. **65** (Ed. Morozov, A.) Springer Science+Business Media, pp 47-68

**Wang, C.,** Wang, C-M., Clark, K.R. and Sferra, T.J. (2003) *Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain* Gene Ther., **10**, 1528-1534

## Depression

- Dogra, S.**, Kumar, A., Umrao, D., Sahasrabudhe, A.A. and Yadav, P.M. (2016) *Chronic Kappa opioid receptor activation modulates NR2B: Implication in treatment resistant depression* Sci. Rep., **6**: 33401
- Landgraf, D.**, Long, J.E., Proulx, C.D., Barandas, R., Malinow, R. and Welsh, D.K. (2016) *Genetic disruption of circadian rhythms in the suprachiasmatic nucleus causes helplessness, behavioral despair, and anxiety-like behavior in mice* Biol. Psych., **80**, 827–835
- Mineur, Y.S.**, Taylor, S.R. and Picciotto, M.R. (2014) *Calcineurin downregulation in the amygdala is sufficient to induce anxiety-like and depression-like behaviors in C57BL/6J male mice* Biol. Psychiatry, **75**, 991–998

## DNA bar-code

- Marsic, D., Méndez-Gómez, H.R. and Zolotukhin, S. (2015) *High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing* Mol. Ther. Methods Clin. Dev., **2**:15041

## Dopaminergic neurons

- Crook, Z.R.** and Housman, D.E. (2012) *Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice* Proc. Natl. Acad. Sci. USA, **109**, 7487–7492
- Decressac, M.**, Mattsson, B. and Björklund, A. (2012) *Comparison of the behavioural and histological characteristics of the 6-OHDA and  $\alpha$ -synuclein rat models of Parkinson's disease* Exp. Neurol., **235**, 306–315
- Doucet-Beaupré, H.**, Gilbert, C., Profes, M.S., Chabrat, A., Pacelli, C., Giguère, N., Rioux, V., Charest, J., Deng, Q. et al (2016) *Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons* Proc. Natl. Acad. Sci. USA, **111**, E4387-E4396
- Gong, Y.**, Meyer, E.M., Meyers, C.A., Klein, R.L., et al (2006) *Memory-related deficits following selective hippocampal expression of Swedish mutation amyloid precursor protein in the rat* Exp. Neurol., **200**, 371-377
- Gordon, R.**, Neal, M.L., Luo, J., Langley, M.R., Harischandra, D.S., Panicker, N., Charli, A., Jin, H., Anantharam, V. et al (2016) *Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration* Nat. Comm., **7**: 12932
- Grieder, T.E.**, Herman, M.A., Contet, C., Tan, L.A., Vargas-Perez, H., Cohen, A., Chwalek, M., Maal-Bared, G. et al (2014) *VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation* Nat. Neurosci., **17**, 1751-1758
- Khodr, C.E.**, Pedapati, J., Han, Y. and Bohn, M.C. (2012) *Inclusion of a portion of the native SNCA 30UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra* Develop. Neurobiol., **72**, 906–917
- Klein, R.L.**, Dayton, R.D., Leidenheimer, N.J., Jansen, K., et al (2006) *Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins* Mol. Ther., **13**, 517-527
- McFarland, N.R.**, Dimant, H., Kibuuka, L., Ebrahimi-Fakhari, D., et al (2014) *Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not  $\alpha$ -synuclein-induced neuronal cell loss* PLoS One, **9**: e86048

## DOPA production

- Cederfjäll, E.**, Sahin, G., Kirik, D. and Björklund, T. (2012) *Design of a single AAV vector for co-expression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease* Mol. Ther., **20**, 1315–1326

## Dorsal root ganglia

- Enomoto, M.**, Hirai, T., Kaburagi, H. and Yokota, T. (2016) *Efficient gene suppression in dorsal root ganglia and spinal cord using adeno-associated virus vectors encoding short-hairpin RNA* In SiRNA Delivery Methods: Methods and Protocols, Methods in Molecular Biology, vol. 1364 (eds. Shum, K. and Rossi, J.) Springer Science+Business Media New York, pp 277-290
- Fischer, G.**, Pan, B., Vilceanu, D., Hogan, Q.H. and Yu, H. (2014) *Sustained relief of neuropathic pain by AAV-targeted expression of CBD3 peptide in rat dorsal root ganglion* Gene Ther., **21**, 44–51
- Foust, K.D.**, Poirier, A., Pacak, C.A., Mandel, R.J. and Flotte, T.R. (2008) *Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons* Hum. Gene Ther., **19**, 61-69
- Iwamoto, N.**, Watanabe, A., Yamamoto, M., Miyake, N., et al (2009) *Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1* J. Gene Med., **11**, 498-505
- Jacques, S.J.**, Ahmed, Z., Forbes, A., Douglas, M.R., et al (2012) *AAV8<sub>gfp</sub> preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection* Mol. Cell. Neurosci., **49**, 464–474



**Machida, A.**, Kuwahara, H., Mayra, A., Kubodera, T., et al (2013) *Intraperitoneal administration of AAV9-shRNA inhibits target gene expression in the dorsal root ganglia of neonatal mice* Mol. Pain, **9**:36  
**Sakai, A.**, Saitow, F., Miyake, N., Miyake, K., et al (2013) *miR-7a alleviates the maintenance of neuropathic pain through regulation of neuronal excitability* Brain: **136**, 2738–2750  
**Van der Kallen, L.R.**, Eggers, R., Ehlert, E.M., Verhaagen, J., Smit, A.B. and van Kesteren, R.E. (2015) *Genetic deletion of the transcriptional repressor NFIL3 enhances axon growth in vitro but not axonal repair in vivo* PLoS One, **10**: e0127163

### Down syndrome

**Ortiz-Abalia, J.**, Sahún, I., Altafaj, X., Andreu, N., Estivill, X., Dierssen, M. and Fillat, C. (2008) *Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome* Am. J. Hum. Genet., **83**, 479-488

### Embryonic mesencephalon

**Lehtonen, E.**, Bonnaud, F., Melas, C., Lubansu, A., et al (2002) *AAV2 vectors mediate efficient and sustained transduction of rat embryonic ventral mesencephalon* Neuroreport, **13**, 1503-1507

### Entorhinal cortex

**Ramirez, J.J.**, Poulton, W.E., Knelson, E., Barton, C., et al (2011) *Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory* Behav. Brain Res., **216**, 332–340

### Epilepsy

**Theofilas, P.**, Brar, S., Stewart, K-A., Shen, H-Y., et al (2011) *Adenosine kinase as a target for therapeutic antisense strategies in epilepsy* Epilepsia, **52**, 589–601

**Young, D.**, Fong, D.M., Lawlor, P.A., Wu, A., Mouravlev, A., McRae, M., Glass, M., Dragunow, M. and Durning, M.J. (2014) *Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy* Gene Ther., **21**, 1029–1040

### ER stress

**Filézac de L'Etang, A.**, Maharjan, N., Braña, M.C., Ruegsegger, C., Rehmann, R., Goswami, A., Roos, A., Troost, D. et al (2015) *Marinesco-Sjögren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS* Nat. Neurosci., **18**, 227-238

**Jara, J.H.**, Genc, B., Cox, G.A., Bohn, M.C., Roos, R.P., Macklis, J.D., Ulupinar, E. and Ozdinler, P.H. (2015) *Corticospinal motor neurons are susceptible to increased ER stress and display profound degeneration in the absence of UCHL1 function* Cerebral Cortex **25**, 4259-4272

### Exosome delivery

**Hudry, E.**, Martin, C., Gandhi, S., György, B., Scheffer, D.I., Mu, D., Merkel, S.F., Mingozi, F., Fitzpatrick, Z. et al (2016) *Exosome-associated AAV vector as a robust and convenient neuroscience tool* Gene Ther., **23**, 380–392

### Expression efficiency

**Choi, J-H.**, Yu, N-K., Baek, G-C., Bakes, J., et al (2014) *Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons* Mol. Brain, **7**: 17

### Familial Danish dementia

**Levites, Y.**, O'Nuallain, B., Puligedda, R.D., Ondrejcek, T., Adekar, S.P., Chen, C., Cruz, P.E., Rosario, A.M. et al (2015) *A human monoclonal IgG that binds Aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo* J. Neurosci., **35**, 6265- 6276

### Familial amyloidotic polyneuropathy

**Batista, A.R.**, Gianni, D., Ventosa, M., Coelho, A.V., Almeida, M.R., Sena-Esteves, M. and Saraiva1, M.J. (2014) *Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model* Gene Ther., **21**, 1041–1050

### Fear/fear memory

**De Solis, C.A.**, Holehonnur, R., Banerjee, A., Luong, J.A., Lella, S.K., Ho, A., Pahlavan, B. and Ploski, J.E. (2015) *Viral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioning* Neurobiol. Learn. Mem., **124**, 34–47

**Ho, M.L.**, Judd, J., Kuypers, B.E., Yamagami, M., Wong, F.F. and Suh, J. (2014) *Efficiency of protease-activatable virus nanonodes tuned through incorporation of wild-type capsid subunits* Cell. Mol. Bioeng., **7**, 334–343

**Klaus, F.**, Paterna, J-C., Marzorati, E., Sigrist, H., Götze, L., Schwendener, S., Bergamini, G., Jehli, E., Azzinnari, D. et al (2016) *Differential effects of peripheral and brain tumor necrosis factor on inflammation, sickness, emotional behavior and memory in mice* Brain Behav. Immun., **58**, 310–326

**Verma, D.**, Wood, J., Lach, G., Mietzsch, M., Weger, S., Heilbronn, R., Herzog, H., Bonaventure, P., Sperk, G. and Tasan, R.O. (2015) *NPY Y2 receptors in the central amygdala reduce cued but not contextual fear* Neuropharmacology, **99**, 665-674

### Fluorescent proteins

**Alves, S.**, Bode, J., Bemelmans, A-P., von Kalle, C., Cartier, N. and Tews, B. (2016) *Ultramicroscopy as a novel tool to unravel the tropism of AAV gene therapy vectors in the brain* Sci. Rep., **6**: 28272

**Harvey, A.R.**, Ehlert, E., de Wit, J., Drummond, E.S., et al (2009) *Use of GFP to analyze morphology, connectivity and function of cells in the central nervous system* In Methods in Molecular Biology, Viral Applications of Green Fluorescent Protein, vol. 515 (ed. Hicks B.W.), Humana Perss, Totowa, NJ, pp 63-95

**Heindorf, M.** and Hasan, M.T. (2015) *Fluorescent calcium indicator protein expression in the mouse brain using recombinant adeno-associated viruses* Cold Spring Harb Protoc; doi: 10.1101/pdb.prot087635

**Jacques, S.J.**, Ahmed, Z., Forbes, A., Douglas, M.R., et al (2012) *AAV8<sub>gfp</sub> preferentially targets large diameter dorsal root ganglion neurones after both intra-dorsal root ganglion and intrathecal injection* Mol. Cell. Neurosci., **49**, 464–474

**Klein, R.L.**, Dayton, R.D., Leidenheimer, N.J., Jansen, K., et al (2006) *Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins* Mol. Ther., **13**, 517-527

**Lim, B.K.**, Huang, K.W., Grueter, B.A., Rothwell, P.E. and Malenka, R.C. (2012) *Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens* Nature, **487**, 183-189

**Lux, K.**, Goerlitz, N., Leike, K., Goldnau, D., et al (2004) *Incorporation of the green fluorescent protein into the adeno-associated virus type 2 capsid* Mol. Ther., **9**, Suppl. 1 S8

**Lux, K.**, Goerlitz, N., Schlemminger, S., Perabo, L., et al (2005) *Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking* J. Virol., **79**, 11776-11787

**Marshall, J.D.**, Li, J.Z., Zhang, Y., Gong, Y., St-Pierre, F., Lin, M.Z. and Schnitzer, M.J. (2016) *Cell-type-specific optical recording of membrane voltage dynamics in freely moving mice* Cell, **167**, 1650–1662

**Marsic, D.**, Méndez-Gómez, H.R. and Zolotukhin, S. (2015) *High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing* Mol. Ther. Methods Clin. Dev., **2**:1504

**Peden, C.S.**, Manfredsson, F.P., Reimsnider, S.K., Poirier, A.E., et al (2009) *Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented* Mol. Ther., **17**, 524–537

### Fragile X Mental Retardation Protein

**Tabeta, R.**, Moutin, E., Becker, J.A.J., Heintz, D., Fouillen, L., Flatter, E., Kręzel, E., Alunni, V., Koebel, P. et al (2016) *Fragile X Mental Retardation Protein (FMRP) controls diacylglycerol kinase activity in neurons* Proc. Natl. Acad. Sci. USA, **113**, E3619–E3628

### FTO gene

**van Gestel, M.A.**, Sanders, L.E., de Jong, J.W., Luijendijk, M.C.M. and Adan, J.A.H. (2014) *FTO knockdown in rat ventromedial hypothalamus does not affect energy balance* Physiol. Rep., **2**: e12152

### GABA receptors/GABAergic neurons

**Aoto, J.**, Földy, C., Ciurea Ilcus, S.M., Tabuchi, K. and Südhof, T.C. (2015) *Distinct circuit-dependent functions of presynaptic neurexin-3 at GABAergic and glutamatergic synapses* Nat. Neurosci., **18**, 997-1007

**Hausrat, T.J.**, Muhia, M., Gerrow, K., Thomas, P., Hirdes, W., Tsukita, S., Heisler, F.F., Herich, L., Dubroqua, S. (2015) *Radixin regulates synaptic GABA<sub>A</sub> receptor density and is essential for reversal learning and short-term memory* Nat. Commun., **6**: 6872

**Ito, T.**, Hioki, H., Sohn, J., Okamoto, S., Kaneko, T., Iino, S. and Oliver, D.L. (2015) *Convergence of lemniscal and local excitatory inputs on large GABAergic tectothalamic neurons* J. Comp. Neurol., **523**, 2277–2296

### Gene switch – vifepristone-regulated

**Maddalena, A.**, Tereshchenko, J., Bähr, M. and Kügler, S. (2013) *Adeno-associated virus-mediated, vifepristone-regulated transgene expression in the brain* Mol. Ther. Nucleic Acids **2**: e106

### Genetic mosaicism

**Kim, J.-Y.**, Ash, R.T., Ceballos-Diaz, C., Levites, Y., et al (2013) *Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo* Eur. J. Neurosci., **37**, 1203–1220

### Ghrelin

**Romero-Picó, A.**, Vázquez, M.J., González-Touceda, D., Folgueira, C., et al (2013) *Hypothalamic  $\kappa$ -opioid receptor modulates the orexigenic effect of ghrelin* Neuropsychopharmacology (2013) **38**, 1296–1307

### Glial/glioma/glioblastoma cells (see “Cultured cells”)

### Glutamate metabolism

**Aoto, J.**, Földy, C., Ciurea Ilcus, S.M., Tabuchi, K. and Südhof, T.C. (2015) *Distinct circuit-dependent functions of presynaptic neurexin-3 at GABAergic and glutamatergic synapses* Nat. Neurosci., **18**, 997–1007

**Fitzsimons, H.L.**, Riban, V., Bland, R.J., Wendelken, J.L., et al (2010) *Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat* J. Gene Med., **12**, 385–398

**Konno, A.**, Shuvaev, A.N., Miyake, N., Miyake, K., et al (2014) *Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells* Cerebellum, **13**, 29–41

### Green fluorescent protein techniques (see “Fluorescent proteins”)

### Heat-shock proteins

**Jung, A.E.**, Fitzsimons, H.L., Bland, R.J., During, M.J. and Young, D. (2008) *HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity* Mol. Ther., **16**, 1048–1055

### Hindbrain delivery

**Kanoski, S.E.**, Zhao, S., Guarnieri, D.J., DiLeone, R.J., et al (2012) *Endogenous leptin receptor signaling in the medial nucleus tractus solitarius affects meal size and potentiates intestinal satiation signals* Am. J. Physiol. Endocrinol. Metab., **303**, E496–E503

### Hippocampal basket cells

**Ledri, M.**, Nikitidou, L., Erdelyi, F., Szabo, G., et al (2012) *Altered profile of basket cell afferent synapses in hyper-excitable dentate gyrus revealed by optogenetic and two-pathway stimulations* Eur. J. Neurosci., **36**, 1971–1983

### Hippocampal delivery

**Aoto, J.**, Martinelli, D.C., Malenka, R.C., Tabuchi, K. and Südhof, T.C. (2013) *Presynaptic neurexin-3 alternative splicing trans-synaptically controls postsynaptic AMPA receptor trafficking* Cell, **154**, 75–88

**Aoto, J.**, Földy, C., Ciurea Ilcus, S.M., Tabuchi, K. and Südhof, T.C. (2015) *Distinct circuit-dependent functions of presynaptic neurexin-3 at GABAergic and glutamatergic synapses* Nat. Neurosci., **18**, 997–1007

**Auffenberg, E.**, Jurik, A., Mattusch, C., Stoffel, R., Genewsky, A., Namendorf, C., Schmid, R.M. Rammes, G. et al (2016) *Remote and reversible inhibition of neurons and circuits by small molecule induced potassium channel stabilization* Sci. Rep., **6**: 19293

**Bean, L.A.**, Kumar, A., Rani, A., Guidi, M., Rosario, A.M., Cruz, P.E., Golde, T.E. and Foster, T.C. (2015) *Re-opening the critical window for estrogen therapy* J. Neurosci., **35**, 16077–16093

**Cao, X.**, Li, L-P., Wang, Q., Wu, Q., et al (2013) *Astrocyte-derived ATP modulates depressive-like behaviors* Nat. Med., **19**, 773–777

**Daily, J.L.**, Nash, K., Jinwal, U., Golde, T., et al (2011) *Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome* PLoS One **6**: e27221

**Dayton, R.D.**, Wang, D.B., Cain, C.D., Schrott, L.M., et al (2012) *Frontotemporal lobar degeneration-related proteins induce only subtle memory-related deficits when bilaterally overexpressed in the dorsal hippocampus* Exp. Neurol., **233**, 807–814

**Elagabani, M.N.**, Brisevac, D., Kintscher, M., Pohle, J., Köhr, G., Schmitz, D. and Kornau, H-C. (2016) *Subunit-selective N-methyl-D-aspartate (NMDA) receptor signaling through brefeldin A-resistant Arf guanine nucleotide exchange factors BRAG1 and BRAG2 during synapse maturation* J. Biol. Chem., **291**, 9105–9118

**Fenno, L.E.**, Mattis, J., Ramakrishnan, C., Hyun, M., Lee, S.Y., He, M., Tucciarone, J., Selimbeyoglu, A., Berndt, A., Grosenick, L. et al (2014) *Targeting cells with single vectors using multiple-feature Boolean logic* Nature Meth., **11**, 762–772

- Foll, R.**, Braudeau, J., Ludewig, S., Abel, T., Weyer, S.W., Roederer, J-P., Brod6, F., Audrain, M. et al (2016) *Viral gene transfer of APPsa rescues synaptic failure in an Alzheimer's disease mouse model* Acta Neuropathol., **131**, 247–266
- Fukuchi, K-i.**, Tahara, K., Kim, H-D., Maxwell, A., et al (2006) *Anti- $\beta$  single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease* Neurobiol. Dis., **23**, 502-511
- Gerstein, H.**, O'Riordan, K., Osting, S., Schwarz, M., Burger, C. (2012) *Rescue of synaptic plasticity and spatial learning deficits in the hippocampus of Homer1 knockout mice by recombinant adeno-associated viral gene delivery of Homer1c* Neurobiol. Learn. Mem., **97**, 17–29
- Gerstein, H.**, Lindstrom, M.J. and Burger, C. (2013) *Gene delivery of Homer1c rescues spatial learning in a rodent model of cognitive aging* Neurobiol. Aging, **34**, 1963-1970
- Gong, Y.**, Meyer, E.M., Meyers, C.A., Klein, R.L., et al (2006) *Memory-related deficits following selective hippocampal expression of Swedish mutation amyloid precursor protein in the rat* Exp. Neurol., **200**, 371-377
- Haberman, R.P.**, Samulski, R.J. and McCown, T.J. (2003) *Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion* Nat. Med., **9**, 1076-1080
- Hausrat, T.J.**, Muhia, M., Gerrow, K., Thomas, P., Hirdes, W., Tsukita, S., Heisler, F.F., Herich, L., Dubroqua, S. (2015) *Radixin regulates synaptic GABA<sub>A</sub> receptor density and is essential for reversal learning and short-term memory* Nat. Commun., **6**: 6872
- Kanter-Schlifke, I.**, Georgievska, B., Kirik, D. and Kokaia, M. (2007) *Brain area, age and viral vector-specific glial cell-line-derived neurotrophic factor expression and transport in rat* Neuroreport, **18**, 845-850
- Kanter-Schlifke, I.**, Georgievska, B., Kirik, D. and Kokaia, M. (2007) *Seizure suppression by GDNF gene therapy in animal models of epilepsy* Mol. Ther., **15**, 1106-1113
- Klein, R.L.**, Lin, W-L., Dickson, D.W., Lewis, J., et al (2004) *Rapid neurofibrillary tangle formation after localized gene transfer of mutated Tau* Am. J. Pathol., **164**, 347-353
- Klein, R.L.**, Dayton, R.D., Leidenheimer, N.J., Jansen, K., et al (2006) *Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins* Mol. Ther., **13**, 517-527
- Klein, R.L.**, Dayton, R.D., Tatom, J.B., Henderson, K.M., et al (2008) *AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method* Mol. Ther., **16**, 89-96
- Latta, C.H.**, Sudduth, T.L., Weekman, E.M., Brothers, H.M., Abner, E.L., Popa, G.J., Mendenhall, M.D., Gonzalez-Oregon, F. Braun, K. and Wilcock, D.M. (2015) *Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid- $\beta$  using BV2 microglial cells and APP/PS1 transgenic mice* J. Neuroinflam., **12**: 41
- Ledri, M.**, Nikitidou, L., Erdelyi, F., Szabo, G., et al (2012) *Altered profile of basket cell afferent synapses in hyper-excitable dentate gyrus revealed by optogenetic and two-pathway stimulations* Eur. J. Neurosci., **36**, 1971–1983
- Lee, Y-S.**, Ehninger, D., Zhou, M., Oh, J-Y., Kang, M., Kwak, C., Ryu, H-H., Butz, D., et al (2014) *Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome* Nat. Neurosci., **17**, 1736-1743
- Malmevik, J.**, Petri, R., Klussendorf, T., Knauff, P., Åkerblom, M., Johansson, J., Soneji, S. and Jakobsson, J. (2015) *Identification of the miRNA targetome in hippocampal neurons using RIP-seq* Sci. Rep., **5**:12609
- Malmevik, J.**, Petri, R., Knauff, P., Brattås, P.L., Åkerblom, M. and Jakobsson, J. (2016) *Distinct cognitive effects and underlying transcriptome changes upon inhibition of individual miRNAs in hippocampal neurons* Sci. Rep., **6**: 19879
- Mineur, Y.S.**, Obayemi, A., Wigstrand, M.B., Fote, G.M., et al (2013) *Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior* Proc. Natl. Acad. Sci. USA, **110**, 3573-3578
- Mosser, S.**, Alattia, J-R., Dimitrov, M., Matz, A., Pascual, J., Schneider, B.L. and Fraering, P.C. (2015) *The adipocyte differentiation protein APMAP is an endogenous suppressor of  $\beta$  production in the brain* Hum. Mol. Genet., **24**, 371–382
- Mudannayake, J.M.**, Mouravlev, A., Fong, D.M. and Young, D. (2016) *Transcriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transfer* Mol. Ther. Meth. Clin. Devel., **3**: 16075
- Muhia, M.**, Willadt, S., Yee, B.K., Feldon, J., et al (2012) *Molecular and behavioral changes associated with adult hippocampus-specific SynGAP1 knockout* Learn. Mem., **19**, 268-281
- Mustroph, M.L.**, King, M.A., Klein, R.L. and Ramirez, J.J. (2012) *Adult-onset focal expression of mutated human tau in the hippocampus impairs spatial working memory of rats* Behav. Brain Res., **233**, 141-148
- Oksman, M.**, Wisman, L.A., Jiang, H., Miettinen, P., et al (2013) *Transduced wild-type but not P301S mutated human tau shows hyperphosphorylation in transgenic mice overexpressing A30P mutated human alpha-synuclein* Neurodegenerative Dis., **12**, 91–102
- O'Riordan, K.**, Gerstein, H., Hullinger, R. and Burger, C. (2014) *The role of Homer1c in metabotropic glutamate receptor-dependent long-term potentiation* Hippocampus, **24**, 1-6



**Paradiso, B.**, Marconi, P., Zucchini, S., Berto, E., et al (2009) *Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model* Proc. Natl. Acad. Sci. USA, **106**, 7191–7196

**Pascual-Lucas, M.**, da Silva, S.V., Di Scala, M., Garcia-Barroso, C., González-Aseguinolaza, G., Mulle, C., Alberini, C.M., Cuadrado-Tejedor, M. and Garcia-Osta, A. (2014) *Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice* EMBO Mol. Med., **6**, 1246-1262

**Pietro Paolo, S.**, Paterna, J-C., Büeler, H., Feldon, J. and Yee, B.K. (2007) *Bidirectional changes in water-maze learning following recombinant adenovirus-associated viral vectotr (rAAV)-mediated brain-derived neurotrophic factor expression in the rat hippocampus* Behav. Pharmacol., **18**, 533-547

**Ren, K.**, Thinschmidt, J., Liu, J., Ai, L., et al (2007)  *$\alpha 7$  Nicotinic receptor gene delivery into mouse hippocampal neurons leads to functional receptor expression, improved spatial memory-related performance and tau hyperphosphorylation* Neuroscience, **145**, 314-322

**Roberts, M.S.**, Macauley, S.L., Wong, A.M., Yilmaz, D., et al (2012) *Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis* J. Inherit. Metab. Dis., **35**, 847–857

**Rodríguez-Lebrón, E.**, Gouvion, C.M., Moore, S.A., Davidson, B.L., et al (2009) *Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease* Mol. Ther., **17**, 1563–1573

**Rosario, A.M.**, Cruz, P.E., Ceballos-Diaz, C., Strickland, M.R., Siemienski, Z., Pardo, M., Schob, K-L., Li, A., Aslanidi, G.V. et al (2016) *Microglia-specific targeting by novel capsid-modified AAV6 vectors* Mol. Ther. Meth. Clin. Dev., **3**: 16026

**Schindler, S.E.**, McCall, J.G., Yan, P., Hyrc, K.L., Li, M., Tucker, C.L., Lee, J-M., Bruchas, M.R. and Diamond, M.I. (2015) *Photo-activatable Cre recombinase regulates gene expression in vivo* Sci. Rep., **5**: 13627

**Sondhi, D.**, Scott, E.C., Chen, A., Hackett, N.R., et al (2014) *Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene* Hum. Gene Ther., **25**, 223–239

**Sun, H-S.**, Jackson, M.F., Martin, L.J., Jansen, K., et al (2009) *Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia* Nat. Neurosci., **12**, 1300-1307

**Theofilas, P.**, Brar, S., Stewart, K-A., Shen, H-Y., et al (2011) *Adenosine kinase as a target for therapeutic antisense strategies in epilepsy* Epilepsia, **52**, 589–601

**Thinschmidt, J.**, López-Hernández, G.Y., Ren, K., King, M.A., et al (2008) *Modulation of spontaneous hippocampal synaptic events with 5-hydroxyindole, 4OH-GTS-21, and rAAV-mediated  $\alpha 7$  nicotinic receptor gene transfer* Brain Res., **1203**, 51-60

**Traunmüller, L.**, Bornmann, C. and Scheiffele, P. (2014) *Alternative splicing coupled nonsense-mediated decay generates neuronal cell type-specific expression of SLM proteins* J. Neurosci., **34**, 16755–16761

**Weekman, E.M.**, Sudduth, T.L., Abner, E.L., Popa, G.J., Mendenhal, M.D., Brothers, H.M., Braun, K., Greenstein, A. and Wilcock, D.M. (2014) *Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice* J. Neuroinflamm., **11**: 127

**Weinberg, M.S.**, Blake, B.L. and McCown, T.J. (2013) *Opposing actions of hippocampus TNF $\alpha$  receptors on limbic seizure susceptibility* Exp. Neurol., **247**, 429–437

**Woldemichael, B.T.**, Jawaid, A., Kremer, E.A., Gaur, N., Krol, J., Marchais, A. and Mansuy, I.M. (2016) *The microRNA cluster miR-183/96/182 contributes to long-term memory in a protein phosphatase 1-dependent manner* Nat. Comm., **7**: 12594

**Woodling, N.S.**, Colas, D., Wang, Q., Minhas, P., Panchal, M., Liang, X., Mhatre, S.D., Brown, H., Ko, N., Zagol-Ikapitte, I. et al (2016) *Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice* Brain, **139**, 2063–2081

**Xu, W.**, Morishita, W., Buckmaster, P.S., Pang, Z.P., et al (2012) *Distinct neuronal coding schemes in memory revealed by selective erasure of fast synchronous synaptic transmission* Neuron, **73**, 990-1001

**Yoon, S.Y.**, Gay-Antaki, C., Ponde, D.E., Poptani, H., et al (2014) *Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene* Mol. Ther. Methods Clin. Dev., **1**, 14016

**Young, D.**, Fong, D.M., Lawlor, P.A., Wu, A., Mouravlev, A., McRae, M., Glass, M., Dragunow, M. and During, M.J. (2014) *Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy* Gene Ther., **21**, 1029–1040

**Zeier, Z.**, Kumar, A., Bodhinathan, K., Feller, J.A., et al (2009) *Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome* Gene Ther., **16**, 1122–1129

**Zhu, L-J.**, Li, T-Y., Luo, C-X., Jiang, N., Chang, L., Lin, Y-H., Zhou, H-H., Chen, C., Zhang, Y., Lu, W. et al. (2014) *CAPON-nNOS coupling can serve as a target for developing new anxiolytics* Nat. Med., **9**, 1050-1054

### Homer 1, 1a, 1c

**Banerjee, A.**, Luong, J.A., Ho, A., Saib, A.O. and Ploski, J.E. (2016) *Overexpression of Homer1a in the basal and lateral amygdala impairs fear conditioning and induces an autism-like social impairment* Mol. Autism, **7**: 16

**Gerstein, H.**, O’Riordan, K., Osting, S., Schwarz, M., Burger, C. (2012) *Rescue of synaptic plasticity and spatial learning deficits in the hippocampus of Homer1 knockout mice by recombinant adeno-associated viral gene delivery of Homer1c* Neurobiol. Learn. Mem., **97**, 17–29

**Gerstein, H.**, Lindstrom, M.J. and Burger, C. (2013) *Gene delivery of Homer1c rescues spatial learning in a rodent model of cognitive aging* Neurobiol. Aging, **34**, 1963-1970

### Hsp90

**McFarland, N.R.**, Dimant, H., Kibuuka, L., Ebrahimi-Fakhari, D., et al (2014) *Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not  $\alpha$ -synuclein-induced neuronal cell loss* PLoS One, **9**: e86048

### Huntingdon’s disease

**Alto, L.T.**, Chen, X., Ruhn, K.A., Trevino, I. and Tansey, M.G. (2014) *AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington’s disease* PLoS One, **9**: e96544

**Agustín-Pavón, C.**, Mielcarek, M., Marriga-Canut, M. and Isalan, M. (2016) *Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice* Mol. Neurodegen., **11**: 64

**Boudreau, R.L.**, Spengler, R.M. and Davidson, B.L. (2011) *Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington’s disease* Mol. Ther., **19**, 2169–2177

**Carty, N.**, Berson, N., Tillack, K., Thiede, C., Scholz, D., Kottig, K., Sedaghat, Y., Gabrysiak, C. et al (2015) *Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington’s disease: an in vivo high-content imaging study* PLoS One, **10**: e0123527

**Crook, Z.R.** and Housman, D.E. (2012) *Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice* Proc. Natl. Acad. Sci. USA, **109**, 7487–7492

**Gabery, S.**, Sajjad, M.U., Hult, S., Soyly, R., et al (2012) *Characterization of a rat model of Huntington’s disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors* Eur. J. Neurosci., **36**, 2789–2800

**Garriga-Canut, M.**, Agustín-Pavón, C., Herrmann, F., Sánchez, A., et al (2012) *Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice* Proc. Natl. Acad. Sci. USA, **E3136-E3145**

**McBride, J.L.**, Pitzer, M.R., Boudreau, R.L., Dufour, B., et al (2011) *Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease* Mol. Ther., **19**, 2152–2162

**Rodriguez-Lebron, E.**, Denovan-Wright, E.M., Nash, K., Lewin, A.S. and Mandel, R.J. (2005) *Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice* Mol. Ther., **12**, 618-633

**Southwell, A.L.**, Ko, J. and Patterson, P.H. (2009) *Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease* J. Neurosci., **29**, 13589–13602

**Tang, T-S.**, Guo, C., Wang, H., Chen, X. and Bezprozvanny, I. (2009) *Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington’s disease mouse model* J. Neurosci., **29**, 1257–1266

**Wu, A.**, Fong, D.M. and Young, D. (2015) *Gene therapy for Huntington’s disease* In Neuromethods, **98**, Gene Delivery and Therapy for Neurological Disorders (ed. Bo, X. and Verhaagen, J.) Springer Science+Business Media New York, pp 121-151

### Hypertension

**Shi, P.**, Diez-Freire, C., Jun, J.Y., Qi, Y., et al (2010) *Brain microglial cytokines in neurogenic hypertension* Hypertension, **56**, 297-303

### Hypoglossal neuron delivery

**ElMallah, M.K.**, Falk, D.J., Lane, M.A., Conlon, T.J., et al (2012) *Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9* Hum. Gene Ther. Methods, **23**, 148–156

### Hypothalamus delivery

**De Backer, M.W.A.**, Brans, M.A.D., Luijendijk, M.C., Garner, K.M., et al (2010) *Optimization of adeno-associated viral vector-mediated gene delivery to the hypothalamus* Hum. Gene Ther., **21**, 673–682

- De Backer, M.W.A.**, Fitzsimons, C.P., Brans, M.A.D., Luijendijk, M.C.M., et al (2010) *An adeno-associated viral vector transduces the rat hypothalamus and amygdala more efficient than a lentiviral vector* BMC Neurosci., **11**: 81
- De Backer, M.W.A.**, Brans, M.A.D., van Rozen, A.J., van der Zwaal, E.M., et al (2010) *Suppressor of cytokine signaling 3 knockdown in the mediobasal hypothalamus: counterintuitive effects on energy balance* J. Mol. Endocrinol., **45**, 341–353
- Gabery, S.**, Sajjad, M.U., Hult, S., Soyly, R., et al (2012) *Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors* Eur. J. Neurosci., **36**, 2789–2800
- Ganella, D.E.**, Callander, G.E., Ma, S., Bye, C.R., et al (2013) *Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus* Gene Ther., **20**, 703–716
- Kim, J.D.**, Toda, C., D'Agostino, G., Zeiss, C.J., DiLeone, R.J., Elsworth, J.D., Kibbey, R.G., Chan, O., Harvey, B.K., Richie, C.T. et al (2014) *Hypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice* Proc. Natl. Acad. Sci. USA, **111**, 11876–11881
- Liu, M.**, Blanco-Centurion, C., Konadhode, R., Begum, S., et al (2011) *Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice* J. Neurosci., **31**, 6028–6040
- Rodriguez, S.S.**, Schwerdt, J.I., Barbeito, C.G., Flamini, M.A., Han, Y., Bohn, M.C. and Goya, R.G. (2013) *Hypothalamic IGF-I gene therapy prolongs estrous cyclicity and protects ovarian structure in middle-aged female rats* Endocrinology, **154**, 2166–2173
- Romero-Picó, A.**, Vázquez, M.J., González-Touceda, D., Folgueira, C., et al (2013) *Hypothalamic  $\kappa$ -opioid receptor modulates the orexigenic effect of ghrelin* Neuropsychopharmacology (2013) **38**, 1296–1307
- Van Gestel, M.A.**, van Erp, S., Sanders, L.E., Brans, M.A.D., Luijendijk, M.C.M., Merkestein, M., Pasterkamp, R.J. and Adan, R.A.H. (2014) *shRNA-induced saturation of the microRNA pathway in the rat brain* Gene Ther., **21**, 205–211
- Van Gestel, M.A.**, Boender, A.J., de Vrind, V.A.J., Garner, K.M., et al (2014) *Recombinant adeno-associated virus: efficient transduction of the rat VMH and clearance from blood* PLoS One, **9**: e97639
- van Gestel, M.A.**, Sanders, L.E., de Jong, J.W., Luijendijk, M.C.M. and Adan, J.A.H. (2014) *FTO knockdown in rat ventromedial hypothalamus does not affect energy balance* Physiol. Rep., **2**: e12152

### Hypoxia-ischaemia

- Weller, M.L.**, Stone, I.M., Goss, A., Rau, T., Rova, C. and Poulsen, D.J. (2008) *Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia* Neuroscience, **155**, 1204–1211

### Inflammation

- Humbert-Claude, M.**, Duc, D., Dwir, D., Thieren, L., Sandstrom von Tobel, J., Begka, C., Legueux, F., Velin, D., Maillard, M.H., Do, K.Q., Monnet-Tschudi, F. and Tenenbaum, L. (2016) *Tollip, an early regulator of the acute inflammatory response in the substantia nigra* J. Neuroinflamm., **13**: 303
- Zhuang, G.Z.**, Keeler, B., Grant, J., Bianchi, L., Fu, E.S., Zhang, Y.P., Erasso, D.M., Cui, J-G., Wiltshire, T. et al (2015) *Carbonic anhydrase-8 regulates inflammatory pain by inhibiting the ITPR1-cytosolic free calcium pathway* PLoS One, **10**: e0118273

### Insulin growth factor

- Pascual-Lucas, M.**, da Silva, S.V., Di Scala, M., Garcia-Barroso, C., González-Aseguinolaza, G., Mulle, C., Alberini, C.M., Cuadrado-Tejedor, M. and Garcia-Osta, A. (2014) *Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice* EMBO Mol. Med., **6**, 1246–1262

### Interneuronal DISC1

- Seshadri, S.**, Faust, T., Ishizuka, K., Delevich, K., Chung, Y., Kim, S-H., Cowles, M., Niwa, M. et al (2015) *Interneuronal DISC1 regulates NRG1-ErbB4 signalling and excitatory-inhibitory synapse formation in the mature cortex* Nat. Commun., **6**: 10118

### Intramuscular injection

- Benkhalifa-Ziyyat, S.**, Besse, A., Roda, M., Duque, S., et al (2013) *Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice* Mol. Ther., **21**, 282–290

### Intraventricular injection

**Filézac de L'Étang, A.**, Maharjan, N., Braña, M.C., Ruegsegger, C., Rehmann, R., Goswami, A., Roos, A., Troost, D. et al (2015) *Marinesco-Sjögren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS* Nat. Neurosci., **18**, 227-238

**Huang, X.**, Stodieck, S.K., Goetze, B., Cui, L., Wong, M.H., Wenzel, C., Hosang, L., Dong, Y., Löwel, S. and Schlüter, O.M. (2015) *Progressive maturation of silent synapses governs the duration of a critical period* Proc. Natl. Acad. Sci. USA, E3131–E3140

**Kim, J-Y.**, Ash, R.T., Ceballos-Diaz, C., Levites, Y., et al (2013) *Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo* Eur. J. Neurosci., **37**, 1203–1220

**Valluy, J.**, Bicker, S., Aksoy-Aksel, A., Lackinger, M., Sumer, S., Fiore, R., Wüst, T., Seffer, D. et al (2015) *A coding-independent function of an alternative Ube3a transcript during neuronal development* Nat. Neurosci., **18**, 666-673

**Xu, Y-F.**, Prudencio, M., Hubbard, J.M., Tong, J., et al (2013) *The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43* PLoS One, **8**: e69864

### Invasive glioblastoma

**Crommentuijn, M.H.W.**, Maguire, C.A., Niers, J.M., Vandertop, W.P., Badr, C.E., Wurdinger, T. and Tannous, B.A. (2016) *Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma* Mol. Oncol., **10**, 625-634

### Kappa opioid receptor

**Dogra, S.**, Kumar, A., Umrao, D., Sahasrabudhe, A.A. and Yadav, P.M. (2016) *Chronic Kappa opioid receptor activation modulates NR2B: Implication in treatment resistant depression* Sci. Rep., **6**: 33401

### Lateral septum delivery

**Harasta, A.E.**, Power, J.M., von Jonquieres, G., Karl, T., Drucker, D.J., Housley, G.D., Schneider, M. and Klugmann, M. (2015) *Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior* Neuropsychopharmacology, **40**, 1969–1978

### Lateral ventricle delivery

**Klaus, F.**, Paterna, J-C., Marzorati, E., Sigrist, H., Götze, L., Schwendener, S., Bergamini, G., Jehli, E., Azzinnari, D. et al (2016) *Differential effects of peripheral and brain tumor necrosis factor on inflammation, sickness, emotional behavior and memory in mice* Brain Behav. Immun., **58**, 310–326

### Learning

**Chen, J.L.**, Margolis, D.J., Stankov, A., Sumanovski, L.T., Schneider, B.L. and Helmchen, F. (2015) *Pathway-specific reorganization of projection neurons in somatosensory cortex during learning* Nat. Neurosci., **18**, 1101-1108

### Lipofuscinosis

**Cabrera-Salazar, M.A.**, Roskelley, E.M., Bu, J., Hodges, B.L., et al (2007) *Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile Batten disease* Mol. Ther., **15**, 1782-1788

**Foley, C.P.**, Rubin, D.G., Santillan, A., Sondhi, D., Dyke, J.P., Gobin, Y.P., Crystal, R.G. and Ballou, D.J. (2014) *Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption* J. Control. Release, **196**, 71–78

**Griffey, M.**, Bible, E., Vogler, C., Levy, B., et al (2004) *Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis* Neurobiol. Dis., **16**, 360-369

**Hackett, N.R.**, Redmond, D.E., Sondhi, D., Giannaris, E.L., et al (2005) *Safety of direct administration of AAV2<sub>CH</sub>CLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to brain of rats and nonhuman primates* Hum. Gene Ther., **16**, 1484-1503

**Lojewski, X.**, Staropoli, J.F., Biswas-Legrand, S., Simas, A.M., et al (2014) *Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway* Hum. Mol. Genet., **23**, 2005–2022

**Passini, M.A.**, Dodge, J.C., Bu, J., Yang, W., et al (2006) *Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis* J. Neurosci., **26**, 1334-1342



**Roberts, M.S.**, Macauley, S.L., Wong, A.M., Yilmaz, D., et al (2012) *Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis* J. Inherit. Metab. Dis., **35**, 847–857

**Sondhi, D.**, Peterson, D.A., Giannaris, E.L., Sanders, C.T., et al (2005) *AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL* Gene Ther., **12**, 1618-1632

**Sondhi, D.**, Johnson, L., Purpura, K., Monette, S., et al (2012) *Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis* Hum. Gene Ther. Methods, **23**, 324–335

### Lumbar sensory neurons

**Yu, H.**, Fischer, G., Ferhatovic, L., Fan, F., et al (2013) *Intraganglionic AAV6 Results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats* PLoS One, **8**: e61266

### Major depressive disorder

**Cao, X.**, Li, L-P., Wang, Q., Wu, Q., et al (2013) *Astrocyte-derived ATP modulates depressive-like behaviors* Nat. Med., **19**, 773-777

**Kang, H.J.**, Voleti, B., Hajszan, T., Rajkowska, G., et al (2012) *Decreased expression of synapse-related genes and loss of synapses in major depressive disorder* Nat. Med., **18**, 1413-1419

### Mechanosensory C fibres

**Vrontou, S.**, Wong, A.M., Rau, K.K., Koerber, R. and Anderson, D.J. (2013) *Genetic identification of C fibres that detect massage-like stroking of hairy skin in vivo* Nature, **493**, 669-673

### MECP2 gene

**Gadalla, K.K.E.**, Bailey, M.E.S., Spike, R.C., Ross, P.D., et al (2013) *Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice* Mol. Ther., **21**, 18–30

### Medial entorhinal cortex delivery

**Asai, H.**, Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S. and Ikezu, T. (2015) *Depletion of microglia and inhibition of exosome synthesis halt tau propagation* Nat. Neurosci., **18**, 1584-1593

### Medial septum delivery

**Hall, H.**, Jewett, M., Landeck, N., Nilsson, N., et al (2013) *Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors* PLoS One **8**: e64844

**Klein, R.L.**, Lin, W-L., Dickson, D.W., Lewis, J., et al (2004) *Rapid neurofibrillary tangle formation after localized gene transfer of mutated Tau* Am. J. Pathol., **164**, 347-353

**Tomioaka, T.**, Shimazaki, T., Yamauchi, T., Oki, T., et al (2014) *LIM homeobox 8 (Lhx8) is a key regulator of the cholinergic neuronal function via a tropomyosin receptor kinase A (TrkA)-mediated positive feedback loop* J. Biol. Chem., **289**, 1000–1010

**Wu, K.**, Meyer, E.M., Bennett, J.A., Meyers, C.A., et al (2005) *AAV2/5-mediated NGF gene delivery protects septal cholinergic neurons following axotomy* Brain Res., **1061**, 107-113

### Memory, working

**Hausrat, T.J.**, Muhia, M., Gerrow, K., Thomas, P., Hirdes, W., Tsukita, S., Heisler, F.F., Herich, L., Dubroqua, S. (2015) *Radixin regulates synaptic GABA<sub>A</sub> receptor density and is essential for reversal learning and short-term memory* Nat. Commun., **6**: 6872

**Mustroph, M.L.**, King, M.A., Klein, R.L. and Ramirez, J.J. (2012) *Adult-onset focal expression of mutated human tau in the hippocampus impairs spatial working memory of rats* Behav. Brain Res., **233**, 141-148

**Woldemichael, B.T.**, Jawaid, A., Kremer, E.A., Gaur, N., Krol, J., Marchais, A. and Mansuy, I.M. (2016) *The microRNA cluster miR-183/96/182 contributes to long-term memory in a protein phosphatase 1-dependent manner* Nat. Comm., **7**: 12594

### Microglia

**Condello, C.**, Yuan, P., Schain, A. and Grutzendler, J. (2015) *Microglia constitute a barrier that prevents neurotoxic protofibrillar Ab42 hotspots around plaques* Nat. Commun., **6**: 6176

**Latta, C.H.**, Sudduth, T.L., Weekman, E.M., Brothers, H.M., Abner, E.L., Popa, G.J., Mendenhall, M.D., Gonzalez-Oregon, F. Braun, K. and Wilcock, D.M. (2015) *Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid- $\beta$  using BV2 microglial cells and APP/PS1 transgenic mice* J. Neuroinflam., **12**: 41

#### **Mid-brain delivery**

**Blits, B.**, Derks, S., Twisk, J., Ehlert, E., et al (2010) *Adeno-associated viral vector (AAV)-mediated gene transfer in the red nucleus of the adult rat brain: Comparative analysis of the transduction properties of seven AAV serotypes and lentiviral vectors* J. Neurosci. Meth., **185**, 257–263

**Eisch, A.J.**, Bolanos, C.A., de Wit, J., Simonak, R.D., et al (2003) *Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression* Biol. Psychiatry, **54**, 994-1005

**Eslamboli, A.**, Romero-Ramos, M., Burger, C., Bjorklund, T., et al (2007) *Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain* Brain, **130**, 799-815

**Hayes, M.R.**, Skibicka, K.P., Leichner, T.M., Guarnieri, D.J., et al (2010) *Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema is required for energy balance regulation* Cell Metab., **11**, 77–83

**Hommel, J.D.**, Sears, R.M., Georgescu, D., Simmons, D.L. and DiLeone, R.J. (2003) *Local gene knockdown in the brain using viral-mediated RNA interference* Nat. Med., **9**, 1539-1544

**Polinski, N.K.**, Gombash, S.E., Manfredsson, F.P., Lipton, J.W., Kemp, C.J., Cole-Strauss, A., Kanaan, N.M. et al (2015) *Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain* Neurobiol. Aging, **36**, 1110-1120

#### **Motor coordination**

**Bosch, M.K.**, Carrasquillo, Y., Ransdell, J.L., Kanakamedala, A., Ornitz, D.M. and Nerbonne, J.M. (2015) *Intracellular FGF14 (iFGF14) is required for spontaneous and evoked firing in cerebellar Purkinje neurons and for motor coordination and balance* J. Neurosci., **35**, 6752– 6769

#### **Muscle-neuron delivery**

**ElMallah, M.K.**, Falk, D.J., Lane, M.A., Conlon, T.J., et al (2012) *Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9* Hum. Gene Ther. Methods, **23**, 148–156

#### **Myelin/MBP-deficient neurons**

**Aggarwall, S.**, Snaidero, N., Pähler, G., Frey, S., et al (2013) *Myelin membrane assembly is driven by a phase transition of myelin basic proteins into a cohesive protein meshwork* PLoS Biol., **11**: e1001577

**Lutz, D.**, Loers, G., Kleene, R., Oezen, I., et al (2014) *Myelin basic protein cleaves cell adhesion molecule L1 and promotes neuritogenesis and cell survival* J. Biol. Chem., **289**, 13503–13518

#### **Myenteric neuron delivery**

**Buckinx, R.**, Van Remoortel, S., Gijsbers, R., Waddington, S.N. and Timmermans, J-P. (2016) *Proof-of-concept: neonatal intravenous injection of adenoassociated virus results in successful transduction of myenteric and submucosal neurons in the mouse small and large intestine* Neurogastroenterol. Motil., **28**, 299–305

#### **Narcolepsy**

**Liu, M.**, Blanco-Centurion, C., Konadhode, R., Begum, S., et al (2011) *Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice* J. Neurosci., **31**, 6028–6040

#### **Neonatal – Forebrain**

**Pilpel, N.**, Landeck, N., Klugmann, M., Seeburg, P.H. and Schwarz, M.K. (2009) *Rapid, reproducible transduction of select forebrain regions by targeted recombinant virus injection into the neonatal mouse brain* J. Neurosci. Methods, **182** 55–63

#### **Neonatal - Intracerebroventricular**

**Wolf, D.A.**, Lenander, A.W., Nan, Z., Belur, L.R., et al (2011) *Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I* Neurobiol. Dis., **43**, 123–133

#### **Neuregulin-1**

**Seshadri, S.**, Faust, T., Ishizuka, K., Delevich, K., Chung, Y., Kim, S-H., Cowles, M., Niwa, M. et al (2015) *Interneuronal DISC1 regulates NRG1-ErbB4 signalling and excitatory–inhibitory synapse formation in the mature cortex* Nat. Commun., **6**: 10118

### Neurexins

- Aoto, J.**, Martinelli, D.C., Malenka, R.C., Tabuchi, K. and Südhof, T.C. (2013) *Presynaptic neurexin-3 alternative splicing trans-synaptically controls postsynaptic AMPA receptor trafficking* Cell, **154**, 75–88
- Aoto, J.**, Földy, C., Ciurea Ilcus, S.M., Tabuchi, K. and Südhof, T.C. (2015) *Distinct circuit-dependent functions of presynaptic neurexin-3 at GABAergic and glutamatergic synapses* Nat. Neurosci., **18**, 997–1007

### Neuritogenesis

- Lutz, D.**, Loers, G., Kleene, R., Oezen, I., et al (2014) *Myelin basic protein cleaves cell adhesion molecule L1 and promotes neuritogenesis and cell survival* J. Biol. Chem., **289**, 13503–13518

### Neurodegenerative model

- Cook, C.**, Kang, S.S., Carlomagno, Y., Lin, W-L., Yue, M., Kurti, A., Shinohara, M., Jansen-West, K., Perkerson, E. et al (2015) *Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model* Hum. Mol. Genet., **24**, 6198–6212
- Huda, F.**, Konno, A., Matsuzaki, Y., Goenawan, H., Miyake, K., Shimada, T. and Hirai, H. (2014) *Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model* Mol. Ther. Methods Clin. Dev., **1**: 14032
- Shumar, S.A.**, Fagone, P., Alfonso-Pecchio, A., Gray, J.T., Rehg, J.E., Jackowski, S. and Leonardi, R. (2015) *Induction of neuron-specific degradation of coenzyme A models pantothenate kinase-associated neurodegeneration by reducing motor coordination in mice* PLoS One, **10**: e0130013

### Neuroendocrine responses

- Bender, J.**, Engholm, M., Ederer, M.S., Breu, J., Møller, T.C., Michalakis, S., Rasko, T. 5, Wanker, E.E. et al (2015) *Corticotropin-releasing hormone receptor type 1 (CRHR1) clustering with MAGUKs is mediated via its C-terminal PDZ binding motif* PLoS One, **10**: e0136768

### Neuroglobin expression

- Yu, Z.**, Liu, N., Li, Y., Xu, J. and Wang, X. (2013) *Neuroglobin overexpression inhibits oxygen–glucose deprivation-induced mitochondrial permeability transition pore opening in primary cultured mouse cortical neurons* Neurobiol. Dis., **56**, 95–103

### Neuroinflammation

- Humbert-Claude, M.**, Duc, D., Dwir, D., Thieren, L., Sandstrom von Tobel, J., Begka, C., Legueux, F., Velin, D., Maillard, M.H., Do, K.Q., Monnet-Tschudi, F. and Tenenbaum, L. (2016) *Tollip, an early regulator of the acute inflammatory response in the substantia nigra* J. Neuroinflamm., **13**: 303
- Latta, C.H.**, Sudduth, T.L., Weekman, E.M., Brothers, H.M., Abner, E.L., Popa, G.J., Mendenhall, M.D., Gonzalez-Oregon, F. Braun, K. and Wilcock, D.M. (2015) *Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid- $\beta$  using BV2 microglial cells and APP/PS1 transgenic mice* J. Neuroinflamm., **12**: 41
- Weekman, E.M.**, Sudduth, T.L., Abner, E.L., Popa, G.J., Mendenhall, M.D., Brothers, H.M., Braun, K., Greenstein, A. and Wilcock, D.M. (2014) *Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice* J. Neuroinflamm., **11**: 1

### Neuroigin-3

- Rothwell, P.E.**, Fuccillo, M.V., Maxeiner, S., Hayton, S.J., Gokce, O., Lim, B.K., Fowler, S.C., Malenka, R.C. and Südhof, T.C. (2014) *Autism-associated neuroligin-3 mutations commonly impair striatal circuits to boost repetitive behaviors* Cell **158**, 198–212

### Neuronal communication/circuits/transmission

- Auffenberg, E.**, Jurik, A., Mattusch, C., Stoffel, R., Genewsky, A., Namendorf, C., Schmid, R.M. Rammes, G. et al (2016) *Remote and reversible inhibition of neurons and circuits by small molecule induced potassium channel stabilization* Sci. Rep., **6**: 19293
- Del Pino, I.**, Koch, D., Schemm, R., Qualmann, B., Betz, H. and Paarman, I. (2014) *Proteomic analysis of glycine receptor  $\beta$  Subunit (GlyR $\beta$ )-interacting proteins – evidence for syndapin I regulating synaptic glycone receptors* J. Biol. Chem., **289**, 1396–11409
- Frühbeis, C.**, Fröhlich, D., Kuo, W.P., Amphornrat, J., Thilemann, S., Saab, A.S., Kirchhoff, F., Möbius, W., Goebels, S., Nave, K-A., Schneider, A., Simons, M., Klugmann, M., Trotter, J., Krämer-Albers, E-M., (2013) *Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte–neuron communication* PLoS Biol., **11**: e1001604

**Patzke, C., Acuna, C., Giam, L.R., Wernig, M. and Südhof, T.C. (2016) Conditional deletion of LICAM in human neurons impairs both axonal and dendritic arborization and action potential generation J. Exp. Med.** **213**, 499–515

**Traunmüller, L., Bornmann, C. and Scheiffele, P. (2014) Alternative splicing coupled nonsense-mediated decay generates neuronal cell type-specific expression of SLM proteins J. Neurosci.**, **34**, 16755–16761

### Neuronal differentiation

**Zheng, D., Sabbagh, J.J., Blair, L.J., Darling, A.L., Wen, X. and Dickey, C.A. (2016) MicroRNA-511 binds to FKBP5 mRNA, which encodes a chaperone protein, and regulates neuronal differentiation J. Biol. Chem.**, **291**, 17897–17906

### Neuropathic pain

**Fischer, G., Pan, B., Vilceanu, D., Hogan, Q.H. and Yu, H. (2014) Sustained relief of neuropathic pain by AAV-targeted expression of CBD3 peptide in rat dorsal root ganglion Gene Ther.**, **21**, 44–51

### Neuropeptide function

**Aoki, M., Watanabe, Y., Yoshimoto, K., Tsujimura, A., Yamamoto, T., Kanamura, N. and Tanaka, M. (2016) Involvement of serotonin 2C receptor RNA editing in accumbal neuropeptide Y expression and behavioural despair Eur. J. Neurosci.**, **43**, 1219–1228

**Callander, G.E., Ma, S., Ganella, D.E., Wimmer, V.C., Gundlach, A.L., Thomas, W.G. and Bathgate, R.A.D. (2012) Silencing relaxin-3 in nucleus incertus of adult rodents: a viral vector-based approach to investigate neuropeptide function PLoS One**, **7**: e42300

**Ledri, M., Nikitidou, L., Erdelyi, F., Szabo, G., Kirik, D., Deisseroth, K. and Kokaia, M. (2012) Altered profile of basket cell afferent synapses in hyper-excitable dentate gyrus revealed by optogenetic and two-pathway stimulations Eur. J. Neurosci.**, **36**, 1971–1983

**Lim, B.K., Huang, K.W., Grueter, B.A., Rothwell, P.E. and Malenka, R.C. (2012) Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens Nature**, **487**, 183–189

### Neurotrophic factors

**Barroso-Chinea, P., Cruz-Muros, I., Afonso-Oramas, D., Castro-Hernández, J., Salas-Hernández, J., Chtarto, A., Luis-Ravelo, D., Humbert-Claude, M., Tenenbaum, L. and González-Hernández, T. (2016) Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system Neurobiol. Dis.**, **88**, 44–54

**Chtarto, A., Bockstael, O., Gebara, E., Vermoesen, K., Melas, C., Pythoud, C., Levivier, M., De Witte, O., Luthi-Carter, R., Clinkers, R. and Tenenbaum, L. (2013) An adeno-associated virus-based intracellular sensor of pathological nuclear factor- $\kappa$ B activation for disease-inducible gene transfer PLoS One**, **8**: e53156

**Drinkut, A., Tereshchenko, Y., Schulz, J.B., Bähr, M. and Kügler, S. (2012) Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery Mol. Ther.**, **20**, 534–543

**Gombash, S.E., Lipton, J.W., Collier, T.J., Madhavan, L., Steece-Collier, K., Cole-Strauss, A., Terpstra, B.T., Spieles-Engemann, A.L., Daley, B.F., Wohlgenant, S.L., Thompson, V.B., Manfredsson, F.P., Mandel, D.J. and Sortwell, C.E. (2012) Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model Mol. Ther.**, **20**, 544–554

**Tereshchenko, J., Maddalena, A., Bähr, M. and Kügler, S. (2014) Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease Neurobiol. Dis.**, **65**, 35–42

### Neurovascular delivery

**Körbelin, J., Dogbevia, G., Michelfelder, S., Ridder, D.A., Hunger, A., Wenze, J., Seismann, H., Lampe, M., Bannach, J. et al (2016) A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases EMBO Mol. Med.**, **8**, 609–625

### Nigro-striatal delivery

**Dalkara, D., Kolstad, K.D., Guerin, K.I., Hoffmann, N.V., et al (2011) AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa Mol. Ther.**, **19**, 1602–1608

**Furler, S., Paterna, J-C., Weibel, M. and Büeler, H. (2001) Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons Gene Ther.**, **8**, 864–873

**Gustafsson, E., Andsberg, G., Darsalia, V., Mohapel, P., et al (2003) Anterograde delivery of brain-derived neurotrophic factor to striatum via nigral transduction of recombinant adeno-associated virus increases neuronal death but promotes neurogenic response following stroke Eur. J. Neurosci.**, **17**, 2667–2678



- Klein, R.L.**, King, M.A., Hamby, M.E. and Meyer, E.M. (2002) *Dopaminergic cell loss induced by human A30P  $\alpha$ -synuclein gene transfer to the rat substantia nigra* Hum. Gene Ther., **13**, 605-612
- Klein, R.L.**, Dayton, R.D., Lin, W-L. and Dickson, D.W. (2005) *Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat* Neurobiol. Dis., **20**, 64-73
- Klein, R.L.**, Dayton, R.D., Henderson, K.M. and Petrucelli, L. (2006) *Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model* Neurosci. Lett., **401**, 130-135
- Klein, R.L.**, Dayton, R.D., Tatom, J.B., Diaczynsky, C.G., et al (2008) *Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states* Eur. J. Neurosci., **27**, 1615-1625
- Klein, R.L.**, Dayton, R.D., Terry, T.L., Vascoe, C., et al (2009) *PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models* Brain Res., **1259**, 113-122
- McFarland, N.R.**, Lee, J-S., Hyman, B.T. and McLean, P.J. (2009) *Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5 and 8 in the rat nigrostriatal system* J. Neurochem., **109**, 838-845
- McFarland, N.R.**, Fan, Z., Xu, K., Schwarzschild, M.A., et al (2009)  *$\alpha$ -Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease* J. Neuropathol. Exp. Neurol., **68**, 515-524
- Manfredsson, F.P.**, Burger, C., Sullivan, L.F., Muzyczka, N., et al (2007) *rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease* Exp. Neurol., **207**, 289-301
- Manfredsson, F.P.**, Tumer, N., Erdos, B., Landa, T., et al (2009) *Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity* Mol. Ther., **17**, 980-991
- Paterna, J-C.**, Feldon, J. and Büeler, H. (2004) *Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats* J. Virol., **78**, 6808-6817
- Seo, B.B.**, Nakamura-Ogiso, E., Flotte, T.R., Matsuno-Yagi, A. and Yagi, T. (2006) *In vivo complementation of complex I by the yeast Ndi enzyme* J. Biol. Chem., **281**, 14250-14255
- Tatom, J.B.**, Wang, D.B., Dayton, R.D., Skalli, O., et al (2009) *Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression* Mol. Ther., **17**, 607-613
- Ulusoy, A.**, Sahin, G., Björklund, T., Aebischer, P. and Kirik, D. (2009) *Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons* Mol. Ther., **17**, 1574-1584
- Yasuda, T.**, Miyachi, S., Kitagawa, R., Wada, K., et al (2007) *Neuronal specificity of  $\alpha$ -synuclein toxicity and effect of Parkin co-expression in primates* Neuroscience., **144**, 743-753
- Yasuda, T.**, Nihira, T., Ren, Y-R., Cao, X-Q., et al (2009) *Effects of UCH-L1 on  $\alpha$ -synuclein over-expression mouse model of Parkinson's disease* J. Neurochem., **108**, 932-944

### NMDA receptors

- Elagabani, M.N.**, Brisevac, D., Kintscher, M., Pohle, J., Köhr, G., Schmitz, D. and Kornau, H-C. (2016) *Subunit-selective N-methyl-D-aspartate (NMDA) receptor signaling through brefeldin A-resistant Arf guanine nucleotide exchange factors BRAG1 and BRAG2 during synapse maturation* J. Biol. Chem., **291**, 9105-9118
- Huang, Y.H.**, Ishikawa, M., Lee, B.R., Nakanishi, N., Schlüter, O.M. and Dong, Y. (2011) *Searching for presynaptic NMDA receptors in the nucleus accumbens* J. Neurosci., **31**, 18453-18463
- Vullhorst, D.**, Mitchell, R.M., Keating, C., Roychowdhury, S., Karavanova, I., Tao-Cheng, J-H. and Buonanno, A. (2015) *A negative feedback loop controls NMDA receptor function in cortical interneurons via neuregulin 2/ErbB4 signalling* Nat. Commun., **6**: 7222

### Noonan syndrome

- Lee, Y-S., Ehninger, D., Zhou, M., Oh, J-Y., Kang, M., Kwak, C., Ryu, H-H., Butz, D., et al (2014) *Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome* Nat. Neurosci., **17**, 1736-1743

### Nucleus accumbens

- Aoki, M.**, Watanabe, Y., Yoshimoto, K., Tsujimura, A., Yamamoto, T., Kanamura, N. and Tanaka, M. (2016) *Involvement of serotonin 2C receptor RNA editing in accumbal neuropeptide Y expression and behavioural despair* Eur. J. Neurosci., **43**, 1219-1228
- Dölen, G.**, Darvishzadeh, A., Huang, K.W. and Malenka, R.C. (2013) *Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin* Nature, **501**, 179-184
- Fénéant, L.**, Potel, J., François, C., Sané, F., Douam, F., Belouzard, S., Calland, N., Vausselin, T. et al (2015) *New insights into the understanding of hepatitis C virus entry and cell-to-cell transmission by using the ionophore monensin A* J. Virol., **89**, 8346-8364

- Huang, Y.H.**, Ishikawa, M., Lee, B.R., Nakanishi, N., et al (2011) *Searching for presynaptic NMDA receptors in the nucleus accumbens* J. Neurosci., **31**, 18453–18463
- Lazarus, M.**, Shen, H-Y., Cherasse, Y., Qu, W-M., et al (2011) *Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens* J. Neurosci., **31**, 10067–10075
- Liefhebber, J.M.P.**, Hague, C.V., Zhang, Q., Wakelam, M.J.O. and McLauchlan, J. (2014) *Modulation of triglyceride and cholesterol ester synthesis impairs assembly of infectious hepatitis C virus* J. Biol. Chem., **289**, 21276-21288
- Lim, B.K.**, Huang, K.W., Grueter, B.A., Rothwell, P.E. and Malenka, R.C. (2012) *Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens* Nature, **487**, 183-189
- Neumann, P.A.**, Wang, Y., Yan, Y., Wang, Y., Ishikawa, M., Cui, R., Huang, Y.H. et al (2016) *Cocaine-induced synaptic alterations in thalamus to nucleus accumbens projection* Neuropsychopharmacology, **41**, 2399–2410
- Suska, A.**, Lee, B.R., Huang, Y.H., Dong, Y. and Schlüter, O.M. (2013) *Selective presynaptic enhancement of the prefrontal cortex to nucleus accumbens pathway by cocaine* Proc. Natl. Acad. Sci. USA, **110**, 710-718

### Nucleus incertus

- Callander, G.E.**, Ma, S., Ganella, D.E., Wimmer, V.C., Gundlach, A.L., et al (2012) *Silencing relaxin-3 in nucleus incertus of adult rodents: a viral vector-based approach to investigate neuropeptide function* PLoS One, **7**: e42300

### Oestrous cycle maintenance

- Rodríguez, S.S.**, Schwerdt, J.I., Barbeito, C.G., Flamini, M.A., et al (2013) *Hypothalamic IGF-I gene therapy prolongs estrous cyclicity and protects ovarian structure in middle-aged female rats* Endocrinology, **154**, 2166–2173

### Olfactory bulb

- Suzuki, Y.**, Kiyokage, E., Sohn, J., Hioki, H. and Toida, K. (2015) *Structural basis for serotonergic regulation of neural circuits in the mouse olfactory bulb* J. Comp. Neurol., **523**, 262–280

### Oligodendroglia

- Francis, J.S.**, Wojtas, I., Markov, V., Gray, S.J., McCown, T.J., Samulski, R.J., Bilaniuk, L.T. Wang, D-J. et al (2016) *N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase* Neurobiol. Dis., **96**, 323–334

### Opioid system

- Romero-Picó, A.**, Vázquez, M.J., González-Touceda, D., Folgueira, C., et al (2013) *Hypothalamic  $\kappa$ -opioid receptor modulates the orexigenic effect of ghrelin* Neuropsychopharmacology (2013) **38**, 1296–1307

### Parkinson's disease

- Angot, E.**, Steiner, J.A., Lema Tomé, C.M., Ekström, P., et al (2012) *Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo* PLoS One, **7**: e39465
- Arawaka, S.**, Fukushima, S., Sato, H., Sasaki, A., et al (2014) *Zonisamide attenuates  $\alpha$ -synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease* PLoS One, **9**: e89076
- Arcuri, L.**, Viaro, R., Bido, S., Longo, F., Calcagno, M., Fernagut, P-O., Zaveri, N.T., Calò, G., Bezard, E. and Morari, M. (2016) *Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease* Neurobiol. Dis., **89**, 55–64
- Barroso-Chinea, P.**, Cruz-Muros, I., Afonso-Oramas, D., Castro-Hernández, J., Salas-Hernández, J., Chtarto, A., Luis-Ravelo, D., Humbert-Claude, M., Tenenbaum, L. and González-Hernández, T. (2016) *Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system* Neurobiol. Dis., **88**, 44–54
- Benskey, M.J.**, Manfredsson, F.P., Lookingland, K.J. and Goudreau, J. L. (2015) *The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure* Neurotoxicology, **46**, 1–11
- Björklund, T.**, Carlsson, T., Cederfjäll, E.A., Carta, M. and Kirik, D. (2010) *Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease* Brain, **133**, 496–511
- Buck, K.**, Landeck, N., Ulusoy, A., Majbour, N.K., El-Agnaf, O.M.A. and Kirik, D. (2015) *Ser129 phosphorylation of endogenous  $\alpha$ -synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function* Neurobiol. Dis., **78**, 100–114

- Cederfjäll, E.**, Sahin, G., Kirik, D. and Björklund, T. (2012) *Design of a single AAV vector for co-expression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease* Mol. Ther., **20**, 1315–1326
- Cederfjäll, E.**, Nilsson, N., Sahin, G., Chu, Y., et al (2013) *Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease* Sci. Rep., **3**: 2157
- Chartaro, A.**, Humbert-Claude, M., Bockstaël, O., Das, A.T., Boutry, S., Breger, L.S., Klaver, B., Melas, C., Barroso-Chinea, P. et al (2016) *A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses* Mol. Ther. Meth. Clin. Dev., **5**: 16027
- Danzer, K.M.**, Kranich, L.R., Ruf, W.P., Cagsal-Getkin, O., et al (2012) *Exosomal cell-to-cell transmission of alpha synuclein oligomers* Mol. Neurodegener., **7**: 42
- Decressac, M.**, Ulusoy, A., Mattsson, B., Georgievska, B., et al (2011) *GDNF fails to exert neuroprotection in a rat  $\alpha$ -synuclein model of Parkinson's disease* Brain, **134**, 2302–2311
- Decressac, M.**, Mattsson, B., Lundblad, M., Weikop, P. and Björklund, A. (2012) *Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of  $\alpha$ -synuclein in midbrain dopamine neurons* Neurobiol. Dis., **45**, 939–953
- Decressac, M.**, Mattsson, B. and Björklund, A. (2012) *Comparison of the behavioural and histological characteristics of the 6-OHDA and  $\alpha$ -synuclein rat models of Parkinson's disease* Exp. Neurol., **235**, 306–315
- Decressac, M.**, Mattssona, B., Weikop, P., Lundblad, M., et al (2013) *FEB-mediated autophagy rescues midbrain dopamine neurons from  $\alpha$ -synuclein toxicity* Proc. Soc. Natl. Acad. Sci. USA, E1817–E1826
- Drinkut, A.**, Tereshchenko, Y., Schulz, J.B., Bähr, M. and Kügler, S. (2012) *Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery* Mol. Ther., **20**, 534–543
- Febbraro, F.**, Andersen, K.J., Sanchez-Guajardo, V., Tentillier, A., et al (2013) *Chronic intranasal deferoxamine ameliorates motor defects and pathology in the  $\alpha$ -synuclein rAAV Parkinson's model* Exp. Neurol., **247**, 45–58
- Febbraro, F.**, Sahin, G., Farran, A., Soares, S., et al (2013) *Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease* Neurobiol. Dis., **56**, 47–58
- Fitzsimons, H.L.**, Riban, V., Bland, R.J., Wendelken, J.L., et al (2010) *Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat* J. Gene Med., **12**, 385–398
- Garrido, M.**, Tereshchenko, Y., Zhevtsova, Z., Taschenberger, G., et al (2011) *Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons* Acta Neuropathol., **121**, 475–485
- Gombash, S.E.**, Lipton, J.W., Collier, T.J., Madhavan, L., et al (2012) *Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model* Mol. Ther., **20**, 544–554
- Gordon, R.**, Neal, M.L., Luo, J., Langley, M.R., Harischandra, D.S., Panicker, N., Charli, A., Jin, H., Anantharam, V. et al (2016) *Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration* Nat. Comm., **7**: 12932
- Hasegawa, K.**, Yasuda, T., Shiraishi, C., Fujiwara, K., Przedborski, S., Mochizuki, H. and Yoshikawa, K. (2016) *Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults* Nat. Comm., **7**: 10943
- Humbert-Claude, M.**, Duc, D., Dwir, D., Thieren, L., Sandstrom von Tobel, J., Begka, C., Legueux, F., Velin, D., Maillard, M.H., Do, K.Q., Monnet-Tschudi, F. and Tenenbaum, L. (2016) *Tollip, an early regulator of the acute inflammatory response in the substantia nigra* J. Neuroinflamm., **13**: 303
- Janelidze, S.**, Nordström, U., Kügler, S. and Brundin, P. (2014) *Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease* J. Gene Med., **16**, 300–308
- Jung, A.E.**, Fitzsimons, H.L., Bland, R.J., During, M.J. and Young, D. (2008) *HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity* Mol. Ther., **16**, 1048-1055
- Khodr, C.E.**, Sapru, M.K., Pedapati, J., Han, Y., et al (2011) *An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons* Brain Res., **1395**, 94-107
- Khodr, C.E.**, Pedapati, J., Han, Y. and Bohn, M.C. (2012) *Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra* Develop. Neurobiol., **72**, 906–917
- Klein, R.L.**, King, M.A., Hamby, M.E. and Meyer, E.M. (2002) *Dopaminergic cell loss induced by human A30P  $\alpha$ -synuclein gene transfer to the rat substantia nigra* Hum. Gene Ther., **13**, 605-612
- Klein, R.L.**, Dayton, R.D., Henderson, K.M. and Petrucelli, L. (2006) *Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model* Neurosci. Lett., **401**, 130-135

- Koprich, J.B.**, Johnston, T.H., Reyes, M.G., Sun, X. and Brotchie, J.M. (2010) *Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease* Mol. Neurodegener., **5** :43
- Krumova, P.**, Meulmeester, E., Garrido, M., Tirard, M., et al (2011) *Sumoylation inhibits  $\alpha$ -synuclein aggregation and toxicity* J. Cell Biol., **194**, 49–60
- Landeck, N.**, Hall, H., Ardah, M.T., Majbour, N.K., El-Agnaf, O.M.A., Halliday, G. and Kirik, D. (2016) *A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein* Mol. Neurodegen., **11**: 61
- Leriche, L.**, Björklund, T., Breysse, N., Besret, L., et al (2009) *Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy* J. Neurosci., **29**, 1544–1553
- Lee, B.**, Lee, H., Nam, Y.R., Oh, J.H., et al (2005) *Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models* Gene Ther., **12**, 1215-1222
- McFarland, N.R.**, Fan, Z., Xu, K., Schwarzschild, M.A., et al (2009)  *$\alpha$ -Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease* J. Neuropathol. Exp. Neurol., **68**, 515-524
- Manfredsson, F.P.**, Burger, C., Sullivan, L.F., Muzyczka, N., et al (2007) *rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease* Exp. Neurol., **207**, 289-301
- Manfredsson, F.P.**, Tumer, N., Erdos, B., Landa, T., et al (2009) *Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity* Mol. Ther., **17**, 980-991
- Oksman, M.**, Wisman, L.A., Jiang, H., Miettinen, P., et al (2013) *Transduced wild-type but not P301S mutated human tau shows hyperphosphorylation in transgenic mice overexpressing A30P mutated human alpha-synuclein* Neurodegenerative Dis., **12**, 91–102
- Saal, K.A.**, Koch, J.C., Tatenhorst, L., Szegő, E.M., Toledo Ribas, V., Michel, U., Bähr, M., Tönges, L. and Lingor, P. (2015) *AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo* Neurobiol. Dis., **73**, 150–162
- Sanchez-Guajardo, V.**, Febbraro, F., Kirik, D. and Romero-Ramos, M. (2010) *Microglia acquire distinct activation profiles depending on the degree of  $\alpha$ -synuclein neuropathology in a rAAV based model of Parkinson's disease* PLoS One, **5**: e8784
- Sato, H.**, Arawaka, S., Hara, S., Fukushima, S., et al (2011) *Authentically phosphorylated  $\alpha$ -synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease* J. Neurosci., **31**, 16884–16894
- Seo, B.B.**, Nakamura-Ogiso, E., Flotte, T.R., Matsuno-Yagi, A. and Yagi, T. (2006) *In vivo complementation of complex I by the yeast Ndi enzyme* J. Biol. Chem., **281**, 14250-14255
- Tereshchenko, J.**, Maddalena, A., Bähr, M. and Kügler, S. (2014) *Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease* Neurobiol. Dis., **65**, 35–42
- Ulusoy, A.**, Björklund, T., Hermening, S. and Kirik, D. (2008) *In vivo delivery for development of mammalian models for Parkinson's disease* Exp. Neurol., **209**, 89-100
- Ulusoy, A.**, Febbraro, F., Jensen, P.H., Kirik, D., et al (2010) *Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology* Eur. J. Neurosci., **32**, 409–422
- Ulusoy, A.**, Björklund, T., Buck, K. and Kirik, D. (2012) *Dysregulated dopamine storage increases the vulnerability to  $\alpha$ -synuclein in nigral neurons* Neurobiol. Dis., **47**, 367–377
- Van der Perren, A.**, Toelen, J., Carlon, M., Van den Haute, C., et al (2011) *Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9* Gene Ther., **18**, 517–527
- Van Rompuy, A-S.**, Lobbstaël, E., Van der Perren, A., Van den Haute, C., et al (2014) *Long-term overexpression of human wild-type and T240R mutant parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration* J. Neuropathol. Exp. Neurol., **73**, 159-174
- Volpicelli-Daley, L.A.**, Kirik, D., Stokya, L.E., Standaert, D.G. and Hartms A.S., J. Neurochem. (2016) *How can rAAV- $\alpha$ -synuclein and the fibril  $\alpha$ -synuclein models advance our understanding of Parkinson's disease?* J. Neurochem., **139** (Suppl. 1), 131–155
- Xue, Y-Q.**, Ma, B-F., Zhao, L-R., Tatom, J.B., et al (2010) *AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease* Gene Ther., **17**, 83–94
- Yang, C.**, Yang, W-H., Chen, S-S., Ma, B-F., et al (2013) *Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brain* PLoS One, **8**: e63876
- Yasuda, T.**, Nihira, T., Ren, Y-R., Cao, X-Q., et al (2009) *Effects of UCH-L1 on  $\alpha$ -synuclein over-expression mouse model of Parkinson's disease* J. Neurochem., **108**, 932–944



**Yasuda, T.**, Hayakawa, H., Nihira, T., Ren, Y-R., et al (2011) *Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of parkinson disease* J. Neuropathol. Exp. Neurol., **70**, 686-697

**Yu, H.**, Fischer, G., Ferhatovic, L., Fan, F., et al (2013) *Intraganglionic AAV6 Results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats* PLoS One, **8**: e61266

### Peripheral nervous system

**Chu, Q.**, Moreland, R., Yew, N.S., Foley, J., et al (2008) *Systemic insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy* Mol. Ther., **16**, 1400-1408

**Pleticha, J.**, Jeng-Singh, C., Rezek, R., Zaibak, M. and Beutler, A.S. (2014) *Intraneural convection enhanced delivery of AAVrh20 for targeting primary sensory neurons* Mol. Cell. Neurosci., **60**, 72–80

**Yu, H.**, Fischer, G., Ferhatovic, L., Fan, F., et al (2013) *Intraganglionic AAV6 Results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats* PLoS One, **8**: e61266

### PET imaging

**Yoon, S.Y.**, Gay-Antaki, C., Ponde, D.E., Poptani, H., et al (2014) *Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene* Mol. Ther. Methods Clin. Dev., **1**, 14016

### Potassium channels

**Auffenberg, E.**, Jurik, A., Mattusch, C., Stoffel, R., Genewsky, A., Namendorf, C., Schmid, R.M. Rammes, G. et al (2016) *Remote and reversible inhibition of neurons and circuits by small molecule induced potassium channel stabilization* Sci. Rep., **6**: 19293

### Precursor cells, expression in

**Bockstaal, O.**, Melas, C., Pythoud, C., Levivier, M., et al (2012) *Rapid transgene expression in multiple precursor cell types of adult rat subventricular zone mediated by adeno-associated type 1 vectors* Hum. Gene Ther., **23**, 742–753

### PreBötzing nuclei

**Tan, W.**, Pagliardini, S., Yang, P., Janczewski, W.A. and Feldman, J.L. (2011) *Projections of preBötzing complex neurons in adult rats* J. Comp. Neurol., **518**, 1862–1878

### Pre-frontal cortex

**Kang, H.J.**, Voleti, B., Hajszan, T., Rajkowska, G., et al (2012) *Decreased expression of synapse-related genes and loss of synapses in major depressive disorder* Nat. Med., **18**, 1413-1419

**Seshadri, S.**, Faust, T., Ishizuka, K., Delevich, K., Chung, Y., Kim, S-H., Cowles, M., Niwa, M. et al (2015) *Interneuronal DISC1 regulates NRG1-ErbB4 signalling and excitatory–inhibitory synapse formation in the mature cortex* Nat. Commun., **6**: 10118

### Purkinje neurons

**Bosch, M.K.**, Nerbonne, J.M., Ornitz, D.M. (2014) *Dual transgene expression in murine cerebellar Purkinje neurons by viral transduction in vivo*. PloS One, **9**: e104062

**Bosch, M.K.**, Carrasquillo, Y., Ransdell, J.L., Kanakamedala, A., Ornitz, D.M. and Nerbonne, J.M. (2015) *Intracellular FGF14 (iFGF14) is required for spontaneous and evoked firing in cerebellar Purkinje neurons and for motor coordination and balance* J. Neurosci., **35**, 6752–6769

**Boudreau, R.L.**, Martins, I. and Davidson, B.L. (2009) *Artificial micro-RNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo* Mol. Ther., **17**, 169–175

**Chen, K.A.**, Cruz, P.E., Lanuto, D.J., Flotte, T.R., et al (2011) *Cellular fusion for gene delivery to SCA1 affected Purkinje neurons* Mol. Cell. Neurosci., **47**, 61–70

**Kim, J-Y.**, Ash, R.T., Ceballos-Diaz, C., Levites, Y., et al (2013) *Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo* Eur. J. Neurosci., **37**, 1203–1220

**Konno, A.**, Shuvaev, A.N., Miyake, N., Miyake, K., et al (2014) *Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells* Cerebellum, **13**, 29–41

**Sawada, Y.**, Konno, A., Nagaoka, J. and Hirai, H. (2016) *Inflammation-induced reversible switch of the neuron-specific enolase promoter from Purkinje neurons to Bergmann glia* Sci. Rep., **6**: 27758

### Retrograde delivery

**ElMallah, M.K.**, Falk, D.J., Lane, M.A., Conlon, T.J., et al (2012) *Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9* Hum. Gene Ther. Methods, **23**, 148–156

### Rett syndrome

**Gadalla, K.K.E.**, Bailey, M.E.S., Spike, R.C., Ross, P.D., et al (2013) *Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice* Mol. Ther., **21**, 18–30

### Schwann cells/Schwannomas

**Homs, J.**, Ariza, L., Pagès, G., Udina, E., et al (2011) *Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration* Gene Ther., **18**, 622–630

**Prabhakar, S.**, Taherian, M., Gianni, D., Conlon, T.J., et al (2013) *Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1* Hum. Gene Ther., **24**, 152–162

### Sciatic nerve

**Homs, J.**, Ariza, L., Pagès, G., Udina, E., et al (2011) *Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration* Gene Ther., **18**, 622–630

**Homs, J.**, Pagès, G., Ariza, L., Casas, C., et al (2014) *Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy* Mol. Ther. Methods Clin. Dev., **1**: 7

**Prabhakar, S.**, Taherian, M., Gianni, D., Conlon, T.J., et al (2013) *Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1* Hum. Gene Ther., **24**, 152–162

**Unzu, C.**, Sampedro, A., Mauleón, I., Alegre, M., et al (2011) *Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice* Mol. Ther., **19**, 243–250

**Zhuang, G.Z.**, Keeler, B., Grant, J., Bianchi, L., Fu, E.S., Zhang, Y.P., Erasso, D.M., Cui, J-G., Wiltshire, T. et al (2015) *Carbonic anhydrase-8 regulates inflammatory pain by inhibiting the ITPR1-cytosolic free calcium pathway* PLoS One, **10**: e0118273

### Seizures

**Ledri, M.**, Nikitidou, L., Erdelyi, F., Szabo, G., et al (2012) *Altered profile of basket cell afferent synapses in hyper-excitable dentate gyrus revealed by optogenetic and two-pathway stimulations* Eur. J. Neurosci., **36**, 1971–1983

### Serotonin

**Aoki, M.**, Watanabe, Y., Yoshimoto, K., Tsujimura, A., Yamamoto, T., Kanamura, N. and Tanaka, M. (2016) *Involvement of serotonin 2C receptor RNA editing in accumbal neuropeptide Y expression and behavioural despair* Eur. J. Neurosci., **43**, 1219–1228

**Dölen, G.**, Darvishzadeh, A., Huang, K.W. and Malenka, R.C. (2013) *Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin* Nature, **501**, 179–184

**Suzuki, Y.**, Kiyokage, E., Sohn, J., Hioki, H. and Toida, K. (2015) *Structural basis for serotonergic regulation of neural circuits in the mouse olfactory bulb* J. Comp. Neurol., **523**, 262–280

### Social behaviour

**Dölen, G.**, Darvishzadeh, A., Huang, K.W. and Malenka, R.C. (2013) *Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin* Nature, **501**, 179–184

### Somatosensory neurons

**Mächler, P.**, Wyss, M.T., Elsayed, M., Stobart, J., Gutierrez, R., von Faber-Castell, A., Kaelin, V., Zuend, M., San Martín, A. et al (2016) *In vivo evidence for a lactate gradient from astrocytes to neurons* Cell Metabolism **23**, 94–102

**Vrontou, S.**, Wong, A.M., Rau, K.K., Koerber, R. and Anderson, D.J. (2013) *Genetic identification of C fibres that detect massage-like stroking of hairy skin in vivo* Nature, **493**, 669–673

### Spinal cord

**Benkhalifa-Ziyyat, S.**, Besse, A., Roda, M., Duque, S., et al (2013) *Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice* Mol. Ther., **21**, 282–290

**Burger, C.**, Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., et al (2004) *Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2 and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system* Mol. Ther., **10**, 302-317

**Challagundla, M.**, Koch, J.C., Ribas, V.T., Michel, U., Kugler, S., Ostendorf, T., Bradke, F., Muller, H.W., Bahr, M. and Lingor, P. (2015) *AAV-mediated expression of BAG1 and ROCK2shRNA promote neuronal survival and axonal sprouting in a rat model of rubrospinal tract injury* J. Neurochem., **134**, 261-275

**Cheah, M.**, Andrews, M.R., Chew, D.J., Moloney, E.B., Verhaagen, J., Fässler, R. and Fawcett, J.W. (2016) *Expression of an activated integrin promotes long-distance sensory axon regeneration in the spinal cord* J. Neurosci., **36**, 7283–7297

**Chen, J.**, Lee, H.J., Jakovcevski, I., Shah, R., et al (2010) *The extracellular matrix glycoprotein tenascin-C is beneficial for spinal cord regeneration* Mol. Ther., **18**, 1769–1777

**Dirren, E.**, Towne, C.L., Setola, V., Redmond Jr. D.E., et al (2014) *Intra-cerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord* Hum. Gene Ther., **25**, 109–120

**Dirren, E.**, Aebischer, J., Rochat, C., Towne, C., Schneider, B.L. and Aebischer, P. (2015) *SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice* Ann. Clin. Transl. Neurol., **2**, 167–184

**Dominguez, E.**, Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., et al (2011) *Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice* Hum. Mol. Genet., **20**, 681–693

**Eaton, M.J.**, Blits, B., Ruitenber, M.J., Verhaagen, J. and Oudega, M. (2002) *Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord* Gene Ther., **9**, 1387-1395

**Ehlert, E.M.**, Eggers, R., Niclou, S.P. and Verhaagen, J. (2010) *Cellular toxicity following application of adeno associated viral vector-mediated RNA interference in the nervous system* BMC Neurosci., **11**:20

**Enomoto, M.**, Hirai, T., Kaburagi, H. and Yokota, T. (2016) *Efficient gene suppression in dorsal root ganglia and spinal cord using adeno-associated virus vectors encoding short-hairpin RNA* In SiRNA Delivery Methods: Methods and Protocols, Methods in Molecular Biology, vol. 1364 (eds. Shum, K. and Rossi, J.) Springer Science+Business Media New York, pp 277-290

**Filézac de L'Etang, A.**, Maharjan, N., Braña, M.C., Ruegsegger, C., Rehmann, R., Goswami, A., Roos, A., Troost, D. et al (2015) *Marinesco-Sjögren syndrome protein SLL1 regulates motor neuron subtype-selective ER stress in ALS* Nat. Neurosci., **18**, 227-238

**Foust, K.D.**, Poirier, A., Pacak, C.A., Mandel, R.J. and Flotte, T.R. (2008) *Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons* Hum. Gene Ther., **19**, 61-69

**Foust, K.D.**, Flotte, T.R., Reier, P.J. and Mandel, R.J. (2008) *Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat* Hum. Gene Ther., **19**, 71-81

**Homs, J.**, Pagès, G., Ariza, L., Casas, C., et al (2014) *Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy* Mol. Ther. Methods Clin. Dev., **1**: 7

**Hutson, T.H.**, Verhaagen, J., Yáñez-Muñoz, R.J. and Moon, L.D.F. (2012) *Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector* Gene Ther., **19**, 49–60

**Jara, J.H.**, Villa, S.R., Khan, N.A., Bohn, M.C. and Özdinler, P.H. (2012) *AAV2 mediated retrograde transduction of corticospinal motor neurons reveals initial and selective apical dendrite degeneration in ALS* Neurobiol. Dis., **47**, 174–183

**Li, K.**, Nicaise, C., Sannie, D., Hala, T.J., Javed, E., Parker, J.L., Putatunda, R., Regan, K.A., Suain, V., Brion, J-P., Rhoderick, F., Wright, M.C., Poulsen, D.J. and Lepore, A.C. (2014) *Overexpression of the astrocyte glutamate transporter GLT1 exacerbates phrenic motor neuron degeneration, diaphragm compromise, and forelimb motor dysfunction following cervical contusion spinal cord injury* J. Neurosci., **34**, 7622–7638

**Li, K.**, Hala, T.J., Seetharama, S., Poulsen, D.J., Wright, M.C. and Lepore, A.C. (2015) *GLT1 over-expression in SOD1G93A mouse cervical spinal cord does not preserve diaphragm function or extend disease* Neurobiol. Dis., **78**, 12–23

**Mason, M.R.J.**, Ehlert, E.M.E., Eggers, R., Pool, C.W., et al (2010) *Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons* Mol. Ther., **18**, 715–724

**Miyake, N.**, Miyake, K., Yamamoto, M., Hirai, Y., et al (2011) *Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors* Brain Res., **1389**, 19-26

**Qiu, K.**, Falk, D.J., Reier, P.R., Byrne, B.J. and Fuller, D.D. (2012) *Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice* Mol. Ther., **20**, 21–27

**Sakai, A.**, Saitow, F., Miyake, N., Miyake, K., et al (2013) *miR-7a alleviates the maintenance of neuropathic pain through regulation of neuronal excitability* Brain: **136**, 2738–2750

**Ruitenbergh, M.J.**, Plant, G.W., Christensen, C.L., Blits, B., et al (2002) *Viral vector-mediated gene expression in olfactory ensheathing glia implants in the lesioned rat spinal cord* Gene Ther., **9**, 135-146

**Ruitenbergh, M.J.**, Eggers, R., Boer, G.J. and Verhaagen, J. (2002) *Adeno-associated viral vectors as agents for gene delivery: application in disorders and trauma of the central nervous system* Methods, **28**, 182-194

**Soderblom, C.**, Lee, D-H., Dawood, A., Carballosa, M., Santamaria, A.J., Benavides, F.D., Jergova, S., Grumbles, R.M., Thomas, C.K. et al (2015) *3D Imaging of axons in transparent spinal cords from rodents and nonhuman primates* e-Neuro, **2**: 0001-15

**Towne, C.**, Schneider, B.L., Kieran, D., Redmond, D.E., et al (2010) *Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6* Gene Ther., **17**, 141–146

**Uchida, A.**, Sasaguri, H., Kimura, N., Tajiri, M., et al (2012) *Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43* Brain, **135**, 833–846

**Villmann, C.**, Oertel, J., Ma-Högemeier, Z-L., Hollmann, M., et al (2009) *Functional complementation of Glra1spd-ot, a glycine receptor subunit mutant, by independently expressed C-terminal domains* J. Neurosci., **29**, 2440–2452

**Yu, H.**, Fischer, G., Ferhatovic, L., Fan, F., et al (2013) *Intraganglionic AAV6 Results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats* PLoS One, **8**: e61266

### Spinocerebellar ataxia

**Huda, F.**, Fan, Y., Suzuki, M., Konno, A., Matsuzaki, Y., Takahashi, N., Chan, J.K.Y. and Hirai, H. (2016) *Fusion of human fetal mesenchymal stem cells with degenerating cerebellar neurons in spinocerebellar ataxia Type 1 model mice* PLoS One, **11**: e0164202

**Konno, A.**, Shuvaev, A.N., Miyake, N., Miyake, K., et al (2014) *Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells* Cerebellum, **13**, 29–41

### Splicing regulators

Traunmüller, L., Bornmann, C. and Scheiffle, P. (2014) *Alternative splicing coupled nonsense-mediated decay generates neuronal cell type-specific expression of SLM proteins* J. Neurosci., **34**, 16755–16761

### Stress responses

**Bender, J.**, Engholm, M., Ederer, M.S., Breu, J., Möller, T.C., Michalakis, S., Rasko, T. 5, Wanker, E.E. et al (2015) *Corticotropin-releasing hormone receptor type 1 (CRHR1) clustering with MAGUKs is mediated via its C-terminal PDZ binding motif* PLoS One, **10**: e0136768

### Strial terminalis (bed nucleus)

**Sink, K.S.**, Chung, A., Ressler, K.J., Davis, M., et al (2013) *Anxiogenic effects of CGRP within the BNST may be mediated by CRF acting at BNST CRFR1 receptors* Behav. Brain Res., **243**, 286–293

### Striatal delivery

**Agustín-Pavón, C.**, Mielcarek, M., Marriga-Canut, M. and Isalan, M. (2016) *Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice* Mol. Neurodegen., **11**: 64

**Ahn, J-H.**, McAvoy, T., Rakhilin, S.V., Nishi, A., et al (2007) *Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56δ subunit* Proc. Natl. Acad. Sci. USA, **104**, 2979-2984

**Aldrin-Kirk, P.**, Davidsson, M., Holmqvist, S., Li, J-Y., et al (2014) *Novel AAV based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons* PLoS One, **9**: e100869

**Auffenberg, E.**, Jurik, A., Mattusch, C., Stoffel, R., Genewsky, A., Namendorf, C., Schmid, R.M. Rammes, G. et al (2016) *Remote and reversible inhibition of neurons and circuits by small molecule induced potassium channel stabilization* Sci. Rep., **6**: 19293

**Arcuri, L.**, Viaro, R., Bido, S., Longo, F., Calcagno, M., Fernagut, P-O., Zaveri, N.T., Calò, G., Bezard, E. and Morari, M. (2016) *Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease* Neurobiol. Dis., **89**, 55–64

**Barroso-Chinea, P.**, Cruz-Muros, I., Afonso-Oramas, D., Castro-Hernández, J., Salas-Hernández, J., Chtarto, A., Luis-Ravelo, D., Humbert-Claude, M., Tenenbaum, L. and González-Hernández, T. (2016) *Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system* Neurobiol. Dis., **88**, 44–54

**Benavides, D.R.**, Quinn, J.J., Zhong, P., Hawasli, A.H., et al (2007) *Cdk5 modulates cocaine reward, motivation and striatal neuron excitability* J. Neurosci., **27**, 12967-12976



- Björklund, T.**, Carlsson, T., Cederfjäll, E.A., Carta, M. and Kirik, D. (2010) *Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease* Brain, **133**, 496–511
- Bockstael, O.**, Melas, C., Pythoud, C., Levivier, M., et al (2012) *Rapid transgene expression in multiple precursor cell types of adult rat subventricular zone mediated by adeno-associated type 1 vectors* Hum. Gene Ther., **23**, 742–753
- Carty, N.**, Berson, N., Tillack, K., Thiede, C., Scholz, D., Kottig, K., Sedaghat, Y., Gabrysiak, C. et al (2015) *Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study* PLoS One, **10**: e0123527
- Cederfjäll, E.**, Sahin, G., Kirik, D. and Björklund, T. (2012) *Design of a single AAV vector for co-expression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease* Mol. Ther., **20**, 1315–1326
- Cederfjäll, E.**, Nilsson, N., Sahin, G., Chu, Y., et al (2013) *Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease* Sci. Rep., **3**: 2157
- Chtarto, A.**, Yang, X., Bockstael, O., Melas, C., et al (2007) *Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector* Exp. Neurol., **204**, 387–399
- Crommentuijn, M.H.W.**, Maguire, C.A., Niers, J.M., Vandertop, W.P., Badr, C.E., Wurdinger, T. and Tannous, B.A. (2016) *Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma* Mol. Oncol., **10**, 625–634
- Crook, Z.R.** and Housman, D.E. (2012) *Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice* Proc. Natl. Acad. Sci. USA, **109**, 7487–7492
- Decressac, M.**, Ulusoy, A., Mattsson, B., Georgievska, B., et al (2011) *GDNF fails to exert neuroprotection in a rat  $\alpha$ -synuclein model of Parkinson's disease* Brain, **134**, 2302–2311
- Dodiya, H.B.**, Björklund, T., Stansell III, J., Mandel, R.J., et al (2010) *Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates* Mol. Ther., **18**, 579–587
- Drinkut, A.**, Tereshchenko, Y., Schulz, J.B., Bähr, M., et al (2012) *Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery* Mol. Ther., **20**, 534–543
- Gabery, S.**, Sajjad, M.U., Hult, S., Soylu, R., et al (2012) *Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors* Eur. J. Neurosci., **36**, 2789–2800
- Garriga-Canut, M.**, Agustín-Pavón, C., Herrmann, F., Sánchez, A., et al (2012) *Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice* Proc. Natl. Acad. Sci. USA, **E3136–E3145**
- Gombash, S.E.**, Lipton, J.W., Collier, T.J., Madhavan, L., et al (2012) *Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model* Mol. Ther., **20**, 544–554
- Gordon, R.**, Neal, M.L., Luo, J., Langley, M.R., Harischandra, D.S., Panicker, N., Charli, A., Jin, H., Anantharam, V. et al (2016) *Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration* Nat. Comm., **7**: 12932
- Hicks, M.J.**, Chiuchiolo, M.J., Ballon, D., Dyke, J.P., Aronowitz, E., Funato, K., Tabar, V., Havlicek, D. et al (2016) *Anti-epidermal growth factor receptor gene therapy for glioblastoma* PLoS One, **10**: 1371
- Kornum, B.R.**, Stott, S.R.W., Mattsson, B., Wisman, L., et al (2010) *Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain* Exp. Neurol., **222**, 70–85
- Landeck, N.**, Hall, H., Ardah, M.T., Majbour, N.K., El-Agnaf, O.M.A., Halliday, G. and Kirik, D. (2016) *A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein* Mol. Neurodegen., **11**: 61
- Lehtonen, E.**, Bonnaud, F., Melas, C., Lubansu, A., et al (2002) *AAV2 vectors mediate efficient and sustained transduction of rat embryonic ventral mesencephalon* Neuroreport, **13**, 1503–1507
- Leriche, L.**, Björklund, T., Breyse, N., Besret, L., et al (2009) *Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy* J. Neurosci., **29**, 1544–1553
- Liu, M.**, Blanco-Centurion, C., Konadhode, R., Begum, S., et al (2011) *Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice* J. Neurosci., **31**, 6028–6040
- Maddalena, A.**, Tereshchenko, J., Bähr, M. and Kügler, S. (2013) *Adeno-associated virus-mediated, vifepripristone-regulated transgene expression in the brain* Mol. Ther. Nucleic Acids **2**: e106
- Marshall, J.D.**, Li, J.Z., Zhang, Y., Gong, Y., St-Pierre, F., Lin, M.Z. and Schnitzer, M.J. (2016) *Cell-type-specific optical recording of membrane voltage dynamics in freely moving mice* Cell, **167**, 1650–1662

- Marsic, D.**, Méndez-Gómez, H.R. and Zolotukhin, S. (2015) *High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing* Mol. Ther. Methods Clin. Dev., **2**:15041
- Matalon, R.**, Surendran S., Rady, P.L., Quast, M.J., et al (2008) *Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome* Am. J. Hum. Genet., **83**, 479-488
- Mudannayake, J.M.**, Mouravlev, A., Fong, D.M. and Young, D. (2016) *Transcriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transfer* Mol. Ther. Meth. Clin. Devel., **3**: 16075
- Peden, C.S.**, Ezell, E.L., Muzyczka, N. and Mandel, R.J. (2003) *Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease* Mol. Ther., **7**, 580-587
- Peden, C.S.**, Manfredsson, F.P., Reimsnider, S.K., Poirier, A.E., et al (2009) *Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented* Mol. Ther., **17**, 524-537
- Piguat, F.**, Sondhi, D., Piraud, M., Fouquet, F., et al (2012) *Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice* Hum. Gene Ther., **23**, 903-914
- Polinski, N.K.**, Manfredsson, F.P., Benskey, M.J., Fischer, D.L., Kemp, C.J., Steece-Collier, K., Sandoval, I.M., Paumier, K.L. and Sortwell, C.E. (2016) *Impact of age and vector construct on striatal and nigral transgene expression* Mol. Ther. Meth. Clin. Devel., **3**: 16082
- Rothwell, P.E.**, Fuccillo, M.V., Maxeiner, S., Hayton, S.J., Gokce, O., Lim, B.K., Fowler, S.C., Malenka, R.C. and Südhof, T.C. (2014) *Autism-associated neuroigin-3 mutations commonly impair striatal circuits to boost repetitive behaviors* Cell **158**, 198-212
- Saal, K.A.**, Koch, J.C., Tatenhorst, L., Szegö, E.M., Toledo Ribas, V., Michel, U., Bähr, M., Tönges, L. and Lingor, P. (2015) *AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo* Neurobiol. Dis., **73**, 150-162
- Sondhi, D.**, Johnson, L., Purpura, K., Monette, S., et al (2012) *Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis* Hum. Gene Ther. Methods, **23**, 324-335
- Sondhi, D.**, Scott, E.C., Chen, A., Hackett, N.R., et al (2014) *Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene* Hum. Gene Ther., **25**, 223-239
- Tabeta, R.**, Moutin, E., Becker, J.A.J., Heintz, D., Fouillen, L., Flatter, E., Kręzel, E., Alunni, V., Koebel, P. et al (2016) *Fragile X Mental Retardation Protein (FMRP) controls diacylglycerol kinase activity in neurons* Proc. Natl. Acad. Sci. USA, **113**, E3619-E3628
- Tang, T.-S.**, Guo, C., Wang, H., Chen, X. and Bezprozvanny, I. (2009) *Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model* J. Neurosci., **29**, 1257-1266
- Tereshchenko, J.**, Maddalena, A., Bähr, M. and Kügler, S. (2014) *Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease* Neurobiol. Dis., **65**, 35-42
- White, E.**, Bienemann, A., Sena-Esteves, M., Taylor, H., et al (2011) *Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convection-enhanced delivery to the striatum* Hum. Gene Ther., **22**, 237-251
- Yang, C.**, Yang, W-H., Chen, S-S., Ma, B-F., et al (2013) *Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brain* PLoS One, **8**: e63876

### Subarachnoid space

- Condello, C.**, Yuan, P., Schain, A. and Grutzendler, J. (2015) *Microglia constitute a barrier that prevents neurotoxic protofibrillar Ab42 hotspots around plaques* Nat. Commun., **6**: 6176

### Submucosal neuron delivery

- Buckinx, R.**, Van Remoortel, S., Gijssbers, R., Waddington, S.N. and Timmermans, J-P. (2016) *Proof-of-concept: neonatal intravenous injection of adenoassociated virus vectors results in successful transduction of myenteric and submucosal neurons in the mouse small and large intestine* Neurogastroenterol. Motil., **28**, 299-305

### Suboccipital puncture/lumbar puncture

- Hinderer, C.**, Bell, P., Vite, C.H., Louboutin, J-P., Grant, R., Bote, E., Yu, H., Pukenas, B., Hurst, R. and Wilson, J.M. (2014) *Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna* Mol. Ther. Methods Clin. Dev., **1**: 14051
- Hinderer, C.**, Bell, P., Louboutin, J-P., Zhu, Y., Yu, H., Lin, G., Choa, R., Gurda, B.L. et al (2015) *Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates* Mol. Ther., **23**, 1298-1307

### Substantia nigra delivery

- Angot, E.**, Steiner, J.A., Lema Tomé, C.M., Ekström, P., et al (2012) *Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo* PLoS One, **7**: e39465
- Arcuri, L.**, Viaro, R., Bido, S., Longo, F., Calcagno, M., Fernagut, P.-O., Zaveri, N.T., Calò, G., Bezard, E. and Morari, M. (2016) *Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease* Neurobiol. Dis., **89**, 55–64
- Barkholt, P.**, Sanchez-Guajardo, V., Kirik, D. and Romero-Ramos, M. (2012) *Long-term polarization of microglia upon  $\alpha$ -synuclein overexpression in nonhuman primates* Neuroscience, **208**, 85–96
- Benskey, M.J.**, Manfredsson, F.P., Lookingland, K.J. and Goudreau, J. L. (2015) *The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure* Neurotoxicology, **46**, 1–11
- Bourdenx, M.**, Dovero, S., Engeln, M., Bido, S., Bastide, M.F., Dutheil, N., Vollenweider, I., Baud, L. et al (2015) *Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by  $\alpha$ -synuclein overexpression* Acta Neuropathologica Comm., **3**: 46
- Buck, K.**, Landeck, N., Ulusoy, A., Majbour, N.K., El-Agnaf, O.M.A. and Kirik, D. (2015) *Ser129 phosphorylation of endogenous  $\alpha$ -synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function* Neurobiol. Dis., **78**, 100–114
- Burger, C.**, Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., et al (2004) *Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2 and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system* Mol. Ther., **10**, 302–317
- Decressac, M.**, Ulusoy, A., Mattsson, B., Georgievska, B., et al (2011) *GDNF fails to exert neuroprotection in a rat  $\alpha$ -synuclein model of Parkinson's disease* Brain, **134**, 2302–2311
- Decressac, M.**, Mattsson, B., Lundblad, M., Weikop, P. and Björklund, A. (2012) *Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of  $\alpha$ -synuclein in midbrain dopamine neurons* Neurobiol. Dis., **45**, 939–953
- Decressac, M.**, Mattsson, B. and Björklund, A. (2012) *Comparison of the behavioural and histological characteristics of the 6-OHDA and  $\alpha$ -synuclein rat models of Parkinson's disease* Exp. Neurol., **235**, 306–315
- Decressac, M.**, Mattssona, B., Weikop, P., Lundblad, M., et al (2013) *FEB-mediated autophagy rescues midbrain dopamine neurons from  $\alpha$ -synuclein toxicity* Proc. Soc. Natl. Acad. Sci. USA, E1817–E1826
- Dodiya, H.B.**, Bjorklund, T., Stansell III, J., Mandel, R.J., et al (2010) *Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates* Mol. Ther., **18**, 579–587
- Dong, Z.**, Ferger, B., Feldon, J. and Büeler, H. (2002) *Overexpression of Parkinson's disease-associated  $\alpha$ -Synuclein<sup>A53T</sup> by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP* J. Neurobiol., **53**, 1-10
- Eslamboli, A.**, Romero-Ramos, M., Burger, C., Bjorklund, T., et al (2007) *Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain* Brain, **130**, 799-815
- Furler, S.**, Paterna, J-C., Weibel, M. and Büeler, H. (2001) *Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons* Gene Ther., **8**, 864-873
- Gorbatyuk, O.S.**, Li, S., Nash, K., Gorbatyuk, M., et al (2010) *In Vivo RNAi-mediated  $\alpha$ -synuclein silencing induces nigrostriatal degeneration* Mol. Ther., **18**, 1450–1457
- Gustafsson, E.**, Andsberg, G., Darsalia, V., Mohapel, P., et al (2003) *Anterograde delivery of brain-derived neurotrophic factor to striatum via nigral transduction of recombinant adeno-associated virus increases neuronal death but promotes neurogenic response following stroke* Eur. J. Neurosci., **17**, 2667-2678
- Humbert-Claude, M.**, Duc, D., Dwir, D., Thieren, L., Sandstrom von Tobel, J., Begka, C., Legueux, F., Velin, D., Maillard, M.H., Do, K.Q., Monnet-Tschudi, F. and Tenenbaum, L. (2016) *Tollip, an early regulator of the acute inflammatory response in the substantia nigra* J. Neuroinflamm., **13**: 303
- Khodr, C.E.**, Sapru, M.K., Pedapati, J., Han, Y., et al (2011) *An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons* Brain Res., **1395**, 94-107
- Khodr, C.E.**, Pedapati, J., Han, Y. and Bohn, M.C. (2012) *Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra* Develop. Neurobiol., **72**, 906–917
- Klein, R.L.**, King, M.A., Hamby, M.E. and Meyer, E.M. (2002) *Dopaminergic cell loss induced by human A30P  $\alpha$ -synuclein gene transfer to the rat substantia nigra* Hum. Gene Ther., **13**, 605-612
- Klein, R.L.**, Dayton, R.D., Lin, W-L. and Dickson, D.W. (2005) *Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat* Neurobiol. Dis., **20**, 64-73

**Klein, R.L.**, Dayton, R.D., Terry, T.L., Vascoe, C., et al (2009) *PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models* Brain Res., **1259**, 113-122

**Klein, R.L.**, Dayton, R.D., Diaczynsky, C.G. and Wang, D.B. (2010) *Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer* Neurobiol. Aging, **31**, 2091–2102

**Koprich, J.B.**, Johnston, T.H., Reyes, M.G., Sun, X. and Brotchie, J.M. (2010) *Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease* Mol. Neurodegener., **5** :43

**Krumova, P.**, Meulmeester, E., Garrido, M., Tirard, M., et al (2011) *Sumoylation inhibits  $\alpha$ -synuclein aggregation and toxicity* J. Cell Biol., **194**, 49–60

**Lawlor, P.A.**, Bland, R.J., Mouravlev, A., Young, D. and During, M.J. (2009) *Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates* Mol. Ther., **17**, 1692-1702

**Löw, K.**, Aebischer, P. and Schneider, B.L. (2013) *Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles* Hum. Gene Ther., **24**, 613–629

**McFarland, N.R.**, Fan, Z., Xu, K., Schwarzschild, M.A., et al (2009)  *$\alpha$ -Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease* J. Neuropathol. Exp. Neurol., **68**, 515-524

**McFarland, N.R.**, Dimant, H., Kibuuka, L., Ebrahimi-Fakhari, D., et al (2014) *Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not  $\alpha$ -synuclein-induced neuronal cell loss* PLoS One, **9**: e86048

**Manfredsson, F.P.**, Burger, C., Sullivan, L.F., Muzyczka, N., et al (2007) *rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease* Exp. Neurol., **207**, 289-301

**Manfredsson, F.P.**, Tumer, N., Erdos, B., Landa, T., et al (2009) *Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity* Mol. Ther., **17**, 980-991

**Mudannayake, J.M.**, Mouravlev, A., Fong, D.M. and Young, D. (2016) *Transcriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transfer* Mol. Ther. Meth. Clin. Devel., **3**: 16075

**Paterna, J-C.**, Feldon, J. and Büeler, H. (2004) *Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats* J. Virol., **78**, 6808-6817

**Polinski, N.K.**, Manfredsson, F.P., Benskey, M.J., Fischer, D.L., Kemp, C.J., Steece-Collier, K., Sandoval, I.M., Paumier, K.L. and Sortwell, C.E. (2016) *Impact of age and vector construct on striatal and nigral transgene expression* Mol. Ther. Meth. Clin. Devel., **3**: 16082

**Sanchez-Guajardo, V.**, Febbraro, F., Kirik, D. and Romero-Ramos, M. (2010) *Microglia acquire distinct activation profiles depending on the degree of  $\alpha$ -synuclein neuropathology in a rAAV based model of Parkinson's disease* PLoS One, **5**: e8784

**Sato, H.**, Arawaka, S., Hara, S., Fukushima, S., et al (2011) *Authentically phosphorylated  $\alpha$ -synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease* J. Neurosci., **31**, 16884 –16894

**Seo, B.B.**, Nakamaru-Ogiso, E., Cruz, P., Flotte, T.R., et al (2004) *Functional expression of the single subunit NADH dehydrogenase in mitochondria in vivo: a potential therapy for complex I deficiencies* Hum. Gene Ther., **15**, 887-895

**Seo, B.B.**, Nakamura-Ogiso, E., Flotte, T.R., Matsuno-Yagi, A. and Yagi, T. (2006) *In vivo complementation of complex I by the yeast Ndi enzyme* J. Biol. Chem., **281**, 14250-14255

**Tang, F-L.**, Erion, J.R., Tian, Y., Liu, W., Yin, D-M., Ye, J., Tang, B., Mei, L. and Xiong, W-C. (2015) *VPS35 in dopamine neurons is required for endosome-to-Golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for  $\alpha$ -synuclein degradation and prevention of pathogenesis of Parkinson's disease* J. Neurosci., **35**, 10613–10628

**Tatom, J.B.**, Wang, D.B., Dayton, R.D., Skalli, O., et al (2009) *Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression* Mol. Ther., **17**, 607–613

**Ulusoy, A.**, Sahin, G. and Kirik, D. (2010) *Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats* Proc. Natl. Acad. Sci. USA, **107**, 13159–13164

**Ulusoy, A.**, Febbraro, F., Jensen, P.H., Kirik, D., et al (2010) *Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology* Eur. J. Neurosci., **32**, 409–422

**Ulusoy, A.**, Björklund, T., Buck, K. and Kirik, D. (2012) *Dysregulated dopamine storage increases the vulnerability to  $\alpha$ -synuclein in nigral neurons* Neurobiol. Dis., **47**, 367–377

**Van der Perren, A.**, Toelen, J., Carlon, M., Van den Haute, C., et al (2011) *Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9* Gene Ther., **18**, 517–527



**Van Rompuy, A-S.**, Lobbestael, E., Van der Perren, A., Van den Haute, C., et al (2014) *Long-term overexpression of human wild-type and T240R mutant parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration* J. Neuropathol. Exp. Neurol., **73**, 159-174

**Van Rompuy, A-S.**, Oliveras-Salvá, M., Van der Perren, A., Corti, O., Van den Haute, C. and Baekelandt, V. (2015) *Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration* Mol. Neurodegen., **10**, 23

**Wang, D.B.**, Dayton, R.D., Zweig, R.M. and Klein, R.L. (2010) *Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response* Exp. Neurol., **224**, 197-206

**Yasuda, T.**, Hayakawa, H., Nihira, T., Ren, Y-R., et al (2011) *Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of parkinson disease* J. Neuropathol. Exp. Neurol., **70**, 686-697

### Subthalamic nucleus delivery

**Fitzsimons, H.L.**, Riban, V., Bland, R.J., Wendelken, J.L., et al (2010) *Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat* J. Gene Med., **12**, 385-398

**Lee, B.**, Lee, H., Nam, Y.R., Oh, J.H., et al (2005) *Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models* Gene Ther., **12**, 1215-1222

### Suprachiasmatic nucleus

**Landgraf, D.**, Long, J.E., Proulx, C.D., Barandas, R., Malinow, R. and Welsh, D.K. (2016) *Genetic disruption of circadian rhythms in the suprachiasmatic nucleus causes helplessness, behavioral despair, and anxiety-like behavior in mice* Biol. Psych., **80**, 827-835

### Synaptic function

**Elagabani, M.N.**, Brisevac, D., Kintscher, M., Pohle, J., Köhr, G., Schmitz, D. and Kornau, H-C. (2016) *Subunit-selective N-methyl-D-aspartate (NMDA) receptor signaling through brefeldin A-resistant Arf guanine nucleotide exchange factors BRAG1 and BRAG2 during synapse maturation* J. Biol. Chem., **291**, 9105-9118

**Gerstein, H.**, O’Riordan, K., Osting, S., Schwarz, M., Burger, C. (2012) *Rescue of synaptic plasticity and spatial learning deficits in the hippocampus of Homer1 knockout mice by recombinant adeno-associated viral gene delivery of Homer1c* Neurobiol. Learn. Mem., **97**, 17-29

**Hausrat, T.J.**, Muhia, M., Gerrow, K., Thomas, P., Hirdes, W., Tsukita, S., Heisler, F.F., Herich, L., Dubroqua, S. (2015) *Radixin regulates synaptic GABA<sub>A</sub> receptor density and is essential for reversal learning and short-term memory* Nat. Commun., **6**: 6872

**O’Riordan, K.**, Gerstein, H., Hullinger, R. and Burger, C. (2014) *The role of Homer1c in metabotropic glutamate receptor-dependent long-term potentiation* Hippocampus, **24**, 1-6

**Rost, B.R.**, Schneider, F., Grauel, M.K., Wozny, C., Bentz, C.G., Blessing, A., Rosenmund, T., Jentsch, T.J. et al (2015) *Optogenetic acidification of synaptic vesicles and lysosomes* Nat. Neurosci., **18**, 1845-1852

**Valluy, J.**, Bicker, S., Aksoy-Aksel, A., Lackinger, M., Sumer, S., Fiore, R., Wüst, T., Seffer, D. et al (2015) *A coding-independent function of an alternative Ube3a transcript during neuronal development* Nat. Neurosci., **18**, 666-673

**Xu, W.**, Morishita, W., Buckmaster, P.S., Pang, Z.P., et al (2012) *Distinct neuronal coding schemes in memory revealed by selective erasure of fast synchronous synaptic transmission* Neuron, **73**, 990-1001

### Syndapin 1

**Del Pino, I.**, Koch, D., Schemm, R., Qualmann, B., et al (2014) *Proteomic analysis of glycine receptor  $\beta$  Subunit (GlyR $\beta$ )-interacting proteins – evidence for syndapin I regulating synaptic glycone receptors* J. Biol. Chem., **289**, 1396-11409

### SynGAP1 signalling

**Muhia, M.**, Willadt, S., Yee, B.K., Feldon, J., et al (2012) *Molecular and behavioral changes associated with adult hippocampus-specific SynGAP1 knockout* Learn. Mem., **19**, 268-281

### $\alpha$ -Synuclein expression

**Angot, E.**, Steiner, J.A., Lema Tomé, C.M., Ekström, P., et al (2012) *Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo* PLoS One, **7**: e39465

**Aldrin-Kirk, P.**, Davidsson, M., Holmqvist, S., Li, J-Y. and Björklund, T. (2014) *Novel AAV based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons* PLoS One, **9**: e100869

- Arawaka, S.**, Fukushima, S., Sato, H., Sasaki, A., Koga, K., Koyama, S. and Kato, T. (2014) *Zonisamide attenuates  $\alpha$ -synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease* PLoS One, **9**: e89076
- Barkholt, P.**, Sanchez-Guajardo, V., Kirik, D. and Romero-Ramos, M. (2012) *Long-term polarization of microglia upon  $\alpha$ -synuclein overexpression in nonhuman primates* Neuroscience, **208**, 85–96
- Bourdenx, M.**, Dovero, S., Engeln, M., Bido, S., Bastide, M.F., Duthiel, N., Vollenweider, I., Baud, L. et al (2015) *Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by  $\alpha$ -synuclein overexpression* Acta Neuropathologica Comm., **3**: 46
- Buck, K.**, Landeck, N., Ulusoy, A., Majbour, N.K., El-Agnaf, O.M.A. and Kirik, D. (2015) *Ser129 phosphorylation of endogenous  $\alpha$ -synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function* Neurobiol. Dis., **78**, 100–114
- Danzer, K.M.**, Kranich, L.R., Ruf, W.P., Cagsal-Getkin, O., Winslow, A.R., Zhu, L., Vanderburg, C.R. and McLean, P.J. (2012) *Exosomal cell-to-cell transmission of alpha synuclein oligomers* Mol. Neurodegener., **7**: 42
- Decressac, M.**, Ulusoy, A., Mattsson, B., Georgievskaja, B., et al (2011) *GDNF fails to exert neuroprotection in a rat  $\alpha$ -synuclein model of Parkinson's disease* Brain, **134**, 2302–2311
- Decressac, M.**, Mattssona, B., Weikop, P., Lundblad, M., et al (2013) *FEB-mediated autophagy rescues midbrain dopamine neurons from  $\alpha$ -synuclein toxicity* Proc. Soc. Natl. Acad. Sci. USA, E1817–E1826
- Dong, Z.**, Ferge, B., Feldon, J. and Büeler, H. (2002) *Overexpression of Parkinson's disease-associated  $\alpha$ -Synuclein<sup>A53T</sup> by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP* J. Neurobiol., **53**, 1-10
- Eslamboli, A.**, Romero-Ramos, M., Burger, C., Bjorklund, T., et al (2007) *Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain* Brain, **130**, 799-815
- Febbraro, F.**, Sahin, G., Farran, A., Soares, S., et al (2013) *Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease* Neurobiol. Dis., **56**, 47–58
- Febbraro, F.**, Andersen, K.J., Sanchez-Guajardo, V., Tentillier, A., et al (2013) *Chronic intranasal deferoxamine ameliorates motor defects and pathology in the  $\alpha$ -synuclein rAAV Parkinson's model* Exp. Neurol., **247**, 45–58
- Gorbatyuk, O.S.**, Li, S., Nash, K., Gorbatyuk, M., et al (2010) *In Vivo RNAi-mediated  $\alpha$ -synuclein silencing induces nigrostriatal degeneration* Mol. Ther., **18**, 1450–1457
- Hall, H.**, Jewett, M., Landeck, N., Nilsson, N., et al (2013) *Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors* PLoS One **8**: e64844
- Khodr, C.E.**, Sapru, M.K., Pedapati, J., Han, Y., West, N.C., Kells, A.P., Bankiewicz, K.S. and Bohn, M.C. (2011) *An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons* Brain Res., **1395**, 94-107
- Klein, R.L.**, King, M.A., Hamby, M.E. and Meyer, E.M. (2002) *Dopaminergic cell loss induced by human A30P  $\alpha$ -synuclein gene transfer to the rat substantia nigra* Hum. Gene Ther., **13**, 605-612
- Koch, J.C.**, Bitow, F., Haack, J., d'Hedouville, Z., Zhang, J-N., Tönges, L., Michel, U. et al (2015) *Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons* Cell Death Dis., **6**: e1811
- Koprich, J.B.**, Johnston, T.H., Reyes, M.G., Sun, X. and Brotchie, J.M. (2010) *Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease* Mol. Neurodegener., **5** :43
- Krumova, P.**, Meulmeester, E., Garrido, M., Tirard, M., et al (2011) *Sumoylation inhibits  $\alpha$ -synuclein aggregation and toxicity* J. Cell Biol., **194**, 49–60
- Kunadt, M.**, Eckermann, K., Stuenkel, A., Gong, J., Russo, B., Strauss, K., Rai, S., Kugler, S. et al (2015) *Extracellular vesicle sorting of  $\alpha$ -synuclein is regulated by sumoylation* Acta Neuropathol., **129**, 695-713
- McFarland, N.R.**, Fan, Z., Xu, K., Schwarzschild, M.A., et al (2009)  *$\alpha$ -Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease* J. Neuropathol. Exp. Neurol., **68**, 515-524
- McFarland, N.R.**, Dimant, H., Kibuuka, L., Ebrahimi-Fakhari, D., et al (2014) *Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not  $\alpha$ -synuclein-induced neuronal cell loss* PLoS One, **9**: e86048
- Oksman, M.**, Wisman, L.A., Jiang, H., Miettinen, P., Kirik, D. and Tanila, H. (2013) *Transduced wild-type but not P301S mutated human tau shows hyperphosphorylation in transgenic mice overexpressing A30P mutated human alpha-synuclein* Neurodegenerative Dis., **12**, 91–102

- Sanchez-Guajardo, V.**, Febbraro, F., Kirik, D. and Romero-Ramos, M. (2010) *Microglia acquire distinct activation profiles depending on the degree of  $\alpha$ -synuclein neuropathology in a rAAV based model of Parkinson's disease* PLoS One, **5**: e8784
- Sato, H.**, Arawaka, S., Hara, S., Fukushima, S., et al (2011) *Authentically phosphorylated  $\alpha$ -synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease* J. Neurosci., **31**, 16884–16894
- Tang, F-L.**, Erion, J.R., Tian, Y., Liu, W., Yin, D-M., Ye, J., Tang, B., Mei, L. and Xiong, W-C. (2015) *VPS35 in dopamine neurons is required for endosome-to-Golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for  $\alpha$ -synuclein degradation and prevention of pathogenesis of Parkinson's disease* J. Neurosci., **35**, 10613–10628
- Ulusoy, A.**, Febbraro, F., Jensen, P.H., Kirik, D., et al (2010) *Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology* Eur. J. Neurosci., **32**, 409–422
- Ulusoy, A.**, Björklund, T., Buck, K. and Kirik, D. (2012) *Dysregulated dopamine storage increases the vulnerability to  $\alpha$ -synuclein in nigral neurons* Neurobiol. Dis., **47**, 367–377
- Ulusoy, A.**, Musgrove, R.E., Rusconi, R., Klinkenberg, M., Helwig, M., Schneider, A. and Di Monte, D.A. (2015) *Neuron-to-neuron  $\alpha$ -synuclein propagation in vivo is independent of neuronal injury* Acta Neuropathol. Commun., **3**: 13
- Van Rompuy, A-S.**, Oliveras-Salvá, M., Van der Perren, A., Corti, O., Van den Haute, C. and Baekelandt, V. (2015) *Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration* Mol. Neurodegen., **10**, 23
- Yasuda, T.**, Miyachi, S., Kitagawa, R., Wada, K., et al (2007) *Neuronal specificity of  $\alpha$ -synuclein toxicity and effect of Parkin co-expression in primates* Neuroscience., **144**, 743-753
- Yasuda, T.**, Nihira, T., Ren, Y-R., Cao, X-Q., et al (2009) *Effects of UCH-L1 on  $\alpha$ -synuclein over-expression mouse model of Parkinson's disease* J. Neurochem., **108**, 932–944

#### Tar DNA binding protein

- Sasaguri, H.**, Chew, J., Xu, Y-F., Gendron, T.F., Garrett, A., Lee, C.W., Jansen-West, K., Bauer, P.O. et al (2016) *The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo* Brain Res., **1647**, 57–64

#### Target area/tropism, serotype effect

- Chakrabarty, P.**, Rosario, A., Cruz, P., Siemienski, Z., et al (2013) *Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain* PLoS One, **8**: e67680
- Holehonnur, R.**, Luong, J.A., Chaturvedi, D., Ho, A., Lella, S.K., Hosek, M.P. and Ploski, J.E. (2014) *Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala* BMC Neurosci., **15**: 28

#### Tau-related neurodegeneration

- Asai, H.**, Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S. and Ikezu, T. (2015) *Depletion of microglia and inhibition of exosome synthesis halt tau propagation* Nat. Neurosci., **18**, 1584-1593
- Cook, C.**, Kang, S.S., Carlomagno, Y., Lin, W-L., Yue, M., Kurti, A., Shinohara, M., Jansen-West, K., Perkerson, E. et al (2015) *Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model* Hum. Mol. Genet., **24**. 6198-6212
- Klein, R.L.**, Lin, W-L., Dickson, D.W., Lewis, J., et al (2004) *Rapid neurofibrillary tangle formation after localized gene transfer of mutated Tau* Am. J. Pathol. **164**, 347-353
- Klein, R.L.**, Dayton, R.D., Diaczynsky, C.G. and Wang, D.B. (2010) *Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer* Neurobiol. Aging, **31**, 2091–2102
- Ljungberg, M.C.**, Ali, Y.O., Zhu, J., Wu, C-S., et al (2012) *CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy* Hum. Mol. Genet., **21**, 251-267
- Mustroph, M.L.**, King, M.A., Klein, R.L. and Ramirez, J.J. (2012) *Adult-onset focal expression of mutated human tau in the hippocampus impairs spatial working memory of rats* Behav. Brain Res., **233**, 141-148
- Oksman, M.**, Wisman, L.A., Jiang, H., Miettinen, P., et al (2013) *Transduced wild-type but not P301S mutated human tau shows hyperphosphorylation in transgenic mice overexpressing A30P mutated human alpha-synuclein* Neurodegenerative Dis., **12**, 91–102
- Platt, T.L.**, Beckett, T.L., Kohleer, Niedowicz, K.D.M. and Murphy, M.P. (2016) *Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease* Neuroscience **315**, 162–174
- Ramirez, J.J.**, Poulton, W.E., Knelson, E., Barton, C., et al (2011) *Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory* Behav. Brain Res., **216**, 332–340

**Yang, S.,** Cacquevel, M., Saksida, L.M., Bussey, T.J., Schneider, B.L., Aebischer, P., Melani, R. et al (2015) *Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology* Exp. Neurol., **265**, 48–58

### **Thalamus/tectothalamic neurons**

**Auffenberg, E.,** Jurik, A., Mattusch, C., Stoffel, R., Genewsky, A., Namendorf, C., Schmid, R.M. Rammes, G. et al (2016) *Remote and reversible inhibition of neurons and circuits by small molecule induced potassium channel stabilization* Sci. Rep., **6**: 19293

**Gilkes, J.A.,** Bloom, M.D. and Heldermon, C.D. (2016) *Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes* Mol. Genet. Metab. Rep., **6**, 48–54

**Ito, T.,** Hioki, H., Sohn, J., Okamoto, S., Kaneko, T., Iino, S. and Oliver, D.L. (2015) *Convergence of lemniscal and local excitatory inputs on large GABAergic tectothalamic neurons* J. Comp. Neurol., **523**, 2277–2296

**Kwon, J-T.,** Nakajima, R., Kim, H-S., Jeong, Y., Augustine, G.J. and Han, J-H. (2014) *Optogenetic activation of presynaptic inputs in lateral amygdala forms associative fear memory* Learn. Mem., **21**, 627-633

**Neumann, P.A.,** Wang, Y., Yan, Y., Wang, Y., Ishikawa, M., Cui, R., Huang, Y.H. et al (2016) *Cocaine-induced synaptic alterations in thalamus to nucleus accumbens projection* Neuropsychopharmacology, **41**, 2399–2410

**Yoon, S.Y.,** Gay-Antaki, C., Ponde, D.E., Poptani, H., et al (2014) *Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene* Mol. Ther. Methods Clin. Dev., **1**, 14016

### **Transthyretin**

**Batista, A.R.,** Sena-Esteves, M. and Saraiva, M.J. (2013) *Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model* Biochim. Biophys. Acta, **1832**, 1183–1193

### **Tuberous sclerosis complex**

**Prabhakar, S.,** Goto, J., Zuang, X., Sena-Esteves, M., et al (2013) *Stochastic model of Tsc1 lesions in mouse brain* PLoS One, **8**: e64224

**Prabhakar, S.,** Zhang, X., Goto, J., Han, S., Lai, C., Bronson, R., Sena-Esteves, M., Ramesh, V. et al (2015) *Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model* Neurobiol. Dis., **82**, 22–31

### **Tumour necrosis factor**

**Klaus, F.,** Paterna, J-C., Marzorati, E., Sigrist, H., Götze, L., Schwendener, S., Bergamini, G., Jehli, E., Azzinnari, D. et al (2016) *Differential effects of peripheral and brain tumor necrosis factor on inflammation, sickness, emotional behavior and memory in mice* Brain Behav. Immun., **58**, 310–326

### **Vagus nerve infusion**

**Ulusoy, A.,** Musgrove, R.E., Rusconi, R., Klinkenberg, M., Helwig, M., Schneider, A. and Di Monte, D.A. (2015) *Neuron-to-neuron  $\alpha$ -synuclein propagation in vivo is independent of neuronal injury* Acta Neuropathol. Commun., **3**: 13

### **Vector properties**

**Polinski, N.K.,** Manfredsson, F.P., Benskey, M.J., Fischer, D.L., Kemp, C.J., Steece-Collier, K., Sandoval, I.M., Paumier, K.L. and Sortwell, C.E. (2016) *Impact of age and vector construct on striatal and nigral transgene expression* Mol. Ther. Meth. Clin. Devel., **3**: 16082

### **Ventral mid-brain delivery**

**Eisch, A.J.,** Bolanos, C.A., de Wit, J., Simonak, R.D., Pudiak, C.M., Barrot, M., Verhagen, J. and Nestler, E.J. (2003) *Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression* Biol. Psychiatry, **54**, 994-1005

**Piguet, F.,** Sondhi, D., Piraud, M., Fouquet, F., et al (2012) *Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice* Hum. Gene Ther., **23**, 903–914

**Tang, F-L.,** Liu, W., Hu, J-X., Erion, J.R., Ye, J., Mei, L. and Xiong, W-C. (2015) *VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function* Cell Rep., **12**, 1631–1643



### Ventral tegmental delivery

**Grieder, T.E.**, Herman, M.A., Contet, C., Tan, L.A., Vargas-Perez, H., Cohen, A., Chwalek, M., Maal-Bared, G. et al (2014) *VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation* Nat. Neurosci., **17**, 1751-1758

**Hall, H.**, Jewett, M., Landeck, N., Nilsson, N., et al (2013) *Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors* PLoS One **8**: e64844

### Zona incerta

**Liu, M.**, Blanco-Centurion, C., Konadhode, R., Begum, S., et al (2011) *Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice* J. Neurosci., **31**, 6028–6040

### Cholesterol metabolism (see also “Lipoprotein-related disorders”)

**Jäger, J.**, Greiner, V., Strzoda, D., Seibert, O., et al (2014) *Hepatic transforming growth factor- $\beta$ 1 stimulated clone-22 D1 controls systemic cholesterol metabolism* Mol. Metab., **3**, 155–166

**Pasta, S.**, Akhile, O., Tabron, D., Ting, F., Shackleton, G. and Watson, G. (2015) *Delivery of the 7-dehydrocholesterol reductase gene to the central nervous system using adeno-associated virus vector in a mouse model of Smith-Lemli-Opitz Syndrome* Mol. Genet. Metab. Rep., **4**, 92–98

**Ying, L.**, Matabosch, X., Serra, M., Watson, B., et al (2014) *Biochemical and physiological improvement in a mouse model of Smith-Lemli-Opitz syndrome (SLOS) following gene transfer with AAV vectors* Mol. Genet. Metab. Rep., **1**, 103–113

### Cholinesterase

**Geng, L.**, Gao, Y., Chen, X., Hou, S., et al (2013) *Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity* PLoS One, **8**: e67446

### Coagulation factor VIII

**Zolotukhin, I.**, Markusic, D.M., Palaschak, B., Hoffman, B.E., Srikanthan, M.A. and Herzog, R.W. (2016) *Potential for cellular stress response to hepatic factor VIII expression from AAV vector* Mol. Ther. Meth. Clin. Dev., **3**: 16063

### Cocaine

**Geng, L.**, Gao, Y., Chen, X., Hou, S., et al (2013) *Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity* PLoS One, **8**: e67446

**Murthy, V.**, Gao, Y., Geng, L., LeBrasseur, N., White, T. and Brimijoin, S. (2014) *Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice* J. Mol. Neurosci., **53**, 409–416

**Murthy, V.**, Geng, L., Gao, Y., Zhang, B., Miller, J.D., Reyes, S. and Brimijoin, S. (2015) *Reward and toxicity of cocaine metabolites generated by cocaine hydrolase* Cell. Mol. Neurobiol., **35**, 819–826

**Murthy, V.**, Reyes, S., Geng, L., Gao, Y. and Brimijoin, S. (2016) *Cocaine hydrolase gene transfer demonstrates cardiac safety and efficacy against cocaine-induced QT prolongation in mice* J. Pharmacol. Exp. Ther., **356**, 720–725

**Rosenberg, J.B.**, Hicks, M.J., De, B.P., Pagovich, O., et al (2012) *AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior* Hum. Gene Ther., **23**, 451–459

### Cochlear delivery

**Akil, O.**, Seal, R.P., Burke, K., Wang, C., et al (2012) *Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy* Neuron **75**, 283–293

**Chang, Q.**, Wang, J., Li, Q., Kim, Y., Zhou, B., Wang, Y., Li, H. and Lin, X. (2015) *Virally mediated Kcnq1 gene replacement therapy in the immature scala media restores hearing in a mouse model of human Jervell and Lange-Nielsen deafness syndrome* EMBO Mol. Med., **7**, 1077–1086

**Schaechinger, T.J.**, Gorbunov, D., Halaszovich, C.R., Moser, T., et al (2011) *A synthetic prestin reveals protein domains and molecular operation of outer hair cell piezoelectricity* EMBO J., **30**, 2793–2804

**Yu, Q.**, Wang, Y., Chang, Q., Wang, J., et al (2014) *Virally expressed connexin26 restores gap junction function in the cochlea of conditional Gjb2 knockout mice* Gene Ther., **21**, 71–80

### Colitis (experimental)

**Polyak, S.,** Mach, A., Porvasnik, S., Dixon, L., et al (2012) *Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis* Am. J. Physiol. Gastrointest. Liver Physiol., **302**, G296–G308

### Complement activated disorders

**Leaderer, D.,** Cashman, S.M. and Kumar-Singh, R. (2015) *Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59* J. Gene Med., **17**, 101-115

### Coxsackie virus/AdV receptor

**Larochelle, N.,** Teng, Q., Gilbert, R., Deol, J.R., et al (2010) *Modulation of coxsackie and adenovirus receptor expression for gene transfer to normal and dystrophic skeletal muscle* J. Gene Med., **12**, 266–275

### Creatine kinase

**Rodino-Klapac, L.R.,** Lee, J-S., Mulligan, R.C., Clark, K.R. and Mendell, J.R. (2008) *Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D* Neurology, **71**, 240-247

### CRISPR-Cas systems delivery

**Gaj, T.** and Schaffer, D.V. (2016) *Adeno-associated virus-mediated delivery of CRISPR–Cas systems for genome engineering in mammalian cells* Cold Spring Harb Protoc; doi:10.1101/pdb.prot086868

### Cultured cell and tissue delivery

#### AAV variant delivery

**Santiago-Ortiz, J.,** Ojala, D.S., Westesson, O., Weinstein, J.R., Wong, S.Y., Steinsapir, A., Kumar, S., Holmes, I and Schaffer, D.V. (2015) *AAV ancestral reconstruction library enables selection of broadly infectious viral variants* Gene Ther., **22**, 934–946

#### Astrocytes

**Gong, Y.,** Chen, S., Sonntag, C.F., Sumners, C., Klein, R.L., King, M.A., Hughes, J.A. and Meyer, E.M. (2004) *Recombinant adeno-associated virus serotype 2 effectively transduces primary rat brain astrocytes and microglia* Brain Res. Brain Res. Protoc., **14**, 18-24

#### Brain slice culture

**Enokia, R.,** Ono, D., Hasan, M.T., Honma, S. and Honma, K-i., (2012) *Single-cell resolution fluorescence imaging of circadian rhythms detected with a Nipkow spinning disk confocal system* J. Neurosci. Methods, **207**, 72– 79

**Lin, W-C.,** Davenport, C.M., Mourot, A., Vytla, D., Smith, C.M., Medeiros, K.A., Chambers, J.J. and Kramer, R.H. (2014) *Engineering a light-regulated GABA<sub>A</sub> receptor for optical control of neural inhibition* ACS Chem. Biol., **9**, 1414–1419

**Nihira, T.,** Yasuda, T., Hirai, Y., Shimada, T., Mizuno, Y. and Mochizuki, H. (2011) *Adeno-associated viral vector-mediated gene transduction in mesencephalic slice culture* J. Neurosci. Methods, **201**, 55– 60

**Rost, B.R.,** Schneider, F., Grauel, M.K., Wozny, C., Bentz, C.G., Blessing, A., Rosenmund, T., Jentsch, T.J. et al (2015) *Optogenetic acidification of synaptic vesicles and lysosomes* Nat. Neurosci., **18**, 1845-1852

#### Carcinoma cells

**Nicolas, A.,** Jolinon, N., Alazard-Dany, N., Barateau, V., et al (2012) *Factors influencing helper-independent adeno-associated virus replication* Virology, **432**, 1–9

#### Cardiomyocytes

**Bénard, L.,** Oh, J.G., Cacheux, M., Lee, A., Nonnenmacher, M., Matasic, D.S., Kohlbrenner, E., Kho, C., Pavoine, C et al (2016) *Cardiac Stim1 silencing impairs adaptive hypertrophy and promotes heart failure through inactivation of mTORC2/Akt signaling* Circulation, **133**, 1458-1471

**Gedicke-Hornung, C.,** Behrens-Gawlik, V., Reischmann, S., Geertz, B., et al (2013) *Rescue of cardiomyopathy through U7snRNA - mediated exon skipping in Mybpc3 - targeted knock - in mice* EMBO Mol. Med., **5**, 1060-1077

**Gröbl, T.**, Hammer, E., Bien-Möller, S., Geisler, A., Pinkert, S., Röger, C., Poller, W., Kurreck, J., Völker, U., Vetter, R. and Fechner, H. (2014) *A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca<sup>2+</sup> uptake into the sarcoplasmic reticulum* PLoS One, **9**: e92188

**Jian, Z.**, Liang, B., Pan, X., Xu, G., Guo, S-S., Li, T., Zhou, T., Xiao, Y-B. and Li, A-L. (2016) *CUEDC2 modulates cardiomyocyte oxidative capacity by regulating GPX1 stability* EMBO Mol. Med., **8**, 813-829

**Karakikes, I.**, Stillitano, F., Nonnenmacher, M., Tzimas, C., Sanoudou, D., Termglinchan, V., Kong, C-W., Rushing, S. et al (2015) *Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy* Nat. Commun., **6**: 6955

**Mearini, G.**, Stimpel, D., Krämer, E., Geertz, B., et al (2013) *Repair of Mybpc3 mRNA by 5'-trans-splicing in a mouse model of hypertrophic cardiomyopathy* Mol. Ther. Nucleic Acids **2**: e102

**Karakikes, I.**, Stillitano, F., Nonnenmacher, M., Tzimas, C., Sanoudou, D., Termglinchan, V., Kong, C-W., Rushing, S. et al (2015) *Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy* Nat. Commun., **6**: 6955

**Rapti, K.**, Stillitano, F., Karakikes, I., Nonnenmacher, M., Weber, T., Hulot, J-S. and Hajjar, R.J. (2015) *Effectiveness of gene delivery systems for pluripotent and differentiated cells* Mol. Ther. Methods Clin. Dev., **2**: 14067

**Rutschow, D.**, Bauer, R., Göhringer, C., Bekeredjian, R., Schinkel, S., Straub, V., Koenen, M., Weichenhan, D., Katus, H.A. and Müller, O.J. (2014) *S151A  $\delta$ -sarcoglycan mutation causes a mild phenotype of cardiomyopathy in mice* Eur. J. Hum. Genet., **22**, 119–125

### Chondrocytes

**Goodrich, L.R.**, Phillips, J.N., McIlwraith, C.W., Foti, S.B., et al (2013) *Optimization of scAAVIL-Ira in vitro and in vivo to deliver high levels of therapeutic protein for treatment of osteoarthritis* Mol. Ther. Nucleic Acids, **2**: e70

### Corneal cells

**Bosiack, A.P.**, Giuliano, E.A., Gupta, R. and Mohan, R.R. (2012) *Canine corneal fibroblast and myofibroblast transduction with AAV5* Vet. Ophthalmol., **15**, 291–298

### COS cells

**Najate, A.**, Fridlich, R., Millet-Pue, G., Clerin, E., Delalande, F., Jaillard, C., Blond, F., Perrocheau, L., Reichman, S. et al (2015) *Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis* Cell, **161**, 817–832

### Embryonic stem cells (see “Stem cells”)

### Dendritic cells

**Aslanidi, G.V.**, Rivers, A.E., Ortiz, L., Govindasamy, L., et al (2012) *High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors* Vaccine, **30**, 3908–3917

**Ussher, J.E.** and Taylor, J.A. (2010) *Optimized transduction of human monocyte-derived dendritic cells by recombinant adeno-associated virus serotype 6* Hum. Gene Ther., **21**, 1675–1686

### Epithelial (polarized) cells

**Sorcher, E.J.**, Harris, J., Alexander, M., Rottgers, A., Hardy, K., Ponnazhagan, S., Collawn, J.F., McClintock, J., Amsler, C.D., Webster, A., Maddry, J., Baker, B.J. and Hong, J.S. (2006) *Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening* Gene Ther., **13**, 781-788

**Yan, Z.**, Lei-Butters, D.C.M., Liu, X., Zhang, L., Luo, M., Zak, R. and Engelhardt, J.F. (2006) *Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia* J. Biol. Chem., **281**, 29684-29692

**White, A.F.**, Mazur, M., Sorscher, E.J., Zinn, K.R. and Ponnazhagan, S. (2008) *Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells* Hum. Gene Ther., **19**, 1407–1414

### Fibroblasts

**Cataldi, M.P.** and McCarty, D.M. (2010) *Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes* J. Virol., **84**, 8673–8682

### Glial/glioma/glioblastoma cells

**Cataldi, M.P.** and McCarty, D.M. (2010) *Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes* J. Virol., **84**, 8673–8682

**Maguire, C.A.**, Gianni, D., Meijer, D.H., Shaket, L.A., Wakimoto, H., Rabkin, S.D., Gao, G. and Sena-Esteves, M. (2010) *Directed evolution of adeno-associated virus for glioma cell transduction* J. Neurooncol., **96**, 337–347

**Maguire, C.A.**, Balaj, L., Sivaraman, S., Crommentuijn, M.H.W., Ericsson, M., Mincheva-Nilsson, L., Baranov, V. et al (2012) *Microvesicle-associated AAV vector as a novel gene delivery system* Mol. Ther., **20**, 960–971

### Haematopoietic stem cells (see “Stem cells”)

#### HEK cells

**Benskey, M.J.**, Sandoval, I.M. and Manfredsson, F.P. (2016) *Continuous collection of adeno-associated virus from producer cell medium significantly increases total viral yield* Hum. Gene Ther. Meth., **27**, 32-45

**Burger, C.** and Nash, K.R. (2016) *Small-scale recombinant adeno-associated virus purification* In Gene Therapy for Neurological Disorders: Methods and Protocols: Methods in Molecular Biology, vol. 1382 (ed. Manfredsson, F.P.) Springer Science+Business Media New York, pp 95-106

**Chamorro, C.**, Mencia, A., Almaraz, D., Duarte, B., Büning, H., Sallach, J., Hausser, I., Del Río, M., Larcher, F. and Murillas, R. (2016) *Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes* Mol. Ther. Nucleic Acids, **5**: e307

**Del Pino, I.**, Koch, D., Schemm, R., Qualmann, B., et al (2014) *Proteomic analysis of glycine receptor  $\beta$  Subunit (GlyR $\beta$ )-interacting proteins – evidence for syndapin I regulating synaptic glycine receptors* J. Biol. Chem., **289**, 1396–11409

**Gedicke-Hornung, C.**, Behrens-Gawlik, V., Reischmann, S., Geertz, B., et al (2013) *Rescue of cardiomyopathy through U7snRNA - mediated exon skipping in Mybpc3 - targeted knock - in mice* EMBO Mol. Med., **5**, 1060-1077

**Gröbl, T.**, Hammer, E., Bien-Möller, S., Geisler, A., et al (2014) *A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves  $Ca^{2+}$  uptake into the sarcoplasmic reticulum* PLoS One, **9**: e92188

**Ho, M.L.**, Judd, J., Kuypers, B.E., Yamagami, M., Wong, F.F. and Suh, J. (2014) *Efficiency of protease-activatable virus nanonodes tuned through incorporation of wild-type capsid subunits* Cell. Mol. Bioeng., **7**, 334–343

**Hölscher, C.**, Sonntag, F., Henrich, K., Chen, Q., Beneke, J., Matula, P., Rohr, K., Kaderali, L. et al (2015) *The SUMOylation pathway restricts gene transduction by adeno-associated viruses* PLoS Pathog., **11**: e1005281

**Jazwa, A.**, Tomczyk, M., Taha, H.M., Hytonen, E., et al (2013) *Arteriogenic therapy based on simultaneous delivery of VEGF-A and FGF4 genes improves the recovery from acute limb ischemia* Vasc. Cell, **5**: 13

**Leaderer, D.**, Cashman, S.M. and Kumar-Singh, R. (2015) *Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59* J. Gene Med., **17**, 101-115

**Li, B.**, Ma, W., Ling, C., Van Vliet, K., Huang, L-Y., Agbandje-McKenna, M., Srivastava, A. and Aslanidi, G.V. (2015) *Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo* Hum. Gene Ther. Methods **26**, 211-220

**Ling, C.**, Wang, Y., Lu, Y., Wang, L., Jayandharan, G.R., Aslanidi, G.V., Li, B. et al (2015) *Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo* J. Virol., **89**, 952-961

**Millet, R.**, Jolinon, N., Nguyen, X-N., Berger, G., Cimarelli, A., Greco, A., Bertrand, P., Odenthal, M., Büning, H. and Salvetti, A. (2015) *Impact of the MRN complex on adeno-associated virus integration and replication during coinfection with herpes simplex virus* J. Virol., **89**, 6824-6834

**Mockenhaupt, S.**, Grosse, S., Rupp, D., Bartenschlager, R., and Grimm, D. (2015) *Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys* Proc. Natl. Acad. Sci., **112**, E4007-E4016

**Neerinx, A.**, Jakobshagen, K., Utermöhlen, O., Büning, H., Steimle, V. and Kufer, T.A. (2014) *The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression* J. Immunol., **193**, 3090–3100

**Nicolas, A.**, Jolinon, N., Alazard-Dany, N., Barateau, V., Epstein, A.L., Greco, A., Büning, H. and Salvetti, A. (2012) *Factors influencing helper-independent adeno-associated virus replication* Virology, **432**, 1–9

**Platt, T.L.**, Beckett, T.L., Kohleer, Niedowicz, K.D.M. and Murphy, M.P. (2016) *Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease* Neuroscience **315**, 162–174

**Schnödt, M.**, Schmeer, M., Kracher, B., Krüsemann, C., Escalona Espinosa, L., Grünert, A., Fuchsluger, T., Rischmüller, A., Schlee, M. and Büning, H. (2016) *DNA minicircle technology improves purity of adeno-associated viral vector preparations* Mol. Ther. Nucleic Acids, **5**, e355

**Sink, K.S.**, Chung, A., Ressler, K.J., Davis, M., et al (2013) *Anxiogenic effects of CGRP within the BNST may be mediated by CRF acting at BNST CRFR1 receptors* Behav. Brain Res., **243**, 286–293



- Truong, D-J.J.**, Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W. and Ortiz, O. (2015) *Development of an intein-mediated split-Cas9 system for gene therapy* Nucleic Acids Res., **43**, 6450–6458
- Wagner, S.**, Thresher, R., Bland, R. and Laible, G. (2015) *Adeno-associated-virus-mediated transduction of the mammary gland enables sustained production of recombinant proteins in milk* Sci. Rep., **5**: 15115
- Yu, H.**, Koilkonda, R.D., Chou, T-H., Porciatti, V., et al (2012) *Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model* Proc. Natl. Acad. Sci. USA, **109**, E1238–E1247
- Yu, N-K.**, Kim, H.F., Shim, J., Kim, S., Kim, D.W., Kwak, C., Sim, S-E., Choi, J-H., Ahn, S. et al (2016) *A transducible nuclear/nucleolar protein, mLLP, regulates neuronal morphogenesis and synaptic transmission* Sci. Rep., **6**: 22892

### HeLa cells

- Aydemir, F.**, Salganik, M., Resztak, J., Singh, J., Bennett, A., Agbandje-McKenna, M. and Muzyczka, N. (2016) *Mutants at the 2-fold interface of adeno-associated virus type 2 (AAV2) structural proteins suggest a role in viral transcription for AAV capsids* J. Virol. **90**, 7196-7204
- Hölscher, C.**, Sonntag, F., Henrich, K., Chen, Q., Beneke, J., Matula, P., Rohr, K., Kaderali, L. et al (2015) *The SUMOylation pathway restricts gene transduction by adeno-associated viruses* PLoS Pathog., **11**: e1005281
- Li, B.**, Ma, W., Ling, C., Van Vliet, K., Huang, L-Y., Agbandje-McKenna, M., Srivastava, A. and Aslanidi, G.V. (2015) *Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo* Hum. Gene Ther. Methods **26**, 211-220
- Nicolas, A.**, Jolinon, N., Alazard-Dany, N., Barateau, V., Epstein, A.L., Greco, A., Büning, H. and Salvetti, A. (2012) *Factors influencing helper-independent adeno-associated virus replication* Virology, **432**, 1–9

### Hepatoma cells/hepatocytes

- Leaderer, D.**, Cashman, S.M. and Kumar-Singh, R. (2015) *Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59* J. Gene Med., **17**, 101-115
- Lee, D-H.**, Park, J.O., Kim, T-S., Kim, S-K., Kim, T-h., Kim, M-c., Park, G.S., Kim, J-H., Kuninaka, S., Olson, E.N. et al (2016) *LATS-YAP/TAZ controls lineage specification by regulating TGF $\beta$  signaling and Hnf4a expression during liver development* Nat. Comm., **7**: 11961
- Li, B.**, Ma, W., Ling, C., Van Vliet, K., Huang, L-Y., Agbandje-McKenna, M., Srivastava, A. and Aslanidi, G.V. (2015) *Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo* Hum. Gene Ther. Methods **26**, 211-220
- Ling, C.**, Wang, Y., Lu, Y., Wang, L., Jayandharan, G.R., Aslanidi, G.V., Li, B. et al (2015) *Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo* J. Virol., **89**, 952-961
- Mockenhaupt, S.**, Grosse, S., Rupp, D., Bartenschlager, R., and Grimm, D. (2015) *Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys* Proc. Natl. Acad. Sci., **112**, E4007-E4016
- Mueller, S.**, Huard, J., Waldow, K., Huang, X., D'Alessandro, L.A., Bohl, S., Börner, K., Grimm, D., Klamt, S., Klingmüller, U. and Schilling, M. (2015) *T160-phosphorylated CDK2 defines threshold for HGF-dependent proliferation in primary hepatocytes* Mol. Syst. Biol., **11**: 795
- Vercauteren, K.**, Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner-Tschakarjan, E., High, K.A., Ertl, H.C.J. et al (2016) *Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid* Mol. Ther., **24**, 1042-1049

### Human corneal endothelial cells

- Gruenert, A.K.**, Czugala, M., Mueller, C., Schmeer, M., Schleef, M., Kruse, F.E. and Fuchsluger, T.A. (2016) *Self-complementary adeno-associated virus vectors improve transduction efficiency of corneal endothelial cells* PLoS One, **11**: e0152589

### Human fibroblasts

- Lojewski, X.**, Staropoli, J.F., Biswas-Legrand, S., Simas, A.M., et al (2014) *Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPPI and CLN3 mutations on the endocytic pathway* Hum. Mol. Genet., **23**, 2005–2022

### Human 293T cells

- Maguire, C.A.**, Balaj, L., Sivaraman, S., Crommentuijn, M.H.W., et al (2012) *Microvesicle-associated AAV vector as a novel gene delivery system* Mol. Ther., **20**, 960–971

### Industrial scale culture

**Chahal, P.S.**, Schulze, E., Tran, R., Montes, J. and Kamen, A.A. (2014) *Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery* J. Virol. Methods, **196**, 163–173

### Keratinocytes

**Chamorro, C.**, Mencía, A., Almarza, D., Duarte, B., Büning, H., Sallach, J., Hausser, I., Del Rio, M., Larcher, F. and Murillas, R. (2016) *Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes* Mol. Ther. Nucleic Acids, **5**: e307

**Sallach, J.**, Di Pasquale, G., Larcher, F., Niehoff, N., et al (2014) *Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy* Mol. Ther., **22**, 929–939

### Lung fibroblasts

**Hüser, D.**, Gogol-Döring, A., Chen, W. and Heilbronn, R. (2014) *Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing* J. Virol., **88**, 11253–11263

### Melanocytes

**Sheppard, H.M.**, Ussher, J.E., Verdon, D., Chen, J., et al (2013) *Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes* PLoS One, **8**: e62753

### Neurons

**Ahn, J.-H.**, Sung, J.Y., McAvoy, T., Nishi, A., Janssens, V., Goris, J., Greengard, P. and Nairn, A.C. (2007) *The B''/PR72 subunit mediates Ca<sup>2+</sup>-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A* Proc. Natl. Acad. Sci., **104**, 9876–9881

**Bender, J.**, Engholm, M., Ederer, M.S., Breu, J., Möller, T.C., Michalakis, S., Rasko, T. 5, Wanker, E.E. et al (2015) *Corticotropin-releasing hormone receptor type 1 (CRHR1) clustering with MAGUKs is mediated via its C-terminal PDZ binding motif* PLoS One, **10**: e0136768

**Ch tarto, A.**, Bockstael, O., Gebara, E., Vermoesen, K., Melas, C., Pythoud, C., Levivier, M., De Witte, O., Luthi-Carter, R., Clinkers, R. and Tenenbaum, L. (2013) *An adeno-associated virus-based intracellular sensor of pathological nuclear factor- $\kappa$ B activation for disease-inducible gene transfer* PLoS One, **8**: e53156

**Dogra, S.**, Kumar, A., Umrao, D., Sahasrabudhe, A.A. and Yadav, P.M. (2016) *Chronic Kappa opioid receptor activation modulates NR2B: Implication in treatment resistant depression* Sci. Rep., **6**: 33401

**Hasegawa, K.**, Yasuda, T., Shiraishi, C., Fujiwara, K., Przedborski, S., Mochizuki, H. and Yoshikawa, K. (2016) *Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults* Nat. Comm., **7**: 10943

**Jin, L.**, Lange, W., Kempmann, A., Maybeck, V., Günther, A., Gruteser, N., Baumann, A. and Offenhäusser, A. (2016) *High-efficiency transduction and specific expression of Chr2opt for optogenetic manipulation of primary cortical neurons mediated by recombinant adeno-associated viruses* J. Biotech., **233**, 171–180

**Kneysberg A.**, Collier, T.J., Manfredsson, F.P. and Kanaan, N.M. (2016) *Quantitative and semi-quantitative measurements of axonal degeneration in tissue and primary neuron cultures* J. Neurosci. Meth., **266**, 32–41

**Koch, J.C.**, Bitow, F., Haack, J., d'Hedouville, Z., Zhang, J.-N., Tönges, L., Michel, U. et al (2015) *Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons* Cell Death Dis., **6**: e1811

**Kunadt, M.**, Eckermann, K., Stuenkel, A., Gong, J., Russo, B., Strauss, K., Rai, S., Kugler, S. et al (2015) *Extracellular vesicle sorting of  $\alpha$ -synuclein is regulated by sumoylation* Acta Neuropathol., **129**, 695–713

**Lutz, D.**, Loers, G., Kleene, R., Oezen, I., Kataria, H., Katagihallimath, N., Braren, I., Harauz, G. and Schachner, M. (2014) *Myelin basic protein cleaves cell adhesion molecule L1 and promotes neurite outgrowth and cell survival* J. Biol. Chem., **289**, 13503–13518

**Maddalena, A.**, Tereshchenko, J., Bähr, M. and Kugler, S. (2013) *Adeno-associated virus-mediated, vifepiristone-regulated transgene expression in the brain* Mol. Ther. Nucleic Acids **2**: e106

**Ortiz-Abalia, J.**, Sahún, I., Altafaj, X., Andreu, N., Estivill, X., Dierssen, M. and Fillat, C. (2008) *Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome* Am. J. Hum. Genet., **83**, 479–488

**Pulizzi, R.**, Musumeci, G., Van den Haute, C., Van De Vijver, S., Baekelandt, V. and Giugliano, M. (2016) *Brief wide-field photostimuli evoke and modulate oscillatory reverberating activity in cortical networks* Sci. Rep., **6**: 24701

**Rosario, A.M.**, Cruz, P.E., Ceballos-Diaz, C., Strickland, M.R., Siemienski, Z., Pardo, M., Schob, K.-L., Li, A., Aslanidi, G.V. et al (2016) *Microglia-specific targeting by novel capsid-modified AAV6 vectors* Mol. Ther. Meth. Clin. Dev., **3**: 16026

- Sasaguri, H.**, Chew, J., Xu, Y-F., Gendron, T.F., Garrett, A., Lee, C.W., Jansen-West, K., Bauer, P.O. et al (2016) *The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo* Brain Res., **1647**, 57–64
- Truong, D-J.J.**, Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W. and Ortiz, O. (2015) *Development of an intein-mediated split-Cas9 system for gene therapy* Nucleic Acids Res., **43**, 6450–6458
- Vullhorst, D.**, Mitchell, R.M., Keating, C., Roychowdhury, S., Karavanova, I., Tao-Cheng, J-H. and Buonanno, A. (2015) *A negative feedback loop controls NMDA receptor function in cortical interneurons via neuregulin 2/ErbB4 signalling* Nat. Commun., **6**: 7222
- Xu, J.**, Ma, C., Bass, C. and Terwilliger, E.F. (2005) *A combination of mutations enhances the neurotropism of AAV-2* Virology, **341**, 203–214
- Yu, Z.**, Liu, N., Li, Y., Xu, J. and Wang, X. (2013) *Neuroglobin overexpression inhibits oxygen–glucose deprivation-induced mitochondrial permeability transition pore opening in primary cultured mouse cortical neurons* Neurobiol. Dis., **56**, 95–103
- Zheng, D.**, Sabbagh, J.J., Blair, L.J., Darling, A.L., Wen, X. and Dickey, C.A. (2016) *MicroRNA-511 binds to FKBP5 mRNA, which encodes a chaperone protein, and regulates neuronal differentiation* J. Biol. Chem., **291**, 17897–17906

### Nucleus pulposus cells

- Mern, D.S.** and Thomé, C. (2015) *Identification and characterization of human nucleus pulposus cell specific serotypes of adeno-associated virus for gene therapeutic approaches of intervertebral disc disorders* BMC Musculoskelet. Disorders, **16**: 341

### Oligodendrocytes

- Aggarwal, S.**, Snaidero, N., Pähler, G., Frey, S., Sánchez, P., Zweckstetter, M., Janshoff, A., Schneider, A., Weil, M-T., Schaap, I.A.T., Görlich, D. and Simons, M. (2013) *Myelin membrane assembly is driven by a phase transition of myelin basic proteins into a cohesive protein meshwork* PLoS Biol., **11**: e1001577
- Frühbeis, C.**, Fröhlich, D., Kuo, W.P., Amphornrat, J., Thilemann, S., Saab, A.S., Kirchhoff, F., Möbius, W., Goebels, S., Nave, K-A., Schneider, A., Simons, M., Klugmann, M., Trotter, J., Krämer-Albers, E-M., (2013) *Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte–neuron communication* PLoS Biol., **11**: e1001604

### Osteosarcoma cells

- Nicolas, A.**, Jolinon, N., Alazard-Dany, N., Barateau, V., Epstein, A.L., Greco, A., Büning, H. and Salvetti, A. (2012) *Factors influencing helper-independent adeno-associated virus replication* Virology, **432**, 1–9

### Ovarian carcinoma

- Münch, R.C.**, Muth, A., Muik, A., Friedel, T., Schmatz, J., Dreier, B., Trkola, A., Plückthun, A., Büning, H. and Buchholz, C.J. (2015) *Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors* Nat. Commun., **6**: 624

### Polymorphonuclear leukocytes

- Koch, J.C.**, Bitow, F., Haack, J., d'Hedouville, Z., Zhang, J-N., Tönges, L., Michel, U. et al (2015) *Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons* Cell Death Dis., **6**: e1811

### Smooth muscle progenitor cells

- Chen, F.**, Zhang, ZD., and Zhu, XH. (2015) *Inhibition of development of experimental abdominal aortic aneurysm by c-jun N-terminal protein kinase inhibitor combined with lysyl oxidase gene modified smooth muscle progenitor cells* Eur. J. Pharmacol., **766**, 114–121

### Stem cells

- Klaus, F.**, Paterna, J-C., Marzorati, E., Sigrist, H., Götze, L., Schwendener, S., Bergamini, G., Jehli, E., Azzinnari, D. et al (2016) *Differential effects of peripheral and brain tumor necrosis factor on inflammation, sickness, emotional behavior and memory in mice* Brain Behav. Immun., **58**, 310–326
- Ling, C.**, Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E. and Srivastava, A. (2016) *High-efficiency transduction of primary human hematopoietic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing* Sci. Rep., **6**: 35495
- Rapti, K.**, Stillitano, F., Karakikes, I., Nonnenmacher, M., Weber, T., Hulot, J-S. and Hajjar, R.J. (2015) *Effectiveness of gene delivery systems for pluripotent and differentiated cells* Mol. Ther. Methods Clin. Dev., **2**: 14067

**Sather, B.D.**, Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y. et al (2015) *Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template* *Sci. Transl. Med.*, **7**: 307ra156

**Song, L.**, Li, X., Jayandharan, G.R., Wang, Y., Aslanidi, G.V., et al (2013) *High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo* *PLoS One*, **8**: e58757

**Song, L.**, Kauss, M.A., Kopin, E., Chandra, M., et al (2013) *Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo* *Cytherapy*, **15**, 986-998

**Weltner, J.**, Anisimov, A., Alitalo, K., Otonkoski, T. and Trokovic, R. (2012) *Induced pluripotent stem cell clones reprogrammed via recombinant adeno-associated virus-mediated transduction contain integrated vector sequences* *J. Virol.*, **86**, 4463–4467

### SV40 tranformed human cell lines

**Nicolas, A.**, Jolinon, N., Alazard-Dany, N., Barateau, V., Epstein, A.L., Greco, A., Büning, H. and Salvetti, A. (2012) *Factors influencing helper-independent adeno-associated virus replication* *Virology*, **432**, 1–9

### Synoviocytes

**Goodrich, L.R.**, Phillips, J.N., McIlwraith, C.W., Foti, S.B., et al (2013) *Optimization of scAAVIL-Ira in vitro and in vivo to deliver high levels of therapeutic protein for treatment of osteoarthritis* *Mol. Ther. Nucleic Acids*, **2**: e70

**Kyostio-Moore, S.**, Bangari, D.S., Ewing, P., Nambiar, B., et al (2013) *Local gene delivery of heme oxygenase-1 by adeno-associated virus into osteoarthritic mouse joints exhibiting synovial oxidative stress* *Osteoarthritis Cartilage*, **21**, 358-367

### Cutaneous therapy

**Sallach, J.**, Di Pasquale, G., Larcher, F., Niehoff, N., et al (2014) *Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy* *Mol. Ther.*, **22**, 929–939

### Cystic fibrosis (see “Respiratory system delivery”)

### Deafness (see “Cochlear delivery”)

### Dental disorders

**Kunze, M.**, Huber, A., Krajewski, A., Lowden, E., et al (2009) *Efficient gene transfer to periodontal ligament cells and human gingival fibroblasts by adeno-associated virus vectors* *J. Dent.*, **37**, 502-508

### Designed ankyrin repeat proteins

**Münch, R.C.**, Janicki, H., Völker, I., Rasbach, A., et al (2013) *Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer* *Mol. Ther.*, **21**, 109–118

### Diabetes

#### Diabetic neuropathy

**Homs, J.**, Pagès, G., Ariza, L., Casas, C., et al (2014) *Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy* *Mol. Ther. Methods Clin. Dev.*, **1**: 7

**Platt, T.L.**, Beckett, T.L., Kohleer, Niedowicz, K.D.M. and Murphy, M.P. (2016) *Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease* *Neuroscience* **315**, 162–174

#### Glucotoxicity

**Poungvarin, N.**, Lee, J.K., Yechool, V.K., Li, M.V., et al (2012) *Carbohydrate response element-binding protein (ChREBP) plays a pivotal role in beta cell glucotoxicity* *Diabetologia* (2012) **55**, 1783–1796

#### Hypothalamic regulation

**Kim, J.D.**, Toda, C., D’Agostino, G., Zeiss, C.J., DiLeone, R.J., Elsworth, J.D., Kibbey, R.G., Chan, O., Harvey, B.K., Richie, C.T. et al (2014) *Hypothalamic prollyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice* *Proc. Natl. Acad. Sci. USA*, **111**, 11876–11881



### Insulin growth factor/insulin receptor

**Chu, Q.**, Moreland, R., Yew, N.S., Foley, J., et al (2008) *Systemic insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy* Mol. Ther., **16**, 1400-1408

**Liu, X.**, Magee, D., Wang, C., McMurphy, T., et al (2014) *Adipose tissue insulin receptor knockdown via a new primate-derived hybrid recombinant AAV serotype* Mol. Ther. Methods Clin. Dev., **1**: 8

### Islet (pancreatic) delivery

**Craig, A.T.**, Gavrilova, O., Dwyer, N.K., Jou, W., et al (2009) *Transduction of rat pancreatic islets with pseudotyped adeno-associated virus vectors* Virol. J. **6**:61

**Flotte, T.**, Agarwal, A., Wang, J., Song, S., et al (2001) *Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors* Diabetes, **50**, 515-520

**Kaptureczak, M.**, Zolotukhin, S., Cross, J., Pileggi, A., et al (2002) *Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector* Mol. Ther., **5**, 154-160

**Loiler, S.A.**, Conlon, T.J., Tang, Q., Warrington, K.H., et al (2003) *Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver* Gene Ther., **10**, 1551-1558

**Loiler, S.A.**, Tang, Q., Clarke, T., Campbell-Thompson, M.L., et al (2005) *Localized gene expression following administration of adeno-associated viral vectors via pancreatic ducts* Mol. Ther., **12**, 519-527

**Lu, Y.**, Tang, M., Wasserfall, C., Kou, Z., et al (2006)  *$\alpha$  1-Antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice* Hum. Gene Ther., **17**, 625-634

**Vizzardelli, C.**, Molano, R.D., Pileggi, A., Berney, T., et al (2002) *Neonatal porcine pancreatic cell clusters as a potential source for transplantation in humans: characterization of proliferation, apoptosis, xenoantigen expression and gene delivery with recombinant AAV* Xenotransplantation, **9**, 14-24

### Pancreatic cell delivery

**Batchu, R.B.**, Gruzdyn, O.V., Kung, S.T., Weaver, D.W., et al (2014) *Novel AAV-DJ capsid tyrosine mutants with enhanced transgene expression in a pancreatic cancer cell line* J. Surg. Res., **186**, 637-638

**Griffin, M.A.**, Restrepo, M.S., Abu-El-Hajja, M., Wallen, T., et al (2014) *A novel gene delivery method transduces porcine pancreatic duct epithelial cells* Gene Ther., **21**, 123-130

**Poungvarin, N.**, Lee, J.K., Yechool, V.K., Li, M.V., et al (2012) *Carbohydrate response element-binding protein (ChREBP) plays a pivotal role in beta cell glucotoxicity* Diabetologia (2012) **55**, 1783-1796

**Tonne, J.M.**, Sakuma, T., Deeds, M.C., Munoz-Gomez, M., et al (2013) *Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced  $\beta$ -cell damage and pancreatic Glp-1 gene therapy* Dis. Mod. Mech., **6**, 1236-1245

### DNA

#### DNA binding proteins

**Xu, Y-F.**, Prudencio, M., Hubbard, J.M., Tong, J., et al (2013) *The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43* PLoS One, **8**: e69864

### Clones

**Schnepp, B.C.**, Jensen, R.L., Clark, K.R. and Johnson, P.R (2009) *Infectious molecular clones of adeno-associated virus isolated directly from human tissues* J. Virol., **83**, 1456-1464

### Inverted terminal repeats

**Aurnhammer, C.**, Haase, M., Muether, N., Haus, M., et al (2012) *Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences* Hum. Gene Ther. Methods, Part B **23**, 18-28

### Manipulation

**Cataldi, M.P.** and McCarty, D.M. (2010) *Differential effects of DNA double-strand break repair pathways on single-strand and self-complementary adeno-associated virus vector genomes* J. Virol., **84**, 8673-8682

**Choi, V.W.**, Samulski, R.J. and McCarty, D. (2005) *Effects of adeno-associated virus DNA hairpin structure on recombination* J. Virol., **79**, 6801-6807

**Choi, V.W.**, McCarty, D.M. and Samulski, R.J. (2006) *Host cell DNA repair pathways in adeno-associated viral genome processing* J. Virol., **80**, 10346-10356

**Fraefel, C.**, Bittermann, A.G., Bueler, H., Heid, I., et al (2004) *Spatial and temporal organization of adeno-associated virus DNA replication in live cells* J. Virol., **78**, 389-398

**Glauser, D.L.**, Strasser, R., Laimbacher, A.S., Saydam, O., et al (2007) *Live covisualization of competing adeno-associated virus and herpes simplex virus type 1 DNA replication: Molecular mechanisms of interaction* J. Virol., **81**, 4723-4743

**Hamilton, H.**, Gomos, J., Berns, K.I. and Falck-Pedersen, E. (2004) *Adeno-associated virus site-specific integration and AAVS1 disruption* J. Virol., **78**, 7874-7882

**Hirsch, M.L.**, Storici, F., Li, C., Choi, V.W., et al (2009) *AAV recombineering with single strand oligonucleotides* PLoS One, **4**: e7705

**Hüser, D.**, Weger, S. and Heilbronn, R. (2003) *Packaging of human chromosome 19-specific adeno-associated virus (AAV) integration sites in AAV virions during AAV wild-type and recombinant AAV vector production* J. Virol., **77**, 4881-4887

**Koerber, J.T.**, Jang, J-H., and Schaffer, D.V. (2008) *DNA shuffling of adeno-associated virus yields functionally diverse viral progeny* Mol. Ther., **16**, 1703-1709

**Miller, D.G.**, Petek, L.M. and Russell, D.W. (2003) *Human gene targeting by adeno-associated virus vectors is enhanced by DVA double-strand breaks* Mol. Cell. Biol., **23**, 3550-3557

**Miller, D.G.**, Petek, L.M. and Russell, D.W. (2004) *Adeno-associated virus vectors integrate at chromosome breakage sites* Nat. Genet., **36**, 767-773

**Miller, D.G.**, Trobridge, G.D., Petek, L.M., Jacobs, M.A., et al (2005) *Large-scale analysis of adeno-associated virus vector integration sites in normal human cells* J. Virol., **79**, 11434-11442

**Miller, D.G.** (2010) *Frequent endonuclease cleavage at off-target locations in vivo* Mol. Ther., **18**, 983-986

Porteus, M.H., Cathomen, T., Weitsman, M.D. and Baltimore, D. (2003) *Efficient gene targeting mediated by adeno-associated virus and DNA double-stranded breaks* Mol. Cell. Biol., **23**, 3558-3565

**Stracker, T.H.**, Cassell, G.D., Ward, P., Loo, Y-M., et al (2004) *The Rep protein of adeno-associated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication* J. Virol., **78**, 441-453

### Polymorphisms

**Deyle, D.R.**, Li, L.B., Ren, G. and Russell, D.W. (2014) *The effects of polymorphisms on human gene targeting* Nucleic Acids Res., **42**, 3119-3124

### Dogs, administration to

**Hinderer, C.**, Bell, P., Louboutin, J-P., Zhu, Y., Yu, H., Lin, G., Choa, R., Gurda, B.L. et al (2015) *Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates* Mol. Ther., **23**, 1298-1307

### Dopaminergic neurons

**Tang, F-L.**, Liu, W., Hu, J-X., Erion, J.R., Ye, J., Mei, L. and Xiong, W-C. (2015) *VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function* Cell Rep., **12**, 1631-1643

### Drug delivery/screening

**Bouard, D.**, Alazard-Dany, N. and Cosset, F-L. (2009) *Viral vectors: from virology to transgene expression* Br. J. Pharmacol., **157**, 153-165

**Yan, Z.**, Lei-Butters, D., Engelhardt, J.F. and Leno, G.H. (2009) *Indexing TNF- $\alpha$  gene expression using a gene-targeted reporter cell line* BMC Biol., **7**:8

### D-sequence substituted rAAV

**Ling, C.**, Wang, Y., Lu, Y., Wang, L., Jayandharan, G.R., Aslanidi, G.V., Li, B. et al (2015) *Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo* J. Virol., **89**, 952-961

### Dystrophic epidermolysis bullosa

**Chamorro, C.**, Mencía, A., Almarza, D., Duarte, B., Büning, H., Sallach, J., Hausser, I., Del Río, M., Larcher, F. and Murillas, R. (2016) *Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes* Mol. Ther. Nucleic Acids, **5**: e307

### Eating disorders (see also “Leptin therapy”)

**Ganella, D.E.**, Callander, G.E., Ma, S., Bye, C.R., et al (2013) *Modulation of feeding by chronic rAAV expression of a relaxin-3 peptide agonist in rat hypothalamus* Gene Ther., **20**, 703-716

### Endonuclease cleavage

**Petek, L.M.**, Russell, D.W. and Miller, D.G. (2010) *Frequent endonuclease cleavage at off-target locations in vivo* Mol. Ther., **18**, 983–986

### Endosomal trafficking

**Aoto, J.**, Martinelli, D.C., Malenka, R.C., Tabuchi, K., et al (2013) *Presynaptic neurexin-3 alternative splicing trans-synaptically controls postsynaptic AMPA receptor trafficking* Cell, **154**, 75–88

**Dickey, D.D.**, Excoffon, K.J.D.A., Koerber, J.T., Bergen, J., et al (2011) *Enhanced sialic acid-dependent endocytosis explains the increased efficiency of infection of airway epithelia by a novel adeno-associated virus* J. Virol., **85**, 9023–9030

**Nam, H.-J.**, Gurda, B.L., McKenna, R., Potter, M., et al (2011) *Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking* J. Virol., **85**, 11791–11799

### Endothelial cell targeting

**Chen, S.**, Kapturczak, M., Loiler, S.A., Zolotukhin, S., et al (2005) *Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors* Hum. Gene Ther., **16**, 235–247

**Karkkainen, M. J.**, Saaristo, A., Jussila, L., Karila, K. A., et al (2001) *A model for gene therapy of human hereditary lymphedema* Proc. Natl. Acad. Sci. USA, **98**, 12677–12682

**Kealy, B.**, Liew, A., McMahon, J.M., Ritter, T., et al (2009) *Comparison of viral and nonviral vectors for gene transfer to human endothelial progenitor cells* Tissue Eng. Part C, **15**, 223–231

**Lipinski, D.M.**, Reid, C.A., Boye, S.L., Peterson, J.J., Qi, X., Boye, S.E., Boulton, M.E. and Hauswirth, W.W. (2015) *Systemic vascular transduction by capsid mutant adeno-associated virus after intravenous injection* Hum. Gene Ther., **26**, 767–776

**Müller, O.J.**, Kaul, F., Weitzman, M.D., Pasqualini, R., et al (2003) *Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors* Nat. Biotechnol., **21**, 1040–1046

**Nykänen, A.I.**, Pajusola, K., Krebs, R., Keränen, M.A.I., et al (2006) *Common protective and diverse smooth muscle cell effects of AAV-mediated angiopoietin-1 and -2 expression in rat cardiac allograft vasculopathy* Circ. Res., **98**, 1373–1380

**Pajusola, K.**, Gruchala, M., Joch, H., Luscher, T. F., et al (2002) *Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells* J. Virol., **76**, 11530–11540

**Sen, S.**, Contoy, S., Hynes, S.O., McMahon, J., et al (2008) *Gene delivery to the vasculature mediated by low-titre adeno-associated virus serotypes 1 and 5* J. Gene Med., **10**, 143–151

**Stachler, M.D.** and Bartlett, J.S. (2006) *Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells* Gene Ther., **13**, 926–931

**Work, L.M.**, Büning, H., Hunt, E., Nicklin, S.A., et al (2006) *Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses* Mol. Ther., **13**, 683–693

### Enveloped vector

**György, B.**, Fitzpatrick, Z., Crommentuijn, M.H.W., Mu, D. and Maguire, C.A. (2014) *Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo* Biomaterials, **35**, 7598–7609

### Evolutionary lineage of

**Zinn, E.**, Pacouret, S., Khaychuk, V., Turunen, H.T., Carvalho, L.S., Andres-Mateos, E., Shah, S. Shelke, R. et al (2015) *In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector* Cell Rep., **12**, 1056–1068

### Exosome gene delivery (see “Vexosome gene delivery”)

### External carotid artery injection

**Foley, C.P.**, Rubin, D.G., Santillan, A., Sondhi, D., Dyke, J.P., Gobin, Y.P., Crystal, R.G. and Ballon, D.J. (2014) *Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption* J. Control. Release, **196**, 71–78

### GABA<sub>A</sub> receptor

**Lin, W.-C.**, Davenport, C.M., Mourrot, A., Vytla, D., Smith, C.M., Medeiros, K.A., Chambers, J.J. and Kramer, R.H. (2014) *Engineering a light-regulated GABA<sub>A</sub> receptor for optical control of neural inhibition* ACS Chem. Biol., **9**, 1414–1419

### Galectin interaction

**Denard, J.**, Beley, C., Kotin, R., Lai-Kuen, R., et al (2012) *Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6* J. Virol., **86**, 6620-6631

### Gene delivery using Cas9

**Truong, D-J.J.**, Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W. and Ortiz, O. (2015) *Development of an intein-mediated split-Cas9 system for gene therapy* Nucleic Acids Res., **43**, 6450–6458

### Gene expression inhibition

**Lentz, T.B.** and Samulski, J. (2015) *Insight into the mechanism of inhibition of adeno-associated virus by the Mre11/Rad50/Nbs1 complex* J. Virol., **89**, 181-194

### Genome packaging

**Drouin, L.M.**, Lins, B., Janssen, M., Bennett, A., Chipman, P., McKenna, R., Chen, W., Muzyczka, N., Cardone, G., Baker, T.S. and Agbandje-McKenna, M. (2016) *Cryo-electron microscopy reconstruction and stability studies of the wild type and the R432A variant of adeno-associated virus type 2 reveal that capsid structural stability is a major factor in genome packaging* J. Virol., **90**, 8542-8541

### Genome release

**Horowitz, E.D.**, Rahman, K.S., Bower, B.D., Dismuke, D.J., et al (2013) *Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release* J. Virol., **87**, 2994–3002

### Glucocorticoid receptor

**De Guia, R.M.**, Rose, A.J., Sommerfeld, A., Seibert, O., Strzoda, D., Zota, A., Feuchter, Y., Krones-Herzig, A., Sijmonsma, T. et al (2015) *microRNA-379 couples glucocorticoid hormones to dysfunctional lipid homeostasis* EMBO J., **34**, 344–360

### Glycan binding

Huang, L-Y., Patel, A., Ng, R., Miller, E.B., Halder, S., McKenna, R., Asokan, A. and Agbandje-McKenna, M. (2016) *Characterization of the adeno-associated virus 1 and 6 sialic acid binding site* J. Virol., **90**, 5219-6230

### Glycogen metabolism (see “Lysosomal storage diseases”)

### Growth factors

**Braun-Falco, M.**, Eisenried, A., Büning, H. and Ring, J. (2005) *Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase* Arch. Dermatol. Res., **296**, 528-535

**Chu, Q.**, Moreland, R., Yew, N.S., Foley, J., et al (2008) *Systemic insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy* Mol. Ther., **16**, 1400-1408

**Jäger, J.**, Greiner, V., Strzoda, D., Seibert, O., et al (2014) *Hepatic transforming growth factor- $\beta$  1 stimulated clone-22 D1 controls systemic cholesterol metabolism* Mol. Metab., **3**, 155–166

**Jazwa, A.**, Kucharzewska, P., Leja, J., Zagorska, A., et al (2010) *Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice* Genet. Vaccines Ther., **8**: 6

**Jazwa, A.**, Tomczyk, M., Taha, H.M., Hytonen, E., et al (2013) *Arteriogenic therapy based on simultaneous delivery of VEGF-A and FGF4 genes improves the recovery from acute limb ischemia* Vasc. Cell, **5**: 13

**Karvinen, H.**, Pasanen, E., Rissanen, T.T., Korpisalo, P., et al (2011) *Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle* Gene Ther., **18**, 1166–1172

**Kuo, C-H.**, Chen, P-K., Chang, B-I., Sung, M-C., et al (2012) *The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen* Blood, **119**, 1302-1313

**Paradiso, B.**, Marconi, P., Zucchini, S., Berto, E., et al (2009) *Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model* Proc. Natl. Acad. Sci. USA, **106**, 7191–7196

**Pinkenburg, O.**, Pfosser, A., Hinkel, R., Böttcher, M., et al (2009) *Recombinant adeno-associated virus-based gene transfer of cathelicidin induces therapeutic neovascularization preferentially via potent collateral growth* Hum Gene Ther., **20**, 159–167

**Schievenbusch, S.**, Strack, I., Scheffler, M., Nischt, R., et al (2010) *Combined paracrine and endocrine AAV9-mediated expression of hepatocyte growth factor for the treatment of renal fibrosis* Mol. Ther. **18**, 1302–1309



**Takei, Y.**, Mizukami, H., Saga, Y., Yoshimura, I., et al (2006) *Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector* Int. J. Cancer, **120**, 278-284

**Tuuminen, R.**, Dashkevich, A., Keränen, M.A.I., Raissadati, A., Krebs, R., Jokinen, J.J., Arnaudova, R., Rouvinen, E., Ylä-Herttua, S. et al (2016) *Platelet-derived growth factor-B protects rat cardiac allografts from ischemia-reperfusion injury* Transplantation, **100**, 303–313

**Watanabe, M.**, Boyer, J.L. and Crystal, R.G. (2010) *AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors* Gene Ther., **17**, 1042–1051

### Haemophilia

**Sen, D.**, Gadkari, R.A., Sudha, G., Gabriel, N., et al (2013) *Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo* Hum. Gene Ther. Methods, **24**, 104–116

**Xu, L.**, Daly, T., Gao, C., Flotte, T.R., et al (2001) *CMV- $\beta$ -actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 $\alpha$  promoter and results in therapeutic levels of human factor X in mice* Hum. Gene Ther., **12**, 563-573

**Zolotukhin, I.**, Markusic, D.M., Palaschak, B., Hoffman, B.E., Srikanthan, M.A. and Herzog, R.W. (2016) *Potential for cellular stress response to hepatic factor VIII expression from AAV vector* Mol. Ther. Meth. Clin. Dev., **3**: 16063

### Haematopoietic cells

**Han, Z.**, Zhong, L., Maina, N., Hu, Z., et al (2008) *Stable integration of recombinant adeno-associated virus vector genomes after transduction of murine hematopoietic stem cells* Hum. Gene Ther., **19**, 267-278

**McMahon, J.M.**, Conroy, S., Lyons, M., Greiser, U., et al (2006) *Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors* Stem Cell. Dev., **15**, 87-96

**Nathwani, A.C.**, Hanwa, H., Vandergriff, J., Kely, P., et al (2000) *Efficient gene transfer into human cord blood CD34<sup>+</sup> cells and the CD34<sup>+</sup> CD38<sup>-</sup> subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV* Gene Ther., **7**, 183-195

**Paiboonsukwong, K.**, Ohbayashi, F., Shiiba, H., Aizawa, E., et al (2009) *Correction of mutant Fanconi anemia gene by homologous recombination in human hematopoietic cells using adeno-associated virus vector* J. Gene Med., **11**, 1012-1019

**Ryu, B.Y.**, Evans-Galea, M.V., Gray, J.T., Bodine, D.M., et al (2008) *An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation* Blood, **111**, 1866-1875

**Sather, B.D.**, Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y. et al (2015) *Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template* Sci. Transl. Med., **7**: 307ra156

### Haem oxygenase delivery

**Kyostio-Moore, S.**, Bangari, D.S., Ewing, P., Nambiar, B., et al (2013) *Local gene delivery of heme oxygenase-1 by adeno-associated virus into osteoarthritic mouse joints exhibiting synovial oxidative stress* Osteoarthritis Cartilage, **21**, 358-367

### Hearing disorders

**Iizuka, T.**, Kanzaki, S., Mochizuki, H., Inoshita, A., et al (2008) *Noninvasive in vivo delivery of transgene via adeno-associated virus into supporting cells of the neonatal mouse cochlea* Human Gene Therapy, **19**, 384-390

**Kilpatrick, L.A.**, Li, Q., Yang, J., Goddard, J.C., et al (2011) *Adeno-associated virus-mediated gene delivery into the scala media of the normal and deafened adult mouse ear* Gene Ther., **18**, 569–578

**Luebke, A.E.**, Foster, P.K., Muller, C.D. and Peel, A.L. (2001) *Cochlear function and transgene expression in the guinea pig cochlea, using adenovirus- and adeno-associated virus-directed gene transfer* Hum. Gene Ther., **12**, 773-781

**Schaechinger, T.J.**, Gorbunov, D., Halaszovich, C.R., Moser, T., et al (2011) *A synthetic prestin reveals protein domains and molecular operation of outer hair cell piezoelectricity* EMBO J., **30**, 2793–2804

**Stone, I.M.**, Lurie, D.I., Kelley, M.W. and Poulsen, D.J. (2005) *Adeno-associated virus-mediated gene transfer to hair cells and support cells of the murine cochlea* Mol. Ther., **11**, 843-848

### Heart/heart failure (see “Vascular smooth muscle”)

### Helper virus functions

**Kang, W.**, Wang, L., Harrell, H., Liu, J., et al (2009) *An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes* Gene Ther., **16**, 229-239

**Mistry, A.R.**, De Alwis, M., Feudner, E., Ali, R.R. and Thrasher, A.J. (2002) *High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors* *Methods Mol. Med.*, **69**, 445-460  
**Pozzuto, T.**, von Kietzell, K., Bock, T., Schmidt-Lucke, C., et al (2011) *Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions* *Virology* **411**, 50–64  
**Toublanc, E.**, Benraiss, A., Bonnin, D., Blouin, V., et al (2004) *Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines* *J. Gene Med.*, **6**, 555-564

### Hepadnavirus infection

**Berraondo, P.**, Di Scala, M., Korolowicz, K., Thampi, L.M., Otano, I., Suarez, L., Fioravanti, J., Aranda, F., Ardaiz, N. et al (2015) *Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I* *J. Hepatol.*, **63**, 329–336

### Hepatic/hepatocyte delivery

#### Acyl-CoA dehydrogenase

**Beattie, S.G.**, Goetzman, E., Conlon, T., Germain, S., Walter, G., et al (2008) *Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD* *Hum. Gene Ther.*, **19**, 579-588

#### Ancestral rAAVs, targeting of,

**Zinn, E.**, Pacouret, S., Khaychuk, V., Turunen, H.T., Carvalho, L.S., Andres-Mateos, E., Shah, S. Shelke, R. et al (2015) *In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector* *Cell Rep.*, **12**, 1056–1068

#### Anti-inflammatory agents

**Gil-Fariña, I.**, Di Scala, M., Vanrell, L., Olagüe, C., et al (2013) *IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression* *PLoS One*, **8**: e67748

#### $\alpha$ -1Anti-trypsin

**Song, S.**, Embury, J., Laipis, P.J., Berns, K.I., et al (2001) *Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors* *Gene Ther.*, **8**, 1299-1306

**Conlon, T.J.**, Cossette, T., Erger, K., Choi, Y-K., et al (2005) *Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped  $\alpha$ 1-antitrypsin vector* *Mol. Ther.*, **12**, 867-875

#### Capsid uncoating

**Tenney, R.M.**, Bell, C.L. and Wilson, J.M. (2014) *AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating* *Virology* **454-455** (2014) 227–236

#### Carcinogenesis

**Gruber, S.**, Straub, B.K., Ackermann, J., Wunderlich, C.M., et al (2013) *Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Ra signaling* *Cell Rep.*, **4**, 669–680

**Santamaria, M.**, Pardo-Saganta, A., Alvarez-Asiain, L., Di Scala, M., et al (2013) *Nuclear  $\alpha$ 1-antichymotrypsin promotes chromatin condensation and inhibits proliferation of human hepatocellular carcinoma cells* *Gastroenterology*, **144**, 818-828

**Vanrell, L.**, Di Scala, M., Blanco, L., Otano, I., et al (2011) *Development of a liver-specific Tet-On inducible system for AAV vectors and its application in the treatment of liver cancer* *Mol. Ther.*, **19**, 1245–1253

#### DNA demethylation

**Gil-Fariña, I.**, Di Scala, M., Vanrell, L., Olagüe, C., et al (2013) *IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression* *PLoS One*, **8**: e67748

#### Fatty liver disease

**Schultze, S.M.**, Dietrich, M., Hynx, D., Geier, A., Niessen, M., Spinass, G.A., Hemmings, B.A. and Tschopp, O. (2015) *Reduced hepatic lipid content in Pten-haplodeficient mice because of enhanced AKT2/PKBb activation in skeletal muscle* *Liver Int.*, **35**, 1354–1366

### **Fibrosis**

**Rezvani, M.**, Espanol-Suner, R., Malato, Y., Dumont, L., Grimm, A.A., Kienle, E., Bindman, J.G., Wiedtke, E., Hsu, B.Y. et al (2016) *In vivo hepatic reprogramming of myofibroblasts with AAV vectors as a therapeutic strategy for liver fibrosis* Cell Stem Cell, **18**, 809–816

### **Green fluorescent protein**

**Piras, B.A.**, O'Connor, D.M. and French, B.A. (2013) *Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver* PLoS One, **8**: e75894

### **Hypercholesterolaemia**

**Kassim, S.H.**, Li, H., Bell, P., Somanathan, S., et al (2013) *Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia* Hum. Gene Ther., **24**, 19–26

### **Hyperoxaluria**

**Salido, E.**, Rodriguez-Pena, M., Santana, A., Beattie, S.G., et al (2011) *Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer* Mol. Ther., **19**, 870–875

### **IFN- $\alpha$**

**Vanrell, L.**, Olague, C., Vales, A., Pineda, A., et al (2009) *Evaluation of AAV-mediated IFN $\alpha$ -gene therapy efficacy in HBV transgenic mice: constitutive versus inducible expression* J. Hepatol., **50** Supp. 1, S215-S215

### **Immunity/immune response**

**Faust, S.M.**, Bell, P., Zhu, Y., Sanmiguel, J. and Wilson, J.M. (2013) *The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer* Mol. Ther., **21**, 2227–2235

**Hurlbut, G.D.**, Ziegler, R.J., Nietupski, J.B., Foley, J.W., et al (2010) *Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy* Mol. Ther., **18**, 1983–1994

**Martino, A.T.**, Suzuki, M., Markusic, D.M., Zolotukhin, I., et al (2011) *The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver* Blood, **117**, 6459-6468

### **Liver-draining lymph nodes**

**Perrin, G.Q.**, Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y.P., Terhorst, C., Davidoff, A.M. and Herzog, R.W. (2016) *Dynamics of antigen presentation to transgene product-specific CD4<sup>+</sup> T cells and of Treg induction upon hepatic AAV gene transfer* Mol. Ther. Meth. Clin. Devel., **3**: 16083

### **Lysosome effects**

**Batista, A.R.**, Sena-Esteves, M. and Saraiva, M.J. (2013) *Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model* Biochim. Biophys. Acta, **1832**, 1183–1193

### **Porphyria**

**Unzu, C.**, Sampedro, A., Mauleón, I., Alegre, M., et al (2011) *Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice* Mol. Ther., **19**, 243–250

### **Propionic acidaemia**

**Guenzel, A.J.**, Hofherr, S.E., Hillestad, M., Barry, M., et al (2013) *Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing* Mol. Ther., **21**, 1316-1323

### **Retroviruses**

**Herquel, B.**, Ouararhni, K., Martjanov, I., Le Gras, S., et al (2013) *Trim24-repressed VL30 retrotransposons regulate gene expression by producing noncoding RNA* Nat. Struct. Mol. Biol., **20**, 339-346

### **Transduction efficiency**

**Gabriel, N.**, Hareendran, S., Sen, D., Gadkari, R.A., et al (2013) *Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo* Hum. Gene Ther. Methods, **24**, 80–93

- Loiler, S.A.**, Conlon, T.J., Tang, Q., Warrington, K.H., et al (2003) *Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver* Gene Ther., **10**, 1551-1558
- Montenegro-Miranda, P.S.**, Pañeda, A., ten Bloemendaal, L., Duijst, S., et al (2013) *Adeno-associated viral vector serotype 5 poorly transduces liver in rat models* PLoS One, **8**: e82597
- Nathwani, A.C.**, Cochrane, M., McIntosh, J., Ng, C.Y.C., et al (2009) *Enhancing transduction of the liver by adeno-associated viral vectors* Gene Ther., **16**, 60–69
- Ling, C.**, Lu, Y., Cheng, B., McGoogan, K.E., et al (2011) *High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors* J. Vis. Exp., **49**, 10.3791/2538
- Mayra, A.**, Tomimitsu, H., Kubodera, T., Kobayashi, M., et al (2011) *Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles* Biochem. Biophys. Res. Comm., **405**, 204–209
- Paneda, A.**, Vanrell, L., Mauleon, I., Crettaz, J.S., et al (2009) *Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders* Hum. Gene Ther., **20**, 908-917
- Raupp, C.**, Naumer, M., Müller, O.J., Gurda, B.L., et al (2012) *The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as post-attachment processing* J. Virol., **86**, 9396-9408
- Sen, D.**, Gadkari, R.A., Sudha, G., Gabriel, N., et al (2013) *Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo* Hum. Gene Ther. Methods, **24**, 104–116
- Tenney, R.M.**, Bell, C.L. and Wilson, J.M. (2014) *AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating* Virology 454-455 (2014) 227–236
- Wang, L.**, Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R. and Wilson, J.M. (2015) *Comparative study of liver gene transfer with AAV vectors based on natural and engineered AAV capsids* Mol. Ther., **23**, 1877–1887

### Herpes simplex helper virus

- Kang, W.**, Wang, L., Harrell, H., Liu, J., et al (2009) *An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes* Gene Ther., **16**, 229-239
- Millet, R.**, Jolinon, N., Nguyen, X-N., Berger, G., Cimarelli, A., Greco, A., Bertrand, P., Odenthal, M., Büning, H. and Salvetti, A. (2015) *Impact of the MRN complex on adeno-associated virus integration and replication during coinfection with herpes simplex virus* J. Virol., **89**, 6824-6834
- Mistry, A.R.**, De Alwis, M., Feudner, E., Ali, R.R. and Thrasher, A.J. (2002) *High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors* Methods Mol. Med., **69**, 445-460
- Toublanc, E.**, Benraiss, A., Bonnin, D., Blouin, V., et al (2004) *Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines* J. Gene Med., **6**, 555-564

### High affinity ligands

- Münch, R.C.**, Janicki, H., Völker, I., Rasbach, A., et al (2013) *Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer* Mol. Ther., **21**, 109–118

### HIV therapy

- De Silva Felixge, H.S.**, Stone, D., Pietz, H.L., Roychoudhury, P., Greninger, A.L., Schiffer, J.T., Aubert, M. and Jerome, K.R. (2016) *Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy* Antiviral Res., **126**, 90-98
- Roychoudhury, P.**, De Silva Felixge, H.S., Pietz, H.L., Stone, D., Jerome, K.R. and Schiffer, J.T. (2016) *Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases* J. Antimicrob. Chemother., **71**, 2089–2099

### Hypercholesterolaemia (see “Lipoprotein-related disorders”)

### Hypertension

- Cataliotti, A.**, Tonne, J.M., Bellavia, D., Martin, F.L., et al (2011) *Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats* Circulation, **123**, 1297-1305

### Hyperoxaluria (see Hepatic/hepatocyte delivery”)



## Immune response

- Aubert, D.**, Pichard, V., Durand, S., Moullier, P. and Ferry, N. (2003) *Cytotoxic immune response after retroviral-mediated hepatic gene transfer in rat does not preclude expression from adeno-associated virus 1 transduced muscles* Hum. Gene Ther., **14**, 473-481
- Chen, S.**, Kapturczak, M.H., Wasserfall, C., Glushakova, O.Y., et al (2005) *Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway* Proc. Natl. Acad. Sci. USA, **102**, 7251-7256
- Chu, Q.**, Moreland, R.J., Gao, L., Taylor, K.M., et al (2010) *Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery* Mol. Ther., **18**, 2146-2154
- Lu, Y.** and Song, S. (2009) *Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors* Proc. Natl. Acad. Sci. USA, **106**, 17158-17162
- Huang, J.**, Li, X., Coelho-dos-Reis, J.G.A., Wilson, J.M., Tsuji, M. (2014) *An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8<sup>+</sup> T cells in mice* PLoS One, **9**: e88205
- Madsen, D.**, Cantwell, E.R., O'Brien, T., Johnson, P.A. and Mahon, B.P. (2009) *Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1* J. Gen. Virol., **90**, 2622-2633
- Maersch, S.**, Huber, A., Büning, H., Hallek, M. and Perabo, L. (2010) *Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes* Virology, **397**, 167-175
- Peden, C.S.**, Manfredsson, F.P., Reimsnider, S.K., Poirier, A.E., et al (2009) *Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented* Mol. Ther., **17**, 524-537
- Rogers, G.L.**, Suzuki, M., Zolotukhin, I., Markusic, D.M., Morel, L.M., Lee, B., Ertl, H.C.J. and Herzog, R.F.W. (2015) *Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer* J. Innate. Immun., **7**, 302-314
- Rybniker, J.**, Nowag, A., Janicki, H., Demant, K., et al (2012) *Incorporation of antigens into viral capsids augments immunogenicity of adeno-associated virus vector-based vaccines* J. Virol., **86**, 13800-13804
- Sun, J.Y.**, Anand-Jawa, V., Chatterjee, S. and Wong, K.K. (2003) *Immune responses to adeno-associated virus and its recombinant vectors* Gene Ther., **10**, 964-976
- Zhang, Y.C.**, Powers, M., Wasserfall, C., Brusko, T., et al (2004) *Immunity to adeno-associated virus serotype 2 delivered transgenes impaired by genetic predisposition to autoimmunity* Gene Ther., **11**, 233-240

## Infectivity

- Excoffon, K.J.D.A.**, Koerber, J.T., Dickey, D.D., Murtha, M., et al (2009) *Directed evolution of adeno-associated virus to an infectious respiratory virus* Proc. Natl. Acad. Sci., **106**, 3865-3870
- Kang, W.**, Wang, L., Harrell, H., Liu, J., et al (2009) *An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes* Gene Ther., **16**, 229-239
- Popa-Wagner, R.**, Porwal, M., Kann, M., Reuss, M., et al (2012) *Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry* J. Virol., **86**, 9163-9174
- Salganik, M.**, Venkatakrishnan, B., Bennett, A., Lins, B., et al (2012) *Evidence for pH-dependent protease activity in the adeno-associated virus capsid* J. Virol., **86**, 11877-11885
- Zeltner, N.**, Kohlbrenner, E., Clément, N., Weber, T., and Linden, R.M. (2010) *Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors* Gene Ther., **17**, 872-879

## Influenza virus

- Sipo, I.**, Knauf, M., Fechner, H., Poller, W. et al (2011) *Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV)* Vaccine **29**, 1690-1699

## Inner ear delivery (see also “Cochlear delivery”)

- Okada, H.**, Iizuka, T., Mochizuki, H., Nihira, T., et al (2012) *Gene transfer targeting mouse vestibule using adenovirus and adeno-associated virus vectors* Otol. Neurotol., **33**, 655-659

## Intervertebral disc disorders

- Mern, D.S.** and Thomé, C. (2015) *Identification and characterization of human nucleus pulposus cell specific serotypes of adeno-associated virus for gene therapeutic approaches of intervertebral disc disorders* BMC Musculoskelet. Disorders, **16**: 341

## Intestinal delivery

- Buckinx, R.**, Van Remoortel, S., Gijsbers, R., Waddington, S.N. and Timmermans, J-P. (2016) *Proof-of-concept: neonatal intravenous injection of adenoassociated virus vectors results in successful transduction of*

*myenteric and submucosal neurons in the mouse small and large intestine* Neurogastroenterol. Motil., **28**, 299–305

**Miyake, N.**, Miyake, K., Yamamoto, M., Hirai, Y. and Shimada, T. (2011) *Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors* Brain Res., **1389**, 19-26

**Polyak, S.**, Mach, A., Porvasnik, S., Dixon, L., et al (2012) *Identification of adeno-associated viral vectors suitable for intestinal gene delivery and modulation of experimental colitis* Am. J. Physiol. Gastrointest. Liver Physiol., **302**, G296–G308

## Intracellular interactions

### Molecular interactions

**Nash, K.**, Chen, W., Salganik, M. and Muzyczka, N. (2009) *Identification of cellular proteins that interact with the adeno-associated virus Rep protein* J. Virol., **83**, 454-469

### Trafficking

**Dickey, D.D.**, Excoffon, K.J.D.A., Koerber, J.T., Bergen, J., et al (2011) *Enhanced sialic acid-dependent endocytosis explains the increased efficiency of infection of airway epithelia by a novel adeno-associated virus* J. Virol., **85**, 9023–9030

**Gurda, B.L.**, Raupp, C., Popa-Wagner, R., Naumer, M., et al (2012) *Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8* J. Virol., **86**, 7739–7751

**Johnson, J.S.** and Samulski, R.J. (2009) *Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus* J. Virol., **83**, 2632-2644

**Lux, K.**, Goerlitz, N., Schlemminger, S., Perabo, L., et al (2005) *Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking* J. Virol., **79**, 11776-11787

**Nam, H-J.**, Gurda, B.L., McKenna, R., Potter, M., et al (2011) *Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking* J. Virol., **85**, 11791–11799

**Nonnenmacher, M.E.**, Cintrat, J-C., Gillet, D. and Weber, T. (2015) *Syntaxin 5-dependent retrograde transport to the trans-Golgi network is required for adeno-associated virus transduction* J. Virol., **89**, 1673-1687

**Popa-Wagner, R.**, Porwal, M., Kann, M., Reuss, M., et al (2012) *Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry* J. Virol., **86**, 9163-9174

**Sonntag, F.**, Bleker, S., Leuchs, B., Fischer, R. and Kleinschmidt, J.A. (2006) *Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus* J. Virol., **80**, 11040-11054

**Stahnke, S.**, Lux, K., Uhrig, S., Kreppel, F., et al (2011) *Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles* Virology, **409**, 77–83

**Xiao, W.**, Warrington, K.H., Hearing, P. Hughes, J. and Muzyczka, N. (2002) *Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2* J. Virol., **76**, 11505-11517

## Intramuscular injection

**Benkhelifa-Ziyyat, S.**, Besse, A., Roda, M., Duque, S., Astord, S., Carcenac, R., Marais, T. and Barkats, M. (2013) *Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice* Mol. Ther., **21**, 282–290

**Chew, W.L.**, Tabebordbar, M., Cheng, J.K.W., Mali, P., Wu, E.Y., Ng, A.H.M., Zhu, K., Wagers, A.J. and Church, G.M. (2016) *A multifunctional AAV–CRISPR–cas9 and its host response* Nat. Meth., **13**, 868-874

## Intraparenchymal gene delivery (see “Blood-brain barrier”)

### Intraperitoneal injection

**Akbar, M.A.**, Cao, J.J., Lu, Y., Nardo, D., Chen, M-J., Elshikha, A.S., Ahamed, R., Brantly, M., Holliday, L.S. and Song, S. (2016) *Alpha-1 antitrypsin gene therapy ameliorates bone loss in ovariectomy-induced osteoporosis mouse model* Hum. Gene Ther., **27**, 679-686

**Machida, A.**, Kuwahara, H., Mayra, A., Kubodera, T., et al (2013) *Intraperitoneal administration of AAV9-shRNA inhibits target gene expression in the dorsal root ganglia of neonatal mice* Mol. Pain, **9**:36

**Medina-Echeverz, J.**, Fioravanti, J., Díaz-Valdés, N., Frank, K., et al (2014) *Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases* PLoS One, **9**: e96799

**Schultze, S.M.**, Dietrich, M., Hynx, D., Geier, A., Niessen, M., Spinaz, G.A., Hemmings, B.A. and Tschopp, O. (2015) *Reduced hepatic lipid content in Pten-haplodeficient mice because of enhanced AKT2/PKCb activation in skeletal muscle* Liver Int., **35**, 1354–1366

**Shettigar, V.**, Zhang, B., Little, S.C., Salhi, H.E., Hansen, B.J., Li, N., Zhang, J., Roof, S.R., Ho, H-T., Brunello, L. et al (2016) *Rationally engineered Troponin C modulates in vivo cardiac function and performance in health and disease* Nat. Comm., **7**: 10794

**Vrontou, S.**, Wong, A.M., Rau, K.K., Koerber, R. and Anderson, D.J. (2013) *Genetic identification of C fibres that detect massage-like stroking of hairy skin in vivo* Nature, **493**, 669-673

### **Intramuscular injection**

**Davis, A.S.**, Federici, T., Ray, W.C., Boulis, N.M., O'Connor, D., Clark, K.R. and Bartlett, J.S. (2015) *Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery* Neurosurgery, **76**, 216-225

### **Intrathecal injection**

**Huda, F.**, Konno, A., Matsuzaki, Y., Goenawan, H., Miyake, K., Shimada, T. and Hirai, H. (2014) *Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model* Mol. Ther. Methods Clin. Dev., **1**: 14032

### **Intrathoracic injection**

**Huang, J.**, Li, X., Coelho-dos-Reis, J.G.A., Wilson, J.M., Tsuji, M. (2014) *An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8<sup>+</sup> T cells in mice* PLoS One, **9**: e88205

### **Intratracheal injection**

**Vidović, D.**, Gijbers, R., Quiles-Jimenez, A., Dooley, J., Van den Haute, C., Van der Perren, A., Liston, A., Baekelandt, V., Debyser, Z. and Carlon, M.S. (2016) *Noninvasive imaging reveals stable transgene expression in mouse airways after delivery of a nonintegrating recombinant adeno-associated viral vector* Hum. Gene Ther., **27**, 60-71

### **Intravenous injection**

**Chaanine, A.H.**, Nonnenmacher, M., Kohlbrenner, E., Jin, D., et al (2014) *Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure* Gene Ther., **21**, 379–386

**Chen, S-J.**, Johnston, J., Sandhu, A., Bish, L.T., et al (2013) *Enhancing the utility of adeno-associated virus gene transfer through inducible tissue-specific expression* Hum. Gene Ther. Methods, **24**, 270–278

**Denard, J.**, Beley, C., Kotin, R., Lai-Kuen, R., et al (2012) *Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6* J. Virol., **86**, 6620-6631

**Faust, S.M.**, Bell, P., Zhu, Y., Sanmiguel, J. and Wilson, J.M. (2013) *The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer* Mol. Ther., **21**, 2227–2235

**Guenzel, A.J.**, Hofherr, S.E., Hillestad, M., Barry, M., et al (2013) *Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing* Mol. Ther., **21**, 1316-1323

**Guenzel, A.J.**, Collard, R., Kraus, J.P., Matern, D. and Barry, M.A. (2015) *Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors* Hum. Gene Ther., **26**, 153–160

**György, B.**, Fitzpatrick, Z., Crommentuijn, M.H.W., Mu, D. and Maguire, C.A. (2014) *Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo* Biomaterials, **35**, 7598-7609

**Han, T.**, Abdel-Motal, U.M., Chang, D-K., Sui, J., et al (2012) *Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma* PLoS One, **7**: e44455

**Hicks, M.J.**, Rosenberg, J.B., De, B.P., Pagovich, O.E., et al (2012) *AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation* Sci. Transl. Med., **4**: 140ra87

**Huang, J.**, Li, X., Coelho-dos-Reis, J.G.A., Wilson, J.M., Tsuji, M. (2014) *An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8<sup>+</sup> T cells in mice* PLoS One, **9**: e88205

**Katwal, A.B.**, Konkalmatt, P.R., Piras, B.A., Hazarika, S., et al (2013) *Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery* Gene Ther., **20**, 930–938

**Konno, A.**, Shuvaev, A.N., Miyake, N., Miyake, K., et al (2014) *Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells* Cerebellum, **13**, 29–41

**Kubodera, T.**, Yamada, H., Anzai, M., Ohira, S., et al (2011) *In vivo application of an RNAi strategy for the selective suppression of a mutant allele* Hum. Gene Ther., **22**, 27-34

**Maczuga, P.**, Lubelski, J., van Logtenstein, R., Borel, F., et al (2013) *Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy* Mol. Ther., **21**, 217–227

**Matabosch, X.**, Ying, L., Serra, M., Wassif, C.A., et al (2010) *Increasing cholesterol synthesis in 7-dehydrosterol reductase (DHCR7) deficient mouse models through gene transfer* J. Steroid Biochem. Mol. Biol., **122**, 303–309

**Murthya, V.**, Gao, Y., Geng, L., LeBrasseur, N.K., et al (2014) *Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice* Vaccine, **32**, 4155–4162

**Rosenberg, J.B.**, Hicks, M.J., De, B.P., Pagovich, O., et al (2012) *AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior* Hum. Gene Ther., **23**, 451–459

**Rutschow, D.**, Bauer, R., Göhringer, C., Bekeredjian, R., et al (2014) *SI51A  $\delta$ -sarcoglycan mutation causes a mild phenotype of cardiomyopathy in mice* Eur. J. Hum. Genet., **22**, 119–125

**Van Gestel, M.A.**, Boender, A.J., de Vrind, V.A.J., Garner, K.M., et al (2014) *Recombinant adeno-associated virus: efficient transduction of the rat VMH and clearance from blood* PLoS One, **9**: e97639

**Wang, L.**, Rosenberg, J.B., De, B.P., Ferris, B., et al (2012) *In vivo gene transfer strategies to achieve partial correction of von Willebrand disease* Hum. Gene Ther., **23**, 576–588

**Ying, L.**, Matabosch, X., Serra, M., Watson, B., et al (2014) *Biochemical and physiological improvement in a mouse model of Smith–Lemli–Opitz syndrome (SLOS) following gene transfer with AAV vectors* Mol. Genet. Metab. Rep., **1**, 103–113

### **In utero administration**

**Picconi, J.L.**, Muff-Luett, M.A., Wu, D., Bunchman, E., Schaefer, F. et al (2014) *Kidney-specific expression of GFP by in-utero delivery of pseudotyped adeno-associated virus 9* Mol. Ther. Methods and Clin. Dev., **1**: 14014

### **Joint delivery (see “Arthritic joint delivery”)**

### **Keratinocyte transduction**

**Roedl, D.**, Oji, V., Buters, J.T.M., Behrendt, H. and Braun-Falco, M. (2011) *rAAV2-Mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients* J. Dermatol. Sci., **61**, 194–198

### **Kidney delivery (incl. Renal fibrosis)**

**Chen, S.**, Agarwal, A., Glushakova, O.Y., Jorgensen, M.A., et al (2003) *Gene delivery in renal tubular epithelial cells using recombinant adeno-associated viral vectors* J. Am. Soc. Nephrol., **14**, 947-958

**Clark, K.R.** (2002) *Recent advances in recombinant adeno-associated virus vector production* Kidney Int., **61**, Sympos. 1, S9-S15

**Miyake, N.**, Miyake, K., Yamamoto, M., Hirai, Y. and Shimada, T. (2011) *Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors* Brain Res., **1389**, 19-26 890

**Mu, W.**, Ouyang, X., Agarwal, A., Zhang, L., et al (2005) *IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic disease* J. Am. Soc. Nephrol., **16**, 3651-3660

**Mu, W.**, Long, D.A., Ouyang, X., Agarwal, A., et al (2009) *Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism* Am. J. Physiol. Renal. Physiol., **296**: F145–F152

**Picconi, J.L.**, Muff-Luett, M.A., Wu, D., Bunchman, E., et al (2014) *Kidney-specific expression of GFP by in-utero delivery of pseudotyped adeno-associated virus 9* Mol. Ther. Methods and Clin. Dev., **1**: 14014

**Schievenbusch, S.**, Strack, I., Scheffler, M., Nischt, R., et al (2010) *Combined paracrine and endocrine AAV9-mediated expression of hepatocyte growth factor for the treatment of renal fibrosis* Mol. Ther. **18**, 1302–1309

**Xie, J.**, Li, X., Meng, D., Liang, Q., Wang, X., Wang, L., Wang, R., Xiang, M. and Chen, S. (2016) *Transduction of interleukin-10 through renal artery attenuates vascular neointimal proliferation and infiltration of immune cells in rat renal allograft* Immunol. Lett., **176**, 105–113

### **Leptin therapy (see Obesity”)**

### **Leptomeningeal amyloidosis**

**Batista, A.R.**, Sena-Esteves, M. and Saraiva, M.J. (2013) *Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model* Biochim. Biophys. Acta, **1832**, 1183–1193

### **Leukaemias**

**Han, T.**, Abdel-Motal, U.M., Chang, D-K., Sui, J., et al (2012) *Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma* PLoS One, **7**: e44455



- Kofler, D.M.**, Büning, H., Mayr, C., Bund, D., et al (2004) *Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors* Gene Ther., **11**, 1415-1424
- Michelfelder, S.**, Lee, M-K., deLima-Hahn, E., Wilmes, T., et al (2007) *Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy* Exp. Hematol., **35**, 1766-1776
- Stiefelhagen, M.**, Sellner, L., Kleinschmidt, J.A., Jauch, A., et al (2008) *Application of a haematopoietic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line* Genet., Vaccines Ther., **6**:12
- Tamai, H.**, Miyake, K., Yamaguchi, H., Takatori, M., et al (2012) *AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in LL/AF4-positive ALL model mice* Blood, **119**, 64-71
- Theiss, H.D.**, Kofler, D.M., Buning, H., Aldenhoff, A-L., et al (2003) *Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides* Exp. Hematol., **31**, 1223-1229
- Wendtner, C-M.**, Kofler, D.M., Theiss, H.D., Kurzeder, C., et al (2002) *Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors* Blood, **100**, 1655-1661
- Wendtner, C-M.**, Kofler, D.M., Mayr, C., Bund, D. and Hallek, M. (2004) *The potential of gene transfer into primary B-CLL cells using recombinant virus vectors* Leuk. Lymphoma, **45**, 897-904

### Leukodystrophy (metachromatic)

- Iwamoto, N.**, Watanabe, A., Yamamoto, M., Miyake, N., et al (2009) *Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1* J. Gene Med., **11**, 498-505
- Kurai, T.**, Hisayasu, S., Kitagawa, R., Migita, M., et al (2007) *AAV1 Mediated co-expression of formylglycine-generating enzyme and arylsulfatase A efficiently corrects sulfatide storage in a mouse model of metachromatic leukodystrophy* Mol. Ther., **15**, 38-43
- Matalon, R.**, Surendran S., Rady, P.L., Quast, M.J., et al (2003) *Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease* Mol. Ther., **7**, 580-587
- Miyake, N.**, Miyake, K., Asakawa, N., Yamamoto, M. and Shimada, T. (2014) *Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector* Gene Ther., **21**, 427-433
- Piguet, F.**, Sondhi, D., Piraud, M., Fouquet, F., et al (2012) *Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice* Hum. Gene Ther., **23**, 903-914

### Life cycle (rAAV)

- Zarate-Perez, F.**, Mansilla-Soto, J., Bardelli, M., Burgner II, J.W., et al (2013) *Oligomeric properties of adeno-associated virus Rep68 reflect its multifunctionality* J. Virol., **87**, 1232-1241

### Limb ischaemia

- Jazwa, A.**, Tomczyk, M., Taha, H.M., Hytonen, E., et al (2013) *Arteriogenic therapy based on simultaneous delivery of VEGF-A and FGF4 genes improves the recovery from acute limb ischemia* Vasc. Cell, **5**: 13

### Limbic seizures

- Weinberg, M.S.**, Blake, B.L. and McCown, T.J. (2013) *Opposing actions of hippocampus TNF $\alpha$  receptors on limbic seizure susceptibility* Exp. Neurol., **247**, 429-437

### Lipid metabolism disorders

- Haug, S.** and Braun-Falco, M. (2005) *Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency, implications for gene therapy in Sjögren-Larsson syndrome* Arch. Dermatol. Res., **296**, 568-572
- Haug, S.** and Braun-Falco, M. (2006) *Restoration of fatty aldehyde dehydrogenase deficiency in Sjögren-Larsson syndrome* Gene Ther., **13**, 1021-1026
- Matabosch, X.**, Ying, L., Serra, M., Wassif, C.A., Porter, F.D., Shackleton, C., Watson, G. (2010) *Increasing cholesterol synthesis in 7-dehydrosterol reductase (DHCR7) deficient mouse models through gene transfer* J. Steroid Biochem. Mol. Biol., **122**, 303-309

## Lipoprotein metabolism and lipoprotein-related disorders

- Bissig-Choisat, B.**, Wang, L., Legras, X., Saha, P.K., Chen, L., Bell, P.K., Pankowicz, F.P., Hill, M.C., Barzi, M. et al (2015) *Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model* Nat. Commun., **6**: 7339
- Boesjes, M.**, Bloks, V.W., Hageman, J., Bos, T., van Dijk, T.H., Havinga, R., Wolters, H., Jonker, J.W., Kuipers, F. and Groen, A.K. (2014) *Hepatic farnesoid X-receptor isoforms  $\alpha 2$  and  $\alpha 4$  differentially modulate bile salt and lipoprotein metabolism in mice* PLoS One, **9**: e115028
- Chen, S.-J., Sanmiguel, J., Lock, M., McMenamin, D.** et al (2013) *Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia* Hum. Gene Ther. Clin. Dev., **24**, 154-160
- Craig, A.T.**, Gavrilova, O., Dwyer, N.K., Jou, W., et al (2009) *Transduction of rat pancreatic islets with pseudotyped adeno-associated virus vectors* Virol. J. **6**:61
- Evans, V.**, Foster, H., Graham, I.R., Foster, K., et al (2008) *Human apolipoprotein E expression from mouse skeletal muscle by electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7)* Hum. Gene Ther., **19**, 569-578
- Evans, V.C.**, Graham, I.R., Athanasopoulos, T., Galley, et al (2011) *Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle* Metab. Clin. Exp., **60**, 491-498
- Harris, J.D.**, Schepelmann, S., Athanasopoulos, T., Graham, I.R., et al (2002) *Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E* Gene Ther., **9**, 21-29
- Hu, J.**, Liu, C.-C., Chen, X-F., Zhang, Y-w., Xu, H. and Bu, G. (2015) *Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and  $\beta$  metabolism in apoE4-targeted replacement mice* Mol. Neurodegen., **10**:6
- Jäger, J.**, Greiner, V., Strzoda, D., Seibert, O., et al (2014) *Hepatic transforming growth factor- $\beta$  1 stimulated clone-22 D1 controls systemic cholesterol metabolism* Mol. Metab., **3**, 155-166
- Jalkanen, J.**, Leppanen, P., Pajusola, K., Mahonen, A., et al (2003) *Adeno-associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice* Mol. Ther., **8**, 903-910
- Kassim, S.H.**, Li, H., Bell, P., Somanathan, S., et al (2013) *Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia* Hum. Gene Ther., **24**, 19-26
- Koornneef, A.**, Maczuga, P., van Logtenstein, R., Borel, F., et al (2011) *Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice* Mol. Ther., **19**, 731-740
- Osman, E.**, Graham, I., Athanasopoulos, T., Nathwani, A.C., Owen, J.S. (2007) *Liver-directed gene transfer of atheroprotective human Apo- $I_{\text{Milano}}$*  Hum. Gene Ther., **18**, 967
- Osman, E.**, Evans, V., Graham, I.R., Athanasopoulos, T., et al (2009) *Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice* Atherosclerosis **204**, 121-126
- Ross, C.J.D.**, Twisk, J., Meulenberg, J.M., Liu, G., van den Oever, K., Moraal, E., Hermens, W.T., Rip, J., Kastelein, J.J.P., Kuivenhoven, J.A. and Hayden, M.R. (2004) *Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL<sup>S447X</sup> beneficial mutation* Hum. Gene Ther., **15**, 906-919
- Ross, C.J.D.**, Twisk, J., Bakker, A.C., Miao, F., Verbart, D., Rip, J., Godbey, T., Dijkhuizen, P., Hermens, W.T.J.M.C., Kastelein, J.J.P., Kuivenhoven, J.A., Meulenberg, J.M. and Hayden, M.R. (2006) *Correction of Feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation* Hum. Gene Ther., **17**, 487-499
- Sharifi, B.G.**, Wu, K., Wang, L., Ong, J.M., et al (2005) *AAV serotype-dependent apolipoprotein A- $I_{\text{Milano}}$  gene expression* Atherosclerosis, **181**, 261-269
- Sun, S.**, Ford, T., Davis, A and Teng, B-B. (2001) *Recombinant adeno-associated virus-mediated gene delivery of apolipoprotein B mRNA site-specific ribozyme* Am. Soc. Gene Ther., 4<sup>th</sup> Annu. Meeting Abstr. 430
- Tian, F.**, Wang, L., Arias, A., Yang, M., Sharifi, B.G. and Shah, P.K. (2015) *Comparative antiatherogenic effects of intravenous AAV8- and AAV2-mediated ApoA- $I_{\text{Milano}}$  gene transfer in hypercholesterolemic mice* J. Cardiovasc. Pharmacol. Therapeut., **20**, 66-75
- Vaessen, S.F.**, Veldman, R.J., Comijn, E.M., Snapper, J., et al (2009) *AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency* J. Gene Med., **11**, 697-707
- Wang, L.**, Tian, F., Arias, A., Yang, M., Sharifi, B.G. and Shah, P.K. (2016) *Comparative effects of diet-induced lipid lowering versus lipid lowering along with Apo A-I Milano gene therapy on regression of atherosclerosis* J. Cardiovasc. Pharmacol. Therapeut., **21** 320-328

- White, K.**, Buning, H., Kritz, A., Janicki, H., et al (2008) *Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions* Gene Ther., **15**, 443-451
- Zhong, S.**, Sun, S. and Teng, B-B. (2004) *The recombinant adeno-associated virus vector (rAAV2)-mediated apolipoprotein B mRNA-specific hammerhead ribozyme: a self-complementary AAV2 vector improves the gene expression* Genet. Vaccines Ther., **2**, 1-11

## Liver (see “Hepatic/hepatocyte delivery”)

## Lung (see “Respiratory system delivery”)

### Lysine residues, surface

- Li, B.**, Ma, W., Ling, C., Van Vliet, K., Huang, L-Y., Agbandje-McKenna, M., Srivastava, A. and Aslanidi, G.V. (2015) *Site-directed mutagenesis of surface-exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo* Hum. Gene Ther. Methods **26**, 211-220

### Lysosomal storage diseases

- Alméciga-Díaz, C.J.**, Montanó, A.M., Tomatsu, S. and Barrera, L.A. (2010) *Adeno-associated virus gene transfer in Morquio A disease – effect of promoters and sulfatase-modifying factor 1* FEBS J., **277**, 3608–3619
- Cresawn, K.O.**, Fraites, T.J., Wasserfall, C., Atkinson, M., et al (2005) *Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived  $\alpha$ -glucosidase in a model of glycogen storage disease type II* Hum. Gene Ther., **16**, 68-80
- Cressant, A.**, Desmaris, N., Verot, L., Brejot, T., et al (2004) *Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIb disease after adeno-associated virus-mediated gene transfer in the striatum* J. Neurosci., **24**, 10229-10239
- Daly, T.M.**, Ohlemiller, K.K., Roberts, M.S., Vogler, C.A. and Sands, M.S. (2001) *Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer* Gene Ther., **8**, 1291-1298
- Desmaris, N.**, Verot, L., Puech, J.P., Caillaud, C., et al (2004) *Prevention of neuropathology in the mouse model of Hurler syndrome* Ann. Neurol., **56**, 68-76
- Ellinwood, N.M.**, Ausseil, J., Desmaris, N., Bigou, S., et al (2011) *Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes* Mol. Ther., **19**, 251–259
- Foley, J.W.**, Bercury, S.D., Finn, P., Cheng, S.H., et al (2010) *Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice* Mol. Ther., **9**, 1584–1591
- Ghosh, A.**, Allamarvasht, M., Pan, C-J., Sun, M-S., et al (2006) *Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer* Gene Ther., **13**, 321-329
- Gilkes, J.A.**, Bloom, M.D. and Heldermon, C.D. (2016) *Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes* Mol. Genet. Metab. Rep., **6**, 48–54
- Hartung, S.D.**, Frandsen, J.L., Pan, D., Koniar, B.L., et al (2004) *Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human  $\alpha$ -L-iduronidase gene* Mol. Ther., **9**, 866-875
- Hennig, A.K.**, Ogilvie, J.M., Ohlemiller, K.K., Timmers, A.M., et al (2004) *AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice* Mol. Ther., **10**, 106-116
- Hinderer, C.**, Bell, P., Gurda, B.L., Wang, Q., Louboutin, J-P., Zhu, Y., Bagel, J., O’Donnell, P., Sikorac, T., Ruane, T., Wang, P., Haskins, M.E. and Wilson, J.M. (2014) *Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I* Proc. Natl. Acad. Sci. USA, **111**, 14894–14899
- Hinderer, C.**, Bell, P., Louboutin, J-P., Zhu, Y., Yu, H., Lin, G., Choa, R., Gurda, B.L. et al (2015) *Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates* Mol. Ther., **23**, 1298-1307
- Ho, T.T.**, Maguire, A.M., Aguirre, G.D., Surace, E.M., et al (2002) *Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI J.* Gene Med., **4**, 613-621
- Hurlbut, G.D.**, Ziegler, R.J., Nietupski, J.B., Foley, J.W., et al (2010) *Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy* Mol. Ther., **18**, 1983–1994
- Kurai, T.**, Hisayasu, S., Kitagawa, R., Migita, M., et al (2007) *AAV1 Mediated co-expression of formylglycine-generating enzyme and arylsulfatase A efficiently corrects sulfatide storage in a mouse model of metachromatic leukodystrophy* Mol. Ther., **15**, 38-43

- Miller, D.G.**, Wang, P-R., Petek, L.M., Hirata, R.K., et al (2006) *Gene targeting in vivo by adeno-associated virus vectors* Nat. Biotechnol., **24**, 1022-1026
- Miyake, N.**, Miyake, K., Asakawa, N., Yamamoto, M. and Shimada, T. (2014) *Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector* Gene Ther., **21**, 427–433
- Qiu, K.**, Falk, D.J., Reier, P.R., Byrne, B.J. and Fuller, D.D. (2012) *Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice* Mol. Ther., **20**, 21–27
- Sondhi, D.**, Scott, E.C., Chen, A., Hackett, N.R., et al (2014) *Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene* Hum. Gene Ther., **25**, 223–239
- Sun, B.**, Chen, Y-T., Bird, A., Xu, F., et al (2003) *Packaging of an AAV vector encoding human acid  $\alpha$ -glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector* Mol. Ther., **7**, 467-477
- Sun, B.**, Zhang, H., Franco, L.M., Young, S.P., et al (2005) *Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II* Mol. Ther., **11**, 57-65
- Sun, M-S.**, Pan, C-J., Shieh, J-J., Ghosh, A., et al (2002) *Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice* Hum. Genet., **11**, 2155-2164
- Sun, T.**, Yi, H., Yang, C., Kishnani, P.S. and Sun, B. (2016) *Starch binding domain containing protein 1 plays a dominant role in glycogen transport to lysosomes in liver* J. Biol. Chem., **291**, 16479–16484
- Tardieu, M.**, Zérah, M., Husson, B., de Bournonville, S., Deiva, K., Adamsbaum, K., Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V. et al (2014) *Intracerebral administration of adeno-associated viral vector Serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with muco-polysaccharidosis type IIIA disease: results of a phase I/II trial* Hum. Gene Ther., **25**, 506–516
- Winner, L.K.**, Beard, H., Hassiotis, S., Lau, A.A., Luck, A.J., Hopwood, J.J. and Hemsley, K.M. (2016) *A preclinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome* Hum. Gene Ther., **27**, 363-375
- Wolf, D.A.**, Lenander, A.W., Nan, Z., Belur, L.R., et al (2011) *Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I* Neurobiol. Dis., **43**, 123–133
- Yi, H.**, Fredrickson, K.B., Das, S., Kishnani, P.S. and Sun, B. (2013) *Stbd1 is highly elevated in skeletal muscle of Pompe disease mice but suppression of its expression does not affect lysosomal glycogen accumulation* Mol. Genet. Metab., **109**, 312–314
- Zhu, Y.**, Jiang, J-L., Gumlaw, N.K., Zhang, J., et al (2009) *Glycoengineered acid  $\alpha$ -glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease* Mol. Ther., **17**, 954-963

### Lysosomal aggregation

- Batista, A.R.**, Sena-Esteves, M. and Saraiva, M.J. (2013) *Hepatic production of transthyretin L12P leads to intracellular lysosomal aggregates in a new somatic transgenic mouse model* Biochim. Biophys. Acta, **1832**, 1183–1193

### Malaria immunity

- Huang, J.**, Li, X., Coelho-dos-Reis, J.G.A., Zhang, M., Mitchell, R., Nogueira, R.T., Tsao, T. et al (2015) *Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria* J. Immunol. Methods, **427**, 42–50

### Mammary gland

- Wagner, S.**, Thresher, R., Bland, R. and Laible, G. (2015) *Adeno-associated-virus-mediated transduction of the mammary gland enables sustained production of recombinant proteins in milk* Sci. Rep., **5**: 15115

### MegaTAL nuclease

- Sather, B.D.**, Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y. et al (2015) *Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template* Sci. Transl. Med., **7**: 307ra156

### Metabotropic glutamate receptor

- O’Riordan, K.**, Gerstein, H., Hullinger, R. and Burger, C. (2014) *The role of Homer1c in metabotropic glutamate receptor-dependent long-term potentiation* Hippocampus, **24**, 1-6



### **Methylmalonic aciduria**

**Erger, K.E.**, Conlon, T.J., Leal, N.A., Zori, R., et al (2007) *In vivo expression of human ATP:cob(I)alamin adenosyltransferase (ATR) using recombinant adeno-associated virus (rAAV) serotypes 2 and 8* J. Gene Med., **9**, 462-469

### **MHC gene regulation**

**Neerinx, A.**, Jakobshagen, K., Utermöhlen, O., Büning, H., Steimle, V. and Kufer, T.A. (2014) *The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression* J. Immunol., **193**, 3090–3100

### **Mitochondrial defects**

**Beattie, S.G.**, Goetzman, E., Tang, Q., Conlon, T., et al (2008) *Recombinant adeno-associated virus-mediated gene delivery of long chain acyl coenzyme A dehydrogenase (LCAD) into LCAD-deficient mice* J. Gene Med., **10**, 1113-1123

**Conlon, T.J.**, Walter, G., Owen, R., Cossette, T., et al (2006) *Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector* Hum. Gene Ther., **17**, 71-80

**Doucet-Beaupré, H.**, Gilbert, C., Profes, M.S., Chabrat, A., Pacelli, C., Giguère, N., Rioux, V., Charest, J., Deng, Q. et al (2016) *Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons* Proc. Natl. Acad. Sci. USA, **111**, E4387-E4396

**Erger, K.E.**, Conlon, T.J., Leal, N.A., Zori, R., et al (2007) *In vivo expression of human ATP:cob(I)alamin adenosyltransferase (ATR) using recombinant adeno-associated virus (rAAV) serotypes 2 and 8* J. Gene Med., **9**, 462-469

**Han, Z.**, Berendzen, K., Zhong, L., Surolia, I., et al (2008) *A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate* Mol. Gen. Metabol., **93**, 381-387

**Kubodera, T.**, Yamada, H., Anzai, M., Ohira, S., et al (2011) *In vivo application of an RNAi strategy for the selective suppression of a mutant allele* Hum. Gene Ther., **22**, 27-34

**Qi, X.**, Lewin, A.S., Sun, L., Hauswirth, W.W. and Guy, J. (2004) *SOD2 gene transfer protects against optic neuropathy induced by deficiency of complex I* Ann. Neurol., **56**, 182-191

**Seo, B.B.**, Wang, J.M., Flotte, T.R., Yagi, T. and Matsuno-Yagi, A. (2000) *Use of the NADH-quinone oxidoreductase (NDII) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells* J. Biol. Chem., **275**, 37774-37778

**Seo, B.B.**, Nakamaru-Ogiso, E., Cruz, P., Flotte, T.R., et al (2004) *Functional expression of the single subunit NADH dehydrogenase in mitochondria in vivo: a potential therapy for complex I deficiencies* Hum. Gene Ther., **15**, 887-895

**Tang, F-L.**, Liu, W., Hu, J-X., Erion, J.R., Ye, J., Mei, L. and Xiong, W-C. (2015) *VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function* Cell Rep., **12**, 1631–1643

**Yu, H.**, Koilkonda, R.D., Chou, T-H., Porciatti, V., et al (2012) *Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model* Proc. Natl. Acad. Sci. USA, **109**, E1238–E1247

### **Muscular dystrophy (see “Skeletal muscle delivery”)**

### **Mucopolysaccharidosis (see “Lysosomal storage diseases”)**

### **Myelin basic proteins**

**Aggarwal, S.**, Snaidero, N., Pähler, G., Frey, S., et al (2013) *Myelin membrane assembly is driven by a phase transition of myelin basic proteins into a cohesive protein meshwork* PLoS Biol., **11**: e1001577

### **Myocardial infarction**

**Prasad, K-M.R.**, Smith, R.S., Xu, Y., French, B.A. (2011) *A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction* J. Gene Med., **13**, 333–341

### **Nanodes (virus)**

**Ho, M.L.**, Judd, J., Kuypers, B.E., Yamagami, M., Wong, F.F. and Suh, J. (2014) *Efficiency of protease-activatable virus nanonodes tuned through incorporation of wild-type capsid subunits* Cell. Mol. Bioeng., **7**, 334–343

### **Nanoparticle binding**

**Musick, M.A.**, McConnell, K.I., Lue, J.K., Wei, F., Chen, C. and Suh, J. (2011) *Reprogramming virus nanoparticles to bind metal ions upon activation with heat* Biomacromolecules, **12**, 2153–2158

**Wei, F.**, McConnell, K.I., Yu, T-K. and Suh, J. (2012) *Conjugation of paclitaxel on adeno-associated virus (AAV) nanoparticles for co-delivery of genes and drugs* Eur. J. Pharm. Sci., **46**, 167–172

### **Neonatal cardiopathy**

**Mearini, G.**, Stimpel, D., Geertz, B., Weinberger, F., Krämer, E., Schlossarek, S., Mourot-Filiatre, J. et al (2014) *Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice* Nature Comm., **5**: 5515

### **Neovascularization**

**Igarashi, T.**, Miyake, K., Masuda, I., Takahashi, H. and Shimada, T. (2010) *Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model* Hum. Gene Ther., **21**, 631-637

**Pinkenburg, O.**, Pfosser, A., Hinkel, R., Böttcher, M., et al C. (2009) *Recombinant adeno-associated virus-based gene transfer of cathelicidin induces therapeutic neovascularization preferentially via potent collateral growth* Hum Gene Ther., **20**,159–167

### **Neutralizing antibodies**

**Rapti, K.**, Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., et al (2012) *Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models* Mol. Ther., **20**, 73–83

### **Nicotine withdrawal**

**Grieder, T.E.**, Herman, M.A., Contet, C., Tan, L.A., Vargas-Perez, H., Cohen, A., Chwalek, M., Maal-Bared, G. et al (2014) *VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation* Nat. Neurosci., **17**, 1751-1758

### **Non-human primate administration**

**Gray, S.J.**, Kalburgi, S.N., McCown, T.J. and Samulski, R.J. (2013) *Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates* Gene Ther., **20**, 450–459

**Hinderer, C.**, Bell, P., Louboutin, J-P., Zhu, Y., Yu, H., Lin, G., Choa, R., Gurda, B.L. et al (2015) *Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates* Mol. Ther., **23**, 1298-1307

### **Nuclear interactions/translocation**

**Gomez, E.J.**, Gerhardt, K., Judd, J., Tabor, J.J. and Suh, J. (2016) *Light-activated nuclear translocation of adeno-associated virus nanoparticles using phytochrome B for enhanced, tunable, and spatially programmable gene delivery* ACS Nano, **10**, 225–237

**Nicolson, S.C.** and Samulski, R.J. (2014) *Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus* J. Virol., **88**, 4132–4144

**Santamaria, M.**, Pardo-Saganta, A., Alvarez-Asiain, L., Di Scala, M., et al (2013) *Nuclear  $\alpha$ 1-antichymotrypsin promotes chromatin condensation and inhibits proliferation of human hepatocellular carcinoma cells* Gastroenterology, **144**, 818-828

**Tenney, R.M.**, Bell, C.L. and Wilson, J.M. (2014) *AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating* Virology 454-455 (2014) 227–236

### **Obesity (including leptin therapy)**

**Bagnasco, M.**, Dube, M.G., Kalra, P.S. and Kalra, S.P. (2002) *Evidence for the existence of distinct central appetite, energy expenditure, and ghrelin stimulation pathways as revealed by hypothalamic site-specific leptin gene therapy* Endocrinology, **143**, 4409-4421

**Boender, A.J.**, Koning, N.A., van den Heuvel, J.K., Luijendijk, M.C.M., et al (2014) *AAV-mediated gene transfer of the obesity-associated gene *Etv5* in rat midbrain does not affect energy balance or motivated behavior* PLoS One, **9**: e94159

**Dhillon, H.**, Ge, Y-L., Minter, R.M., Prima, V., et al (2000) *Long-term differential modulation of genes encoding orexigenic and anorexigenic peptides by leptin delivered by rAAV vector in ob/ob mice* Regul. Pept., **92**, 97-105

- Dhillon, H.**, Kalra, S.P., Prima, V., Zolotukhin, S., et al (2001) *Central leptin gene therapy suppresses body weight gain, adiposity and serum insulin without affecting food consumption in normal rats* Regul. Pept., **99**, 69-77
- Dhillon, H.**, Kalra, S.P. and Kalra, P.S. (2001) *Dose-dependent effects of central leptin gene therapy on genes that regulate body weight and appetite in the hypothalamus* Mol. Ther., **4**, 139-145
- Dube, M.G.**, Beretta, E., Dhillon, H., Ueno, N., et al (2002) *Central leptin gene therapy blocks high-fat diet-induced weight gain, hyperleptinemia, and hyperinsulinemia* Diabetes, **51**, 1729-1736
- Gardiner, J.V.**, Kong, W.M., Ward, H., Murphy, K.G., et al (2005) *AAV mediated expression of anti-sense neuropeptide Y cRNA in the arcuate of rats results in decreased weight gain and food intake* Biochem. Biophys. Res. Commun., **327**, 1088-1093
- Gruber, S.**, Straub, B.K., Ackermann, J., Wunderlich, C.M., et al (2013) *Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Ra signaling* Cell Rep., **4**, 669-680
- Hayes, M.R.**, Skibicka, K.P., Lechner, T.M., Guarnieri, D.J., et al (2010) *Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema is required for energy balance regulation* Cell Metab., **11**, 77-83
- He, W.**, Lam, T.K.T., Obici, S. and Rossetti, L. (2006) *Molecular disruption of hypothalamic nutrient sensing induces obesity* Nat. Neurosci., **9**, 227-233
- Hommel, J.D.**, Trinko, R., Sears, R.M., Georgescu, D., et al (2006) *Leptin receptor signaling in midbrain dopamine neurons regulates feeding* Neuron, **51**, 801-810
- Kanoski, S.E.**, Zhao, S., Guarnieri, D.J., DiLeone, R.J., Yan, J., De Jonghe, B.C., Bence, K.K., Hayes, M.R. and Grill, H.J. (2012) *Endogenous leptin receptor signaling in the medial nucleus tractus solitarius affects meal size and potentiates intestinal satiation signals* Am. J. Physiol. Endocrinol. Metab., **303**, E496-E503
- Kas, M.J.H.**, Tiesjema, B., van Dijk, G., Garner, K.M., et al (2004) *Induction of brain region-specific forms of obesity by Agouti* J. Neurosci., **24**, 10176-10181
- Lecklin, A.**, Dube, M.G., Torto, R.N., Kalra, P.S. and Kalra, S.P. (2005) *Perigestational suppression of weight gain with central leptin gene therapy results in lower weight F1 generation* Peptides, **26**, 1176-1187
- Manfredsson, F.P.**, Tümer, N., Erdos, B., Landa, T., et al (2009) *Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity* Mol. Ther., **17**, 980-991
- Platt, T.L.**, Beckett, T.L., Kohleer, Niedowicz, K.D.M. and Murphy, M.P. (2016) *Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease* Neuroscience **315**, 162-174
- Prima, V.**, Tennant, M., Gorbatyuk, O.S., Muzyczka, N., et al (2004) *Differential modulation of energy balance by leptin, ciliary neurotrophic factor, and leukemia inhibitory factor gene delivery: microarray deoxyribonucleic acid-chip analysis of gene expression* Endocrinology, **145**, 2035-2045
- Scarpace, P.J.**, Matheny, M., Zhang, Y., Tümer, N., et al (2002) *Central leptin gene delivery evokes persistent leptin signal transduction in young and aged-obese rats but physiological responses become attenuated over time in aged-obese rats* Neuropharmacology, **42**, 548-561
- Scarpace, P.J.**, Matheny, M., Zhang, Y., Shek, E.W., et al (2002) *Leptin-induced leptin resistance reveals separate roles for the anorexic and thermogenic responses in weight maintenance* Endocrinology, **143**, 3026-3035
- Tümer, N.**, Scarpace, P.J., Dogan, M.D., Broxson, C.S., et al (2006) *Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity* Neurobiol. Aging, **27**, 459-470
- Van Gestel, M.A.**, Sanders, L.E., de Jong, J.W., Luijendijk, M.C.M. and Adan, J.A.H. (2014) *FTO knockdown in rat ventromedial hypothalamus does not affect energy balance* Physiol. Rep., **2**: e12152
- Wilsey, J.**, Zolotukhin, S., Prima, V. and Scarpace, P.J. (2003) *Central leptin gene therapy fails to overcome leptin resistance associated with diet-induced obesity* Am. J. Physiol. Regul. Integ. Comp. Physiol., **285**, R1101-R1020

## Optical dysfunction

### Achromatopsia

- Banin, E.**, Gootwine, E., Obolensky, A., Ezra-Elia, R., Eijzenberg, A., Zelinger, L., Honig, H., Rosov, A. et al (2015) *Gene augmentation therapy restores retinal function and visual behavior in a sheep model of CNGA3 achromatopsia* Mol. Ther., **23**, 1423-1433
- Michalakakis, S.**, Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., et al (2012) *Gene therapy restores missing cone-mediated vision in the CNGA3<sup>-/-</sup> mouse model of achromatopsia* In Retinal degenerative diseases: Advances in experimental medicine and biology, vol. **723** (eds. LaVail, M.M. et al) Springer Science+Business Media, LLC, pp 183-189
- Schön, C.**, Asteriti, S., Koch, S., Sothilingam, V., Garrido, N.G., Tanimoto, N., Herms, J., Seeliger, M.W., Cangiano, L., Biel, M. and Michalakakis, S. (2016) *Loss of HCN1 enhances disease progression in mouse models of CNG channel-linked retinitis pigmentosa and achromatopsia* Hum. Mol. Genet., **25**, 1165-1175

**Ye, G-J.**, Budzynski, E., Sonnentag, P., Nork, T.M., Sheibani, N., Gurel, Z., Boye, S.L., Peterson, J.J., . Boye, S.E., Hauswirth, W.W. and Chulay, J.D. (2016) *Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases* Hum. Gene Ther., **27**, 72-82

#### **Ancestral rAAVs, targeting of**

**Zinn, E.**, Pacouret, S., Khaychuk, V., Turunen, H.T., Carvalho, L.S., Andres-Mateos, E., Shah, S. Shelke, R. et al (2015) *In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector* Cell Rep., **12**, 1056–1068

#### **Angiogenesis**

**Joyal, J-S.**, Sun, Y., Gantner, M.L., Shao, Z., Evans, L.P., Saba, N., Fredrick, T., Burnim, S., Kim, J.S., Pate, G., Juan, A.M. et al (2016) *Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1* Nat. Med., **22**, 439-445

#### **AIPL1 mutations**

**Sun, X.**, Pawlyk, B., Xu, X., Liu, X., Bulgakov, O.V., Adamian, M., Sandberg, M.A., Khani, S.C., Tan, M-H., Smith, A.J., Ali, R.R. and Li, T. (2010) *Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations* Gene Ther., **17**, 117–131

#### **Axonal degeneration/growth/misguidance**

**Koch, J.C.**, Tönges, L., Barski, E., Michel, U., et al (2014) *ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS* Cell Death Dis., **5**: e1225

**Koch, J.C.**, Solis, G.P., Bodrikov, V., Michel, U., Haralampieva, D., Shypitsyna, A., Tönges, L., Bähr, M., Lingor, P. and Stuermer, C.A.O. (2013) *Upregulation of reggie-1/flotillin-2 promotes axon regeneration in the rat optic nerve in vivo and neurite growth in vitro* Neurobiol. Dis., **51**, 168–176

**Koch, J.C.**, Tönges, L., Barski, E., Michel, U., et al (2014) *ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS* Cell Death Dis., **5**: e1225

**Pernet, V.**, Joly, S., Dalkara, D., Jordi, N., et al (2013) *Long-distance axonal regeneration induced by CNTF gene transfer is impaired by axonal misguidance in the injured adult optic nerve* Neurobiol. Dis., **51**, 202–213

**Planchamp, V.**, Bermel, C., Tönges, L., Ostendorf, T., et al (2008) *BAG1 promotes axonal outgrowth and regeneration in vivo via Raf-1 and reduction of ROCK activity* Brain **131**, 2606-2619

#### **Bardet-Biedl syndrome**

**Seo, S.**, Mullins, R.F., Dumitrescu, A.V., Bhattarai, S., et al (2013) *Subretinal gene therapy of mice with Bardet-Biedl syndrome type 1* Invest. Ophthalmol. Vis. Sci., **54**, 6118–6132

#### **Capsid modification**

**Cronin, T.**, Vandenbergh, L.H., Hantz, P., Juttner, J., Reimann, A., Kacso, A.E., Huckfeldt, R.M., Busskamp, V., Kohler, H., Lagali, P.S. et al (2014) *Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter* EMBO Mol. Med., **6**, 1175-1190

#### **Channelrhodopsin 2**

**Sengupta, A.**, Chaffiol, A., Macé, E., Caplette, R., Desrosiers, M., Lampič, M., Forster, V., Marre, O. Lin, J.Y. et al (2016) *Red-shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina* EMBO Mol. Med., **8**, 148-1264

#### **Cone vision**

**Li, Q.**, Timmers, A.M., Guy, J., Pang, J. and Hauswirth, W.W. (2008) *Cone-specific expression using a human red opsin promoter in recombinant AAV* Vision Res., **48**, 332-338

**Masseck, O.A.**, Spoida, K., Dalkara, D., Maejima, T., et al (2014) *Vertebrate cone opsins enable sustained and highly sensitive rapid control of Gi/o signaling in anxiety circuitry* Neuron **81**, 1263–1273

**Michalakakis, S.**, Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., et al (2010) *Restoration of cone vision in the CNGA3<sup>-/-</sup> mouse model of congenital complete lack of cone photoreceptor function* Mol. Ther., **18**, 2057–2063

**Michalakakis, S.**, Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., et al (2012) *Gene therapy restores missing cone-mediated vision in the CNGA3<sup>-/-</sup> mouse model of achromatopsia* In Retinal degenerative diseases: Advances in experimental medicine and biology, vol. **723** (eds. LaVail, M.M. et al) Springer Science+Business Media, LLC, pp 183-189



- Najate, A.**, Fridlich, R., Millet-Pue, G., Clerin, E., Delalande, F., Jaillard, C., Blond, F., Perrocheau, L., Reichman, S. et al (2015) *Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis* Cell, **161**, 817–832
- Szikra, T.**, Trenholm, S., Drinnenberg, A., Jüttner, J., Raics, Z., Farrow, K., Biel, M. et al (2014) *Rods in daylight act as relay cells for cone-driven horizontal cell-mediated surround inhibition* Nat. Neurosci., **17**, 1728–1735
- Ye, G-J.**, Budzynski, E., Sonnentag, P., Nork, T.M., Sheibani, N., Gurel, Z., Boye, S.L., Peterson, J.J., . Boye, S.E., Hauswirth, W.W. and Chulay, J.D. (2016) *Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases* Hum. Gene Ther., **27**, 72-82

### Corneal disorders/transduction

- Gruenert, A.K.**, Czugala, M., Mueller, C., Schmeer, M., Schleef, M., Kruse, F.E. and Fuchsluger, T.A. (2016) *Self-complementary adeno-associated virus vectors improve transduction efficiency of corneal endothelial cells* PLoS One, **11**: e0152589
- Hippert, C.**, Ibanes, S., Serratrice, N., Court, F., et al V. (2012) *Corneal transduction by intra-stromal injection of AAV vectors in vivo in the mouse and ex vivo in human explants* PLoS One **7**: e35318
- Mohan, R.R.**, Sinha, S., Tandon, A., Gupta, R., et al (2011) *Efficacious and safe tissue-selective controlled gene therapy approaches for the cornea* PloS One, **6**: e18771
- Mohan, R.R.**, Tandon, A., Sharma, A., Cowden, J.W. et al (2011) *Significant inhibition of corneal scarring in vivo with tissue-selective, targeted AAV5 decorin gene therapy* Invest. Ophthalmol. Vis. Sci., **52**, 4833–4841
- Mohan, R.R.**, Tovey, J.C.K., Sharma, A., Schultz, G.S., et al (2011) *Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo* PLoS One **6**: e26432

### Delivery procedures (cells and tissues)

- Boye, S.L.**, Bennett, A., Scalabrino, M.L., McCullough, K.T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M. and Boye, S.E. (2016) *Impact of heparan sulfate binding on transduction of retina by recombinant adeno-associated virus vectors* J. Virol., **90**, 4215-4231
- Buie, L.K.**, Rasmussen, C.A., Porterfield, E.C., Ramgolam, V.S., (2010) *Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys* Invest. Ophthalmol. Vis. Sci., **51**, 236–248
- Charbel Issa, P.**, De Silva, S.R., Lipinski, D.M., Singh, M.S., et al (2013) *Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina* PLoS One, **8**: e60361y
- Dalkara, D.**, Byrne, L.C., Lee, T., Hoffmann, N.V., Schaffer, D.V. and Flannery, J.G. et al (2012) *Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9* Gene Ther., **19**, 176–181
- Fischer, M.D.**, Hickey, D.G., Singh, M.S. and MacLaren, R.E. (2016) *Evaluation of an optimized injection system for retinal gene therapy in human patients* Hum. Gene Ther. Meth., **27**, 150-148
- Flannery, J.G.** and Visel, M. (2013) *Adeno-associated viral vectors for gene therapy of inherited retinal degenerations* In Methods Mol. Biol., **935**, Retinal Degeneration: Methods and Protocols (ed. Weber, B.H.F. and Langmann, T) Springer Science+Business Media, LLC pp 351-369
- Jacobson, S.G.**, Acland, G.M., Aguirre, G.D., Aleman, T.S., et al (2006) *Safety of recombinant adeno-associated virus type-2 RPE65 vector delivered by ocular subretinal injection* Mol. Ther., **13**, 1074-1084
- Kolstad, K.D.**, Dalkara, D., Guerin, K., Visel, M., et al (2010) *Changes in adeno-associated virus-mediated gene delivery in retinal degeneration* Hum. Gene Ther., **21**, 571-578
- You, Q.**, Brown, L.A., McClements, M., Hankins, M.W., et al (2012) *Tetradecanoyl-phorbol-13-acetate (TPA) significantly increases AAV2/5 transduction of human neuronal cells in vitro* Exp. Eye Res., **97**, 148-153

### Diabetic retinopathy

- Adhi, M.**, Cashman, S.M. and Kumar-Singh, R. (2013) *Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice* PLoS One, **8**: e79661

### Experimental autoimmune encephalomyelitis

- Talla, V.**, Koilkonda, R., Porciatti, V., Chiodo, V., Boye, S.L., Hauswirth, W.W. and Guy, J. (2015) *Complex I subunit gene therapy with NDUFA6 ameliorates neurodegeneration in EAE* Invest. Ophthalmol. Vis. Sci., **56**, 1129–1140

### GABA<sub>A</sub>ergic inhibition

**Zhang, C.**, Rompani, S.B., Roska, B. and McCall, M.A. (2014) *Adeno-associated virus-RNAi of GlyR $\alpha$ 1 and characterization of its synapse-specific inhibition in OFF alpha transient retinal ganglion cells* J. Neurophysiol., **112**, 3125–3137

### Gated channel complexes

**Doroudchi, M.M.**, Greenberg, K.P., Liu, J., Silka, K.A., et al (2011) *Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness* Mol. Ther., **19**, 1220–1229

**Michalakis, S.**, Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., et al (2010) *Restoration of cone vision in the CNGA3<sup>-/-</sup> mouse model of congenital complete lack of cone photoreceptor function* Mol. Ther., **18**, 2057–2063

### Glaucoma

**Borras, T.**, Xue, W., Choi, V.W., Bartlett, J.S., et al (2006) *Mechanisms of AAV transduction in glaucoma-associated human trabecular meshwork cells* J. Gene Med., **8**, 589–602

**Folliot, S.**, Briot, D., Conrath, H., Provost, N., et al (2003) *Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector* J. Gene Med., **5**, 493–501

**Martin, K.R.G.**, Quigley, H.A., Zack, D.J., Levkovitch-Verbin, H., et al (2003) *Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model* Invest. Ophthalmol. Vis. Sci., **44** 4357–4365

**Pease, M.E.**, Zack, D.J., Berlinicke, C., Bloom, K., et al (2009) *Effect of CNTF on retinal ganglion cell survival in experimental glaucoma* Invest. Ophthalmol. Vis. Sci., **50**, 2194–2200

**Renwick, J.**, Narang, M.A., Coupland, S.G., Xuan, J.Y., et al (2006) *XIAP-mediated neuroprotection in retinal ischemia* Gene Ther., **13**, 339–347

### Growth factors

**Mao, Y.**, Kiss, S., Boyer, J.L., Hackett, N.R., et al (2011) *Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab* Hum. Gene Ther., **22**, 1525–1535

### Juvenile retinal dysfunction

**Acland, G.M.**, Aguirre, G.D., Ray, J., Zhang, Q., et al (2001) *Gene therapy restores vision in a canine model of childhood blindness* Nat. Genet., **28**, 92–95

**Acland, G.M.**, Aguirre, G.D., Bennett, J., Aleman, T.S., et al (2005) *Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness* Mol. Ther., **12**, 1072–1082

**Griffey, M.**, Shannon, L., Macauley, J.M.O. and Sands, M.S. (2005) *AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis* Mol. Ther., **12**, 413–421

**Min, S.H.**, Molday, L.L., Seeliger, M.W., Dinculescu, A., et al (2005) *Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of X-linked juvenile retinoschisis* Mol. Ther., **12**, 644–651

### Leber congenital amaurosis/hereditary neuropathy

**Acland, G.M.**, Aguirre, G.D., Ray, J., Zhang, Q., et al (2001) *Gene therapy restores vision in a canine model of childhood blindness* Nat. Genet., **28**, 92–95

**Pawlyk, B.S.**, Bulgakov, O.V., Liu, X., Xu, X., et al (2010) *Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of Leber congenital amaurosis* Human Gene Ther., **21**, 993–1004

**Sun, X.**, Pawlyk, B., Xu, X., Liu, X., et al (2010) *Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations* Gene Ther., **17**, 117–131

**Yu, H.**, Koilkonda, R.D., Chou, T-H., Porciatti, V., et al (2012) *Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model* Proc. Natl. Acad. Sci. USA, **109**, E1238–E1247

### Lysosome-related diseases

**Griffey, M.**, Shannon, L., Macauley, J.M.O. and Sands, M.S. (2005) *AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis* Mol. Ther., **12**, 413–421

**Hennig, A.K.**, Ogilvie, J.M., Ohlemiller, K.K., Timmers, A.M., et al (2004) *AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice* Mol. Ther., **10**, 106–116

**Ho, T.T.**, Maguire, A.M., Aguirre, G.D., Surace, E.M., et al (2002) *Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI* J. Gene Med., **4**, 613-621

### Macular degeneration

**Ardeljan, D.**, Wang, Y., Park, S., Shen, D., et al (2014) *Interleukin-17 retinotoxicity is prevented by gene transfer of a soluble interleukin-17 receptor acting as a cytokine blocker: implications for age-related macular degeneration* PLoS One, **9**: e95900

**Joyal, J-S.**, Sun, Y., Gantner, M.L., Shao, Z., Evans, L.P., Saba, N., Fredrick, T., Burnim, S., Kim, J.S., Pate, G., Juan, A.M. et al (2016) *Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1* Nat. Med., **22**, 439-445

### Mitochondrial dysfunction

**Koilkonda, R.D.**, Chou, T-H., Porciatti, V., Hauswirth, W.H. and Guy, J. (2010) *Induction of rapid and highly efficient expression of the human ND4 complex I subunit in the mouse visual system by self-complementary adeno-associated virus* Arch. Ophthalmol., **128**, 876-883

**Qi, X.**, Lewin, A., Hauswirth, W.W. and Guy, J. (2003) *Optic neuropathy induced by reductions in mitochondrial superoxide dismutase* Invest. Ophthalm. Vis. Sci., **44**, 1088-1096

**Qi, X.**, Lewin, A.S., Hauswirth, W.W. and Guy, J. (2003) *Suppression of complex I gene expression induces optic neuropathy* Ann. Neurol., **53**, 198-205

**Qi, X.**, Lewin, A.S., Sun, L., Hauswirth, W.W. and Guy, J. (2004) *SOD2 gene transfer protects against optic neuropathy induced by deficiency of complex I* Ann. Neurol., **56**, 182-191

### Müller glial cells

**Aartsen, W.M.**, van Cleef, K.W.R., Pellissier, L.P., Hoek, R.M., et al (2010) *GFAP-driven GFP expression in activated mouse Müller glial cells aligning retinal blood vessels following intravitreal injection of AAV2/6 vectors* PLoS One, **5**: e12387

**Alves, C.H.**, Pellissier, L.P., Vos, R.M., Garrido, M.G., et al (2014) *Targeted ablation of Crb2 in photoreceptor cells induces retinitis pigmentosa* Hum. Mol. Genet., **23**, 3384-3401

**Byrne, L.C.**, Khalid, F., Lee, T., Zin, E.A., et al (2013) *AAV-mediated, optogenetic ablation of Müller glia leads to structural and functional changes in the mouse retina* PLoS One, **8**: e76075

**Byrne, L.C.**, Öztürk, B.E., Lee, T., Fortuny, C., Visel, M., Dalkara, D., Schaffer, D.V. and Flannery, J.G. (2014) *Retinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h<sup>-/-</sup> mouse* Gene Ther., **21**, 585-592

**Klimczak, R.R.**, Koerber, J.T., Dalkara, D., Flannery, J.G. and Schaffer, D.V. (2009) *A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells* PLoS One **4**: e7467

**Pellissier, L.P.**, Hoek, R.M., Vos, R.M., Aartsen, et al (2014) *Specific tools for targeting and expression in Müller glial cells* Mol. Ther. Methods and Clin. Dev., **1**: 14009

**Pellissier, L.P.**, Quinn, P.M., Alves, H., Vos, R.M., Klooster, J., Flannery, J.G., Heime, A. and Wijnholds, J. (2015) *Gene therapy into photoreceptors and Müller glial cells restores retinal structure and function in CRB1 retinitis pigmentosa mouse models* Hum.Mol. Genet., **24**, 3104-3118

**Vacca, O.**, Darce, M., Schaffer, D.V., Flannery, J.G., et al (2014) *AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers* Glia, **62**, 468-476

**Yao, K.**, Qiu, S., Tian, L., Snider, W.D., Flannery, J.G., Schaffer, D.V. and Chen, B. (2016) *Wnt regulates proliferation and neurogenic potential of Müller glial cells via a Lin28/let-7 miRNA-dependent pathway in adult mammalian retinas* Cell Rep., **17**, 165-178

### Neovascularization

**Bainbridge, J.W.B.**, Mistry, A., De Alwis, M., Paleolog, E., et al (2002) *Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1* Gene Ther., **9**, 320-326

**Haurigot, V.**, Villacampa, P., Ribera, A., Bosch, A., et al (2012) *Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy* PLoS One, **7**: e41511

**Mao, Y.**, Kiss, S., Boyer, J.L., Hackett, N.R., et al (2011) *Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab* Hum. Gene Ther., **22**, 1525-1535

### Neurotrophins/neurotrophic factor

**Adamus, G.**, Sugden, B., Shiraga, S., Timmers, A.M. and Hauswirth, W.W. (2003) *Anti-apoptotic effects of CNTF gene transfer on photoreceptor degeneration in experimental antibody-induced retinopathy* J. Autoimmun., **21**, 121-129

- Cheng, L.**, Sapieha, P., Kittlerova, P., Hauswirth, W.W. and Di Polo, A. (2002) *TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo* J. Neurosci., **22**, 3977-3986
- Dalkara, D.**, Kolstad, K.D., Guerin, K.I., Hoffmann, N.V., et al (2011) *AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa* Mol. Ther., **19**, 1602–1608
- Leaver, S.G.**, Cui, Q., Plant, G.W., Arulpragasam, A., Hisheh, S., et al (2006) *AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells* Gene Ther., **13**, 1328-1341
- Pernet, V.**, Joly, S., Dalkara, D., Jordi, N., et al (2013) *Long-distance axonal regeneration induced by CNTF gene transfer is impaired by axonal misguidance in the injured adult optic nerve* Neurobiol. Dis., **51**, 202–213
- Shevtsova, Z.**, Malik, I., Garrido, M., Schöll, U., et al (2006) *Potential of in vivo neuroprotection by BclXL and GDNF co-expression depends on post-lesion time in deafferented CNS neurons* Gene Ther., **13**, 1569-1578
- Martin, K.R.G.**, Quigley, H.A., Zack, D.J., Levkovitch-Verbin, H., et al (2003) *Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model* Invest. Ophthalmol. Vis. Sci., **44** 4357-4365
- Pease, M.E.**, Zack, D.J., Berlinicke, C., Bloom, K., et al (2009) *Effect of CNTF on retinal ganglion cell survival in experimental glaucoma* Invest. Ophthalmol. Vis. Sci., **50**, 2194–2200

### Optic nerve function/injury/regeneration

- Koch, J.C.**, Solis, G.P., Bodrikov, V., Michel, U., et al (2013) *Upregulation of reggie-1/flotillin-2 promotes axon regeneration in the rat optic nerve in vivo and neurite growth in vitro* Neurobiol. Dis., **51**, 168–176
- Koch, J.C.**, Bitow, F., Haack, J., d'Hedouville, Z., Zhang, J-N., Tönges, L., Michel, U. et al (2015) *Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons* Cell Death Dis., **6**: e1811
- Pernet, V.**, Joly, S., Dalkara, D., Schwarz, O., et al (2012) *Neuronal Nogo-A upregulation does not contribute to ER stress-associated apoptosis but participates in the regenerative response in the axotomized adult retina* Cell Death Differ., **19**, 1096–1108
- Pernet, V.**, Joly, S., Jordi, N., Dalkara, D., et al (2013) *Misguidance and modulation of axonal regeneration by Stat3 and Rho/ROCK signaling in the transparent optic nerve* Cell Death Dis., **4**: e734
- Pulizzi, R.**, Musumeci, G., Van den Haute, C., Van De Vijver, S., Baekelandt, V. and Giugliano, M. (2016) *Brief wide-field photostimuli evoke and modulate oscillatory reverberating activity in cortical networks* Sci. Rep., **6**: 24701
- Talla, V.**, Koilkonda, R., Porciatti, V., Chiodo, V., Boye, S.L., Hauswirth, W.W. and Guy, J. (2015) *Complex I subunit gene therapy with NDUFA6 ameliorates neurodegeneration in EAE* Invest. Ophthalmol. Vis. Sci., **56**, 1129–1140

### Photoreceptor delivery/degeneration

- Pellissier, L.P.**, Quinn, P.M., Alves, H., Vos, R.M., Klooster, J., Flannery, J.G., Heime, A. and Wijnholds, J. (2015) *Gene therapy into photoreceptors and Müller glial cells restores retinal structure and function in CRB1 retinitis pigmentosa mouse models* Hum.Mol. Genet., **24**, 3104–3118
- Van Wyk, M., Pielecka-Fortuna, J., Löwel, S. and Kleinlogel, S. (2015) *Restoring the ON switch in blind retinas: Opto-mGluR6, a next-generation, cell-tailored optogenetic tool* PLoS Biol **13**: e1002143

### Primary visual cortex

- Lee, S-H.**, Kwan, A.C., Zhang, S., Phoumthippavong, V., Flannery, J.G., et al (2012) *Activation of specific interneurons improves V1 feature selectivity and visual perception* Nature **488**, 379-382

### Recombinant-AAV serotypes and variants

- Charbel Issa, P.**, De Silva, S.R., Lipinski, D.M., Singh, M.S., et al (2013) *Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina* PLoS One, **8**: e60361y
- Dalkara, D.**, Kolstad, K.D., Caporale, N., Visel, M., et al (2009) *Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous* Mol. Ther., **17**, 2096–2102
- Giove, T.J.**, Sena-Esteves, M. and Eldred, W.D. (2010) *Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection* Exp. Eye Res., **91**, 652-659
- Hellström, M.**, Ruitenber, M.J., Pollett, M.A., Ehlert, E.M.E., et al (2009) *Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection* Gene Ther., **16**, 521–532
- Klimczak, R.R.**, Koerber, J.T., Dalkara, D., Flannery, J.G., et al (2009) *A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells* PLoS One **4**: e7467



**Petrs-Silva, H.**, Dinculescu, A., Li, Q., Min, S-H., et al (2009) *High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors* Mol., Ther., **17**, 463–471

**Petrs-Silva, H.**, Dinculescu, A., Li, Q., Deng, W-T., et al (2011) *Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina* Mol. Ther., **19**, 293–301

### Retinal bipolar cells

**Cronin, T.**, Vandenbergh, L.H., Hantz, P., Juttner, J., Reimann, A., Kacso, A.E., Huckfeldt, R.M., Busskamp, V., Kohler, H., Lagali, P.S. et al (2014) *Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter* EMBO Mol. Med., **6**, 1175-1190

### Retinal cell transduction efficiency

**Harvey, A.R.**, Kamphuis, W., Eggers, R., Symons, N.A., Blits, B., et al (2002) *Intravitreal injection of adeno-associated viral vectors results in the transduction of different types of retinal neurons in neonatal and adult rats: A comparison with Lentivirus vectors* Mol. Cell. Neurosci., **21**, 141-157

**Lai, C-M.**, Yu, M.J.T., Brankov, M., Barnett, N.L., Zhou, X., et al (2004) *Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65<sup>-/-</sup> knockout mouse eye results in limited rescue* Genet. Vaccines Ther., **2**:3

**Malik, J.M.I.**, Shevtsova, Z., Bähr, M. and Kügler, S. (2005) *Long-term in vivo inhibition of CNS neurodegradation by Bcl-X<sub>L</sub> gene transfer* Mol. Ther., **11**, 373-381

**Shen, W-Y.**, Lai, C-M., Lai, Y.K.Y., Zhang, D., et al (2003) *Practical considerations of recombinant adeno-associated virus-mediated gene transfer for treatment of retinal degenerations* J. Gene Med., **5**, 576-587

### Retinal ganglion cells

**Cruz-Martín, A.**, El-Danaf, R.N., Osakada, F., Sriram, B., et al (2014) *A dedicated circuit links direction-selective retinal ganglion cells to the primary visual cortex* Nature, **507**, 358-361

**Koch, J.C.**, Solis, G.P., Bodrikov, V., Michel, U., et al (2013) *Upregulation of reggie-1/flotillin-2 promotes axon regeneration in the rat optic nerve in vivo and neurite growth in vitro* Neurobiol. Dis., **51**, 168–176

**Koch, J.C.**, Tönges, L., Barski, E., Michel, U., et al (2014) *ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS* Cell Death Dis., **5**: e1225

**Langouet-Astrie, C.J.**, Yang, Z., Poliseti, S.M., Welsbie, D.S., Hauswirth, W.W., Zack, D.J., Merbs, S.L. and Enke, R.A. (2016) *Characterization of intravitreally delivered capsid mutant AAV2-Cre vector to induce tissue-specific mutations in murine retinal ganglion cells* Exp. Eye Res., **151**, 61-67

**Pernet, V.**, Joly, S., Dalkara, D., Jordi, N., et al (2013) *Long-distance axonal regeneration induced by CNTF gene transfer is impaired by axonal misguidance in the injured adult optic nerve* Neurobiol. Dis., **51**, 202–213

**Pernet, V.**, Joly, S., Dalkara, D., Schwarz, O., Christ, F., Schaffer, D., Flannery, J.G. and Schwab, M.E. (2012) *Neuronal Nogo-A upregulation does not contribute to ER stress-associated apoptosis but participates in the regenerative response in the axotomized adult retina* Cell Death Differ., **19**, 1096–1108

**Zhang, C.**, Rompani, S.B., Roska, B. and McCall, M.A. (2014) *Adeno-associated virus-RNAi of GlyR $\alpha$ 1 and characterization of its synapse-specific inhibition in OFF alpha transient retinal ganglion cells* J. Neurophysiol., **112**, 3125–3137

### Retinal lipid/glucose metabolism

**Joyal, J-S.**, Sun, Y., Gantner, M.L., Shao, Z., Evans, L.P., Saba, N., Fredrick, T., Burnim, S., Kim, J.S., Pate, G., Juan, A.M. et al (2016) *Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1* Nat. Med., **22**, 439-445

### Retinal vascularization

**Aartsen, W.M.**, van Cleef, K.W.R., Pellissier, L.P., Hoek, R.M., et al (2010) *GFAP-driven GFP expression in activated mouse Müller glial cells aligning retinal blood vessels following intravitreal injection of AAV2/6 vectors* PLoS One, **5**: e12387

**Bainbridge, J.W.B.**, Mistry, A., De Alwis, M., Paleolog, E., et al (2002) *Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1* Gene Ther., **9**, 320-326

**Igarashi, T.**, Miyake, K., Masuda, I., Takahashi, H. and Shimada, T. (2010) *Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model* Hum. Gene Ther., **21**, 631-637

**Pechan, P.**, Rubin, H., Lukason, M., Ardinger, J., et al (2009) *Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization* Gene Ther., **16**, 10–16

### Retinitis pigmentosa/retinal pigmented epithelium

- Alves, C.H.**, Pellissier, L.P., Vos, R.M., Garrido, M.G., et al (2014) *Targeted ablation of Crb2 in photoreceptor cells induces retinitis pigmentosa* Hum. Mol. Genet., **23**, 3384–3401
- Dalkara, D.**, Kolstad, K.D., Guerin, K.I., Hoffmann, N.V., et al (2011) *AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa* Mol. Ther., **19**, 1602–1608
- Folliot, S.**, Briot, D., Conrath, H., Provost, N., et al (2003) *Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector* J. Gene Med., **5**, 493-501
- Koch, S.**, Sothilingam, V., Garcia Garrido, M., Tanimoto, N., et al (2012) *Gene therapy restores vision and delays degeneration in the CNGB1/2 mouse model of retinitis pigmentosa* Hum. Mol. Genet., **21**, 4486–4496
- Kole, C.**, Berdugo, N., Da Silva, C., Ait-Ali, N., Millet-Puel, G., Pagan, D., Blond, F., Poidevin, L., Ripp, R., Fontaine, V. et al (2016) *Identification of an alternative splicing product of the Otx2 gene expressed in the neural retina and retinal pigmented epithelial cells* PLoS One, **11**: e0150758
- Leonard, K.C.**, Petrin, D., Coupland, S.G., Baker, A.N., et al (2007) *XIAP protection of photoreceptors in animal models of retinitis pigmentosa* PLoS ONE, **3**:e314
- Lipinski, D.M.**, Barnard, A.R., Singh, M.S., Martin, C., Lee, E.J., Davies, W.I.L. and MacLaren, R.E. (2015) *CNTF gene therapy confers lifelong neuroprotection in a mouse model of human retinitis pigmentosa* Mol. Ther., **23**, 1308–1319
- Najate, A.**, Fridlich, R., Millet-Pue, G., Clerin, E., Delalande, F., Jaillard, C., Blond, F., Perrocheau, L., Reichman, S. et al (2015) *Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis* Cell, **161**, 817–832
- Pawlyk, B.S.**, Bulgakov, O.V., Liu, X., Xu, X., et al (2010) *Replacement gene therapy with a human RPGRIP1 sequence slows photoreceptor degeneration in a murine model of Leber congenital amaurosis* Human Gene Ther., **21**, 993–1004
- Pellissier, L.P.**, Quinn, P.M., Alves, H., Vos, R.M., Klooster, J., Flannery, J.G., Heime, A. and Wijnholds, J. (2015) *Gene therapy into photoreceptors and Müller glial cells restores retinal structure and function in CRB1 retinitis pigmentosa mouse models* Hum.Mol. Genet., **24**, 3104–3118
- Schön, C.**, Asteriti, S., Koch, S., Sothilingam, V., Garrido, N.G., Tanimoto, N., Herms, J., Seeliger, M.W., Cangiano, L., Biel, M. and Michalakis, S. (2016) *Loss of HCN1 enhances disease progression in mouse models of CNG channel-linked retinitis pigmentosa and achromatopsia* Hum. Mol. Genet., **25**, 1165–1175
- Sun, X.**, Pawlyk, B., Xu, X., Liu, X., et al (2010) *Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations* Gene Ther., **17**, 117–131
- Zou, J.**, Luo, L., Shen, Z., Chiodo, V.A., et al (2011) *Whirlin replacement restores the formation of the USH2 protein complex in whirlin knockout photoreceptors* Invest. Ophthalmol. Vis. Sci., **52**, 2343–2351

### Rhodopsin

- Dalkara, D.**, Byrne, L.C., Lee, T., Hoffmann, N.V., et al (2012) *Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9* Gene Ther., **19**, 176–181
- Khani, S.C.**, Pawlyk, B.S., Bulgakov, O.V., Kasperek, E., et al (2007) *AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter* Invest. Ophthalmol. Vis. Sci., **48**, 3954-3961
- Ying, G.**, Gerstner, C.D., Frederick, J.M., Boye, S.L., Hauswirth, W.W. and Baehr, W. (2016) *Small GTPases Rab8a and Rab11a are dispensable for rhodopsin transport in mouse photoreceptors* PLoS One, **11**: e0161236

### Starburst amacrine cells

- Grau, T.**, Michalakis, S. and Euler, T. (2013) *Viral transfer of the genetically-encoded chloride indicator Clomeleon into ChAT/Cre retinæ to study chloride dynamics in "starburst" amacrine cells* Invest. Ophthalmol. Vis. Sci., **54**: e-Abstract 2504

### Subretinal delivery

- Seo, S.**, Mullins, R.F., Dumitrescu, A.V., Bhattarai, S., et al (2013) *Subretinal gene therapy of mice with Bardet-Biedl syndrome type 1* Invest. Ophthalmol. Vis. Sci., **54**, 6118–6132
- Ye, G-J.**, Budzynski, E., Sonnentag, P., Nork, T.M., Sheibani, N., Gurel, Z., Boye, S.L., Peterson, J.J., . Boye, S.E., Hauswirth, W.W. and Chulay, J.D. (2016) *Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases* Hum. Gene Ther., **27**, 72-82

### Usher syndrome type IID

- Zou, J.**, Luo, L., Shen, Z., Chiodo, V.A., et al (2011) *Whirlin replacement restores the formation of the USH2 protein complex in whirlin knockout photoreceptors* Invest. Ophthalmol. Vis. Sci., **52**, 2343–2351

### VIP<sup>+</sup> interneurons

**Park, S.J.H.**, Borghuis, B.G., Rahmani, P., Zeng, Q., Kim, I-J. and Demb, J.B. (2015) *Function and circuitry of VIP<sup>+</sup> interneurons in the mouse retina* J. Neurosci., **35**, 10685–10700

### Visual cortex

**Huang, X.**, Stodieck, S.K., Goetze, B., Cui, L., Wong, M.H., Wenzel, C., Hosang, L. Dong, Y., Löwel, S. and Schlüter, O.M. (2015) *Progressive maturation of silent synapses governs the duration of a critical period* Proc. Natl. Acad. Sci. USA, E3131–E3140

### Visual perception

**Lee, S-H.**, Kwan, A.C., Zhang, S., Phoumthippavong, V., et al (2012) *Activation of specific interneurons improves V1 feature selectivity and visual perception* Nature **488**, 379-382

### Vitreous delivery

**Dalkara, D.**, Byrne, L.C., Klimczak, R.R., Visel, M., et al (2013) *In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous*.Sci. Translat. Med., **5**: 189ra76

**Langouet-Astrie, C.J.**, Yang, Z., Poliseti, S.M., Welsbie, D.S., Hauswirth, W.W., Zack, D.J., Merbs, S.L. and Enke, R.A. (2016) *Characterization of intravitreally delivered capsid mutant AAV2-Cre vector to induce tissue-specific mutations in murine retinal ganglion cells* Exp. Eye Res., **151**, 61-67

### XIAP-mediated gene therapy

**Leonard, K.C.**, Petrin, D., Coupland, S.G., Baker, A.N., et al (2007) *XIAP protection of photoreceptors in animal models of retinitis pigmentosa* PLoS ONE, **3**:e314

**Renwick, J.**, Narang, M.A., Coupland, S.G., Xuan, J.Y., et al (2006) *XIAP-mediated neuroprotection in retinal ischemia* Gene Ther., **13**, 339-347

### X-linked retinoschisis

**Byrne, L.C.**, Öztürk, B.E., Lee, T., Fortuny, C., Visel, M., Dalkara, D., Schaffer, D.V. and Flannery, J.G. (2014) *Retinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h<sup>-/-</sup> mouse* Gene Ther., **21**, 585–592

### Optogenetic expression/inhibition

**Lin, J.Y.**, Sann, S.B., Zhou, K., Nabavi, S., Proulx, C.D., Malinow, R., Jin, Y. and Tsien, R.Y. (2013) *Optogenetic inhibition of synaptic release with chromophore-assisted light inactivation (CALI)* Neuron, **79**, 241–253

**Lin, W-C.**, Davenport, C.M., Mouro, A., Vytla, D., Smith, C.M., Medeiros, K.A., Chambers, J.J. and Kramer, R.H. (2014) *Engineering a light-regulated GABA<sub>A</sub> receptor for optical control of neural inhibition* ACS Chem. Biol., **9**, 1414–1419

**Cronin, T.**, Vandenberghe, L.H., Hantz, P., Juttner, J., Reimann, A., Kacso, A.E., Huckfeldt, R.M., Busskamp, V., Kohler, H., Lagali, P.S. et al (2014) *Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter* EMBO Mol. Med., **6**, 1175-1190

### Ornithine transcarbamylase deficiency

**Wang, L.**, Morizono, H., Lin, J., Bell, P., et al (2012) *Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome* Mol. Genet. Metab., **105**, 203–211

### Osteoarthritis/osteoporosis

**Akbar, M.A.**, Cao, J.J., Lu, Y., Nardo, D., Chen, M-J., Elshikha, A.S., Ahamed, R., Brantly, M., Holliday, L.S. and Song, S. (2016) *Alpha-1 antitrypsin gene therapy ameliorates bone loss in ovariectomy-induced osteoporosis mouse model* Hum. Gene Ther., **27**, 679-686

**Goodrich, L.R.**, Phillips, J.N., McIlwraith, C.W., Foti, S.B., et al (2013) *Optimization of scAAVIL-Ira in vitro and in vivo to deliver high levels of therapeutic protein for treatment of osteoarthritis* Mol. Ther. Nucleic Acids, **2**: e70

**Kyostio-Moore, S.**, Bangari, D.S., Ewing, P., Nambiar, B., et al (2013) *Local gene delivery of heme oxygenase-1 by adeno-associated virus into osteoarthritic mouse joints exhibiting synovial oxidative stress* Osteoarthritis Cartilage, **21**, 358-367

**Watson, R.S.**, Broome, T.A., Levings, P.P., Rice, B.L., et al (2013) *scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints* Gene Ther., **20**, 670–677

### Pathological shear stress

**Kang, L.**, Hillestad, M.L., Grande, J.P., Croatt, A.J., Barry, M.A., Farrugia, G., Katusic, Z.S. and Nath, K.A. (2015) *Induction and functional significance of the heme oxygenase system in pathological shear stress in vivo*. *Am. J. Physiol. Heart Circ. Physiol.*, **308**: H1402–H1413

### Peritoneal delivery

**Pagovich, O.E.**, Wang, B., Chiuchiolo, M.J., Kaminsky, S.M., Sondhi, D., Jose, C.L., Price, C.C., Brooks, S.F. et al (2016) *Anti-IgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy* *J. Allergy Clin. Immunol.*, **138**, 1652-1662

### Phenotyping (organ and body)

**Yang, B.**, Treweek, J.B., Kulkarni, R.P., Deverman, B.E., Chen, C-K., Lubeck, E., Shah, S., Cai, L. and Gradinaru, V. (2014) *Single-cell phenotyping within transparent intact tissue through whole-body clearing* *Cell*, **158**, 945–958

### Propionic acidemia

**Guenzel, A.J.**, Hofherr, S.E., Hillestad, M., Barry, M., et al (2013) *Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing* *Mol. Ther.*, **21**, 1316-1323

**Guenzel, A.J.**, Collard, R., Kraus, J.P., Matern, D. and Barry, M.A. (2015) *Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors* *Hum. Gene Ther.*, **26**, 153–160

### Protein monoubiquitination

**Bratena, O.**, Livneh, I., Ziv, T., Admon, A., Kehat, I., Caspi, L.H., Gonen, H., Bercovich, B., Godzik, A. (2016) *Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination* *Proc. Natl. Acad. Sci. USA*, **111**, E4639-E4647

### Protocols for production and quantitation of rAAV

#### Clinical application reviews

**Blits, B.** and Bunge, M.B. (2006) *Direct gene therapy for repair of the spinal cord* *J. Neurotrauma*, **23**, 508-520

**Monahan, P.E.** and Samulski, R.J. (2000) *AAV vectors: is clinical success on the horizon?* *Gene Ther.* **7**, 24-30

Pfeifer, A. and Verma, I.M. (2001) *Gene therapy: Promises and problems* *Annu. Rev. Genom. Hum. Genet.*, **2**, 177-211

#### Purification, scale-up and ancillary techniques for clinical use

**Benskey, M.J.**, Sandoval, I.M. and Manfredsson, F.P. (2016) *Continuous collection of adeno-associated virus from producer cell medium significantly increases total viral yield* *Hum. Gene Ther. Meth.*, **27**, 32-45

**Burova, E.** and Ioffe, E. (2005) *Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications* *Gene Ther.*, **12**, S5-S17

**Chahal, P.S.**, Schulze, E., Tran, R., Montes, J., et al (2014) *Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery* *J. Virol. Methods*, **196**, 163–173

**Clément, N.**, Knop, D.R. and Byrne, B.J. (2009) *Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies* *Hum. Gene Ther.*, **20**, 796-806

**De Backer, M.W.A.**, Garner, K.M., Luijendijk, M.C.M. and Adan, R.A.H. (2011) *Recombinant adeno-associated viral vectors* In *Methods Mol. Biol.*, 789, *Neuropeptides: Methods and Protocols* (ed. Merighi, A.), Springer Science+Business Media, pp 357-376

**Dias-Florencio, G.**, Precigout, G., Beley, C., Buclez, P., Garcia, L. and Benchaouir, R. (2015) *Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors* *Hum. Gene Ther.*, **26**, A101

**Doerfler, P.A.**, Byrne, B.J. and Clément, N. (2014) *Copackaging of multiple adeno-associated viral vectors in a single production step* *Hum. Gene Ther. Methods*, **25**, 269–276

**Duffy, A.M.**, O'Doherty, A.M., O'Brien, T. and Strappe, P.M. (2005) *Purification of adenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional techniques* *Gene Ther.*, **12**, S62-S72

**Faust, S.M.**, Bowles, D.E., Cunningham, S.E., Rabinowitz, J.E., et al (2004) *Universal purification of AAV serotypes 1-5 modified to contain a heparin binding epitope* *Mol. Ther.*, **9** Suppl. 1 S36

**Florencio, G.D.**, Precigout, G., Beley, C., Buclez, P-O., Garcia, L. and Benchaouir, R. (2015) *Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors* *Mol. Ther. Methods Clin. Devel.*, **2**: 15024



**Grieger, J.C.**, Choi, V.W. and Samulski, R.J. (2006) *Production and characterization of adeno-associated viral vectors* Nat. Protoc., **1**, 1412-1428

**Hermens, W.T.J.M.C.**, Ter Brake, O., Dijkhuizen, P.A., Sonnemans, M.A.F., et al (1999) *Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system* Hum. Gene Ther., **10**, 1885-1891

**Huang, X.**, Hartley, A-V., Yin, Y., Herskowitz, J.H., et al (2013) *AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications* J. Virol. Methods, **193**, 270– 277

**Khan, I.F.**, Hirata, R.K. and Russell, D.W. (2011) *AAV-mediated gene targeting methods for human cells* Nat. Protoc., **6**, 482-501

**Koerber, J.T.**, Jang, J-Y., Yu, J.H., Kane, R.S., et al (2007) *Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography* Hum. Gene Ther., **18**, 367-378

**Kohlbrener, E.**, Aslanidi, G., Nash, K., Shklyae, S., et al (2005) *Successful production of pseudotyped rAAV vectors using a modified Baculovirus expression system* Mol. Ther., **12**, 1217-1225

**Kotin, R.M.** (2011) *Large-scale recombinant adeno-associated virus production* Hum. Mol. Genet., **20**, R2-R6

**Leonard, J.N.**, Ferstl, P., Delgado, A. and Schaffer, D.V. (2007) *Enhanced preparation of adeno-associated viral vectors by using high hydrostatic pressure to selectively inactivate helper adenovirus* Biotechnol. Bioeng., **97**, 1170-1179

**Lock, M.**, Alvira, M., Vandenberghe, L.H., Samanta, A., et al (2010) *Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale* Hum. Gene Ther., **21**, 1259–1271

**Merten, O-W.**, Geny-Fiamma, C. and Douar, A.M. (2005) *Current issues in adeno-associated viral vector production* Gene Ther., **12**, S51-S61

**Morenweiser, R.** (2005) *Downstream processing of viral vectors and vaccines* Gene Ther., **12**, S103-S110

**Piedra, J.**, Ontiveros, M., Miravet, S., Penalva, C., Monfar, M. and Chillon, M. (2015) *Development of a rapid, robust, and universal PicoGreen-based method to titer adeno-associated vectors* Hum. Gene Ther. Methods, **26**, 35–42

**Potter, M.**, Lins, B., Mietzsch, M., Heilbronn, R., Van Vliet, K., Chipman, P., Agbandje-McKenna, M., Cleaver, B.D., Clement, N., Byrne, B.J. and Zolotukhin, S. (2014) *A simplified purification protocol for recombinant adeno-associated virus vectors* Mol. Ther. Methods. Clin. Dev., **1**: 14034

**Qu, W.**, Wang, M., Wu, Y. and Xu, R. (2015) *Scalable downstream strategies for purification of recombinant adeno-associated virus vectors in light of the properties* Curr. Pharm. Biotechnol., **16**, 684-695

**Rohr, U-P.**, Wulf, M-A., Stahn, S., Steidl, U., et al (2002) *Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR* J. Virol. Methods, **106**, 81-88

**Schnödt, M.**, Schmeer, M., Kracher, B., Krüsemann, C., Escalona Espinosa, L., Grünert, A., Fuchsluger, T., Rischmüller, A., Schlee, M. and Büning, H. (2016) *DNA minicircle technology improves purity of adeno-associated viral vector preparations* Mol. Ther. Nucleic Acids, **5**, e355

**Segura, M.M.**, Kamen, A.A. and Garnier, A. (2011) *Overview of current scalable methods for purification of viral vectors* In, Viral Vectors for Gene Therapy: Methods and Protocols, Methods in Molecular Biology, **737** (eds. Merten O.W. and Al-Rubeai, M.) Springer Science+Business Media, pp 89-116

**Summerford, C.** and Samulski, R.J. (1999) *Viral receptors and vector purification: New approaches for generating clinical-grade reagents* Nat. Med., **5**, 587-588

**Toelen, J.**, Lock, M., Vandenberghe, L., Carlon, M., et al (2009) *Novel and scalable approach to research grade AAV vector manufacturing and separation of distinct AAV serotypes* Hum. Gene Ther., ESGCT, DGGT, GSZ, and ISCT 2009 Poster Presentations, # 52

**Tomono, T.**, Hirai, Y., Okada, H., Adachi, K., Ishii, A., Shimada, T., Onodera, M., Tamaoka, A. and Okada, T. (2016) *Ultracentrifugation-free chromatography-mediated large-scale purification of recombinant adeno-associated virus serotype 1 (rAAV1)* Mol. Ther. Methods Clin. Dev., **3**: 15058

**Wang, L.**, Blouin, V., Brument, N., Bello-Roufai, M. and Francois, A. (2011) *Production and purification of recombinant adeno-associated vectors* In Adeno-Associated Virus: Methods and Protocols, Methods Mol. Biol., **807** (ed. Snyder, R.O. and Moullier, P.), Springer Science+Business Media, pp 361-404

**Wang, Q.**, Lock, M., Prongay, A.J., Alvira, M.R., Petkov, B. and Wilson, J.M. (2015) *Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin* Mol. Ther. Methods Clin. Dev., **2**: 15040

**Zolotukhin, S.**, Byrne, B.J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R.J. and Muzyczka, N. (1999) *Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield* Gene Ther., **6**, 973-985

**Zolotukhin, S.** (2005) *Production of recombinant adeno-associated virus vectors* Hum. Gene Ther., **16**, 551-557

### Fluorescent Ca indicator protein

**Heindorf, M.** and Hasan, M.T. (2015) *Fluorescent calcium indicator protein expression in the mouse brain using recombinant adeno-associated viruses* Cold Spring Harb Protoc; doi: 10.1101/pdb.prot087635

### Particle heterogeneity

**Lock, M.**, Alvira, M.R. and Wilson, J.M. (2012) *Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography* Hum. Gene Ther. Methods, Part B **23**, 56-64

**Pierson, E.E.**, Keifer, D.Z., Asokan, A. and Jarrold, M.F. (2016) *Resolving adeno-associated viral particle diversity with charge detection mass spectrometry* Anal. Chem., **88**, 6718–6725

**Strobel, B.**, Miller, F.D., Rist, W. and Lamla, T. (2015) *Comparative analysis of cesium chloride- and iodixanol-based purification of recombinant adeno-associated viral vectors for preclinical applications* Hum. Gene Ther. Methods, **26**, 147-157

### rAAV-3

Ling, C., Yin, Z., Li, J., Zhang, D., Aslanidi, G. and Srivastava, A. (2016) *Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors* Mol. Ther. Meth. Clin. Dev., **3**: 16029

### Recombinant AAV libraries

**Koerber, J.T.**, Maheshri, N., Kaspar, B.K. and Schaffer, D.V. (2006) *Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles* Nat. Protoc., **1**, 701-706

**Waterkamp, D.A.**, Müller, O.J., Ying, Y., Trepel, M. and Kleinschmidt, J.A. (2006) *Isolation of targeted AAV2 vectors from novel virus display libraries* J. Gene Med., **8**, 1307-1319

### Receptor-targeted

**Münch, R.C.**, Muth, A., Muik, A., Friedel, T., Schmatz, J., Dreier, B., Trkola, A., Plückthun, A., Büning, H. and Buchholz, C.J. (2015) *Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors* Nat. Commun., **6**: 6246

### Small-scale production

**Burger, C.** and Nash, K.R. (2016) *Small-scale recombinant adeno-associated virus purification* In Gene Therapy for Neurological Disorders: Methods and Protocols: Methods in Molecular Biology, vol. 1382 (ed. Manfredsson, F.P.) Springer Science+Business Media New York, pp 95-106

### Technological reviews

**Ayuso, E.** (2016) *Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome* Mol. Ther. Methods. Clin. Dev., **3**, 15049

**Hastie, E.** and Samulski, R.J. (2015) *Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success - a personal perspective* Hum. Gene Ther., **26**, 257–265

**Merten, O-W.** and Gaillet, B. (2016) *Viral vectors for gene therapy and gene modification approaches* Biochem. Eng. J., **108**, 98–115

### Transduction efficiency

**Grimm, D.**, Kay, M.A. and Kleinschmidt, J.A. (2003) *Helper virus-free, optically controllable and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6* Mol. Ther., **7**, 839-850

**Khan, I.F.**, Hirata, R.K. and Russell, D.W. (2011) *AAV-mediated gene targeting methods for human cells* Nat. Protoc., **6**, 482-501

**Lane, M.D.**, Nam, H-J., Padron, E., Gurda-Whitaker, B., et al (2005) *Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8* Acta Cryst., **F61**, 558-561

**Lee, K.**, Kim, Y-G., Jo, E-C. (2003) *Shuttle PCR-based cloning of the infectious adeno-associated virus type 5 genome* J. Virol. Methods, **111**, 75-84

**McConnell, K.I.**, Gomez, E.J. and Suh, J. (2012) *The identity of the cell adhesive protein substrate affects the efficiency of adeno-associated virus reverse transduction* Acta Biomater., **8**, 4073–4079

**Wright, J.F.**, Chunlin Tang, G.Q. and Sommer, J.M (2003) *Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector* Curr. Opin. Drug Discov. Devel., **6**, 174-178

**Zolotukhin, S.**, Potter, M., Zolotukhin, I., Sakai, Y., et al (2002) *Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors* Methods, **28**, 158-167

### Virion integrity and genome integration

**Arnold, G.S.**, Sasser, A.K., Stachler, M.D. and Bartlett, J.S. (2006) *Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes* Mol. Ther., **14**, 97-106

- Büning, H.**, Perabo, L., Coutelle, O., Quadts-Humme, S., et al (2008) *Recent developments in adeno-associated virus vector technology* J. Gene Med., **10**, 717-733
- Van Vliet, K.M.**, Blouin, V., Brument, N., Agbandje-McKenna, M., et al (2008) *The role of the adeno-associated virus capsid in gene transfer* Methods Mol Biol., **437**, 51-91
- Weitzman, M.**, Young Jr., S.M., Cathomen, T. and Samulski, T.J. (2003) *Targeted integration by adeno-associated virus* Methods Mol. Med., **76**, 201-219
- Weitzman, M.D.** and Linden, R.M. (2011) *Adeno-associated virus biology* In Adeno-Associated Virus: Methods and Protocols, Methods Mol. Biol., **807** (ed. Snyder, R.O. and Moullier, P.), Springer Science+Business Media, pp 1-23
- Wu, Z.**, Asokan, A. and Samulski, R.J. (2006) *Adeno-associated virus serotypes: vector toolkit for human gene therapy* Mol. Ther., **14**, 316-327

### Virus titre measurement and enhancement

- Clark, K.R.** (2002) *Recent advances in recombinant adeno-associated virus vector production* Kidney Int., **61**, Sympos. 1, S9-S15
- De, B., Mendez, B., Hackett, N.R., Kaminsky, S.M. and Crystal, R.G. (2002) *Adaptation of laboratory grade recombinant AAV production to manufacture of vector for human administration* 5<sup>th</sup>. Annu. Meeting Am. Soc. Gene Ther., Abstr. 147
- Harris, J.D.**, Beattie, S.G. and Dickson, J.G. (2003) *Novel tools for production and purification of recombinant adeno-associated viral vectors* Methods Mol. Med., **76**, 255-267
- Kohlbrenner, E.**, Henckaerts, E., Rapti, K., Gordon, R.E., et al (2012) *Quantification of AAV particle titers by infrared fluorescence scanning of Coomassie-stained sodium dodecyl sulfate–polyacrylamide gels* Hum. Gene Ther. Methods, **23**, 198–203
- Lock, M.**, Alvira, M.R., Chen, S-J. and Wilson, J.M. (2014) *Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR* Hum. Gene Ther. Methods **25**, 115–125
- Mistry, A.R.**, De Alwis, M., Feudner, E., Ali, R.R., et al (2002) *High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors* Methods Mol. Med., **69**, 445-460
- Rohr, U-P.**, Wulf, M-A., Stahn, S., Steidl, U., et al (2002) *Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR* J. Virol. Methods, **106**, 81-88
- Rohr, U-P.**, Heyd, F., Neukirchen, J., Wulf, M-A., et al (2005) *Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles* J. Virol. Methods, **127**, 40-45

### Reporter proteins

- Fluri, D.A.**, Kelm, J.M., Lesage, G., Daoud-El Baba, M., et al (2007) *InXy and SeXy, compact heterologous reporter proteins for mammalian cells* Biotechnol. Bioeng., **98**, 655-667

### Respiratory system delivery

#### Acute lung injury

- MacLoughlin, R.J.**, Higgins, B.D., Devaney, J., O’Toole, D., Laffey, J.G. and O’Brien, T. (2015) *Aerosol-mediated delivery of AAV2/6-I $\kappa$ B $\alpha$  attenuates lipopolysaccharide-induced acute lung injury in rats* Hum. Gene Ther., **26**, 36–46

#### Anti-apoptosis

- Petrache, I.**, Fijalkowska, I., Medler, T.R., Skirball, J., et al (2006)  *$\alpha$ -1 Antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis* Am. J. Pathol., **169**, 1155-1166

#### $\alpha$ -Anti-trypsin

- De, B.P.**, Wasif, N., Hackett, N.R., Gao, G., et al (2004) *Therapeutic levels for  $\alpha$ 1-antitrypsin following intrapleural administration of a non-human primate serotype rh10 AAV vector expressing  $\alpha$ 1-antitrypsin* Mol. Ther., **9**, Suppl. 1, S128
- De, B.**, Heguy, A., Leopold, P.L., Wasif, N., et al (2004) *Intrapleural administration of a serotype 5 adeno-associated virus coding for  $\alpha$ 1-antitrypsin mediates persistent, high lung and serum levels of  $\alpha$ 1-antitrypsin* Mol. Ther., **10**, 1003-1010
- De, B.P.**, Heguy, A., Hackett, N.R., Ferris, B., et al (2006) *High levels of persistent expression of  $\alpha$ 1 antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses* Mol. Ther., **13**, 67-76

### Cystic fibrosis

- Schuster, B.S.**, Kim, A.J., Kays, J.C., Kanzawa, M.M., Guggino, W.B., Boyle, M.P., Rowe, S.M., Muzyczka, N. Suk, J.S. and Hanes, J. (2014) *Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors* Mol. Ther., **22**, 1484–1493
- Sirninger, J.**, Muller, C., Braag, S., Tang, Q., et al (2004) *Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector* Hum. Gene Ther., **15**, 832-841
- Song, Y.**, Lou, H.H., Boyer, J.L., Limberis, M.P., et al (2009) *Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing* Hum. Gene Ther., **20**, 267–281

### Delivery

- Carlson, M.**, Toelen, J., Van der Perren, A., Vandenberghe, L.H., et al (2010) *Efficient gene transfer into the mouse lung by fetal intratracheal injection of rAAV2/6.2* Mol. Ther., **18**, 2130–2138
- Dickey, D.D.**, Excoffon, K.J.D.A., Koerber, J.T., Bergen, J., et al (2011) *Enhanced sialic acid-dependent endocytosis explains the increased efficiency of infection of airway epithelia by a novel adeno-associated virus* J. Virol., **85**, 9023–9030
- Dickey, D.D.**, Excoffon, K.J.D.A., Young, K.R., Parekh, K.R., et al (2012) *Hoechst increases adeno-associated virus-mediated transgene expression in airway epithelia by inducing the cytomegalovirus promoter* J. Gene Med., **14**, 366–373
- Flotte, T.R.**, Fischer, A.C., Goetzmann, J., Mueller, C., et al (2010) *Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway* Mol. Ther., **18**, 594–600
- Körbelin, J.**, Sieber, T., Michelfelder, S., Lunding, L., Spies, E., Hunger, A., Alawi, M. Rapti, K., Indenbirken, D. et al (2016) *Pulmonary targeting of adeno-associated viral vectors by next-generation sequencing-guided screening of random capsid displayed peptide libraries* Mol. Ther., **24**, 1050-1061
- Lipinski, D.M.**, Reid, C.A., Boye, S.L., Peterson, J.J., Qi, X., Boye, S.E., Boulton, M.E. and Hauswirth, W.W. (2015) *Systemic vascular transduction by capsid mutant adeno-associated virus after intravenous injection* Hum. Gene Ther., **26**, 767-776
- Vidović, D.**, Gijsbers, R., Quiles-Jimenez, A., Dooley, J., Van den Haute, C., Van der Perren, A., Liston, A., Baekelandt, V., Debyser, Z. and Carlson, M.S. (2016) *Noninvasive imaging reveals stable transgene expression in mouse airways after delivery of a nonintegrating recombinant adeno-associated viral vector* Hum. Gene Ther., **27**, 60-71
- Virella-Lowell, I.**, Zusman, B., Foust, K., Loiler, S., et al (2005) *Enhancing rAAV vector expression in the lung* J. Gene Med., **7**, 842-850
- White, A.F.**, Mazur, M., Sorscher, E.J., Zinn, K.R., et al (2008) *Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells* Hum. Gene Ther., **19**, 1407–1414
- Yan, Z.**, Lei-Butters, D.C.M., Liu, X., Zhang, L., et al (2006) *Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia* J. Biol. Chem., **281**, 29684-29692
- Yan, Z.**, Sun, X., Evans, I.A., Tyler, S.R., Song, Y., et al (2013) *Postentry processing of recombinant adeno-associated virus type 1 and transduction of the ferret lung are altered by a factor in airway secretions* Hum. Gene Ther., **24**, 786–796

### Lung tumours

- Watanabe, M.**, Boyer, J.L. and Crystal, R.G. (2010) *AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors* Gene Ther., **17**, 1042–1051

### Pompe disease

- Doerfler, P.A.**, Todd, A.G., Clément, N., Falk, D.J., Nayak, S., Herzog, R.W. and Byrne, B.J. (2016) *Copackaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of Pompe disease* Hum. Gene Ther., **27**, 43-59
- Qiu, K.**, Falk, D.J., Reier, P.R., Byrne, B.J., et al (2012) *Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice* Mol. Ther., **20**, 21–27

### Respiratory rhythm

- Tan, W.**, Pagliardini, S., Yang, P., Janczewski, W.A., et al (2011) *Projections of preBötzing complex neurons in adult rats* J. Comp. Neurol., **518**, 1862–1878

### Rheumatoid arthritis (see “Arthritic joint delivery”)



## RNA

### Interference applications

**Wagner, A.**, Röhrs, V., Kedzierski, R., Fechner, H. and Kurreck, J. (2013) *A novel method for the quantification of adeno-associated virus vectors for RNA interference applications using quantitative polymerase chain reaction and purified genomic adeno-associated virus DNA as a standard* Hum. Gene Ther. Methods, **24**, 355–363

### miRNA/shRNA/siRNA/RNAi

- Ahn, J.-H.**, Kim, Y., Kim, H.-S., Greengard, P., et al (2011) *Protein kinase C-dependent dephosphorylation of tyrosine hydroxylase requires the B56 $\delta$  heterotrimeric form of protein phosphatase 2A* PloS One, **6**: e26292
- Alves, C.H.**, Pellissier, L.P., Vos, R.M., Garrido, M.G., et al (2014) *Targeted ablation of Crb2 in photoreceptor cells induces retinitis pigmentosa* Hum. Mol. Genet., **23**, 3384–3401
- Boudreau, R.L.**, Spengler, R.M. and Davidson, B.L. (2011) *Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease* Mol. Ther., **19**, 2169–2177
- Bourhill, T.**, Arbuthnot, P. and Ely, A. (2016) *Successful disabling of the 5'UTR of HCV using adeno-associated viral vectors to deliver modular multimeric primary microRNA mimics* J. Virol. Meth., **235**, 26–33
- Burger, C.** and Nash, K.R. (2016) *Small-scale recombinant adeno-associated virus purification* In Gene Therapy for Neurological Disorders: Methods and Protocols: Methods in Molecular Biology, vol. 1382 (ed. Manfredsson, F.P.) Springer Science+Business Media New York, pp 95-106
- Challagundla, M.**, Koch, J.C., Ribas, V.T., Michel, U., Kugler, S., Ostendorf, T., Bradke, F., Muller, H.W., Bahr, M. and Lingor, P. (2015) *AAV-mediated expression of BAG1 and ROCK2shRNA promote neuronal survival and axonal sprouting in a rat model of rubrospinal tract injury* J. Neurochem., **134**, 261-275
- Dardou, D.**, Monlezun, S., Foerch, P., Courade, J.-P., et al (2013) *A role for Sv2c in basal ganglia functions* Brain Res., **1507**, 61-73
- De Backer, M.W.A.**, Brans, M.A.D., van Rozen, A.J., van der Zwaal, E.M., et al (2010) *Suppressor of cytokine signaling 3 knockdown in the mediobasal hypothalamus: counterintuitive effects on energy balance* J. Mol. Endocrinol., **45**, 341–353
- De Guia, R.M.**, Rose, A.J., Sommerfeld, A., Seibert, O., Strzoda, D., Zota, A., Feuchter, Y., Krones-Herzig, A., Sijmonsma, T. et al (2015) *microRNA-379 couples glucocorticoid hormones to dysfunctional lipid homeostasis* EMBO J., **34**, 344–360
- De Solis, C.A.**, Holehonnur, R., Banerjee, A., Luong, J.A., Lella, S.K., Ho, A., Pahlavan, B. and Ploski, J.E. (2015) *Viral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioning* Neurobiol. Learn. Mem., **124**, 34–47
- Elagabani, M.N.**, Brisevac, D., Kintscher, M., Pohle, J., Köhr, G., Schmitz, D. and Kornau, H.-C. (2016) *Subunit-selective N-methyl-D-aspartate (NMDA) receptor signaling through brefeldin A-resistant Arf guanine nucleotide exchange factors BRAG1 and BRAG2 during synapse maturation* J. Biol. Chem., **291**, 9105–9118
- Enomoto, M.**, Hirai, T., Kaburagi, H. and Yokota, T. (2016) *Efficient gene suppression in dorsal root ganglia and spinal cord using adeno-associated virus vectors encoding short-hairpin RNA* In siRNA Delivery Methods: Methods and Protocols, Methods in Molecular Biology, vol. 1364 (eds. Shum, K. and Rossi, J.) Springer Science+Business Media New York, pp 277-290
- Fechner, H.** and Kurreck, J. (2012) *Viral vectors for RNA interference applications in cancer research and therapy* In Drug delivery in oncology: From basic research to cancer therapy, (ed. Kratz, F., Senter, P. and Steinhagen, H.) 1<sup>st</sup> edition, Wiley-VCH Verlag GmbH & Co. KGaA, pp 1415-1442
- Gröbl, T.**, Hammer, E., Bien-Möller, S., Geisler, A., et al (2014) *A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca<sup>2+</sup> uptake into the sarcoplasmic reticulum* PLoS One, **9**: e92188
- Kang, H.J.**, Voleti, B., Hajszan, T., Rajkowska, G., et al (2012) *Decreased expression of synapse-related genes and loss of synapses in major depressive disorder* Nat. Med., **18**, 1413-1419
- Kanoski, S.E.**, Zhao, S., Guarnieri, D.J., DiLeone, R.J., et al (2012) *Endogenous leptin receptor signaling in the medial nucleus tractus solitarius affects meal size and potentiates intestinal satiation signals* Am. J. Physiol. Endocrinol. Metab., **303**, E496–E503
- Koornneef, A.**, Maczuga, P., van Logtenstein, R., Borel, F., et al (2011) *Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice* Mol. Ther., **19**, 731–740
- Kubodera, T.**, Yamada, H., Anzai, M., Ohira, S., et al (2011) *In vivo application of an RNAi strategy for the selective suppression of a mutant allele* Hum. Gene Ther., **22**, 27-34
- Lim, B.K.**, Huang, K.W., Grueter, B.A., Rothwell, P.E., et al (2012) *Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens* Nature, **487**, 183-189

**Maczuga, P.**, Lubelski, J., van Logtenstein, R., Borel, F., et al (2013) *Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy* Mol. Ther., **21**, 217–227

**Malmevik, J.**, Petri, R., Klussendorf, T., Knauff, P., Åkerblom, M., Johansson, J., Soneji, S. and Jakobsson, J. (2015) *Identification of the miRNA targetome in hippocampal neurons using RIP-seq* Sci. Rep., **5**:12609

**Malmevik, J.**, Petri, R., Knauff, P., Brattås, P.L., Åkerblom, M. and Jakobsson, J. (2016) *Distinct cognitive effects and underlying transcriptome changes upon inhibition of individual miRNAs in hippocampal neurons* Sci. Rep., **6**: 19879

**Mayra, A.**, Tomimitsu, H., Kubodera, T., Kobayashi, M., et al (2011) *Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles* Biochem. Biophys. Res. Comm., **405**, 204–209

**McBride, J.L.**, Pitzer, M.R., Boudreau, R.L., Dufour, B., et al (2011) *Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease* Mol. Ther., **19**, 2152–2162

**Mockenhaupt, S.**, Grosse, S., Rupp, D., Bartenschlager, R., and Grimm, D. (2015) *Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys* Proc. Natl. Acad. Sci., **112**, E4007-E4016

**Nicolson, S.C.** and Samulski, R.J. (2014) *Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus* J. Virol., **88**, 4132–4144

**Piras, B.A.**, O'Connor, D.M. and French, B.A. (2013) *Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver* PLoS One, **8**: e75894

**Rothe, D.**, Gisela Wajant, G., Grunert, H-P., Zeichhardt, H., et al (2010) *Rapid Construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30* Oligonucleotides, **20**, 191-198

**Schreiber, C.A.**, Sakuma, T., Izumiya, Y., Holditch, S.J., Hickey, R.D., Bressin, R.K., Basu, U., Koide, K., Asokan, A. and Ikeda, Y. (2015) *An siRNA screen identifies the U2 snRNP spliceosome as a host restriction factor for recombinant adeno-associated viruses* PLoS Pathog., **11**: e1005082

**Stoica, L.**, Todeasa, S.H., Cabrera, G.T., Salameh, J.S., ElMallah, M.K., Mueller, C., Brown, Jr, R.H., and Sena-Esteves, M. (2016) *Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model* Ann. Neurol., **79**, 687–700

**Ulusoy, A.**, Sahin, G., Björklund, T., Aebischer, P., et al (2009) *Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons* Mol. Ther., **17**, 1574-1584

**Van Gestel, M.A.**, van Erp, S., Sanders, L.E., Brans, M.A.D., et al (2014) *shRNA-induced saturation of the microRNA pathway in the rat brain* Gene Ther., **21**, 205–211

**Woldemichael, B.T.**, Jawaid, A., Kremer, E.A., Gaur, N., Krol, J., Marchais, A. and Mansuy, I.M. (2016) *The microRNA cluster miR-183/96/182 contributes to long-term memory in a protein phosphatase 1-dependent manner* Nat. Comm., **7**: 12594

**Zheng, D.**, Sabbagh, J.J., Blair, L.J., Darling, A.L., Wen, X. and Dickey, C.A. (2016) *MicroRNA-511 binds to FKBP5 mRNA, which encodes a chaperone protein, and regulates neuronal differentiation* J. Biol. Chem., **291**, 17897–17906

### Salivary gland transduction

**Srinivasan, P.**, Shanmugam, T., Dayton, R.D., Palaniyandi, S., et al (2013) *Recombinant AAV9-TLK1B administration ameliorates fractionated radiation-induced xerostomia* Hum. Gene Ther., **24**, 604–612

### Sarcoplasmic reticulum

**Gröbl, T.**, Hammer, E., Bien-Möller, S., Geisler, A., et al (2014) *A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca<sup>2+</sup> uptake into the sarcoplasmic reticulum* PLoS One, **9**: e92188

### Self-complimentary genomes (sc-AAV-Cre vectors)

**Hillestad, M.L.**, Guenzel, A.J., Nath, K.A. and Barry, M.A. (2012) *A vector–host system to fingerprint virus tropism* Hum. Gene Ther., **23**, 1116–1126

**Langouet-Astric, C.J.**, Yang, Z., Polisetti, S.M., Welsbie, D.S., Hauswirth, W.W., Zack, D.J., Merbs, S.L. and Enke, R.A. (2016) *Characterization of intravitreally delivered capsid mutant AAV2-Cre vector to induce tissue-specific mutations in murine retinal ganglion cells* Exp. Eye Res., **151**, 61-67

**Lee, D-H.**, Park, J.O., Kim, T-S., Kim, S-K., Kim, T-h., Kim, M-c., Park, G.S., Kim, J-H., Kuninaka, S., Olson, E.N. et al (2016) *LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4a expression during liver development* Nat. Comm., **7**: 11961

**Prabhakar, S.**, Goto, J., Zuang, X., Sena-Esteves, M., et al (2013) *Stochastic model of Tsc1 lesions in mouse brain* PLoS One, **8**: e64224

**Wang, Y.,** Ling, C., Song, L., Wang, L., et al (2012) *Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation* Hum. Gene Ther. Methods, **23**, 225–233

### **Skeletal muscle delivery**

#### **AAV variants, transduction efficiency of**

**Chew, W.L.,** Tabebordbar, M., Cheng, J.K.W., Mali, P., Wu, E.Y., Ng, A.H.M., Zhu, K., Wagers, A.J. and Church, G.M. (2016) *A multifunctional AAV–CRISPR–cas9 and its host response* Nat. Meth., **13**, 868–874

**Choudhury, S.R.,** Fitzpatrick, Z., Harris, A.F., Maitland, S.A., Ferreira, J.S., Zhang, Y., Ma, S., Sharma, R.B. et al (2016) *In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy* Mol. Ther., **24**, 1247–1257

**Santiago-Ortiz, J.,** Ojala, D.S., Westesson, O., Weinstein, J.R., Wong, S.Y., Steinsapir, A., Kumar, S., Holmes, I and Schaffer, D.V. (2015) *AAV ancestral reconstruction library enables selection of broadly infectious viral variants* Gene Ther., **22**, 934–946

#### **Acidic oligopeptide effects**

**Lee, N-C.,** Falk, D.J., Byrne, B.J., Conlon, T.J., et al (2012) *An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery* Genet. Vacc. Ther., **10**: 3

#### **Actin cytoskeleton**

**Vassilopoulos, S.,** Gentil, C., Lainé, J., Buclez, P-O., Franck, A., et al (2014) *Actin scaffolding by clathrin heavy chain is required for skeletal muscle sarcomere organization* J. Cell Biol., **205**, 377–393

#### **AKT2/PKCB**

**Schultze, S.M.,** Dietrich, M., Hynx, D., Geier, A., Niessen, M., Spinaz, G.A., Hemmings, B.A. and Tschopp, O. (2015) *Reduced hepatic lipid content in Pten-haplodeficient mice because of enhanced AKT2/PKCB activation in skeletal muscle* Liver Int., **35**, 1354–1366

#### **ALS (see Amyotrophic lateral sclerosis)**

#### **Alpha-1-antitrypsin**

**Song, S.,** Morgan, M., Ellis, T., Poirier, A., et al (1998) *Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors* Proc. Natl. Acad. Sci. USA, **95**, 14384–14388

**Song, S.,** Embury, J., Laipis, P.J., Berns, K.I., et al (2001) *Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors* Gene Ther., **8**, 1299–1306

#### **Alpha-sarcoglycan**

**Mendell, J.R.,** Rodino-Klapac, L.R., Rosales-Quintero, X., Kota, J., et al (2009) *Limb-girdle muscular dystrophy type 2D gene therapy restores  $\alpha$ -sarcoglycan and associated proteins* Ann. Neurol., **66**, 290–297

**Mendell, J.R.,** Rodino-Klapac, L.R., Rosales, X.Q., Coley, B.D., et al (2010) *Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D* Ann. Neurol. **68**, 629–638

**Rodino-Klapac, L.R.,** Lee, J-S., Mulligan, R.C., Clark, K.R., et al (2008) *Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D* Neurology, **71**, 240–247

#### **Alzheimer's disease**

**Yang, J.,** Pattanayak, A., Song, M., Kou, J., Taguchi, H., et al (2013) *Muscle-directed anti-A $\beta$  single-chain antibody delivery via AAV1 reduces cerebral A $\beta$  load in an Alzheimer's disease mouse model* J. Mol. Neurosci., **49**, 277–288

#### **Ancestral rAAVs, targeting of**

**Zinn, E.,** Pacouret, S., Khaychuk, V., Turunen, H.T., Carvalho, L.S., Andres-Mateos, E., Shah, S. Shelke, R. et al (2015) *In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector* Cell Rep., **12**, 1056–1068

#### **Apo-E expression**

**Evans, V.,** Foster, H., Graham, I.R., Foster, K., et al (2008) *Human apolipoprotein E expression from mouse skeletal muscle by electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7)* Hum. Gene Ther., **19**, 569–578

**Evans, V.C.**, Graham, I.R., Athanasopoulos, T., Galley, D.J., et al (2011) *Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle* Metab. Clin. Exp., **60**, 491–498

**Harris, J.D.**, Schepelmann, S., Athanasopoulos, T., Graham, I.R., et al (2002) *Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E* Gene Ther., **9**, 21-29

### **CCBE1 gene**

**Jeltsch, M.**, Jha, S.K., Tvorogov, D., Anisimov, A., et al (2014) *CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation* Circulation, **129**, 1962-1971

### **Caveolin-cavin system**

**Lo, H.P.**, Nixon, S.J., Hall, T.E., Cowling, B.S., Ferguson, C., Morgan, G.P., Schieber, N.L., Fernandez-Rojo, M.A., Bastiani, M. et al (2015) *The caveolin-cavin system plays a conserved and critical role in mechanoprotection of skeletal muscle* J. Cell Biol., **210**, 833–849

### **Desmin**

**Joanne, P.**, Chourbagi, O., Hourdé, C., Ferry, A., et al (2013) *Viral-mediated expression of desmin mutants to create mouse models of myofibrillar myopathy* Skelet. Muscle **3**: 4

### **DNA bar-code**

**Marsic, D.**, Méndez-Gómez, H.R. and Zolotukhin, S. (2015) *High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing* Mol. Ther. Methods Clin. Dev., **2**:15041

### **DNA-dependent protein kinase**

**Song, S.**, Laipis, P.J., Berns, K.I. and Flotte, T.R. (2001) *Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle* Proc. Natl. Acad. Sci. USA, **98**, 4084-4088

### **Dynammin**

**Cowling, B.S.**, Toussaint, A., Amoasii, L., Koebel, P., Ferry, A., et al (2011) *Increased expression of wild-type or a centronuclear myopathy mutant of dynammin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness* Am. J. Pathol., **178**, 2224-2235

**Trochet, D.**, Prudhon, B., Jollet, A., Lorain, S. and Bitoun, M. (2016) *Reprogramming the dynammin 2 mRNA by spliceosome-mediated RNA trans-splicing* Mol. Ther. Nucleic Acids, **5**: e362

### **Dysferlinopathy**

**Grose, W.E.**, Clark, K.R., Griffin, D., Malik, V., et al (2012) *Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer* PLoS One, **7**: e39233

### **Dyslipidaemias**

**Ross, C.J.D.**, Twisk, J., Meulenberg, J.M., Liu, G., et al (2004) *Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL<sup>S447X</sup> beneficial mutation* Hum. Gene Ther., **15**, 906-919

**Wang, L.F.**, Fan, L.M., Chen, B.R., Wang, R.N., et al (2002) *Expression of lecithin cholesterol acyltransferase and/or apoA-I mediated by recombinant adeno-associated virus in myogenic cells* Acta Biochim. Biophys. Sinica, **34**, 33-38

### **Extracellular SOD**

**Saqib, A.**, Prasad, K-M.R., Katwal, A.B., Sanders, J.M., et al (2011) *Adeno-associated virus serotype 9-mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind-limb ischemia in BALB/c mice* J. Vasc. Surg., **54**, 810-8

### **Fibrosis**

**Karvinen, H.**, Pasanen, E., Rissanen, T.T., Korpisalo, P., et al (2011) *Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle* Gene Ther., **18**, 1166–1172

**Schwarz, E. M.** (2000) *The adeno-associated virus vector for orthopaedic gene therapy* Clin. Orthop. Relat. Res., **379S**, S31-S39



### **Follistatin**

**Foley, J.W.**, Bercury, S.D., Finn, P., Cheng, S.H., et al (2010) *Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice* Mol. Ther., **9**, 1584–1591

**Kota, J.**, Handy, C.R., Haidet, A.M., Montgomery, C.L., et al (2009) *Follistatin gene delivery enhances muscle growth and strength in nonhuman primates* Sci. Transl. Med., **1**: 6ra15

### **Glycogen storage diseases (see also “Lysosomal storage diseases”)**

**Ghosh, A.**, Allamarvasht, M., Pan, C-J., Sun, M-S., et al (2006) *Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer* Gene Ther., **13**, 321-329

**Sun, M-S.**, Pan, C-J., Shieh, J-J., Ghosh, A., et al (2002) *Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice* Hum. Mol. Genet., **11**, 2155-2164

### **Haemophilia B**

**Rogers, G.L.**, Martino, A.T., Zolotukhin, I., Ertl, H.C.J., et al (2014) *Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B* J. Translat. Med., **12**: 25

### **Histone deacetylases**

**Berdeaux, R.**, Goebel, N., Banaszynski, L., Takemori, H., et al (2007) *SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes* Nat. Med., **13**, 597-603

### **Immune response**

Aubert, D., Pichard, V., Durand, S., Moullier, P., et al (2003) *Cytotoxic immune response after retroviral-mediated hepatic gene transfer in rat does not preclude expression from adeno-associated virus 1 transduced muscles* Hum. Gene Ther., **14**, 473-481

### **Ischaemia**

**Katwal, A.B.**, Konkalmatt, P.R., Piras, B.A., Hazarika, S., et al (2013) *Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery* Gene Ther., **20**, 930–938

**Tuuminen, R.**, Dashkevich, A., Keränen, M.A.I., Raissadati, A., Krebs, R., Jokinen, J.J., Arnaudova, R., Rouvinen, E., Ylä-Herttua, S. et al (2016) *Platelet-derived growth factor-B protects rat cardiac allografts from ischemia-reperfusion injury* Transplantation, **100**, 303–313

### **Lymphangiogenesis (see “CCBE1 gene”)**

### **McArdle’s disease**

Howell, J. McC., Walker, K.R., Davies, L., Dunton, E., et al (2008) *Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle’s disease: Expression and re-expression of glycogen phosphorylase* Neuromusc. Disord., **18**, 248-258

### **Mechanoprotection (see “Caveolin-cavin system”)**

### **Muscular dystrophy (incl. $\gamma$ -sarcoglycanopathy)**

**Athanasopoulos, T.**, Graham, I.R., Foster, H. and Dickson, G. (2004) *Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for duchenne muscular dystrophy (DMD)* Gene Ther., **11**, 109-121

**Fabb, S.A.**, Wells, D.J., Serpente, P. and Dickson, G. (2002) *Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice* Hum. Mol. Genet., **11**, 733-741

**Foster, H.**, Sharp, P.S., Athanasopoulos, T., Trollet, C., et al (2008) *Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer* Mol. Ther., **16**, 1825-1832

**Ghahramani Seno, M.M.**, Graham, I.R., Athanasopoulos, T. Trollet, C., et al (2008) *RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology* Hum. Mol. Genet., **17**, 2622-2632

**Goyenvall, A.**, Babbs, A., Wright, J., Wilkins, V., et al (2012) *Rescue of severely affected dystrophin/utrophin deficient mice through scAAV-U7snRNA-mediated exon skipping* Hum. Mol. Genet., **21**, 2559–2571

**Goyenvall, A.**, Wright, J., Babbs, A., Wilkins, V., et al (2012) *Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy* Mol. Ther., **20**, 1212-1221

**Grose, W.E.**, Clark, K.R., Griffin, D., Malik, V., et al (2012) *Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer* PLoS One, **7**: e39233

- Heller, K.N.**, Montgomery, C.L., Janssen, P.M.L., Clark, K.R., et al (2013) *AAV-mediated overexpression of human  $\alpha 7$  integrin leads to histological and functional improvement in dystrophic mice* Mol. Ther., **21**, 520–525
- Herson, S.**, Hentati, F., Rigolet, A., Behin, A., Romero, N.B., et al (2012) *A phase I trial of adeno-associated virus serotype 1- $\gamma$ -sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C* Brain, **135**, 483–492
- Koo, T.**, Malerba, A., Athanasopoulos, T., Trollet, C., et al (2011) *Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of  $\alpha 1$ -syntrophin and  $\alpha$ -dystrobrevin in skeletal muscles of mdx mice* Hum. Gene Ther., **22**, 1379–1388
- Koo, T.**, Popplewell, L., Athanasopoulos, T., and Dickson, G. (2014) *Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice* Hum. Gene Ther., **25**, 98–108
- Larochelle, N.**, Teng, Q., Gilbert, R., Deol, J.R., et al (2010) *Modulation of coxsackie and adenovirus receptor expression for gene transfer to normal and dystrophic skeletal muscle* J. Gene Med., **12**, 266–275
- Martin, P.T.**, Xu, R., Rodino-Klapac, L.R., Oglesbay, E., et al (2009) *Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice* Am. J. Physiol. Cell Physiol., **296**, C476–C488
- Mendell, J.R.**, Rodino-Klapac, L.R., Rosales-Quintero, X., Kota, J., et al (2009) *Limb-girdle muscular dystrophy type 2D gene therapy restores  $\alpha$ -sarcoglycan and associated proteins* Ann. Neurol., **66**, 290–297
- Mendell, J.R.**, Rodino-Klapac, L.R., Rosales, X.Q., Coley, B.D., et al (2010) *Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D* Ann. Neurol. **68**, 629–638
- Rodino-Klapac, L.R.**, Janssen, P.M.L., Montgomery, C.L., Coley, B.D., et al (2007) *A translational approach for limb vascular delivery of the micro-dystrophin gene without volume or high pressure for treatment of Duchenne muscular dystrophy* J. Translat. Med., **5**:45
- Wein, N.**, Vulin, A., Falzarano, M.S., Al-Khalili Szigyarto, C., Maiti, B., Findlay, A., Heller, K.N., Uhlén, M., Bakthavachalu, B., Messina, S. et al (2014) *Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice* Nat. Med., **9**, 992–1000

### Muscular hypotrophy

- Al-Qusairi, L.**, Prokic, I., Amoasii, L., Kretz, C., et al (2013) *Lack of myotubularin (MTM1) leads to muscle hypotrophy through unbalanced regulation of the autophagy and ubiquitin-proteasome pathways* FASEB J., **27**, 3384–3394

### Myostatin

- Cleasby, M.E.**, Jarmin, S., Eilers, W., Elashry, M., et al (2014). *Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal.* Am. J. Physiol. Endocrinol. Metab., **306**:E814–E823

### Myofibre transduction

- Riaz, M., Raz, Y., Moloney, E.B., van Putten, M., Krom, Y.D., van der Maarel, S.M., Verhaagen, J. and Raz, V. (2015) *Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9* Skelet. Muscle, **5**: 37

### Myofibrillar myopathy

- Joanne, P.**, Chourbagi, O., Hourdé, C., Ferry, A., et al (2013) *Viral-mediated expression of desmin mutants to create mouse models of myofibrillar myopathy* Skelet. Muscle **3**: 4

### Narcolepsy

- Liu, M.**, Blanco-Centurion, C., Konadhode, R., Begum, S., et al (2011) *Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice* J. Neurosci., **31**, 6028–6040

### Neprilysin

- Liu, Y.**, Studzinski, C., Beckett, T., Guan, H., et al (2009) *Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease* Mol. Ther., **17**, 1381–1386
- Liu, Y.**, Studzinski, C., Beckett, T., Murphy, M.P., et al (2010) *Circulating neprilysin clears brain amyloid* Mol. Cell. Neurosci., **45**, 101–107

### Pompe disease

- Foley, J.W.**, Bercury, S.D., Finn, P., Cheng, S.H., et al (2010) *Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice* Mol. Ther., **9**, 1584–1591

**Yi, H.**, Fredrickson, K.B., Das, S., Kishnani, P.S. and Sun, B. (2013) *Stbd1 is highly elevated in skeletal muscle of Pompe disease mice but suppression of its expression does not affect lysosomal glycogen accumulation* Mol. Genet. Metab., **109**, 312–314

**Zhu, Y.**, Jiang, J.-L., Gumlaw, N.K., Zhang, J., et al (2009) *Glycoengineered acid  $\alpha$ -glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease* Mol. Ther., **17**, 954-963

### Regeneration

**Bryan, B.A.**, Mitchell, D.C., Zhao, L., Ma, W., et al (2005) *Modulation of muscle regeneration, myogenesis, and adipogenesis by the Rho family nucleotide exchange factor GEFT* Mol. Cell. Biol., **25**, 11089-11101

### RNA: shRNA-AAV

**Mayra, A.**, Tomimitsu, H., Kubodera, T., Kobayashi, M., et al (2011) *Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles* Biochem. Biophys. Res. Comm., **405**, 204–209

### RNA trans-splicing

Trochet, D., Prudhon, B., Jollet, A., Lorain, S. and Bitoun, M. (2016) *Reprogramming the dynamin 2 mRNA by spliceosome-mediated RNA trans-splicing* Mol. Ther. Nucleic Acids, **5**: e362

### Transgene expression

**Chenuaud, P.**, Larcher, T., Rabinowitz, J.E., Provost, N., et al (2004) *Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle* Mol. Ther., **9**, 410-418

**Ren, C.**, Kumar, S., Shaw, D.R. and Ponnazhagan, S. (2005) *Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo* Hum. Gene Ther., **16**, 1-11

### Wnt/ $\beta$ -catenin signalling

**Aslanidi, G.**, Kroutov, V., Philipsberg, G., Lamb, K., et al (2007) *Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats* Am. J. Physiol. Endocrinol. Metab., **293**, E726-E736

### Skin targeting

**Balaji, S.**, King, A., Dhamija, Y., Le, L.D., et al (2013) *Pseudotyped adeno-associated viral vectors for gene transfer in dermal fibroblasts: implications for wound-healing applications* J. Surg. Res., **184**, 691-698

**Braun-Falco, M.**, Eisenried, A., Büning, H. and Ring, J. (2005) *Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both the ubiquitin/proteasome pathway and epidermal growth factor receptor tyrosine kinase* Arch. Dermatol. Res., **296**, 528-535

**Büning, H.**, Braun-Falco, M. and Hallek, M. (2004) *Progress in the use of adeno-associated viral vectors for gene therapy* Cell. Tissue. Organ., **177**, 139-150

**Cross, K.J.**, Bomsztyk, E.D., Weinstein, A.L., Teo, E.H., et al (2009) *A novel method for targeted gene therapy in ischemic tissues through viral transfection of an expression cassette containing multiple repetitions of hypoxia response element* Plast. Reconstr. Surg. **123**: Suppl 76S

**Petek, L.M.**, Fleckman, P. and Miller, D.G. (2010) *Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex* Mol. Ther., **9**, 1624–1632

**Roedl, D.**, Oji, V., Buters, J.T.M., Behrendt, H. et al (2011) *rAAV2-Mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients* J. Dermatol. Sci., **61**, 194–198

### Spleen delivery

**Miyake, N.**, Miyake, K., Yamamoto, M., Hirai, Y., et al (2011) *Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors* Brain Res., **1389**, 19-26

### Spliceosomes

**Schreiber, C.A.**, Sakuma, T., Izumiya, Y., Holditch, S.J., Hickey, R.D., Bressin, R.K., Basu, U., Koide, K., Asokan, A. and Ikeda, Y. (2015) *An siRNA screen identifies the U2 snRNP spliceosome as a host restriction factor for recombinant adeno-associated viruses* PLoS Pathog., **11**: e1005082

### Stem cell delivery

**Bartel, M.A.** and Schaffer, M.A. (2014) *Enhanced gene targeting of adult and pluripotent stem cells using evolved adeno-associated virus* In Methods Mol. Biol., **1114**, Gene Correction: Methods and Protocols, (ed. Storici, F.) Springer Science+Business Media, LLC pp 169-179

**Chen, K.A.**, Cruz, P.E., Lanuto, D.J., Flotte, T.R., et al (2011) *Cellular fusion for gene delivery to SCA1 affected Purkinje neurons* Mol. Cell. Neurosci., **47**, 61–70

**Han, Z.**, Zhong, L., Maina, N., Hu, Z., et al (2008) *Stable integration of recombinant adeno-associated virus vector genomes after transduction of murine hematopoietic stem cells* Hum. Gene Ther., **19**, 267-278

**Jang, J-H.**, Koerber, J.T., Kim, J-S., Asuri, P., et al (2011) *An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells* Mol. Ther., **19**, 667–675

**Kumar, S.**, Nagy, T.R. and Ponnazhagan, S. (2010) *Therapeutic potential of genetically modified adult stem cells for osteopenia* Gene Ther., **17**, 105–116

**Kumar, S.**, Wan, C., Ramaswamy, G., Clemens, T.L., et al (2010) *Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect* Mol. Ther., **18**, 1026–1034

**Locke, M.**, Ussher, J.E., Mistry, R., Taylor, J.A., et al (2011) *Transduction of human adipose-derived mesenchymal stem cells by recombinant adeno-associated virus vectors* Tissue Eng., **17**, 949-959

**McMahon, J.M.**, Conroy, S., Lyons, M., Greiser, U., et al (2006) *Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors* Stem Cell. Dev., **15**, 87-96

**Mitsui, K.**, Suzuki, K., Aizawa, E., Kawase, E., et al (2009) *Gene targeting in human pluripotent stem cells with adeno-associated virus vectors* Biochem. Biophys. Res. Commun., **388**, 711–717

**Ren, C.**, Kumar, S., Chanda, D., Chen, J., et al (2008) *Therapeutic potential of mesenchymal stem cells producing interferon- $\alpha$  in a mouse melanoma lung metastasis model* Stem Cells, **26**, 2332-2338

**Ryu, B.Y.**, Evans-Galea, M.V., Gray, J.T., Bodine, D.M., et al (2008) *An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation* Blood, **111**, 1866-1875

**Schuhmann, N.K.**, Pozzoli, O., Sallach, J., Huber, A., Avitabile, D., Perabo, L., Rappl, G., Capogrossi, M.C., Hallek, M., Pesce, M. and Büning, H. (2010) *Gene transfer into human cord blood derived CD34<sup>+</sup> cells by adeno-associated viral vectors* Exp. Hematol., **38**, 707–717

**Sellner, L.**, Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., et al (2008) *Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells* Exp. Hematol., **957**, 957-964

**Stiefelhagen, M.**, Sellner, L., Kleinschmidt, J.A., Jauch, A., et al (2008) *Application of a haematopoietic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line* Genet., Vaccines Ther., **6**:12

**Weltner, J.**, Anisimov, A., Alitalo, K., Otonkoski, T., et al (2012) *Induced pluripotent stem cell clones reprogrammed via recombinant adeno-associated virus-mediated transduction contain integrated vector sequences* J. Virol., **86**, 4463–4467

### Targeting/delivery mechanisms

**Büning, H.**, Ried, M.U., Perabo, L., Gerner, N.A., et al (2003) *Receptor targeting of adeno-associated virus vectors* Gene Ther. **10**, 1142-1151

**Chtarto, A.**, Bender, H.U., Hanemann, C.O., Kemp, T., et al (2003) *Tetracycline-inducible transgene expression mediated by a single AAV vector* Gene Ther., **10**, 84-94

**Fenno, L.E.**, Mattis, J., Ramakrishnan, C., Hyun, M., Lee, S.Y., He, M., Tucciarone, J., Selimbeyoglu, A., Berndt, A., Grosenick, L. et al (2014) *Targeting cells with single vectors using multiple-feature Boolean logic* Nature Meth., **11**, 762-772

**Henckaerts, E.**, Duthheil, N., Zeltner, N., Kattman, S., et al (2009) *Site-specific integration of adeno-associated virus involves partial duplication of the target locus* Proc. Natl. Acad. Sci. USA, **106**, 7571–7576

**Hirata, R.K.**, Xu, C., Dong, R., Miller, D., et al (2004) *Efficient PRNP gene targeting in bovine fibroblasts by adeno-associated virus vectors* Cloning Stem Cells, **6**, 31-36

**Hirata, R.**, Chamberlain, J., Dong, R. and Russell, D.W. (2002) *Targeted transgene insertion into human chromosomes by adeno-associated virus vectors* Nat. Biotechnol., **20**, 735-738

**Judd, J.**, Ho, M.L., Tiwari, A., Gomez, E.J., et al (2014) *Tunable protease-activatable virus nanonodes* ACS Nano, **8**, 4740–4746

**Lu, Y.** (2004) *Recombinant adeno-associated virus as delivery vector for gene therapy – a review* Stem Cells Dev., **13**, 133-145

**Müller, O.J.**, Kaul, F., Weitzman, M.D., Pasqualini, R., et al (2003) *Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors* Nat. Biotechnol., **21**, 1040-1046

**Maheshri, N.**, Koerber, J.T., Kaspar, B.K. and Schaffer, D.V. (2006) *Directed evolution of adeno-associated virus yields enhanced gene delivery vectors* Nat. Biotechnol., **24**, 198-204

**Michelfelder, S.**, Kohlschütter, J., Skorupa, A., Pfenning, S, et al (2009) *Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries* PLoS One **4**:e5122



**Mitchell, A.M.**, Li, C. and Samulski, R.J. (2013) *Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo* J. Virol., **87**, 4571–4583

**Negishi, A.**, Chen, J., McCarty, D.M., Samulski, R.J., et al (2004) *Analysis of the interaction between adeno-associated virus and heparan sulfate using atomic force microscopy* Glycobiology, **14**, 969–977

**Ried, M.U.**, Girod, A., Leike, K., Büning, H. et al (2002) *Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors* J. Virol., **76**, 4559–4566

**Raupp, C.**, Naumer, M., Müller, O.J., Gurda, B.L., et al (2012) *The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as post-attachment processing* J. Virol., **86**, 9396–9408

**Shi, W.**, Arnold, G.S. and Bartlett, J.S. (2001) *Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors* Hum. Gene Ther., **12**, 1697–1711

**Shi, W.** and Bartlett, J.S. (2003) *RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism* Mol. Ther., **7**, 515–525

**Stachler, M.D.**, Chen, I., Ting, A.Y. and Bartlett, J.S. (2008) *Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase* Mol. Ther., **16**, 1467–1473

**Vasileva, A.**, Linden, R.M. and Jessberger, R. (2006) *Homologous recombination is required for AAV-mediated gene targeting* Nucleic Acids Res., **34**, 3345–3360

**Ying, Y.**, Müller, O.J., Goehringer, C., Leuchs, B., et al (2010) *Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library* Gene Ther., **17**, 980–990

### T-cell activation

**Huang, J.**, Li, X., Coelho-dos-Reis, J.G.A., Wilson, J.M., Tsuji, M. (2014) *An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8<sup>+</sup> T cells in mice* PLoS One, **9**: e88205

**Mays, L.E.**, Wang, L., Tenney, R., Bell, P., et al (2013) *Cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33* J. Virol., **87**, 9473–9485

### Transforming growth factor $\beta$ (TGF- $\beta$ ) signalling

**Jäger, J.**, Greiner, V., Strzoda, D., Seibert, O., Niopek, K., Sijmonsma, D.P., Schäfer, M., Jones, A., De Guia, R., Martignoni, M., Dallinga-Thie, G.M., Diaz, M.B., Hofmann, T.G. and Herzig, S. (2014) *Hepatic transforming growth factor- $\beta$  1 stimulated clone-22 D1 controls systemic cholesterol metabolism* Mol. Metab., **3**, 155–166

**Lee, D-H.**, Park, J.O., Kim, T-S., Kim, S-K., Kim, T-h., Kim, M-c., Park, G.S., Kim, J-H., Kuninaka, S., Olson, E.N. et al (2016) *LATS-YAP/TAZ controls lineage specification by regulating TGF $\beta$  signaling and Hnf4a expression during liver development* Nat. Comm., **7**: 11961

### Thymic delivery

**Chu, Q.**, Moreland, R.J., Gao, L., Taylor, K.M., Meyers, E., Cheng, S.H. and Scheule, R.K. (2010) *Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery* Mol. Ther., **18**, 2146–2154

### Tissue specificity

**Chen, S-J.**, Johnston, J., Sandhu, A., Bish, L.T., et al (2013) *Enhancing the utility of adeno-associated virus gene transfer through inducible tissue-specific expression* Hum. Gene Ther. Methods, **24**, 270–278

### TNF- $\alpha$

**Alto, L.T.**, Chen, X., Ruhn, K.A., Trevino, I. and Tansey, M.G. (2014) *AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease* PLoS One, **9**: e96544

**Yan, Z.**, Lei-Butters, D., Engelhardt, J.F. and Leno, G.H. (2009) *Indexing TNF- $\alpha$  gene expression using a gene-targeted reporter cell line* BMC Biol., **7**:8

**Weinberg, M.S.**, Blake, B.L. and McCown, T.J. (2013) *Opposing actions of hippocampus TNF $\alpha$  receptors on limbic seizure susceptibility* Exp. Neurol., **247**, 429–437

### Transduction efficiency/inhibition

**Arap, M.A.**, Lahdenranta, J., Hajitou, A., Marini, F.C., et al (2004) *Model of unidirectional transluminal gene transfer* Mol. Ther., **9**, 305–310

**Aslanidi, G.V.**, Rivers, A.E., Ortiz, L., Govindasamy, L., et al (2012) *High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors* Vaccine, **30**, 3908–3917

- Fan, S.**, Maguire, C.A., Ramirez, S.H., Bradel-Tretheway, B., (2005) *Valproic acid enhances gene expression from viral gene transfer vectors* J. Virol. Methods, **125**, 23-33
- Fluri, D.A.**, Daoud-el baba, M. and Fussenegger, M.T (2007) *Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and mice* BMC Biotech., **7**:75
- Gurda, B.L.**, Raupp, C., Popa-Wagner, R., Naumer, M., et al (2012) *Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8* J. Virol., **86**, 7739–7751
- Hölscher, C.**, Sonntag, F., Henrich, K., Chen, Q., Beneke, J., Matula, P., Rohr, K., Kaderali, L. et al (2015) *The SUMOylation pathway restricts gene transduction by adeno-associated viruses* PLoS Pathog., **11**: e1005281
- Huang, L-Y.**, Patel, A., Ng, R., Miller, E.B., Halder, S., McKenna, R., Asokan, A. and Agbandje-McKenna, M. (2016) *Characterization of the adeno-associated virus 1 and 6 sialic acid binding site* J. Virol., **90**, 5219-6230
- Lee, N-C.**, Falk, D.J., Byrne, B.J., Conlon, T.J., et al (2012) *An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery* Genet. Vacc. Ther., **10**: 3
- McCarty, D.M.**, Fu, H., Monahan, P.E., Toulson, C.E., et al (2003) *Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo* Gene Ther., **10**, 2112-2118
- McFarland, N.R.**, Lee, J-S., Hyman, B.T. and McLean, P.J. (2009) *Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5 and 8 in the rat nigrostriatal system* J. Neurochem., **109**, 838–845
- Mitchell, A.M.**, Li, C. and Samulski, R.J. (2013) *Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo* J. Virol., **87**, 4571–4583
- Nathwani, A.C.**, Cochrane, M., McIntosh, J., Ng, C.Y.C., et al (2009) *Enhancing transduction of the liver by adeno-associated viral vectors* Gene Ther., **16**, 60–69
- Paneda, A.**, Vanrell, L., Mauleon, I., Crettaz, J.S., et al (2009) *Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders* Hum. Gene Ther., **20**, 908-917
- Perabo, L.**, Büning, H., Kofler, D.M., Ried, M.U., et al (2003) *In vitro selection of viral vectors with modified tropism: the adeno-associated virus display* Mol. Ther., **8**, 151-157
- Petrs-Silva, H.**, Dinculescu, A., Li, Q., Min, S-H., et al (2009) *High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors* Mol., Ther., **17**, 463–471
- Prudencio, M.**, Jansen-West, K.R., Lee, W.C., Gendron, T.F., et al (2012) *Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor* Proc. Natl. Acad. Sci. USA, **109**, 21510–21515
- Rabinowitz, J.E.**, Rolling, F., Li, C., Conrath, H., et al (2002) *Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity* J. Virol., **76**, 791-801
- Ren, C.**, Kumar, S., Shaw, D.R. and Ponnazhagan, S. (2005) *Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo* Hum. Gene Ther., **16**, 1-11
- Seppen, J.**, Bakker, C., de Jong, B., Kunne, C., et al (2006) *Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats* Mol. Ther., **13**, 1085-1092
- Shen, W-Y.**, Lai, Y.K.Y., Lai, C-M. and Rakoczy, P.E. (2003) *Impurity of recombinant adeno-associated virus type 2 affects the transduction characteristics following subretinal injection in the rat* Vision Res., **44**, 339-348
- Shi, X.**, Fang, G. and Shi, W. (2006) *Insertional mutagenesis at position 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin-binding ability and introduced novel tropism* Hum. Gene Ther., **17**, 353-361
- Steel, M.**, Woodburn, K., Kniffin, T., Gebretsadik, K., Chan, J., Vijay, S., Chen, H., Chalberg, T.W. and Gasmi, N. (2015) *In vitro and in vivo comparability assessment of an AAV vector manufactured by triple transfection in HEK293 cells or in the baculovirus expression system* Hum. Gene Ther., **26**, A70
- Virella-Lowell, I.**, Poirier, A., Chesnut, K.A., Brantly, M. et al (2000) *Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients* Gene Ther., **7**, 1783-1789
- Yan, Z.**, Lei-Butters, D.C.M., Zhang, Y., Zak, R. et al (2007) *Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo* Hum. Gene Ther., **18**, 81-87
- Zeltner, N.**, Kohlbrenner, E., Clément, N., Weber, T., et al (2010) *Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors* Gene Ther., **17**, 872–879
- Zhou, X.**, Zeng, X., Fan, Z., Li, C., et al (2008) *Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo* Mol. Ther., **16**, 494-499

## Tropism

- Alves, S.**, Bode, J., Bemelmans, A-P., von Kalle, C., Cartier, N. and Tews, B. (2016) *Ultramicroscopy as a novel tool to unravel the tropism of AAV gene therapy vectors in the brain* Sci. Rep., **6**: 28272

## Tumour cells, effect on

- Batchu, R.B.**, Gruzdyn, O.V., M. Moreno-Bost, A.M., Szmania, S., et al (2014) *Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector* Vaccine, **32**, 938–943
- Berlinghoff, S.**, Veldwijk, M.R., Laufs, S., Maser, H-P., et al (2004) *Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy* Lung Cancer, **46**, 179-186
- George, J.**, Gondi, C.S., Dinh, D.H., Gujrati, M. et al (2007) *Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis* Clin. Cancer Res., **13**, 3507-3517
- Hacker, U.T.**, Wingenfeld, L., Kofler, D. M., Schuhmann, N.K., et al (2005) *Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency* J. Gene Med., **7**, 1429-1438
- Klaus, F.**, Paterna, J-C., Marzorati, E., Sigrist, H., Götze, L., Schwendener, S., Bergamini, G., Jehli, E., Azzinnari, D. et al (2016) *Differential effects of peripheral and brain tumor necrosis factor on inflammation, sickness, emotional behavior and memory in mice* Brain Behav. Immun., **58**, 310–326
- Medina-Echeverz, J.**, Fioravanti, J., Diaz-Valdés, N., Frank, K., et al (2014) *Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases* PLoS One, **9**: e96799
- Müñch, R.C.**, Janicki, H., Völker, I., Rasbach, A., et al (2013) *Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer* Mol. Ther., **21**, 109–118
- Neukirchen, J.**, Meier, A., Rohrbeck, A., Garcia-Pardillos, G., et al (2007) *The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells* Cancer Gene Ther., **14**, 431-439
- Pandya, M.**, Britt, K., Hoffman, B., Ling, C. and Aslanidi, G.V. (2015) *Reprogramming immune response with capsid-optimized AAV6 vectors for immunotherapy of cancer* J. Immunother., **38**, 292–298
- Ponnazhagan, S.**, Mahendra, G., Lima, J., Aldrich, W.A., et al (2004) *Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant* Hum. Gene Ther., **15**, 856-864
- Rohr, U-P.**, Wulf, M-A., Stahn, S., Heyd, F., et al (2003) *Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector* Cancer Gene Ther., **10**, 898-906
- Santamaria, M.**, Pardo-Saganta, A., Alvarez-Asiain, L., Di Scala, M., et al (2013) *Nuclear  $\alpha$ -antichymotrypsin promotes chromatin condensation and inhibits proliferation of human hepatocellular carcinoma cells* Gastroenterology, **144**, 818-828
- Tamai, H.**, Miyake, K., Yamaguchi, H., Takatori, M., et al (2012) *AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in LL/AF4-positive ALL model mice* Blood, **119**, 64-71
- Teschendorf, C.**, Emons, B., Muzyczka, N., Graeven, U. et al (2010) *Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells* Anticancer Res., **30**, 1931-1936
- Triozzi, P.L.**, Aldrich, W. and Ponnazhagan, S. (2010) *Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists* Vaccine, **28**, 7837–7843
- Veldwijk, M.R.**, Herskind, C., Laufs, S., Zeller, W.J., et al (2004) *Recombinant adeno-associated virus 2-mediated transfer of the human superoxide-dismutase gene does not confer radioresistance on HeLa cervical carcinoma cells* Radiother. Oncol., **72**, 341-350
- Xie, Y.**, Hicks, M.J., Kaminsky, S.M., Moore, M.A.S., Crystal, R.G. and Rafii, A. (2014) *AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer* Gynecol. Oncol., **135**, 325–332
- Yanamandra, N.**, Kondraganti, S., Gondi, C.S., Gujrati, M., et al (2005) *Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line* Int. J. Cancer, **115**, 998-1005
- Yoo, J.**, Choi, S., Hwang, K-S., Cho, W-K., et al (2006) *Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model* J. Gene Med., **8**, 163-174

## Unfolded protein response

- Balakrishnan, B.**, Sen, D., Hareendran, S., Roshini, V., et al (2013) *Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors* PLoS One, **8**: e53845

## Vascular smooth muscle delivery

### Abdominal aortic aneurysm

**Chen, F.**, Zhang, ZD., and Zhu, XH. (2015) *Inhibition of development of experimental abdominal aortic aneurysm by c-junN-terminal protein kinase inhibitor combined with lysyl oxidase gene modified smooth muscle progenitor cells* Eur. J. Pharmacol., **766**, 114–121

### Actin filaments

**Pappas, C.T.**, Mayfield, R.M., Henderson, C., Jamilpour, N., Cover, C., Hernandez, Z., Hutchinson, K.R., Chu, M. et al (2015) *Knockout of Lmod2 results in shorter thin filaments followed by dilated cardiomyopathy and juvenile lethality* Proc. Natl. Acad. Sci. USA, **112**, 13573–13578

### Autoimmune myocarditis

**Kaya, Z.**, Leib, C., Werfel, S., Göser, S., et al (2011) *Comparison of IL-10 and MCP-1-7ND gene transfer with AAV9 vectors for protection from murine autoimmune myocarditis* Cardiovasc. Res., **91**, 116–123

### Ca<sup>2+</sup> cycling

**Park, C.S.**, Cha, H., Kwon, E.J., Jeong, D., et al (2012) *AAV-mediated knock-down of HRC exacerbates transverse aorta constriction-induced heart failure* PLoS One, **7**: e43282

### Cardiac contractility

**Gröbl, T.**, Hammer, E., Bien-Möller, S., Geisler, A., et al (2014) *A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca<sup>2+</sup> uptake into the sarcoplasmic reticulum* PLoS One, **9**: e92188

**Oh, J.G.**, Jeong, D., Cha, H., Kim, J.M., et al (2012) *PICOT increases cardiac contractility by inhibiting PKC $\zeta$  activity* J. Mol. Cell. Cardiol., **53**, 53–63

**Wahlquist, C.**, Jeong, D., Rojas-Munõz, A., Kho, C., et al (2014) *Inhibition of miR-25 improves cardiac contractility in the failing heart* Nature, **508**, 531-535

### Cardiac fibrosis

**Kim, J.**, Kim, J., Lee, S.H., Kepreotis, S.V., Yoo, J., Chun, J-S., Hajjar, R.J., Jeong, D. and Park, W.J. (2016) *Cytokine-like 1 regulates cardiac fibrosis via modulation of TGF- $\beta$  signaling* PLoS One, **11**: e0166480

### Cardiac gene knock-out

**Werfel, S.**, Jungmann, A., Lehmann, L., Ksienzyk, J., Bekeredjian, R., Kaya, Z., Leuchs, B., Nordheim, A., Backs, J., Engelhardt, S. et al (2014) *Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase* Cardiovasc. Res., **104**, 15–23

### Cardiac hypertrophy

**González-Terán, B.**, López, J.A., Rodríguez, E., Leiva, L., Martínez-Martínez, S., Bernal, J.A., Jiménez-Borreguero, L.J., Redondo, J.M., Vazquez, J. and Sabio, G. (2016) *p38g and d promote heart hypertrophy by targeting the mTOR-inhibitory protein DEPTOR for degradation* Nat. Comm., **7**: 10477

**Völkers, M.**, Toko, H., Doroudgar, S., Din, S., et al (2013) *Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1* Proc. Natl. Acad. Sci. USA, **110**, 12661–12666

### Cardiac remodeling

**Ramanujam, D.**, Sassi, Y., Laggerbauer, B. and Engelhardt, S. (2016) *Viral vector-based targeting of miR-21 in cardiac nonmyocyte cells reduces pathologic remodeling of the heart* Mol. Ther., **24**, 1939–1948

**Viereck, J.**, Kumarswamy, R., Foinquinos, A., Xiao, K., Avramopoulos, P., Kunz, M., Dittrich, M., Maetzig, T., Zimmer, K., et al (2016) *Long noncoding RNA Chast promotes cardiac remodeling* Sci. Transl. Med., **8**, 326ra22

**Wong, F.F.**, Ho, M.L., Yamagami, M., Lam, M.T., Grande-Allen, K.J. and Suh, J. (2015) *Effective gene delivery to valvular interstitial cells using adeno-associated virus serotypes 2 and 3* Tissue Eng. Part C, **21**, 808-815

### Cardiomyopathy

**Fechner, F.**, Sipo, I., Westermann, D., Pinkert, S., et al (2008) *Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy* J. Mol. Med., **86**, 987-997

**Gedicke-Hornung, C.**, Behrens-Gawlik, V., Reischmann, S., Geertz, B., et al (2013) *Rescue of cardiomyopathy through U7snRNA - mediated exon skipping in Mybpc3 - targeted knock - in mice* EMBO Mol. Med., **5**, 1060-1077



**Karakikes, I.**, Stillitano, F., Nonnenmacher, M., Tzimas, C., Sanoudou, D., Termglinchan, V., Kong, C-W., Rushing, S. et al (2015) *Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy* Nat. Commun., **6**: 6955

**Mearini, G.**, Stimpel, D., Krämer, E., Geertz, B., et al (2013) *Repair of Mybpc3 mRNA by 5'-trans-splicing in a mouse model of hypertrophic cardiomyopathy* Mol. Ther. Nucleic Acids **2**: e102

**Rutschow, D.**, Bauer, R., Göhringer, C., Bekeredjian, R., et al (2014) *S151A  $\delta$ -sarcoglycan mutation causes a mild phenotype of cardiomyopathy in mice* Eur. J. Hum. Genet., **22**, 119–125

### Coronary artery delivery

**Moulay, G.**, Ohtani, T., Ogut, O., Guenzel, A., Behfar, A., Zakeri, R., Haines, P., Storlie, J. et al (2015) *Cardiac AAV9 gene delivery strategies in adult canines: assessment by long-term serial SPECT imaging of sodium iodide symporter expression* Mol. Ther., **23**, 1211–1221

### Extracellular SOD

**Prasad, K-M.R.**, Smith, R.S., Xu, Y., French, B.A. (2011) *A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction* J. Gene Med., **13**, 333–341

### Heart transplants

**Raissadati, A.**, Jokinen, J.J., Syrjälä, S.O., Keränen, M.A.I., et al (2013) *Ex vivo intracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants* Transplant Int., **26**, 1126–1137

### Inflammatory responses

**Chen, S.**, Kapturczak, M.H., Wasserfall, C., Glushakova, O.Y., et al (2005) *Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway* Proc. Natl. Acad. Sci. USA, **102**, 7251–7256

### Interleukins

**Chen, S.**, Kapturczak, M.H., Wasserfall, C., Glushakova, O.Y., et al (2005) *Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway* Proc. Natl. Acad. Sci. USA, **102**, 7251–7256

**Kaya, Z.**, Leib, C., Werfel, S., Göser, S., et al (2011) *Comparison of IL-10 and MCP-1-7ND gene transfer with AAV9 vectors for protection from murine autoimmune myocarditis* Cardiovasc. Res., **91**, 116–123

### Left ventricular remodelling

**Konkalmatt, P.R.**, Wang, F., Piras, B.A., Xu, Y., et al (2012) *Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling* J. Gene Med., **14**, 609–620

**Konkalmatt, P.R.**, Beyers, R.J., O'Connor, D.M., Xu, Y., Seaman, M.E. and French, B.A. (2013) *Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling* Circ. Cardiovasc. Imaging, **6**, 478–456

### Myocardial dysfunction (incl. fibrosis/hypertension/infarction etc)

**Bénard, L.**, Oh, J.G., Cacheux, M., Lee, A., Nonnenmacher, M., Matasic, D.S., Kohlbrenner, E., Kho, C., Pavoine, C et al (2016) *Cardiac Stim1 silencing impairs adaptive hypertrophy and promotes heart failure through inactivation of mTORC2/Akt signaling* Circulation, **133**, 1458–1471

**Cataliotti, A.**, Tonne, J.M., Bellavia, D., Martin, F.L., et al (2011) *Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats* Circulation, **123**, 1297–1305

**Chemaly, E.R.**, Hadri, L., Zhang, S., Kim, M., et al (2011) *Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats* J. Mol. Cell. Cardiol., **51**, 144–155

**Fish, K.M.**, Ladage, D., Kawase, Y., Karakikes, I., et al (2013) *AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling* Circ. Heart Fail., **6**, 310–317

**Kho, C.**, Lee, A., Jeong, D., Oh, J.G., et al (2011) *SUMO1-dependent modulation of SERCA2a in heart failure* Nature, **477**, 601–606

**LaRocca, T.J.**, Jeong, D., Kohlbrenner, E., Lee, A., et al (2012) *CXCR4 gene transfer prevents pressure overload induced heart failure* J. Mol. Cell. Cardiol., **53**, 223–232

- Moilanen, A-M.,** Rysä, J., Serpi, R., Mustonen, E., et al (2012) *(Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function* PLoS One, 7(7): e41404
- Park, C.S.,** Cha, H., Kwon, E.J., Jeong, D., et al (2012) *AAV-mediated knock-down of HRC exacerbates transverse aorta constriction-induced heart failure* PLoS One, 7: e43282
- Pleger, S.T.,** Shan, C., Ksienzyk, J., Bekeredjian, R., et al (2011) *Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model* Sci. Transl. Med., 3: 92ra64
- Prasad, K-M.R.,** Smith, R.S., Xu, Y., French, B.A. (2011) *A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction* J. Gene Med., 13, 333–341
- Schmid, E.,** Neef, S., Berlin, C., Tomasovic, A., Kahlert, K., Nordbeck, P., Deiss, K., Denzinger, S., Herrmann, S. et al (2015) *Cardiac RKIP induces a beneficial  $\beta$ -adrenoceptor-dependent positive inotropy* Nat. Med., 21, 1298-1306
- Shettigar, V.,** Zhang, B., Little, S.C., Salhi, H.E., Hansen, B.J., Li, N., Zhang, J., Roof, S.R., Ho, H-T., Brunello, L. et al (2016) *Rationally engineered Troponin C modulates in vivo cardiac function and performance in health and disease* Nat. Comm., 7: 10794
- Wahlquist, C.,** Jeong, D., Rojas-Munõz, A., Kho, C., et al (2014) *Inhibition of miR-25 improves cardiac contractility in the failing heart* Nature, 508, 531-535

### Myocardial gene delivery

- White, J.D.,** Thesier, D.M., Swain, J.B.D., Katz, M.G., et al (2011) *Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo* Gene Ther., 18, 546–552

### Myocyte cytokinesis

- Jiang, J.,** Burgon, P.G., Wakimoto, H., Onoue, K., Gorham, J.M., O’Meara, C.C., Fomovsky, G., McConnell, B.K, Lee, R.T., Seidman, J.G. and Seidman, C.E. (2015) *Cardiac myosin binding protein C regulates postnatal myocyte cytokinesis* Proc. Natl. Acad. Sci. USA, 112, 9046-9051

### Myotonic dystrophy

- Freyermuth, F.,** Rau, F., Kokunai, Y., Linke, T., Sellier, C., Nakamori, M., Kino, Y., Arandel, L., Jollet, A., Thibault, C. et al (2016) *Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy* Nat. Comm., 7: 11067

### Natriuretic peptide (B type)

- Cataliotti, A.,** Tonne, J.M., Bellavia, D., Martin, F.L., et al (2011) *Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats* Circulation, 123, 1297-1305

### Phospholamban suppression

- Andino, L.M.,** Takeda, M., Kashara, H., Jakymiw, A., et al (2008) *AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes* J. Gene Med., 10, 132-142

### Resistin overexpression

- Chemaly, E.R.,** Hadri, L., Zhang, S., Kim, M., et al (2011) *Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats* J. Mol. Cell. Cardiol., 51, 144–155

### RNA: micro-RNAs

- Wahlquist, C., Jeong, D., Rojas-Munõz, A., Kho, C., Lee, A., Mitsuyama, S., van Mil, A., Park, W.J., Sluijter, J.P.G., Doevendans, P.A.F., Hajjar, R.J. and Mercola, M. (2014) *Inhibition of miR-25 improves cardiac contractility in the failing heart* Nature, 508, 531-535

### RNA: RNAi

- Fechner, F.,** Sipo, I., Westermann, D., Pinkert, S., et al (2008) *Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy* J. Mol. Med., 86, 987-997

### RNA: sh RNA

- Andino, L.M.,** Takeda, M., Kashara, H., Jakymiw, A., et al (2008) *AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes* J. Gene Med., 10, 132-142

**Mayra, A.**, Tomimitsu, H., Kubodera, T., Kobayashi, M., et al (2011) *Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles* Biochem. Biophys. Res. Comm., **405**, 204–209

**Suckau, L.**, Fechner, H., Chemaly, E., Krohn, S., et al (2009) *Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy* Circulation, **119** 1241-1252

### **δ-Sarcoglycan**

**Ying, Y.**, Müller, O.J., Goehring, C., Leuchs, B., et al (2010) *Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library* Gene Ther., **17**, 980–990

### **Small ubiquitin-related modifier**

**Kho, C.**, Lee, A., Jeong, D., Oh, J.G., et al (2011) *SUMO1-dependent modulation of SERCA2a in heart failure* Nature, **477**, 601-606

### **Somatic gene transfer**

**Chen, S-J.**, Johnston, J., Sandhu, A., Bish, L.T., et al (2013) *Enhancing the utility of adeno-associated virus gene transfer through inducible tissue-specific expression* Hum. Gene Ther. Methods, **24**, 270–278

### **Vector specificity and transduction efficiency**

**Bish, L.T.**, Sweeney, H.L., Müller, O.J. and Bekeredjian, R. (2011) *Adeno-associated virus vector delivery to the heart* In Adeno-Associated Virus: Methods and Protocols, Methods Mol. Biol., **807** (ed. Snyder, R.O. and Moullier, P., Springer Science+Business Media, pp 219-237

**Du, L.**, Kido, M., Lee, D.V., Rabinowitz, J.E., et al (2004) *Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors* Mol. Ther., **10**, 604-608

**Gruchala, M.**, Bhardwaj, S., Pajusola, K., Roy, H., et al (2004) *Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors* J. Gene Med., **6**, 545-554

**Merentie, M.**, Lottonen-Raikaslehto, L., Parviainen, V., Huusko, J., Pikkarainen, S., Mendel, M., Laham-Karam, N., Kärjä, V. et al (2016) *Efficacy and safety of myocardial gene transfer of adenovirus, adeno-associated virus and lentivirus vectors in the mouse heart* Gene Ther., **23**, 296–305

**Miyake, N.**, Miyake, K., Yamamoto, M., Hirai, Y. and Shimada, T. (2011) *Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors* Brain Res., **1389**, 19-26

**Müller, O.J.**, Leuchs, B., Pleger, S.T., Grimm, D., et al (2006) *Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors* Cardiovasc. Res., **70**, 70-78

**Müller, O.J.**, Schinkel, S., Kleinschmidt, J.A., Katus, H.A., et al (2008) *Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats* Gene Ther. **15**, 1558–1565

**Pleger, S.T.**, Shan, C., Ksienzyk, J., Bekeredjian, R., et al (2011) *Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model* Sci. Transl. Med., **3**: 92ra64

**Piras, B.A.**, O'Connor, D.M. and French, B.A. (2013) *Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver* PLoS One, **8**: e75894

**Prasad, K-M.R.**, Xu, Y., Yang, Z., Acton, S.T. and French, B.A. (2011) *Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution* Gene Ther., **18**, 43–52

**Raake, P.W.**, Hinkel, R., Müller, S., Delker, S., et al (2008) *Cardio-specific long term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors* Gene Ther., **15**, 12-17

**Rapti, K.**, Hajjar, R.J. and Weber, T. (2012) *Novel approaches to deliver molecular therapeutics in cardiac disease using adeno-associated virus vectors* In Translational Cardiology, Molecular and Translational Medicine (ed. Patterson, C. and Willis, M.S) (eds.), Springer Science+Business Media, pp 391-458

**Rapti, K.**, Stillitano, F., Karakikes, I., Nonnenmacher, M., Weber, T., Hulot, J-S. and Hajjar, R.J. (2015) *Effectiveness of gene delivery systems for pluripotent and differentiated cells* Mol. Ther. Methods Clin. Dev., **2**: 14067

**Sasano, T.**, Kikuchi, K., McDonald, A., Lai, S., et al (2007) *Targeted high-efficiency, homogenous myocardial gene transfer* J. Mol. Cell. Cardiol., **42**, 954-961

**Sen, S.**, Contoy, S., Hynes, S.O., McMahan, J., et al (2008) *Gene delivery to the vasculature mediated by low-titre adeno-associated virus serotypes 1 and 5* J. Gene Med., **10**, 143-151

**Sharif, F.**, Hynes, S.O., McMahan, J., Cooney, R., et al (2006) *Gene-eluting stents: Comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo* Hum. Gene Ther., **17**, 741-750

**Sipo, I.**, Fechner, H., Pinkert, S., Suckau, L., et al (2007) *Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction* Gene Ther., **14**, 1319-1329

**Work, L.M.**, Nicklin, S.A., Brain, N.J.R., Dishart, K.L., et al (2004) *Development of efficient viral vectors selective for vascular smooth muscle cells* Mol. Ther., **9** 198-208

### **Vexosome (exosome) gene delivery**

**György, B.**, Fitzpatrick, Z., Crommentuijn, M.H.W., Mu, D. and Maguire, C.A. (2014) *Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo* Biomaterials, **35**, 7598-7609

**Hudry, E.**, Martin, C., Gandhi, S., György, B., Scheffer, D.I., Mu, D., Merkel, S.F., Mingozi, F., Fitzpatrick, Z. et al (2016) *Exosome-associated AAV vector as a robust and convenient neuroscience tool* Gene Ther., **23**, 380–392

**Maguire, C.A.**, Balaj, L., Sivaraman, S., Crommentuijn, M.H.W., et al (2012) *Microvesicle-associated AAV vector as a novel gene delivery system* Mol. Ther., **20**, 960–971

### **Von Willebrand's disease**

**Wang, L.**, Rosenberg, J.B., De, B.P., Ferris, B., Wang, R., et al (2012) *In vivo gene transfer strategies to achieve partial correction of von Willebrand disease* Hum. Gene Ther., **23**, 576–588

### **Wound healing**

**Balaji, S.**, King, A., Dhamija, Y., Le, L.D., et al (2013) *Pseudotyped adeno-associated viral vectors for gene transfer in dermal fibroblasts: implications for wound-healing applications* J. Surg. Res., **184**, 691-698

**Jazwa, A.**, Kucharzewska, P., Leja, J., Zagorska, A., et al (2010) *Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice* Genet. Vaccines Ther., **8**: 6

### **Xerostomia**

**Srinivasan, P.**, Shanmugam, T., Dayton, R.D., Palaniyandi, S., et al (2013) *Recombinant AAV9-TLK1B administration ameliorates fractionated radiation-induced xerostomia* Hum. Gene Ther., **24**, 604–612

### **X-ray crystallography**

**Lane, M.D.**, Nam, H-J., Padron, E., Gurda-Whitaker, B., et al (2005) *Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8* Acta Cryst., **F61**, 558-561

Mini-Review MV02: 3<sup>rd</sup> edition, February 2017

**Alere Technologies AS**

Axis-Shield Density Gradient Media  
is a brand of Alere Technologies AS